<SEC-DOCUMENT>0001193125-12-152092.txt : 20120405
<SEC-HEADER>0001193125-12-152092.hdr.sgml : 20120405
<ACCEPTANCE-DATETIME>20120405163409
ACCESSION NUMBER:		0001193125-12-152092
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20120525
FILED AS OF DATE:		20120405
DATE AS OF CHANGE:		20120405
EFFECTIVENESS DATE:		20120405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		12746071

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d285899ddef14a.htm
<DESCRIPTION>DEFINITIVE NOTICE & PROXY
<TEXT>
<HTML><HEAD>
<TITLE>&lt;![CDATA[Definitive Notice &amp; Proxy]]&gt;</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>(Rule 14a-101) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SCHEDULE 14A INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities
Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Filed by the
Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed by a
Party other than the Registrant&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary Proxy Statement </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) </B></FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Proxy Statement </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitive Additional Materials </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting Material Pursuant to &#167; 240.14a-12 </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Name of Registrant as Specified In Its Charter)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name of Person(s) Filing Proxy Statement if Other Than the Registrant) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box) </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">No fee required. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated
and state how it was determined): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fee paid previously with preliminary materials. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Amount Previously Paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Form, Schedule or Registration Statement No.: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Filing Party: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Date Filed: </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8001 Arista Place, Suite 430 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Broomfield, Colorado 80021 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;5, 2012 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Stockholders of ARCA biopharma, Inc.: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You are cordially invited to attend the Annual Meeting of Stockholders of ARCA biopharma, Inc., a Delaware corporation (the &#147;Company&#148; or &#147;ARCA&#148;). The meeting will be held on Friday,
May&nbsp;25, 2012 at 9:00 a.m. local time at the Renaissance Boulder Flatiron Hotel, 500 Flatiron Boulevard, Broomfield, CO 80021. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The matters scheduled to be considered at the meeting are (1)&nbsp;to elect the Board&#146;s nominees, Dr.&nbsp;Burton&nbsp;E. Sobel and Dr.&nbsp;Jean-Fran&ccedil;ois Formela, to the Board of Directors to
hold office until the 2015 Annual Meeting of Stockholders, (2)&nbsp;to ratify the selection by the Board of Directors of KPMG LLP (KPMG) as independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31,
2012 and (3)&nbsp;to conduct any other business properly brought before the meeting. These items of business are more fully described in this proxy statement that you are encouraged to read in its entirety. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with the Securities and Exchange Commission (&#147;SEC&#148;) rule (&#147;Notice and Access Rule&#148;) that allows
companies to furnish their proxy materials (including the form of proxy, this proxy statement and our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2011, filed with the SEC on March&nbsp;27, 2012) over the Internet, we
intend to send a Notice of Internet Availability of Proxy Materials (&#147;Notice&#148;) on or about April&nbsp;13, 2012 to our stockholders of record as of March&nbsp;28, 2012. We will also provide access to our proxy materials over the Internet by
April&nbsp;13, 2012. As a result of the Notice and Access Rule, all stockholders receiving the Notice have the ability to access the proxy materials over the Internet and request to receive a paper copy of the proxy materials by mail. Instructions
on how to access the proxy materials over the Internet or to request a paper copy may be found on the Notice. In addition, the Notice contains instructions on how stockholders may request to receive proxy materials electronically by e-mail.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All stockholders are cordially invited to attend the Annual Meeting in person. Whether or not you expect to attend the Annual
Meeting, please vote, as instructed in the Notice of Internet Availability of Proxy Materials, via the Internet or the telephone, as promptly as possible in order to ensure your representation at the Annual Meeting. Alternatively, you may follow the
procedures outlined in the Notice of Internet Availability of Proxy Materials to request a paper proxy card to submit your vote by mail. Even if you have voted by proxy, you may still vote in person if you attend the Annual Meeting. Please note,
however, that if your shares are held of record by a broker, bank or other agent and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:53%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely, </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:53%; text-indent:-2%">


<IMG SRC="g285899g95l79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:53%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CHRISTOPHER OZEROFF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:53%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary,&nbsp;Senior&nbsp;Vice&nbsp;President&nbsp;and&nbsp;General&nbsp;Counsel </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8001 Arista Place, Suite 430 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Broomfield, Colorado 80021 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TO BE HELD ON MAY&nbsp;25, 2012 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Notice is hereby given that the Annual Meeting of Stockholders of (the &#147;Annual Meeting&#148;) ARCA biopharma, Inc., a Delaware corporation (the &#147;Company&#148; or &#147;ARCA&#148;) will be held
on Friday, May&nbsp;25, 2012 at 9:00 a.m. local time at the Renaissance Boulder Flatiron Hotel, 500 Flatiron Boulevard, Broomfield, CO 80021 for the following purposes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>To elect the Board&#146;s nominees, Dr.&nbsp;Burton&nbsp;E. Sobel and Dr.&nbsp;Jean-Fran&ccedil;ois Formela, to the Board of Directors to hold office until the
2015 Annual Meeting of Stockholders. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>To ratify the selection by the Board of Directors of KPMG LLP as independent registered public accounting firm of the Company for its fiscal year ending
December&nbsp;31, 2012. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>To conduct any other business properly brought before the meeting. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These items of business are more fully described in the proxy statement accompanying this Notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The record date for the Annual Meeting is March&nbsp;28, 2012. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:53%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:53%; text-indent:-2%">


<IMG SRC="g285899g95l79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:53%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CHRISTOPHER OZEROFF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:53%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary, Senior Vice President and General Counsel </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>B<SMALL>ROOMFIELD</SMALL>, CO </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PRIL</SMALL>&nbsp;5, 2012 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pursuant to the Internet proxy rules promulgated by the Securities and Exchange Commission, the Company has elected to provide access
to its proxy materials over the Internet. Accordingly, stockholders of record at the close of business on March&nbsp;28, 2012 will receive a Notice of Internet Availability of Proxy Materials and may vote at the Annual Meeting and any adjournment or
postponement thereof. The Company expects to mail the Notice of Internet Availability of Proxy Materials on or about April&nbsp;13, 2012. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>All stockholders are cordially invited to attend the annual meeting in person. Whether or not you expect to attend the annual meeting, please vote, as instructed in the Notice of Internet Availability
of Proxy Materials, via the Internet or the telephone, as promptly as possible in order to ensure your representation at the annual meeting. Alternatively, you may follow the procedures outlined in the Notice of Internet Availability of Proxy
Materials to request a paper proxy card to submit your vote by mail. Even if you have voted by proxy, you may still vote in person if you attend the annual meeting. Please note, however, that if your shares are held of record by a broker, bank or
other agent and you wish to vote at the annual meeting, you must obtain a proxy issued in your name from that record holder. </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8001 Arista Place, Suite 430 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Broomfield, Colorado 80021 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROXY STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE 2012 ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MAY 25, 2012 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This proxy statement (this &#147;Proxy Statement&#148;) is
being furnished to holders of ARCA biopharma, Inc. (sometimes referred to as the &#147;Company,&#148; &#147;ARCA,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148;) common stock, par value $0.001 per share (the &#147;Common Stock&#148;).
Proxies are being solicited on behalf of the Board of Directors of ARCA (the &#147;Board of Directors&#148;) to be used at the Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) to be held on Friday, May&nbsp;25, 2012 at 9:00 a.m. local
time at the Renaissance Boulder Flatiron Hotel, 500 Flatiron Boulevard, Broomfield, CO 80021 and at any postponement or adjournment thereof, for the purposes set forth in the Notice of Annual Meeting of Stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA is using the Securities and Exchange Commission (the &#147;SEC&#148;) rule that allows companies to furnish their proxy materials
over the Internet. As a result, we intend to mail to our stockholders a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) instead of a paper copy of the proxy materials (including the form of proxy, this Proxy Statement and
our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2011, filed with the SEC on March&nbsp;27, 2012 (the &#147;2011 Annual Report&#148;), collectively, the &#147;Proxy Materials&#148;) on or about April&nbsp;13, 2012. We will
also provide access to our Proxy Materials over the Internet by April&nbsp;13, 2012. By furnishing the Notice to our stockholders of record, you <B><I><U>will not</U></I></B> receive a printed copy of the Proxy Materials in the mail. Instead, the
Notice instructs you on how to access and review all of the important information contained in the Proxy Statement and Annual Report electronically or to receive a printed version in the mail. The Notice also instructs you on how you may submit your
proxy over the Internet, by toll-free number or in person at the Annual Meeting. Subsequent to receiving the Notice, all stockholders have the ability to access the Proxy Materials over the Internet and request to receive a paper copy of the Proxy
Materials by mail. Instructions on how to access the Proxy Materials over the Internet or to request a paper copy may be found on the Notice. In addition, the Notice contains instructions on how stockholders may request to receive Proxy Materials
electronically by e-mail. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All stockholders may view and print ARCA&#146;s proxy statement and the 2011 Annual Report, which
are available at www.arcabiopharma.com. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Why did I receive a notice regarding the availability of the Proxy Materials on the Internet? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As described above, pursuant to rules adopted by the SEC, we have elected to provide access to the Proxy Materials over the Internet.
Accordingly, on or about April&nbsp;13, 2012, we expect to send the Notice to ARCA&#146;s stockholders of record. The Board of Directors is soliciting your proxy to vote at the Annual Meeting. All stockholders will have the ability to access the
Proxy Materials on the website referred to in the Notice or request to receive a printed or electronic set of the Proxy Materials. Instructions on how to access the Proxy Materials over the Internet or to request a printed copy may be found in the
Notice. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How do I attend the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>The meeting will be held on Friday, May&nbsp;25, 2012 at 9:00 a.m. local time at the Renaissance Boulder Flatiron Hotel, 500
Flatiron Boulevard, Broomfield, CO 80021. Directions to the annual meeting may be found at www.arcabiopharma.com. Information on how to vote in person at the Annual Meeting is discussed below.<B> </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who can vote at the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Only stockholders of record at the close of business on March&nbsp;28, 2012 will be entitled to vote at the Annual Meeting. On this record date, there were 12,182,999 shares of common stock outstanding
and entitled to vote. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stockholder of Record: Shares Registered in Your Name </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If on March&nbsp;28, 2012 your shares were registered directly in your name with ARCA&#146;s transfer agent, Computershare Trust Company
N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the meeting or vote by proxy. Whether or not you plan to attend the meeting, we urge you to vote by proxy over the telephone or on the Internet as
instructed below or return the proxy card we may mail to you to ensure your vote is counted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Beneficial Owner: Shares
Registered in the Name of a Broker or Bank </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If, on March&nbsp;28, 2012, your shares were held, not in your name, but rather
in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in &#147;street name&#148; and the Notice is being forwarded to you by that organization. The organization holding your
account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited
to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you request and obtain a valid proxy from your broker or other agent. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What am I voting on? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are two matters scheduled for a vote: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Election of two directors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ratification of selection by the Board of Directors of KPMG as independent registered public accounting firm of the Company for its fiscal year ending
December&nbsp;31, 2012. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What if another matter is properly brought before the meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are
properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>How do I vote? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may either vote &#147;For&#148; all the nominees to the
Board of Directors or you may &#147;Withhold&#148; your vote for any nominee you specify. For all other matters to be voted on, you may vote &#147;For&#148; or &#147;Against&#148; or abstain from voting. The procedures for voting are fairly simple:
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stockholder of Record: Shares Registered in Your Name </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a stockholder of record, you may vote in person at the Annual Meeting, vote by proxy over the telephone, vote by proxy through
the Internet or vote by proxy using a proxy card that you may request or that </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
we may elect to deliver at a later time. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in
person even if you have already voted by proxy. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the proxy card, simply complete, sign and date the proxy card that may be delivered and return it promptly in the envelope provided. If
you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote over the telephone, dial toll-free <B>1-800-652-VOTE (8683)</B>&nbsp;using a touch-tone phone and follow the recorded instructions. You will be
asked to provide the company number and control number from the Notice. Your vote must be received by 1:00 a.m. Mountain Time on May&nbsp;25, 2012 to be counted. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote through the Internet, go to http://www.investorvote.com/ABIO to complete an electronic proxy card. You will be asked to provide the company
number and control number from the Notice. Your vote must be received by 1:00 a.m. Mountain Time on May&nbsp;25, 2012 to be counted. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Beneficial Owner: Shares Registered in the Name of Broker or Bank </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you
are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a Notice containing voting instructions from that organization rather than from ARCA. Simply follow the voting instructions in the
Notice to ensure that your vote is counted. To vote in person at the Annual Meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or
contact your broker or bank to request a proxy form. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px; margin-left:1%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We provide internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the
authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your access to the Internet, such as usage charges from internet access providers and telephone companies.
</B></FONT></P></div> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How many votes do I have? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On each matter to be voted upon, you have one vote for each share of common stock you own as of March&nbsp;28, 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>What if I return a proxy card or otherwise vote but do not make specific choices? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#147;For&#148; the election of both nominees for director and
&#147;For&#148; the ratification of KMPG as the Company&#146;s independent auditor for the fiscal year 2012. If any other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your
shares using his or her best judgment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who is paying for this proxy solicitation? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, the directors and employees may also solicit
proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of
forwarding proxy materials to beneficial owners. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What does it mean if I receive more than one Notice? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the
voting instructions on the Notices to ensure that all of your shares are voted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Can I change my vote after submitting my proxy? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your shares, you may
revoke your proxy in any one of the following ways: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may submit another properly completed proxy card with a later date. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may grant a subsequent proxy by telephone or through the Internet. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may send a timely written notice that you are revoking your proxy to ARCA&#146;s Secretary at 8001 Arista Place, Suite 430, Broomfield, CO 80021.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may attend the Annual Meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your most current proxy card or telephone or the internet proxy is the one that is counted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>When are stockholder proposals due for next year&#146;s annual meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be considered for inclusion in next year&#146;s proxy materials, your proposal must be submitted in writing by December&nbsp;14, 2012,
to ARCA&#146;s Secretary at 8001 Arista Place, Suite 430, Broomfield, CO 80021. If you wish to submit a proposal that is not to be included in next year&#146;s proxy materials or nominate a director, you must do so by no earlier than
February&nbsp;24, 2013 and no later than March&nbsp;26, 2013. You are also advised to review the Company&#146;s Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How are votes counted? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#147;For&#148; and
&#147;Withhold&#148; and, with respect to proposals other than the election of directors, &#147;Against&#148; votes, abstentions and broker non-votes. Abstentions will be counted towards the vote total for each proposal, and will have the same
effect as &#147;Against&#148; votes. Broker non-votes have no effect and will not be counted towards the vote total for any proposal. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What
are &#147;broker non-votes&#148;? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Broker non-votes occur when a beneficial owner of shares held in &#147;street name&#148;
does not give instructions to the broker or nominee holding the shares as to how to vote on matters deemed &#147;non-routine.&#148; Generally, if shares are held in street name, the beneficial owner of the shares is entitled to give voting
instructions to the broker or nominee holding the shares. If the beneficial owner does not provide voting instructions, the broker or nominee can still vote the shares with respect to matters that are considered to be &#147;routine,&#148; but not
with respect to &#147;non-routine&#148; matters. Under the rules and interpretations of the New York Stock Exchange (&#147;NYSE&#148;), &#147;non-routine&#148; matters are matters that may substantially affect the rights or privileges of
shareholders, such as mergers, shareholder proposals and, for the first time, under a new amendment to the NYSE rules, elections of directors, even if not contested. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>How many votes are needed to approve each proposal? </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the election of directors, the two nominees receiving the most &#147;For&#148; votes (from the holders of votes of shares present in person or
represented by proxy and entitled to vote on the election of directors) will be elected. Only votes &#147;For&#148; or &#147;Withheld&#148; will affect the outcome. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be approved, Proposal No.&nbsp;2 to ratify the selection of KPMG LLP as the Company&#146;s independent auditors for fiscal year 2012 must receive
&#147;For&#148; votes from the holders of a majority of shares present and entitled to vote either in person or by proxy. If you &#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. Broker non-votes will have
no effect. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is the quorum requirement? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding a majority of the outstanding shares entitled to vote are present at the meeting in person
or represented by proxy. On the record date, there were 12,182,999 shares outstanding and entitled to vote. Thus, the holders of 6,091,500 shares must be present in person or represented by proxy at the meeting to have a quorum. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank
or other nominee) or if you vote in person at the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present at the meeting in person or represented by
proxy may adjourn the meeting to another date. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How can I find out the results of the voting at the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current
report on Form 8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form&nbsp;8-K within four business days after the meeting, we intend to file a
Form&nbsp;8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form&nbsp;8-K to publish the final results. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XPLANATORY</SMALL> N<SMALL>OTE</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company, a Delaware Corporation formerly known as Nuvelo, Inc., completed a merger transaction on January&nbsp;27, 2009, with ARCA biopharma, Inc., a Delaware Corporation (&#147;ARCA Colorado&#148;),
in which ARCA Colorado became a subsidiary of the Company, and ARCA Colorado shareholders acquired a majority of the outstanding stock of the Company. The Company then changed its name to ARCA biopharma, Inc. These transactions are referred to
herein as the &#147;merger.&#148; Unless the context otherwise requires or as otherwise stated herein, all references herein to the &#147;Company,&#148; &#147;ARCA,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to ARCA Colorado
prior to the completion of the merger and to ARCA biopharma, Inc. following the completion of the merger and the name change, and all references to &#147;Nuvelo&#148; refer to Nuvelo, Inc. prior to the completion of the merger and the name change.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ROPOSAL</SMALL> 1 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>LECTION</SMALL> O<SMALL>F</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Amended and Restated Certificate of Incorporation provides that the Board of Directors is divided into three classes
to provide for staggered terms and that each director will serve for a term of three years or less, depending on the class to which the Board of Directors has assigned a director not previously elected by the stockholders. There are currently two
Class II directors, whose terms expire at the annual stockholders&#146; meeting in 2014, two Class III directors, whose terms expire at the annual stockholders&#146; meeting in 2012, and two Class I directors whose terms expire at the annual
stockholders&#146; meeting in 2013. The Board of Directors has nominated two Class III directors, Dr.&nbsp;Burton&nbsp;E. Sobel and Dr.&nbsp;Jean-Fran&ccedil;ois Formela, for election to the Board of Directors, each for a three-year term ending on
the date of the annual meeting in 2015 or until a successor is duly elected and qualified or appointed. There are currently no vacancies on the Board. Vacancies on the Board may be filled only by persons elected by a majority of the remaining
directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#146;s successor is
duly elected and qualified. The Company may also reduce the size of the Board by resolution adopted by the affirmative vote of a majority of the directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If elected at the Annual Meeting, each of these nominees would serve until the 2015 annual meeting and until his or her successor has been duly elected and qualified, or, if sooner, until the
director&#146;s death, resignation or removal. It is the Company&#146;s policy to encourage directors and nominees for director to attend the Annual Meeting. All of the Company&#146;s directors then on the Board, except Mr.&nbsp;Richard&nbsp;B.
Brewer and Dr.&nbsp;Jean-Fran&ccedil;ois Formela, attended the 2011 Annual Meeting of Stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors are elected by
a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. The two nominees receiving the highest number of affirmative votes will be elected. Each person nominated
for election has agreed to serve if elected. The Company&#146;s management has no reason to believe that any nominee will be unable to serve. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Qualifications and Diversity </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The below paragraphs provide information as of the date of this proxy statement about each nominee and current members of the Board of Directors, including age, all positions currently held, principal
occupation and business experience for the past five years. In addition to the information presented regarding each nominee&#146;s specific experience, qualifications, attributes and skills that led the Board to conclude that such director or
nominee should be able to serve as a director, the Board also believes that all of the directors and nominees have a reputation of integrity, honesty and adherence to high ethical standards. They each have demonstrated business acumen and an ability
to exercise sound judgment as well as a commitment to service to ARCA and the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Nominating and Corporate Governance
Committee considers diversity in the director identification and nomination process. The Nominating and Corporate Governance Committee seeks nominees with a broad diversity of experience, professions, skills, geographic representation and
backgrounds. Such Committee does not assign specific weights to particular criteria and no particular criterion is necessarily applicable to all prospective nominees. ARCA believes that the backgrounds and qualifications of the directors, considered
as a group, should provide a significant composite mix of experience, knowledge and abilities that will allow the Board to fulfill its responsibilities. Nominees are not discriminated against on the basis of race, religion, national origin, sexual
orientation, disability or any other basis proscribed by law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>OMINEES</SMALL> <SMALL>FOR</SMALL> E<SMALL>LECTION</SMALL> <SMALL>FOR</SMALL> <SMALL>A</SMALL>
T<SMALL>HREE</SMALL>-<SMALL>YEAR</SMALL> T<SMALL>ERM</SMALL> E<SMALL>XPIRING</SMALL> <SMALL>AT</SMALL> <SMALL>THE</SMALL> 2015 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> E<SMALL>ACH</SMALL> N<SMALL>AMED</SMALL> N<SMALL>OMINEE</SMALL>. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jean-Fran&ccedil;ois Formela, M.D. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Formela, age 55, has served as a member of Company&#146;s Board of Directors since the merger with Nuvelo. Dr.&nbsp;Formela had also served as a director of ARCA Colorado from February 2006 until
the merger. Dr.&nbsp;Formela is a Partner of and joined Atlas Venture in 1993 to help build the U.S. Life Sciences franchise. Previously, he was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough Corporation , a worldwide
pharmaceutical company, in the U.S. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough&#146;s alpha-interferon. In his last position at Schering-Plough, Dr.&nbsp;Formela directed the U.S. Phase IV studies in
all therapeutic areas, as well as the health economics and biotechnology pre-marketing groups. As a medical doctor, Dr.&nbsp;Formela practiced emergency medicine at Necker University Hospital in Paris. Since joining Atlas Venture, Dr.&nbsp;Formela
has been involved in the formation of companies such as Adnexus, Archemix, ArQule, Aureon Laboratories, Cellzome, deCODE, Exelixis, MorphoSys, NxStage, Resolvyx Pharmaceuticals, and SGX Pharmaceuticals. He was also an investor in Achillion and
Nuvelo and director of biochem pharma and Novexel. In the past five years, Dr.&nbsp;Formela has served on the Boards of Directors of Achillon Pharmaceuticals, Inc., SGX Pharmaceuticals, Inc., NxStage Medical, Inc., deCODE genetics and Horizon
Pharma, Inc. Dr.&nbsp;Formela received his M.D. from Paris University School of Medicine, and his M.B.A. from Columbia University. Dr.&nbsp;Formela is an appropriate member of the Company&#146;s Board of Directors, given his medical background, his
extensive experience in the pharmaceutical industry, and his extensive experience as an investor in and board member of new biotechnology and pharmaceutical companies. Dr.&nbsp;Formela also has extensive experience with, and knowledge of ARCA&#146;s
business, having been on the Board of ARCA Colorado since 2006, and on the Board and a Committee member of the Company since January 2009. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Burton E. Sobel, M.D. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Sobel, age 74 has served as a member of the Company&#146;s Board of Directors since the merger with Nuvelo and as a member of
Nuvelo&#146;s Board of Directors since September 2004. Since June 2005, Dr.&nbsp;Sobel has served as Professor of Medicine and Biochemistry at the University of Vermont and Fletcher Allen Health Care, where he formerly served as Chair of the
Department of Medicine from 1994 to June 2005. Dr.&nbsp;Sobel served as Senior Counsel to the Executive Dean of the University of Vermont College of Medicine and to the Executive Vice President of Fletcher Allen Health Care from 1996 to 1998. From
1994 to 1996, Dr.&nbsp;Sobel served as Professor of Medicine at Washington University in St. Louis, Missouri. In the last five years, Dr.&nbsp;Sobel has also served on the Boards of Directors of Ariad Pharmaceuticals, Inc., Clinical Data, Inc., New
River Pharmaceuticals, Inc. and Intrexon, Inc. Dr.&nbsp;Sobel received his M.D. from the Harvard Medical School, magna cum laude, and his A.B. from Cornell University. Dr.&nbsp;Sobel is an appropriate member of the Company&#146;s Board of Directors,
given his medical training, his background in cardiovascular research, and his experience in cardiovascular drug development. Dr.&nbsp;Sobel also has extensive experience with, and knowledge of ARCA&#146;s business, having been on the Board and
Committees of Nuvelo, Inc. prior to the merger, and on the Board and Committees of the Company since January 2009. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL> O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL> 2013
A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Linda Grais, M.D. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Grais, age 55, has served as a member of the Company&#146;s Board of Directors since the merger with Nuvelo in January 2009.
Before the merger, Dr.&nbsp;Grais had served as a director of ARCA Colorado since May 2007. Dr.&nbsp;Grais served as a Managing Member at InterWest Partners, a venture capital firm from May 2005 until February 2011. From July 1998 to July 2003,
Dr.&nbsp;Grais was a founder and executive vice president of SGX </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich&nbsp;&amp; Rosati, where she practiced
in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr.&nbsp;Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco.
Dr.&nbsp;Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. Dr.&nbsp;Grais is an appropriate nominee to the Company&#146;s Board of Directors because
of her diverse training and experience as both a medical doctor and a lawyer, her experience as a founder and senior executive of a pharmaceutical company, and her experience as an investor in new life sciences companies. She also has extensive
experience with and knowledge of the Company&#146;s business from her service on the Board of ARCA Colorado since 2007, and her service as a Board and Committee member for the Company since January 2009. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>John L. Zabriskie, Ph.D. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Zabriskie, age 72, has served as a member of the Company&#146;s Board of Directors since the merger with Nuvelo in January 2009.
Before the merger, Dr.&nbsp;Zabriskie had served as a director of ARCA Colorado since March 2005. Dr.&nbsp;Zabriskie is Co-Founder and Director of PureTech Ventures, LLC, a firm that co-founds life science companies, and the past Chairman of the
Board, Chief Executive Officer, and President of NEN Life Science Products, Inc., a supplier of kits for labeling and detection of DNA. Prior to joining NEN Life Science Products in July 1997, Dr.&nbsp;Zabriskie was President and Chief Executive
Officer of Pharmacia and Upjohn Inc. Prior to joining Upjohn in 1994, Dr.&nbsp;Zabriskie was Executive Vice President for Merck&nbsp;&amp; Co., Inc. He currently serves on the Board of Directors of Array BioPharma Inc., Kellogg Co. and Puretech
Ventures. As part of a member of the Board of Directors for Kellogg Co., Dr.&nbsp;Zabriskie has served on the audit committee for the past ten years. Within the past five years, Dr.&nbsp;Zabriskie has also served on the Board of Directors of Momenta
Pharmaceuticals, Inc. and MacroChem Corporation. Dr.&nbsp;Zabriskie received his undergraduate degree in chemistry from Dartmouth College and his Ph.D. in organic chemistry from the University of Rochester. Dr.&nbsp;Zabriskie is an appropriate
nominee to the Company&#146;s Board of Directors due to his extensive experience in the pharmaceutical industry, including senior management experience up to the level of president and chief executive officer of significant public companies, as well
as his experience on the boards of directors of public companies, including service on audit committees. Dr.&nbsp;Zabriskie also has extensive experience with and knowledge of the Company&#146;s business from his service on the Board of ARCA
Colorado since 2005, his service as a Board member and Chairman of the Audit Committee of the Company since January 2009, and his service as a member of the Compensation Committee since March 2011. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL> O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL> 2014
A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Richard B. Brewer </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Brewer, age 61, has served as a director since the merger with Nuvelo and currently serves as the Company&#146;s Chairman of the
Board of Directors. Mr.&nbsp;Brewer also served as the Company&#146;s President and Chief Executive Officer from the date of the merger with Nuvelo until July 2009. Mr.&nbsp;Brewer also served as the President and Chief Executive Officer and a
director of ARCA Colorado from November 2006 until the merger. Prior to joining ARCA Colorado, from January 2003, Mr.&nbsp;Brewer was Managing Partner of Crest Asset Management, a management advisory and investment firm, where he provided guidance
to and invested in biotechnology opportunities. Before that, Mr.&nbsp;Brewer was President and Chief Executive Officer of Scios, Inc, a biopharmaceutical company. Before Scios, Mr.&nbsp;Brewer served as Chief Operating Officer of Heartport, a
cardiovascular device company developing minimally invasive approaches to major heart surgery. Prior to that, he spent over a decade at Genentech in various management positions, including Senior Vice President of Sales and Marketing and Senior Vice
President of Genentech Europe and Canada. Mr.&nbsp;Brewer was appointed Executive Chairman of the Board of Directors of Nile Therapeutics on July&nbsp;21, 2010. Mr.&nbsp;Brewer also currently serves as a director of Dendreon Corporation and SRI
International, an independent, non-profit research group. Mr.&nbsp;Brewer holds a B.S. from Virginia Polytechnic Institute and an M.B.A. from Northwestern University. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Mr.&nbsp;Brewer is an appropriate member of the Company&#146;s Board of Directors, given his extensive experience in the biotechnology and pharmaceutical industries, including
cardiovascular-focused companies, and including senior management experience up to the level of president and chief executive officer of a public, cardiovascular-focused, pharmaceutical company. Mr.&nbsp;Brewer also has extensive experience with,
and knowledge of ARCA&#146;s business, as the former President and Chief Executive Officer of both ARCA and ARCA Colorado, and as a Board member of ARCA Colorado since 2006, of the Company since January 2009, and as its current Chairman. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Michael R. Bristow, M.D., Ph.D. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Bristow, age 67, has served as the Company&#146;s President and Chief Executive Officer since July 2009. Prior to that time, Dr.&nbsp;Bristow served as the Company&#146;s Chief Science and
Medical Officer and a director since the merger with Nuvelo. Dr.&nbsp;Bristow has also served as a director of ARCA Colorado since November 2006. Dr.&nbsp;Bristow was one of the founders of ARCA Colorado in September 2004, and served as its Chairman
and Chief Executive Officer from that date until he was appointed to the position of Chief Science and Medical Officer in November 2006. Dr.&nbsp;Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado
Health Sciences Center, where he has been since October 1991. Dr.&nbsp;Bristow was one of the founders of Myogen, Inc., a cardiovascular therapeutics company, and served as Myogen&#146;s Chief Science and Medical Officer from October 1996 to
February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr.&nbsp;Bristow is an appropriate member of the Company&#146;s Board of Directors given his extensive
experience and expertise as a cardiologist, medical researcher and drug developer in the field of cardiovascular medicine, and heart failure specifically, and his experience as a founder and manager of a cardiovascular-focused, public pharmaceutical
company. Dr.&nbsp;Bristow also has extensive experience with and knowledge of ARCA&#146;s business, as the founder and former Chief Science and Medical Officer of ARCA Colorado, and the current President and Chief Executive Officer of ARCA, and as a
Board member of ARCA Colorado since 2005, and of the Company since January 2009. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><SMALL>INFORMATION</SMALL>
<SMALL>REGARDING</SMALL> <SMALL>THE</SMALL> <SMALL>BOARD</SMALL> <SMALL>OF</SMALL> <SMALL>DIRECTORS</SMALL> <SMALL>AND</SMALL> <SMALL>CORPORATE</SMALL> <SMALL>GOVERNANCE</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>I<SMALL>NDEPENDENCE</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As required under the NASDAQ Stock Market (&#147;NASDAQ&#148;) listing standards, a majority of the members of a listed company&#146;s
Board of Directors must qualify as &#147;independent,&#148; as affirmatively determined by the Board of Directors. The Board consults with the Company&#146;s counsel to ensure that the Board&#146;s determinations are consistent with relevant
securities and other laws and regulations regarding the definition of &#147;independent,&#148; including those set forth in pertinent listing standards of the NASDAQ, as in effect from time to time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any
of his or her family members, and the Company, its senior management and its independent auditors, the Board has affirmatively determined that the following four directors are independent directors within the meaning of the applicable NASDAQ listing
standards: Dr.&nbsp;Formela, Dr.&nbsp;Grais, Dr.&nbsp;Sobel and Dr.&nbsp;Zabriskie. In making this determination, the Board found that none of the these directors or nominees for director had a material or other disqualifying relationship with the
Company. Dr.&nbsp;Bristow, the Company&#146;s President and Chief Executive Officer and Mr.&nbsp;Brewer, the Company&#146;s former President and Chief Executive Officer are not independent directors by virtue of their relationship or former
relationship with the Company.<B> </B> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B<SMALL>OARD</SMALL> L<SMALL>EADERSHIP</SMALL> S<SMALL>TRUCTURE</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Board of Directors is currently chaired by Mr.&nbsp;Richard Brewer. The Board has also appointed Dr.&nbsp;Linda Grais
as Lead Independent Director. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company separates the roles of CEO and Chairman of the Board in recognition of the
differences between the two roles. The Company believes that the CEO should be responsible for the day to day leadership </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and performance of the Company, while the Chairman of the Board should set the strategic direction and provide guidance to the CEO. The Chairman also sets the agenda for Board meetings and
presides over them. Mr.&nbsp;Brewer is the Company&#146;s former Chief Executive Officer and is uniquely positioned to understand the detailed operations of the Company as well as provide the leadership to help to develop strategy. As CEO,
Dr.&nbsp;Bristow is then able to implement the strategic initiatives and business plans approved by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because
Mr.&nbsp;Brewer, the Chairman, is not &#147;independent,&#148; the Board appointed Dr.&nbsp;Linda Grais as Lead Independent Director to help reinforce the independence of the Board as a whole. The position of Lead Independent Director has been
structured to serve as an effective balance to the Chief Executive Officer and Board Chair. The Lead Independent Director is empowered to coordinate the activities of the other independent directors and perform such other duties and responsibilities
as the Board may determine, including: scheduling and presiding over regular meetings of the independent directors; serving as principal liaison between the Chairman of the Board and the independent directors; providing the Chairman with input as to
the preparation of the agendas for Board; providing the Chairman with input as to the information submitted by the Company&#146;s management in order for the independent directors to perform their duties; making recommendations to the Board on
behalf of the independent directors; and undertaking such further responsibilities that the independent directors as a whole may designate to the Lead Independent Director from time to time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the Company believes that the Lead Independent Director can effectively coordinate between the Board and management with
regard to the determination and implementation of responses to any problematic risk management issues. As a result, the Company believes that the Lead Independent Director can help ensure the effective independent functioning of the Board in its
oversight responsibilities. In addition, the Company believes that the Lead Independent Director is well positioned to build a consensus among directors and to serve as a conduit between the other independent directors and the Board Chair, for
example, by facilitating the inclusion on meeting agendas of matters of concern to the independent directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>R<SMALL>OLE</SMALL>
<SMALL>OF</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>IN</SMALL> R<SMALL>ISK</SMALL> O<SMALL>VERSIGHT</SMALL> <SMALL>AND</SMALL> R<SMALL>ISK</SMALL> M<SMALL>ANAGEMENT</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">One of the Board&#146;s key functions is informed oversight of the Company&#146;s risk management process. The Board does not have a
standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. In
particular, while the Board is responsible for monitoring and assessing strategic risk exposure, the audit committee has the responsibility to consider and discuss the major financial risk exposures and the steps management has taken to monitor and
control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements, in addition to oversight of
the performance of ARCA&#146;s accounting and financial reporting processes. The nominating and corporate governance committee monitors the effectiveness of the corporate governance guidelines, including whether they are successful in preventing
illegal or improper liability-creating conduct. The compensation committee assesses and monitors whether any compensation policies and programs have the potential to encourage excessive risk-taking. The entire Board and its Committees address risk
management issues from time-to-time and at least annually meet with the employees responsible for risk management in the committees&#146; respective areas of oversight. Both the Board as a whole and the various standing committees receive periodic
reports from the employees responsible for risk management, as well as incidental reports as matters may arise. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the Board as quickly as
possible. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>EETINGS</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors met nine times during the 2011 fiscal year. Each Board member attended 75% or more of the aggregate
number of meetings of the Board and of the committees on which s/he served, held during the portion of the last fiscal year for which s/he was a director or committee member. The independent members of the Board met separately as a group in
connection with each of the four regularly scheduled meetings in 2011. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I<SMALL>NFORMATION</SMALL> R<SMALL>EGARDING</SMALL> C<SMALL>OMMITTEES</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board has three standing
committees: an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for fiscal year 2011, for each of the Board committees: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:19pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Name</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Audit</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Compensation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Nominating&nbsp;and<BR>Corporate<BR>Governance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Michael Bristow</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Richard Brewer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Jean-Fran&ccedil;ois Formela</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Burton&nbsp;E. Sobel**</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;John&nbsp;L. Zabriskie***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Linda Grais****</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total meetings in fiscal 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current Committee Chairperson </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective May&nbsp;20, 2011, Dr.&nbsp;Sobel was elected to serve as chair of the Nomination and Corporate Governance Committee Chairperson </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective March&nbsp;29, 2011, Dr.&nbsp;Zabriskie was elected to serve on the Compensation Committee. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">****</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective March, 29, 2011, Dr.&nbsp;Grais was elected to serve as Compensation Committee Chairperson. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Below is a description of each committee of the Board of Directors. Each of the committees has authority to engage legal counsel or other
experts or consultants, as it deems appropriate to carry out its responsibilities. The Board of Directors has determined that each member of each committee meets the applicable NASDAQ rules and regulations regarding &#147;independence&#148; and that
each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Audit Committee of the Board of Directors was established by the Board in accordance with Section&nbsp;3(a)(58)(A) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), to oversee the Company&#146;s corporate accounting
and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent auditors;
determines and approves the engagement of the independent auditors; determines whether to retain or terminate the existing independent auditors or to appoint and engage new independent auditors; reviews and approves the retention of the independent
auditors to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent auditors on the Company&#146;s audit engagement team as required by law; reviews and approves or rejects transactions between the
company and any related persons; confers with management and the independent auditors regarding the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and
treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and
meets to review the Company&#146;s annual audited financial statements and quarterly financial statements with management and the independent auditor, including a review of the Company&#146;s disclosures under &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations.&#148; The Audit Committee is composed of three directors: Dr.&nbsp;Zabriskie (chair), Dr.&nbsp;Grais, and Dr.&nbsp;Sobel. The Audit Committee met four times during the fiscal year. The Audit
Committee has adopted a written charter that is available to stockholders on the Company&#146;s website at www.arcabiopharma.com. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors reviews the NASDAQ listing standards definition
of independence for Audit Committee members on an annual basis and has determined that all members of the Company&#146;s Audit Committee are independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii)&nbsp;of the NASDAQ
listing standards). The Board of Directors has also determined that Dr.&nbsp;Zabriskie qualifies as an &#147;audit committee financial expert,&#148; as defined in applicable SEC rules.<B> </B>The Board made a qualitative assessment of
Dr.&nbsp;Zabriskie&#146;s level of knowledge and experience based on a number of factors, including his prior experience, business acumen and independence. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Report of the Audit Committee of the Board of Directors<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> </FONT></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee has reviewed and discussed the audited financial
statements for the fiscal year ended December&nbsp;31, 2011 with management of the Company. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by Statement on Auditing
Standards No.&nbsp;61, as amended (AICPA, <I>Professional Standards</I>, Vol. 1, AU section 380), as adopted by the Public Company Accounting Oversight Board (&#147;PCAOB&#148;) in Rule 3200T. The Audit Committee has also received the written
disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants&#146; communications with the audit committee concerning independence, and has
discussed with the independent registered public accounting firm the accounting firm&#146;s independence. Based on the foregoing, the Audit Committee has recommended to the Board of Directors that the audited financial statements be included in the
Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;John
Zabriskie </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Burton Sobel </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Linda Grais </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee is composed of three
directors: Dr.&nbsp;Linda Grais (chair), Dr.&nbsp;Jean-Fran&ccedil;ois Formela, and Dr.&nbsp;John Zabriskie. All members of the Compensation Committee are independent, as independence is currently defined in Rule 5605(a)(2) of the NASDAQ listing
standards. The Compensation Committee met four times during the fiscal year. The Compensation Committee has adopted a written charter that is available to stockholders on the Company&#146;s website at www.arcabiopharma.com. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee of the Board of Directors acts on behalf of the Board to review, adopt and oversee the Company&#146;s
compensation strategy, policies, plans and programs, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overseeing succession planning for senior management of the Company, including a review of the performance and advancement potential of current and
future senior management and succession plans for each and recommending, as appropriate, the retention of potential succession candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assessing the overall compensation structure of the Company and evaluating and recommending changes to the Company&#146;s compensation philosophies and
strategies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and approving performance-based compensation plans or programs, including establishing goals and targets, applicable to the Chief Executive
Officer and other members of the management team; </FONT></P></TD></TR></TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The material in this report is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the Commission and is not to be incorporated
by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">administering, reviewing, and approving all executive compensation programs or plans, and all of the Company&#146;s incentive compensation and stock
plans and awards thereunder of the Company, including amendments to the programs, plans or awards made thereunder; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preparing and discussing with the Company&#146;s management the Compensation Discussion and Analysis, or the CD&amp;A, if required to be included in
the Company&#146;s annual meeting proxy statement and recommending to the Board that the CD&amp;A be included in the annual meeting proxy statement, to the extent required; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">preparing and approving the Report of the Compensation Committee to be included as part of the Company&#146;s annual meeting proxy statement, to the
extent required. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Compensation Committee Processes and Procedures </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Typically, the Compensation Committee meets on a regular basis as it deems appropriate. The agenda for each meeting is usually developed
by the Chair of the Compensation Committee.<B> </B>The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be
invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be
present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The Compensation Committee has the sole authority to retain compensation consultants to assist in its
evaluation of executive and director compensation, including the authority to approve the consultant&#146;s reasonable fees and other retention terms. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In early 2009, the Compensation Committee retained the services of a compensation consultant, Compensia, to assist the Compensation Committee in assessing ARCA&#146;s equity and cash compensation to all
employees. In February 2009, the Company&#146;s Board of Directors and Compensation Committee completed a review of the Company&#146;s executive compensation in light of general market conditions in the life science industry and the completion of
the merger with Nuvelo, pursuant to which the management of ARCA became the management of the Company. Compensia assisted in this review. As part of this review process, Compensia identified a peer group of pre-revenue generating biotechnology
companies that had become public companies prior to the middle of 2006. This peer group included Acadia Pharmaceuticals, Alexza Pharmaceuticals, Allos Therapeutics, Array Biopharma, Cytokinetics, Cytori Therapeutics, Dendreon, Geron, Incyte,
Intermune, Neurocrin Biosciences and Pain Therapeutics. No other services were retained from compensation consultants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In setting 2009 base salary and cash bonus award amounts for the ARCA Named Executive Officers, the Compensation Committee analyzed the peer group data and targeted cash compensation in the 50</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> percentile of cash compensation paid to similarly situated executive
officers within the peer group. In 2010, the Compensation Committee reassessed these salary determinations in light of the Company&#146;s financial condition and current market conditions, and adjusted these salaries accordingly. The Board
recommended and approved no increases in salaries for executive officers for the fiscal year 2010, except for an increase in salary for the Chief Financial Officer. In early 2011, the Board recommended and approved three percent increases to
executive officer salaries for the fiscal year 2011. In early 2012, the Compensation Committee determined not to increase executive salaries in light of Company financial status and uncertainty regarding the timing or nature of Company financing
activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historically, the Compensation Committee has made most of the significant adjustments to annual compensation,
determined bonus and equity awards and established new performance objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as
compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of the Company&#146;s compensation strategy, potential modifications to that strategy and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&#146;s process comprises two related elements: the determination of
compensation levels and the establishment of performance objectives for the current year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Committee reviews and approves
the compensation of the Chief Executive Officer and the other executive officers of the Company, including annual base salaries, annual and long-term incentive or bonus awards, employment agreements, and severance and change in control
agreements/provisions, in each case as, when and if appropriate, and any special or supplemental benefits. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations
submitted to the Committee by the Chief Executive Officer. The Committee evaluates the performance of the Chief Executive Officer in light of Company and individual goals and objectives, and makes appropriate recommendations for improving
performance. In performing the evaluation, the Chair of the Committee may solicit comments from the other non-employee members of the Board and lead the Board in an overall review of the Chief Executive Officer&#146;s performance in an executive
session of non-employee Board members. If the compensation for the Chief Executive Officer or any other executive officer is governed by an employment agreement, the Committee approves such employment agreement and any amendments thereto.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For all executives as part of its deliberations, the Compensation Committee may review and consider, as appropriate,
materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director
stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Nominating and Corporate Governance Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Nominating and Corporate
Governance Committee of the Board of Directors is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent directors,
recommending to the Board candidates for election to the Board of Directors, making recommendations to the Board regarding compensation for Board and Committee service, making recommendations to the Board regarding the membership of the committees
of the Board, assessing the performance of the Board and developing a set of corporate governance principles for the Company. The Nominating and Corporate Governance Committee is composed of two directors: Dr.&nbsp;Sobel (Chair), and Dr.&nbsp;Grais.
All members of the Nominating and Corporate Governance Committee are independent (as independence is currently defined in Rule 5605(a)(2) of the NASDAQ listing standards). The Nominating and Corporate Governance Committee met four times during the
fiscal year. The Nominating and Corporate Governance Committee has adopted a written charter that is available to stockholders on the Company&#146;s website and www.arcabiopharma.com. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board has adopted a process for identifying and evaluating director nominees, including stockholder nominees. Before recommending an
individual to the Board for Board membership, the Nominating and Corporate Governance Committee canvasses its members and the Company&#146;s management team for potential members of the Board of Directors. The Nominating and Corporate Governance
Committee will consider stockholders&#146; recommendations for nominees to serve as director if notice is timely received by the Secretary of the Company. Candidates nominated by stockholders will be evaluated in the same manner as other candidates.
The Nominating and Corporate Governance Committee keeps the Board regularly apprised of its discussions with potential nominees, and the names of potential nominees received from its current directors, management, and stockholders, if the
stockholder notice of nomination is timely made. Although the Board has not adopted a fixed set of minimum qualifications for candidates for Board membership, the Nominating and Corporate Governance Committee generally considers several factors in
its evaluation of each potential member, such as the potential member&#146;s area of expertise, education, and professional background, experience in corporate governance, the reasonable availability of the potential member to devote time to the
affairs of the Company, as well as any other criteria deemed relevant by the Board or the Nominating and Corporate Governance </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Committee. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the
context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity,
age, skills and such other factors as it deems appropriate given the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability. The Nominating and Corporate Governance Committee believes it is
essential that Board members come from a variety of backgrounds and experiences. In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#146; overall
service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors&#146; independence. In the case of new
director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for NASDAQ purposes, which determination is based upon applicable NASDAQ listing standards, applicable SEC rules and
regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee then uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search
firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating and
Corporate Governance Committee meets to discuss and consider the candidates&#146; qualifications and then selects a nominee for recommendation to the Board by majority vote. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board of Directors may do so by delivering a
written recommendation to the Nominating and Corporate Governance Committee addressed to the Corporate Secretary, between 60 and 90 days before the anniversary date of ARCA&#146;s last Annual Meeting of Stockholders. Recommendations must include the
full name of the proposed nominee, a description of the proposed nominee&#146;s business experience for at least the previous five years, complete biographical information, a description of the proposed nominee&#146;s qualifications as a director,
and a representation that the recommending stockholder is a beneficial or record owner of ARCA&#146;s stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director
if elected. To date, the Nominating and Corporate Governance Committee has not rejected a timely director nominee from a stockholder or stockholders holding more than 5% of the Company&#146;s voting stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2011, the Nominating and Corporate Governance Committee did not pay any fees to anyone to assist in the process of identifying or
evaluating director candidates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>TOCKHOLDER</SMALL> C<SMALL>OMMUNICATIONS</SMALL> W<SMALL>ITH</SMALL> T<SMALL>HE</SMALL>
B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Board has adopted a formal process by
which stockholders may communicate with the Board or any of its directors. Stockholders who wish to communicate with the Board may do so by mail or e-mail as specifically set forth on ARCA&#146;s website at www.arcabiopharma.com, under the section
titled, &#147;Investors&#148; and the subsection titled &#147;Corporate Governance&#148;. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ODE</SMALL> <SMALL>OF</SMALL>
E<SMALL>THICS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has adopted the ARCA biopharma, Inc. Code of Business Conduct and Ethics that applies to
all officers, directors and employees. The Code of Business Conduct and Ethics is available on the Company&#146;s website at www.arcabiopharma.com. If the Company makes any substantive amendments to the Code of Business Conduct and Ethics or grants
any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver on its website and file any current report on Form 8-K required by
applicable law or NASDAQ listing standards. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ROPOSAL</SMALL> 2 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>R<SMALL>ATIFICATION</SMALL> <SMALL>OF</SMALL> S<SMALL>ELECTION</SMALL> <SMALL>OF</SMALL> I<SMALL>NDEPENDENT</SMALL>
A<SMALL>UDITORS</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee of the Board of Directors has selected KPMG LLP as the Company&#146;s
independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2012 and has further directed that management submit the selection of independent registered public accounting firm for ratification by the stockholders at
the Annual Meeting. KPMG audited the Company&#146;s 2009, 2010 and 2011 fiscal year financial statements as well. Representatives of KPMG are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so
desire and will be available to respond to appropriate questions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither the Company&#146;s Bylaws nor other governing
documents or law require stockholder ratification of the selection of KPMG as the Company&#146;s independent registered public accounting firm. However, the Board is submitting the selection of KPMG to the stockholders for ratification as a matter
of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee of the Board will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee of the Board in its discretion
may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in the best interests of the Company and its stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote at the
Annual Meeting will be required to ratify the selection of KPMG LLP. Broker non-votes are counted towards a quorum, but are not counted for any purpose in determining whether this matter has been approved. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>RINCIPAL</SMALL> A<SMALL>CCOUNTANT</SMALL> F<SMALL>EES</SMALL> <SMALL>AND</SMALL> S<SMALL>ERVICES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table represents aggregate fees billed, or expected to be billed, to the Company for the fiscal year ended December&nbsp;31,
2011 and December&nbsp;31, 2010 by KPMG, the Company&#146;s independent registered public accounting firm. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year<BR>Ended&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year<BR>Ended&nbsp;2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Fees (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">134,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit-related Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax Fees (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All Other Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">189,259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">166,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Fees include fees for the (i)&nbsp;audit of the consolidated financial statements included in our Form 10-K for our fiscal years ended December&nbsp;31, 2010 and
December&nbsp;31, 2011, (ii)&nbsp;review of interim consolidated financial statements included on Forms 10-Q and (iii)&nbsp;attest, consent and review services normally provided by the accountant in connection with SEC filings.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax fees include fees for services rendered for tax compliance, tax advice and tax planning. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All fees described above were approved by the Audit Committee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>RE</SMALL>-A<SMALL>PPROVAL</SMALL> P<SMALL>OLICIES</SMALL> <SMALL>AND</SMALL> P<SMALL>ROCEDURES</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The above services performed by the independent registered public accounting firm were pre-approved in accordance with the pre-approval policy and procedures adopted by the Audit Committee. This policy
describes the permitted audit, audit-related, tax, and other services that the independent registered public accounting firm may perform. The policy also requires that the independent registered public accounting firm provide in writing: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual description of all relationships between the auditor and the client that may reasonably be thought to bear on independence;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirm that, in the auditor&#146;s professional judgment, the auditor is independent of the client under SEC requirements;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discuss with the Audit Committee the auditor&#146;s independence and the potential effects on its independence of performing any non-audit related
services. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The services expected to be performed by the independent registered public accounting firm during
the subsequent fiscal year are presented to the Audit Committee for pre-approval. Any pre-approval describes in writing the particular service or category of services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Requests for audit, audit-related, tax, and other services not contemplated by those pre-approved services must be submitted to the Audit Committee for specific pre-approval. Generally, pre-approval is
considered at the Audit Committee&#146;s regularly scheduled meetings. However, the authority to grant specific pre-approval between meetings, as necessary, has been delegated to the chairman of the Audit Committee. In the event that the chairman is
not available, the other two Audit Committee members together have the authority to grant specific pre-approval between meetings. The chairman or the other two members must update the Audit Committee at the next regularly scheduled meeting of any
services that were granted specific pre-approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The report of independent registered public accountant, KPMG, on the
consolidated financial statements of the Company for the year ended December&nbsp;31, 2011, included in the Form 10-K filed with the SEC on March&nbsp;27, 2012 states that the Company&#146;s recurring losses from operations, dependence upon raising
additional funds from strategic transactions, sales of equity, and/or issuance of debt, and the uncertainty surrounding the Company&#146;s ability to consummate such transactions, raise substantial doubt about the Company&#146;s ability to continue
as a going concern. KPMG&#146;s report on the financial statements for the past two years contained no adverse opinion or disclaimer of opinion and was not qualified as to audit scope or accounting principles. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 2. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>ECURITY</SMALL> O<SMALL>WNERSHIP</SMALL> <SMALL>OF</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ERTAIN</SMALL> B<SMALL>ENEFICIAL</SMALL> O<SMALL>WNERS</SMALL> <SMALL>AND</SMALL> M<SMALL>ANAGEMENT</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth certain information regarding the ownership of the Company&#146;s common stock as of March&nbsp;26, 2012
by: (i)&nbsp;each director and nominee for director; (ii)&nbsp;each of the executive officers named in the Summary Compensation Table; (iii)&nbsp;all executive officers and directors of the Company as a group; and (iv)&nbsp;all those known by the
Company to be beneficial owners of more than five percent of its common stock. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Beneficial&nbsp;Ownership&nbsp;(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:70pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Beneficial Owner (1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent&nbsp;of<BR>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Directors and Named Executive Officers</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael R. Bristow, M.D., Ph.D. (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">322,944</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard B. Brewer (5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">278,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jean-Francois Formela, M.D. (6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,353,279</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Linda Grais, M.D. (7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Burton Sobel, M.D. (8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John L. Zabriskie, Ph.D. (9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>All current directors and executive officers as a group (8 persons)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,171,541</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17.2</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>%&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5% Stockholders</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Atlas Venture Fund VII, L.P. (10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,337,612</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Represents beneficial ownership of less than 1% of our common stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act and generally includes voting or investment power with respect to securities.
Applicable percentages are based on 12,182,999 shares outstanding on March&nbsp;26, 2012. Shares of common stock subject to options and warrants which are currently exercisable, or will become exercisable within 60 days of March&nbsp;26, 2012, are
deemed outstanding for computing the percentage of the person or entity holding such securities but are not outstanding for computing the percentage of any other person or entity. Except as indicated by footnote, and subject to the community
property laws where applicable, to our knowledge the persons named in the table above have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. Unless otherwise indicated, the address for
each person is our address at 8001&nbsp;Arista Place, Suite 430, Broomfield, CO 80021. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes options to purchase 42,873 shares that are exercisable within 60 days of March&nbsp;26, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes options to purchase 61,811 shares that are exercisable within 60 days of March&nbsp;26, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes options to purchase 11,466 shares that are exercisable within 60 days of March&nbsp;26, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes options to purchase 194,684 shares that are exercisable within 60 days of March&nbsp;26, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes the following owned directly by Atlas Venture Fund VII, L.P. (&#147;AV VII&#148;): (a)&nbsp;1,262,163 shares and (b)&nbsp;75,449 shares issuable upon exercise
of a warrant, which warrant is immediately exercisable. Atlas Venture Associates VII, L.P. (&#147;AVA VII LP&#148;) is the general partner of AV VII. Atlas Venture Associates VII, Inc (&#147;AVA VII Inc.&#148;) is the general partner of AVA VII LP.
Each AVA VII LP and AVA VII Inc., may also be deemed to beneficially own these shares. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Formela, a
director at AV VII Inc., and one of the Company&#146;s directors may be deemed to beneficially own these shares. Dr.&nbsp;Formela disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Each of AV VII,
AVA VII LP and AVA VII Inc. disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein. Also includes options to purchase 15,667 shares that are exercisable within 60 days of March&nbsp;26, 2012. These
options were granted to Dr.&nbsp;Formela and the proceeds of any sale of the Company&#146;s common stock issued to Dr.&nbsp;Formela upon the exercise of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
this option will be transferred to Atlas Venture Advisors, Inc. (&#147;Atlas Advisors&#148;) and therefore Dr.&nbsp;Formela disclaims beneficial ownership of such shares which belong to Atlas
Advisors. The address for Dr.&nbsp;Formela is 25 First Street, Suite 303, Cambridge, MA 02141. </FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes options to purchase 15,667 shares that are exercisable within 60 days of March&nbsp;26, 2012. As of February 2011, Dr.&nbsp;Grais no longer has voting or
investment control over the shares held by Interwest Partners IX, LP. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes options to purchase 18,542 shares that are exercisable within 60 days of March&nbsp;26, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (a)&nbsp;options to purchase 35,382 shares that are exercisable within 60 days of March&nbsp;26, 2012, and (b)&nbsp;29,180 shares owned directly by Lansing
Brown Investments, LLC. Dr.&nbsp;Zabriskie, one of the Company&#146;s directors, is the President of Lansing Brown Investments, LLC. Dr.&nbsp;Zabriskie has shared voting and dispositive powers over the shares held by Lansing Brown Investments, LLC.
He disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the following owned directly by Atlas Venture Fund VII, L.P., or AV VII, (a)&nbsp;1,262,163 shares and (b)&nbsp;75,449 shares issuable upon exercise of a
warrant, which warrant is immediately exercisable. AVA VII LP is the general partner of AVA VII. AV VII Inc. is the general partner of AVA VII LP. Each of AV VII, AVA VII LP, and AVA VII Inc. disclaims beneficial ownership of the shares except to
the extent of its pecuniary interest therein. The address for Atlas Venture Fund VII, L.P. is 25 First Street, Suite 303, Cambridge, MA 02141. </FONT></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>ECTION</SMALL>&nbsp;16(<SMALL>A</SMALL>) B<SMALL>ENEFICIAL</SMALL> O<SMALL>WNERSHIP</SMALL> R<SMALL>EPORTING</SMALL> C<SMALL>OMPLIANCE</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;16(a) of the Exchange Act requires the Company&#146;s directors and executive officers, and persons who own more than ten
percent of a registered class of the Company&#146;s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company. Officers, directors and greater
than ten percent stockholders are required by SEC regulation to furnish the Company with copies of all Section&nbsp;16(a) forms they file. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To the Company&#146;s knowledge, based solely on a review of the copies of such reports furnished to the Company and written representations that no other reports were required, during the fiscal year
ended December&nbsp;31, 2011, all Section&nbsp;16(a) filing requirements applicable to its officers, directors and greater than ten percent beneficial owners were complied with. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XECUTIVE</SMALL> O<SMALL>FFICERS</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Set forth below is information regarding each of the executive officers as of March&nbsp;28, 2012. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="60%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael R. Bristow, M.D., Ph.D.*</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary, Senior Vice President and General Counsel</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">*</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also serves as a director. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Michael R. Bristow, M.D., Ph.D.</I> Dr.&nbsp;Bristow&#146;s biography is included under &#147;Directors Continuing in Office Until the 2014 Annual Meeting&#148; above. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Patrick M. Wheeler</I>. Mr.&nbsp;Wheeler has served as the Company&#146;s Chief Financial Officer since May&nbsp;21, 2010. Previously,
he held the position of Acting Chief Financial Officer since December&nbsp;7, 2009, and he held the position of Senior Vice President, Finance of the Company since the merger with Nuvelo. Mr.&nbsp;Wheeler joined
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ARCA Colorado in July 2006 as Vice President, Finance and held the position of Senior Vice President, Finance from February 2008 until the completion of the merger. Prior to his time with ARCA
Colorado, he served as Director of Finance for Dharmacon, Inc., a Fisher Scientific, Inc. life science company, from June 2003 to July 2006. Mr.&nbsp;Wheeler has a B.A. in economics from the University of Colorado and an M.B.A. from Regis
University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Christopher D. Ozeroff</I>. Mr.&nbsp;Ozeroff has served as the Company&#146;s Senior Vice President since
December 2009. Additionally, Mr.&nbsp;Ozeroff has served as the Company&#146;s General Counsel and Secretary since January, 2009. Previously, Mr.&nbsp;Ozeroff served as the Company&#146;s Executive Vice President of Business Development, General
Counsel and Secretary since the merger. Before the merger, Mr.&nbsp;Ozeroff was one of the founders of ARCA Colorado in September 2004, and had served as its Executive Vice President of Business Development, General Counsel and Secretary since that
date. From August 1999, Mr.&nbsp;Ozeroff was previously a partner with the law firm of Hogan&nbsp;&amp; Hartson L.L.P., where he practiced in such areas as finance, acquisitions, public offerings, and licensing. Mr.&nbsp;Ozeroff completed his
undergraduate degree at Stanford University and his law degree at the University of Chicago Law School. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XECUTIVE</SMALL> C<SMALL>OMPENSATION</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows for the fiscal years ended December&nbsp;31, 2010 and December&nbsp;31, 2011, compensation awarded to, paid to,
or earned by the Company&#146;s principal executive officers and its other named executive officers as of December&nbsp;31, 2011, collectively, the Named Executive Officers: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>UMMARY</SMALL> C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> <SMALL>FOR</SMALL> F<SMALL>ISCAL</SMALL> 2011 <SMALL>AND</SMALL> 2010 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:91pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Name and Principal Position</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Year</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Salary&nbsp;($)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Option<BR>Awards<BR>($) (1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">All Other<BR>Compensation&nbsp;($)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Total ($)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael R. Bristow,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">272,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,756</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">338,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">265,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">308,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">221,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,504</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,853</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">266,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">215,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,965</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">236,180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff,</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">266,770</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,504</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,509</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">307,783</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">259,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">276,683</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reported under &#147;Option Awards&#148; in the above table reflect the grant date fair value of these awards as determined in accordance with Financial
Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation, excluding the effects of estimated forfeitures. The value of stock option awards was estimated using the Black-Scholes option-pricing
model. The valuation assumptions used in the valuation of option awards may be found in Note 11 to the Company&#146;s consolidated financial statements included in our annual report on Form 10-K for the year ended December&nbsp;31, 2011 and filed
with the SEC on March&nbsp;27, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to Dr.&nbsp;Bristow&#146;s total compensation for the fiscal year 2011, the Board has approved a $60,049 cash bonus, payable to him, if at all, upon the
Company&#146;s meeting a performance goal related to successfully completing a transaction providing financing for the Company&#146;s planned atrial fibrillation clinical trial (the &#147;AF Milestone&#148;). </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to Mr.&nbsp;Wheeler&#146;s total compensation for the fiscal year 2011, the Board has approved a $29,231 cash bonus, payable to him, if at all, upon the
Company&#146;s meeting a performance goal relating to successfully completing the AF Milestone. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to Mr.&nbsp;Ozeroff&#146;s total compensation for the fiscal year 2011, the Board has approved a $35,214 cash bonus, payable to him, if at all, upon the
Company&#146;s meeting a performance goal relating to successfully completing the AF Milestone. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Narrative Disclosure to
Summary Compensation Table </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Employment Agreements or Arrangements </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Michael R. Bristow, M.D., Ph.D.</I> Dr.&nbsp;Bristow serves as the Company&#146;s President and Chief Executive Officer under an
Employment and Retention Agreement that was amended and restated as of June&nbsp;4, 2008 and further amended pursuant to a Waiver and Amendment Agreement executed as of March&nbsp;30, 2012. Pursuant to such employment agreement, Dr.&nbsp;Bristow is
permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it does not interfere with his duties as President and Chief Executive Officer of ARCA. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Board of Directors approved 2010 base salary for Dr.&nbsp;Bristow of $265,000 and a 2011 base salary of $272,950.
Dr.&nbsp;Bristow&#146;s salary is subject to annual increases if approved by the Company&#146;s Board of Directors or Compensation Committee and he is eligible to receive an annual bonus as determined by the Board of Directors or Compensation
Committee in its sole discretion. As part of a Company-wide cost-saving measure, Dr.&nbsp;Bristow is currently being paid at the rate of 90% of his base salary. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;26, 2012, the Compensation Committee approved a 2011 cash bonus for
Dr.&nbsp;Bristow in the amount of $60,049 for partial achievement of the Company&#146;s 2011 performance goals. Specifically, the Board determined that the Company had achieved certain of its 2011 performance goals during the fiscal year 2011 by
maintaining Nasdaq listing requirements, meeting Company budget goals and by achieving certain product development goals, and had engaged in substantial efforts towards achieving the goal to advance the Company&#146;s Gencaro atrial fibrillation
regulatory approval process. However, due to the Company&#146;s limited financial resources, the Board concluded that the Company would pay cash bonuses for partial achievement of the 2011 performance goals during the 2012 fiscal year upon the
Company&#146;s completing a transaction providing financing for the Company&#146;s planned atrial fibrillation clinical trial (the &#147;<B>AF Milestone</B>&#148;). Upon achievement of the AF Milestone, Dr.&nbsp;Bristow&#146;s deferred 2011 cash
bonus will be paid. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Company terminates Dr.&nbsp;Bristow&#146;s employment without &#147;cause,&#148; or if
Dr.&nbsp;Bristow terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Dr.&nbsp;Bristow a severance payment equivalent to (i)&nbsp;12 months of his base salary
(if such termination occurs on the same day as or within thirteen months after a change of control of the Company), (ii)&nbsp;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors
payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover out-of-pocket costs to continue
group health insurance benefits under COBRA for 12 months, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses
paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12 months of base salary, which additional payment
would extend the covenants and obligations under Dr.&nbsp;Bristow&#146;s Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Dr.&nbsp;Bristow
of a legal release in a form acceptable to the Company. A termination for &#147;cause&#148; includes willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to
the Company; refusal, unwillingness, failure, or inability to perform material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of the employment agreement
or the Employee Intellectual Property, Confidentiality and Non-Compete Agreement, or any other agreement, with the Company. &#147;Good reason&#148; includes a relocation of normal work location greater than 30 miles; a decrease in current base
salary by more than 15%, with certain exceptions; and the Company&#146;s unilateral decision to significantly and detrimentally reduce Dr.&nbsp;Bristow&#146;s job responsibilities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Patrick M. Wheeler.</I> Mr.&nbsp;Wheeler serves as the Company&#146;s Chief Financial Officer under an Employment Agreement dated
February&nbsp;11, 2009, as amended pursuant to a Waiver and Amendment Agreement executed as of March&nbsp;30, 2012. Under his employment agreement, Mr.&nbsp;Wheeler is entitled to receive an annual base salary of $215,000, subject to annual
increases if approved by the Company&#146;s Board of Directors or Compensation Committee and is eligible to receive an annual bonus as determined by the Board of Directors or Compensation Committee in its sole discretion. The Company&#146;s Board of
Directors approved 2010 base salary for Mr.&nbsp;Wheeler of $215,000 and a 2011 base salary of $221,450. As part of a Company-wide cost-saving measure, Mr.&nbsp;Wheeler is currently being paid at the rate of 90% of his base salary. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;26, 2012, the Compensation Committee approved a 2011 cash bonus for Mr.&nbsp;Wheeler in the amount of $29,231 for partial
achievement of the Company&#146;s 2011 performance goals. Specifically, the Board determined that the Company had achieved certain of its 2011 performance goals during the fiscal year 2011 by maintaining Nasdaq listing requirements, meeting Company
budget goals and by achieving certain product development goals, and had engaged in substantial efforts towards achieving the goal to advance the Company&#146;s Gencaro atrial fibrillation regulatory approval process. However, due to the
Company&#146;s limited financial resources, the Board concluded that the Company would pay cash bonuses for partial achievement of the 2011 performance goals during the 2012 fiscal year upon the achievement of the AF Milestone. Upon achievement of
the AF Milestone, Mr.&nbsp;Wheeler&#146;s deferred 2011 cash bonus will be paid. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Company terminates Mr.&nbsp;Wheeler&#146;s employment without &#147;cause,&#148; or
if Mr.&nbsp;Wheeler terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Mr.&nbsp;Wheeler severance benefits that include (i)&nbsp;a payment equal to, as
applicable, (A)&nbsp;12 months of his base salary, if such termination occurs on the same day as or within thirteen months after a change of control of the Company, or (B)&nbsp;four months of his base salary, if a change of control of the Company
has not occurred as of or within thirteen months of such termination, (ii)&nbsp;a payment equal to a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the board of directors payable to him for the
fiscal year in which his employment terminated, to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&nbsp;reimbursement of out-of-pocket costs to continue group health insurance
benefits (and dependent coverage, if applicable) under COBRA for a period equivalent to that set forth in clause (i)&nbsp;above, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to
receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition the Company may elect in its sole discretion to pay
additional severance equal to up to 12 months of his base salary, which additional payment would extend certain of the covenants and obligations under Mr.&nbsp;Wheeler&#146;s Employee Intellectual Property, Confidentiality and Non-Compete Agreement
for such additional period. The severance benefits are conditioned on the execution by Mr.&nbsp;Wheeler of a legal release in a form acceptable to the Company. A termination for &#147;cause&#148; includes willful misconduct, gross negligence, theft,
fraud or other illegal or dishonest conduct, any of which are considered to be materially harmful to the Company; refusal, unwillingness, failure or inability to perform material job duties or habitual absenteeism; or violation of fiduciary duty,
violation of any duty of loyalty or material breach of any material term of the employment agreement or the Employee Intellectual Property, Confidentiality and Non-Compete Agreement, or any other agreement, with the Company. &#147;Good reason&#148;
includes a relocation of normal work location greater than 30&nbsp;miles; a decrease in current base salary by more than 15%, other than any such decrease resulting from a general reduction by the Company in the base salary of all Company executive
officers; and the Company&#146;s unilateral decision to significantly and detrimentally reduce Mr.&nbsp;Wheeler&#146;s job responsibilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Christopher D. Ozeroff.</I> Mr.&nbsp;Ozeroff serves as the Company&#146;s Senior Vice President and General Counsel under an Employment and Retention Agreement that was amended and restated as of
June&nbsp;12, 2008 and further amended pursuant to a Waiver and Amendment Agreement executed as of March&nbsp;30, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under
his employment agreement, Mr.&nbsp;Ozeroff is entitled to receive an annual base salary of $259,000, subject to annual increases if approved by the Company&#146;s Board of Directors or Compensation Committee and is eligible to receive an annual
bonus as determined by the Board of Directors or Compensation Committee in its sole discretion. The Board of Directors approved 2010 base salary for Mr.&nbsp;Ozeroff of $259,000 and a 2011 base salary of $266,770. As part of a Company-wide
cost-saving measure, Mr.&nbsp;Ozeroff is currently being paid at the rate of 90% of his base salary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;26, 2012,
the Compensation Committee approved a 2011 cash bonus for Mr.&nbsp;Ozeroff in the amount of $35,214 for partial achievement of the Company&#146;s 2011 performance goals. Specifically, the Board determined that the Company had achieved certain of its
2011 performance goals during the fiscal year 2011 by maintaining Nasdaq listing requirements, meeting Company budget goals and by achieving certain product development goals, and had engaged in substantial efforts towards achieving the goal to
advance the Company&#146;s Gencaro atrial fibrillation regulatory approval process. However, due to the Company&#146;s limited financial resources, the Board concluded that the Company would pay cash bonuses for partial achievement of the 2011
performance goals during the 2012 fiscal year upon the achievement of the AF Milestone. Upon achievement of the AF Milestone, Mr.&nbsp;Ozeroff&#146;s deferred 2011 cash bonus will be paid. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Company terminates Mr.&nbsp;Ozeroff&#146;s employment without &#147;cause,&#148; or if Mr.&nbsp;Ozeroff terminates his employment
with &#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Mr.&nbsp;Ozeroff a severance payment equivalent to (i)&nbsp;12 months of his base salary (if such termination occurs on the same day
as or within thirteen months after a change of control of the Company), (ii)&nbsp;a pro rata </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the fiscal year in which his employment terminated to be paid
at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA for 12 months, whether he elects or
is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the benefits would equal under COBRA
if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12 months of base salary, which additional payment would extend the covenants and obligations under Mr.&nbsp;Ozeroff&#146;s
Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&nbsp;Ozeroff of a legal release in a form acceptable to the Company. A termination for
&#147;cause&#148; includes willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to the Company; refusal, unwillingness, failure, or inability to perform
material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of the employment agreement or the Employee Intellectual Property, Confidentiality and Non-Compete
Agreement, or any other agreement, with the Company. &#147;Good reason&#148; includes a relocation of normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and the Company&#146;s
unilateral decision to significantly and detrimentally reduce Mr.&nbsp;Ozeroff&#146;s job responsibilities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Non-Equity
Incentive Plan Compensation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2007, the Compensation Committee and the Board of Directors of ARCA established a
bonus structure for its entire executive team. The philosophy employed was to create incentives for the executive officers to achieve key corporate goals. The Compensation Committee retained discretion to change the bonus structure and the bonus
payment amounts as it considered appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For incentive bonuses tied to 2011 performance, the Compensation Committee and
Board of Directors approved a similar bonus structure as they approved for 2010. For 2011 performance, the Compensation Committee of the Board of Directors set a potential bonus target of 50% of base salary for Dr.&nbsp;Bristow and 30% of base
salary for Mr.&nbsp;Wheeler and Mr.&nbsp;Ozeroff. For incentive bonuses tied to ARCA&#146;s 2011 performance, the Compensation Committee approved a set of weighted goals, which the Board of Directors of ARCA believed were attainable with a very high
level of executive performance and would be challenging to achieve. These goals included: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">finalizing the planning and regulatory process for an atrial fibrillation clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtaining funding for the atrial fibrillation clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtaining government or partner support for another clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">complying with securities laws and stock exchange listing requirements applicable to public companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing additional product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee and Board of Directors reviewed the 2011 corporate goals described above and determined that they had been partially achieved; however, due to the Company&#146;s limited
financial resources, it was concluded that the Company would pay cash bonuses related to 2011 performance, if at all, upon the achievement of the AF Milestone. Specifically, the Board determined that the Company had achieved certain of its 2011
performance goals during the fiscal year 2011 by completing much of the work necessary for the further clinical development of Gencaro, including the planning process and the regulatory process with the Food and Drug Administration related to a
Phase 3 clinical trial for Gencaro in atrial fibrillation, maintaining Nasdaq listing requirements, and development of other assets. Upon achievement of the AF Milestone, deferred 2011 cash bonuses will be paid. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In early 2012, the Compensation Committee and Board of Directors approved a similar bonus
structure as they approved for 2011 for incentive bonuses tied to 2012 performance. For 2012 performance, the Compensation Committee of the Board of Directors set a potential bonus target of 50% of base salary for Dr.&nbsp;Bristow and 30% of base
salary for Mr.&nbsp;Wheeler and Mr.&nbsp;Ozeroff. For incentive bonuses tied to ARCA&#146;s 2012 performance, the Compensation Committee approved a revised set of weighted goals consisting of 2011 goals that were not attained or were only partially
attained during the fiscal year 2011. The Board of Directors believes the 2012 goals are attainable with a very high level of executive performance and will be challenging to achieve. These goals include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtaining funding for the atrial fibrillation clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">completing the planning and regulatory process for the atrial fibrillation clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtaining government or partner support for another clinical study; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">complying with securities laws and stock exchange listing requirements applicable to public companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing additional product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Equity Incentive Compensation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The option awards reported in the table
above were granted to the Executives in 2011. Each of the option awards were priced at $2.24, the market closing price on the date of grant. These awards vest in monthly installments through May&nbsp;20, 2014 and have an acceleration provision in
the event of a Change of Control of the Company. Upon a Change in Control of the Company, the vesting of these option grants accelerates as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a) Fifty percent (50%)&nbsp;of the unvested option shares become fully vested and exercisable upon the closing date of such Change in Control and any remaining unvested option shares continue to vest
according to the original vesting schedule, and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b) Upon the one year anniversary of the closing of the Change of Control, or
the Executive&#146;s involuntary termination, whichever occurs first, the remaining unvested option shares shall become fully vested and exercisable. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Other Elements of Executive Compensation Program </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The remaining elements of
the Company&#146;s executive compensation program, like its broader employee compensation programs, are intended to make the Company&#146;s overall compensation program competitive with those of its peer companies, keeping in mind the constraints
imposed by the Company&#146;s reliance on capital markets as a primary source of cash. The remaining elements of the Company&#146;s executive compensation program, (401(k)&nbsp;Plan, Medical, Dental, and Vision Plans, Life and Disability Insurance)
are available to all Company employees. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>QUITY</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>LAN</SMALL>
I<SMALL>NFORMATION</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information as of December&nbsp;31, 2011 for all of our equity
compensation plans: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.&nbsp;of&nbsp;Securities</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>to&nbsp;
be<BR>Issued&nbsp;Upon</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise&nbsp;of<BR>Outstanding<BR>Options</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(a)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>Price of<BR>Outstanding</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(b)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.&nbsp;of&nbsp;
Securities</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Remaining&nbsp;Available<BR>for Future Issuance<BR>Under Equity<BR>Compensation Plans<BR>Excluding Securities<BR>Reflected in<BR>Column(a)</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(c)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans approved by security holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">864,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">506,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">864,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">506,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A description of the equity incentive plans we maintain is set forth in Note 11 to the
Company&#146;s consolidated financial statements included in our annual report on Form 10-K for the year ended December&nbsp;31, 2011 and filed with the SEC on March&nbsp;27, 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Compensation Risks </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA believes its approach to goal setting, setting of
targets with payouts at multiple levels of performance, and evaluation of performance results assist in mitigating excessive risk-taking that could harm the value or reward poor judgment by its executives. Several features of the Company&#146;s
programs reflect sound risk management practices. ARCA believes it has allocated compensation among base salary and short and long-term compensation target opportunities in such a way as to not encourage excessive risk-taking. The mix of equity
award instruments used under long-term incentive program that includes full value awards also mitigates risk. Finally, the multi-year vesting of equity awards and share ownership guidelines properly account for the time horizon of risk. Furthermore,
the Company&#146;s compensation committee assesses and monitors whether any of ARCA&#146;s compensation policies and programs has the potential to encourage excessive risk-taking. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>O<SMALL>UTSTANDING</SMALL> E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL> <SMALL>AT</SMALL> F<SMALL>ISCAL</SMALL> <SMALL>YEAR</SMALL>
<SMALL>END</SMALL>. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows for the fiscal year ended December&nbsp;31, 2011, certain information
regarding outstanding equity awards at fiscal year end for the Named Executive Officers. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>O<SMALL>UTSTANDING</SMALL>
E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL> A<SMALL>T</SMALL> D<SMALL>ECEMBER</SMALL>&nbsp;31, 2011 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(#)&nbsp;Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(#)<BR>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael R. Bristow, President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/23/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,222</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/18/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/20/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ROWSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick Wheeler, Chief Financial Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8/3/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/3/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/12/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/25/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/23/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,911</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/18/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/20/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher Ozeroff, Senior Vice President and General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,911</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/18/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/20/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest in monthly installments through January&nbsp;23, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest in monthly installments through June&nbsp;25, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest in quarterly installments through February&nbsp;12, 2012. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest in quarterly installments through May&nbsp;3, 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest in quarterly installments through July&nbsp;31, 2010. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest in monthly installments through February&nbsp;18, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest in monthly installments through May&nbsp;20, 2014. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>The following table shows for the fiscal year ended December&nbsp;31, 2011 certain information with respect to the compensation of
all non-employee directors of the Company: <I> </I></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> <SMALL>FOR</SMALL>
F<SMALL>ISCAL</SMALL> 2011 (1) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid in&nbsp;Cash<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock&nbsp;Awards<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jean-Fran&ccedil;ois Formela, M.D. (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Linda Grais, M.D. (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mary K. Pendergast (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Burton E. Sobel, M.D. (5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John L. Zabriskie, Ph.D. (6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Richard B. Brewer (7)&nbsp;(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ted Love, M.D. (9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">See Summary Compensation Table for disclosure related to Dr.&nbsp;Michael Bristow. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate number of options awards outstanding at December&nbsp;31, 2011 for Dr.&nbsp;Formela was 11,000. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate number of options awards outstanding at December&nbsp;31, 2011 for Dr.&nbsp;Grais was 11,000. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms. Pendergast left the Board of Directors when her term expired on May 20, 2011. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate number of options awards outstanding at December&nbsp;31, 2011 for Dr.&nbsp;Sobel was 13,875. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate number of options awards outstanding at December&nbsp;31, 2011 for Dr.&nbsp;Zabriskie was 30,715. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Brewer received $45,000 in compensation for his duties as Chairman and $53,000 for additional services in assisting the Company in soliciting and evaluating
potential licensing and strategic collaborators. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate number of options awards outstanding at December&nbsp;31, 2011 for Mr.&nbsp;Brewer was 194,191. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Love resigned from the Board of Directors on March 22, 2011. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In 2011, nonemployee directors were compensated for their service on the Company&#146;s Board, as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each non-employee director is entitled to an annual retainer fee of $30,000; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As additional compensation for their services, each non-employee director, upon joining the Board, is entitled to an initial grant of options to
purchase 7,500 shares of the Company&#146;s common stock under the ARCA biopharma, Inc. 2004 Equity Incentive Plan (the &#147;<B>Option Plan</B>&#148;) and an annual grant of an additional 3,500 shares of the Company&#146;s common stock under the
Option Plan; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee chair is entitled to receive an additional $15,000 for service as the Audit Committee chair; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a non-employee director serves as the chair of any other Committee, that director is entitled to receive an additional $10,000 per chair and the
Chairman of the Board is entitled to receive an additional $15,000; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each of the members of the Audit Committee, other than the chair, is entitled to receive an additional $5,000 for his or her service on the Audit
Committee; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">For membership on any other Committee, except for the chair of such Committee, a non-employee director is entitled to receive an additional $5,000; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The director designated as the Lead Independent Director is entitled to an annual fee of $10,000. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;7, 2009, the Company&#146;s Board of Directors approved the engagement of Richard Brewer, the chairman of the board of directors and the
former Chief Executive Officer of the Company, to assist the Company in completing a strategic transaction in order to further the clinical development of Gencaro, the Company&#146;s lead product candidate. Pursuant to this arrangement, the Company
compensated Mr.&nbsp;Brewer at a rate of $6,625 per month. The Company compensated Mr.&nbsp;Brewer at a rate of $6,625 per month, for the first eight months in 2011, after which the board of directors terminated this engagement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;10, 2012, Mr.&nbsp;Brewer, Dr.&nbsp;Formela, Dr.&nbsp;Sobel,
Dr.&nbsp;Zabriskie and Dr.&nbsp;Grais each were granted options to purchase 7,000 shares of the Company&#146;s common stock under the Option Plan, 3,500 of which were compensation for service on the Board in 2011 and 3,500 of which were compensation
for service rendered and to be rendered on the Board in 2012. The purchase price for these options was $1.00, which was equal to the closing price of the Company&#146;s common stock on the date of the grant on the Nasdaq Global Market
(&#147;Nasdaq&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ERTAIN</SMALL> R<SMALL>ELATIONSHIPS</SMALL> <SMALL>AND</SMALL> R<SMALL>ELATED</SMALL>
T<SMALL>RANSACTIONS</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transactions with the Company&#146;s President and Chief Executive Officer </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has entered into certain transactions with the University of Colorado Foundation (&#147;CU Foundation&#148;), in the form of
unrestricted gifts, intended to support the laboratory of Dr.&nbsp;Bristow, its President and Chief Executive Officer (the Lab), for the advancement of research in cardiovascular disease. Effective July&nbsp;1, 2011, the Company entered into an
unrestricted research grant to the CU Foundation for $160,000 for a one-year term for the advancement of research in chronic heart failure. For the period from July&nbsp;1, 2010 through June&nbsp;30, 2011, the Company provided funding to the Lab
under another unrestricted research grant for $226,000. In the first half of 2011 the Company provided research funding for the lab of approximately $92,000, in accordance with a similar unrestricted research grant arrangement. Funding of the
unrestricted research grants is contingent upon the Company&#146;s financial condition, and can be deferred or terminated, in the Company&#146;s sole discretion, at any time. Total expense under these arrangements for the years ended
December&nbsp;31, 2011 and 2010 was $155,000 and $255,000, respectively, and $1.4 million from Inception through December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>H<SMALL>OUSEHOLDING</SMALL> <SMALL>OF</SMALL> P<SMALL>ROXY</SMALL> M<SMALL>ATERIALS</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices of Internet Availability of Proxy Materials or other Annual Meeting
materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting materials addressed to those stockholders. This process, which is commonly
referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This year, a number of brokers with account holders who are ARCA biopharma, Inc. stockholders will be &#147;householding&#148; the
Company&#146;s proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have
received notice from your broker that they will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish
to participate in &#147;householding&#148; and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify your broker or ARCA biopharma, Inc. Direct your written request to Secretary, ARCA biopharma, Inc.,
8001 Arista Place, Suite 430, Broomfield, CO 80021 or contact Investor Relations at 720-940-2100. The Company undertakes to promptly deliver a separate copy of the Notice of Internet Availability of Proxy Materials promptly upon receiving your
written request. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request &#147;householding&#148; of their communications should contact their
brokers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>O<SMALL>THER</SMALL> M<SMALL>ATTERS</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are
properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%">


<IMG SRC="g285899g95l79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher Ozeroff </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary, Senior Vice President and General Counsel </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;5, 2012 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A copy of the Company&#146;s Annual Report to the Securities and Exchange
Commission on Form 10-K for the fiscal year ended December&nbsp;31, 2011 is available without charge upon written request to: Corporate Secretary, ARCA biopharma, Inc., 8001 Arista Place, Suite 430, Broomfield, CO 80021. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ROWSPAN="6">


<IMG SRC="g285899img1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">


<IMG SRC="g285899img2.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Electronic Voting
Instructions</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Available 24 hours a day, 7 days a
week!</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1">Instead of mailing your proxy, you may choose one of
the voting methods outlined below to vote your proxy.</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1">VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE
BAR.</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Proxies submitted by the Internet or telephone
must be received by 1:00 a.m., Mountain Time, on May 25, 2012.</B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="4">


<IMG SRC="g285899img3.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vote by Internet</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#149; Go to <B>www.investorvote.com/ABIO</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#149; Or scan the QR code with your smartphone</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#149; Follow the steps outlined on the secure website</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vote by telephone</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:0.63em; text-indent:-0.63em"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#149;&nbsp;&nbsp;Call toll free 1-800-652-VOTE (8683) within the USA, US
territories &amp; Canada on a touch tone telephone</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0.63em; text-indent:-0.63em"><FONT
STYLE="font-family:Times New Roman" SIZE="1">&#149;&nbsp;&nbsp;Follow the instructions provided by the recorded message</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Using a <B><U>black ink</U></B> pen, mark your votes with an <B>X</B> as shown in this example. Please do not write outside the designated areas.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="5"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g285899img4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS 3">&#113;</FONT><B>&nbsp;IF YOU HAVE NOT VOTED VIA THE INTERNET
<U>OR</U> TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.</B>&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS 3">&#113;</FONT> </FONT></P> <P STYLE="margin-top:1px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ff00ff">-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;- </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR>
<TD VALIGN="top" BGCOLOR="#000000"> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff"></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff">&nbsp;A&nbsp;</FONT></B></FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#ffffff"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#ffffff"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Proposals&nbsp;&#151;&nbsp;The Board of Directors recommends a vote <U>FOR</U> all the nominees listed and <U>FOR</U> Proposal
2.</B></FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">1.&nbsp;Election of Two Directors for a three-year term ending at the Annual Meeting of
Stockholders in 2015 or until the election and qualification of their respective</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;successors.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="font-family:Times New Roman" SIZE="6">+</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;NOMINEES:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR>
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Withhold</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Withhold</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle" COLSPAN="3" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;01&nbsp;-&nbsp;Jean-Fran&ccedil;ois&nbsp;Formela,&nbsp;M.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="5"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>
</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="5"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>
</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Times New Roman" SIZE="1">02&nbsp;-&nbsp;Burton&nbsp;E.&nbsp;Sobel,&nbsp;M.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="5"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>
</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="5"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>
</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Against</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Abstain</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">Ratification of the selection of KPMG LLP as the Company&#146;s independent registered public accounting firm for the fiscal year
ending</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1">December 31, 2012.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">In their discretion, the proxies are also authorized to vote upon such other matters as may properly come before the
Annual Meeting. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD></TR>


<TR>
<TD VALIGN="top" BGCOLOR="#000000"> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff"></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff">&nbsp;B&nbsp;</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Non-Voting Items</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Change of Address </B>&#151; Please print your new address below.</FONT></P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Comments</B> &#151; Please print your comments below.</FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Meeting&nbsp;Attendance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Mark the box to the right</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ROWSPAN="2" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="5"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:2px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">if you plan to attend the</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:2px solid #000000; BORDER-BOTTOM:2px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Annual Meeting.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top" BGCOLOR="#000000"><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ffffff">&nbsp;C&nbsp;
</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Authorized Signatures &#151; This section must be completed for your vote to be counted. &#151; Date and Sign Below</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-family:Times New Roman" SIZE="1">Please date and sign exactly as the name appears on this card. Joint owners should each sign. Please give full title when signing as executor, administrator, trustee,
attorney, guardian for a minor, etc. Signatures for corporations and partnerships should be in the corporate or firm name by a duly authorized person.</FONT></TD></TR>
</TABLE> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">Date (mm/dd/yyyy) &#151; Please print date below.</FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT
SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">Signature 1 &#151; Please keep signature within the box.</FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT
SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">Signature 2 &#151; Please keep signature within the box.</FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT
SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER:2px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="5">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g285899img5.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Important notice regarding the Internet availability of </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>proxy materials for the Annual Meeting of stockholders. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>The ARCA biopharma, Inc. Annual Report </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>and ARCA biopharma, Inc. Notice
of Annual Meeting are available at: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>www.edocumentview.com/ABIO </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS 3">&#113;</FONT><B></B><B>&nbsp;IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG
THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.&nbsp;</B><FONT STYLE="FONT-FAMILY:WINGDINGS 3">&#113;</FONT><B></B><B> </B></FONT></P> <P STYLE="margin-top:1px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1" COLOR="#ff00ff">-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;- </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g285899img6.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Proxy &#151; ARCA BIOPHARMA, INC.</B> </FONT></P>
<P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROXY SOLICITED BY THE BOARD OF DIRECTORS OF
ARCA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 25, 2012 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy Statement of ARCA biopharma, Inc. (the
&#147;Company&#148;), dated April 5, 2012, in connection with the Company&#146;s Annual Meeting of Stockholders to be held at the Renaissance Boulder Flatiron Hotel, 500 Flatiron Boulevard, Broomfield, CO 80021, at 9:00 a.m., Mountain Time, on
Friday, May 25, 2012, and does hereby appoint Michael R. Bristow, M.D., Ph.D., Patrick M. Wheeler and Christopher D. Ozeroff, and each of them (with full power to act alone), proxies of the undersigned with all the powers the undersigned would
possess if personally present and with full power of substitution in each of them, to appear and vote all shares of Common Stock of the Company which the undersigned would be entitled to vote if personally present at the 2012 Annual Meeting of
Stockholders, and at any adjournment or adjournments thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares represented hereby will be voted as directed herein. <B>IN EACH
CASE, IF NO DIRECTION IS INDICATED, SUCH SHARES WILL BE VOTED &#147;FOR&#148; PROPOSALS 1 AND 2. AS TO ANY OTHER MATTER THAT MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENTS THEREOF, SAID PROXY HOLDERS WILL VOTE IN ACCORDANCE WITH THEIR BEST
JUDGMENT. THIS PROXY MAY BE REVOKED IN WRITING AT ANY TIME PRIOR TO THE VOTING THEREOF.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PLEASE VOTE, DATE AND SIGN ON THE REVERSE SIDE
AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Please be sure to sign and date this Proxy.</B> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g285899g95l79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g285899g95l79.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0H84&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````+P```*X````&`&<`.0`U
M`&P`-P`Y`````0`````````````````````````!``````````````"N````
M+P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!WL````!````<````!X`
M``%0```G8```!U\`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``>`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U55\[/Q.GXYR,I^QDAC0`7.>]QVUTTU,#K+KK'>VNFIOJ6*'4NI8W
M3<4Y.0202&55,&ZRVQVE6/CU_P"$NM=]!O\`Z+7(=:QLEV5CYOU@NBRUKC5T
MS#>3<UD'U<2B[]#5AXS*?^6.MNNJ];^B>M@87Z/+2G;Z1US.R?VAU#J0HQ.D
MTO%>)#MUFYI->1]HO:YV-;9ZVRC9B>K7]H]7%9;?Z7JVUL?.ZI]:<L'$]3IW
MU>QK079()9DYCZS_`#%$>[$P/5;^M6?TF[9]E_1?K/I`PNC9'7Q5=FN%/2:@
M&XN-CAU59K`V-KP6Q397B^E^A_:#ZZ<O-K]3[!3TSIUG^4>LJJJIJ932QM=5
M;0RNM@#6M:T;6L8UOM:UK4E,TDEE]9ZM?B&K"Z=2,KJN9/V:EQ+:V-;`MS,R
MQL^EAX^]N_\`PEUGIX]'Z6U)2?J76,#IGI-RGN];(+ACX]3'W76%@WV>CC8[
M;;[/2;[K7MK_`$7^$6?U#ZPYO3@S,R,`.Z0ZQC'95=I=<QMKFU4Y%F`ZFMWI
M^I97O95?;D,_T"M8'3\7H]%N;FY`MRWMWY_4K]K"X#7N=F+AT_X#&:[TJ?\`
MA+O6OMJXEMWUBLIS=KZ.B4O;=B,>"RS+>P[Z,NQCX?1@U6;;L6MWZ?*M]+(_
M18[&?:DIW4DDDE*2261USZS].Z*T,L#\O,>6MJP,8>I>]SOH?HI]C?ZZ2G75
M'IW6<#JEES<!YR*L?:'9+`30YQW;JZ,C^;R'5;?TWH[V5[_WUET=*ZOUH-N^
MLA;CXLAS.BX[]U>@.G4\INUV=]+^BU>G@?H_TK,E=!77756VNMH96P!K&-$-
M#1HUK6CZ+6I*?__0Z2JGZP]1ZQ?GC#=1EL=;CX>5G!OV?#H#_3WX6%5:Z[.Z
MAG4_I[LE_P!FH^AB_:?2J]/(>WZI]6?GWM8^A^)<YEEF7EN????<WWB[,Q*V
M8U%E&*[]'T[IS,BCIV+_`$O[)=;Z-=/8))*>>R/JG:^RC+HZKE,ZG387'.N=
MZLL<UU5U->#^BZ93N8_V;,/V/8RS9:NA2224I<[]D^L^/U3J.3C8^'>_,<WT
M<R_(M;Z=-;0RG%^QLQ[/YI[LB_\`1Y5?K79%C_T?T%T222GE^J=!ZA;6W(SL
MZF]["ZV[*RF!N)B,8'O%V%TMSG8[\EF[VY?4LC)^S^F^WU/^TRYZPT9!J^L5
M3'96%BVMLQ,WJ+W.?==N--&0UMAI94U]UOZATS#;@8?_`&KZEDX7I58R[KKG
M['_9K_VWZ?[.WU>KZ_\`-3ZE?H>M^9Z?VCTOYS]%_I?T:AUC_F_]AJ_;/V;[
M#ZC/2^T[?1WP?1_G/T7T?HI*<FGJ7UHZOTDLZ4[&JRA6X6=5<QXQ7W0?;TNE
MYMMR*&/_`.]&[]5?_.8]&9O_`$)\#HG7'5>CU#J%E./N+WUT7/MOM)+7.];J
M=M>-]GI=_P!QNF86!Z/^"R%T*Y[ZT8_UAR@VO"RV].Z96W?EWTLNOR[(/]&Q
M\?%:RVNK;_.6X]_VO_1^G_A$IQ6XO5<>?J]TGJ=F<*?4?D65`T^F7/W[>K];
MMNS;6V[7_P!&Z;1C]0_\)T_IU:Z/D?5WI;W#IC;>O=2)#;;<&KU6-+_<]K<I
M[_L6+^_=]JZA]MO_`.U>1E6^FH48WU'Q\/%;F91S.G.`.,^YKF],!W/]NW'J
MIZ)ZOJ^K_2O4S/4_G;/4784>AZ%?V;9Z&T>EZ<;-L>ST]GMV;4E.,W)^N66`
MZK"PNEL),_:K7Y-L#Z.ZC#;10W=_)S[59QL/ZPMN99E=2HMK!E]5>(:P6]VM
M>[*O>W^LM1))3__9`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`
M(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O
M`',`:`!O`'``(``V`"X`,`````$`.$))300&```````'``@``0`!`0#_[@`.
M061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!
M`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P/_P``1"``O`*X#`1$``A$!`Q$!_]T`!``6_\0`:P`!``("
M`P````````````````@)!PH#!08!`0`````````````````````0```&`@("
M`@$"!04```````(#!`4&!P$(``D1$A,4%2$Q02)"(R0R,T,6&!$!````````
M`````````````/_:``P#`0`"$0,1`#\`W^.`X#@5([C]O5.ZM;#4WJE!ZUL#
M9^^;/M"LZWED3IY0Q&-='F6N]EM$./MB2N*KZ#')I`C`M=V^/`"8ZGQ]F<G8
MX"9M1F*LA;;G.,8SG.<8QC&<YSG/C&,8_7.<YS^F,8QP-:+;OM^NC::^\]<'
M2HTH[4OMT+2CNG=Y>T@>M9]5H&H<US2]R]H?E"=4P61)T)C8I)1G$A5M!RXO
M*1%^37@.3)0V+*ZC#G":_@\->I:^3UYBD1CD<=IS)S"C9',G-D:$;:OE+\82
M$!(WA_5)AJU.08P'YC1>,>.![+@.`X#@0.LCM'ZW:>GJZK[1WMU.@=@M+J>Q
M/T3DM\5NV.\8>TIF2E3/+2#Y#@,2=4Q@<X,3N0DIH/XAQC@35C,GC4UCS++H
M;(6.6Q22-J1YCLGC+L@?H\_L[@2%0@=65Z:E"MM=&U:G&$PD\@TPHP&<""+.
M,^>!WG`<!P'`<!P'`<!P/__0W^.`X%'.^G8_DA-:E4:\VW'J8@E1/26#[;[Z
MO#.9-8M04F=CB$)&OFMT';TKHNV,W?DQRL*1''VQ*O0Q-48'+F`]RP2SG!C/
M1_7J#ZK1N2;[;71Y)J=2=<,<F?Z.K:Z9"FDMT1Y39>4J*Q]K=R)J:)[73_>[
M8,GZ[02E0*EZ]@:711'$>5"MT5I^!'_9O8K;'L^MI3IEKW')%4T$=FAI>)W!
MY.E=F%VB%327)@2+9W^5M:Y"Y0:*SV/#-_Z5KHVJDL[G.1X5351'X^4M:U(7
ML:7:44CHK4"6I:9:#A#6J27NP)^^`1'SFT9@%`F;393,7)$D1)S#24",I(WH
M$Q1#:SMI!*)"00F)++P$NN`X#@12VVW!J_3^$,;_`#-')9O/["?@PBCZ(K5N
M)D=R7Q8R@@2A+"*TB@U23[ZDA,'*IR<%)J9I9&\!BQP4ITX,CX$`2=,NP?;M
M6CN?:K=FWM+GE&YM,DI_531F7M;1"JM2)7)$[DM>R5FO3&XN&T,N<$:8")[0
M)BV>(IA"4EH0*RQEJ^!:I8\`I1RJ690ZU(;7"NDLQA]'.HS,&"/CKH,2*0*E
M,A.?VEQ2_@BF@ENP<:H&:#```P(><X\>>!5_T,:Z.&MG7=$(Z4Z20==6/;-X
MWAK_`!*3*5RA57.MMK6.]2.AHNF*<\_DFX#Q6IC?)%2-2$M4D<GY44>`!X3`
MX"Y?@.`X#@.`X$0-O][=8]&H@T2?8*PBV9YF#@%AJZJHJUN,XNNYI<H,*2ML
M-J*J(P0X3*<R!S<E1"4/U4WTTIJ@L2L].4+)F`K_`"*2[".QB61>8[0R-XT(
MTE0/3;)FW3&LI"%5M1?#2@5FJVYIVVN2..!D;K*'/H2$PW2#1(YR-5(5!Z!Q
M<PFXSD(7?\#_T=_C@59WE:5G[E6;*=-]3IR]UM74(=/P6Z6W\/$GP\P)-E*`
M]?K5K:]'%+&XS8^4)E91;Y(<E*$=>-!IHPX,D!J(E*$'9116JG7K=E8S*P@N
MFR-Y1T+]$NK?K>U]B!0$U2,`R\(7J5PV'2.6.(9);3V0I-73RZYZZMR-.$U0
M(CZ(A?"I#'\:@>U'8)?@'B23Z(NT_JJ7NR256E#$>9;J5UTGX"H;G&L=/T$H
M:R&W;?L2);SLI':TI"W&Q*O#<G#1MP%&,,3@%_.N^MU0ZLURDK&FXSEC9/OK
M'^0O+FX+9!-)_,W<0#I%8%CS-X.5R"<3R4+`_.X.C@><I/,SC'D)80`"&=>`
MX#@0PWBW3A.E-6-,G<8W(;3MZSY0BJW6[7R"EE*;$ORZ'\@\<=@T;*.$%*TM
M*<)(UKX]J\@;V-H(.4G"$/!)!P8<TCTVL>(RAUW%W9D;#:V^=I,`FAX<&()Q
ME7:QUJO5_E4>N&N+8LR8)HB#,:('YU^'[/$N<RLJ5APB`)2"`GM9]HUS2L`E
M5J6W-HU75<0=H4OTMFDN=DC)'F!I28QDU6X.*TPLDK&1""`L&,Y,--$$L`1#
M$$.0J%B"6Q>W]^1SVP(S**HZKF16C=:NJJ3HE\7M+L#>4"LM4AM&Y&)2!,]5
MYJ2@/3A,C</48)=IR+.')[`G;/JMIX77I4J9$F3HD2<A(C2$%)4B1*46G3)4
MR<L)1"=.04$!1)!)0,!``.,!"'&,8QC&.!S\!P'`<#R4[GT&JZ(OL_LJ81B`
M0>+H#G21R^8OC;&XTQ-Q&/)JUU>G=2D;T*<'G&/8PP.,YSC&/USC'`UBKW[B
M=^-V+_D.D_2WK4G2N35Y*L3?'9=)AMJNL(XM+6E(9E'*\PG<W!*!Z*RG<(Z?
M(T:MQ>$8L&DQ=2D-+68"T'0KJ:JK4*3+MA+<L&9[D;VS1NRGLC<*\QX=9CX5
M$A+71JHHV>I<6FFZ]+_F+(;FT8U64XLE'JSBL`++"V'@.!__TMDG;_:"[]FM
MFW3K$T;E;E63]%F./R[??<IJ`F$/5.H)0F+<$%:5*M6)UC3_`.J+;CYOLTJ%
M)9A<6:S1NGQ&'@+&D#P<8V:&]1TC0SHTKJOW]DJL9L)L'<^6X=)+I_KHKRL+
M43%:DDZ1:I>-O-F59ZY2M4-:-Q&0<]J?NR!W\94E&A4M"+QU82V'.8=$MF["
ME3!8C\ZP_8[=%N<'2T.T+M;FS&['MKS0&B-?U8@62^E-2V"18-9U<BB*%M0E
M)B@M\>-1J`'R4(71P6*=D=OUU'JXU<@5*].VL$99DK-6X)K7$=V+VN%&DIOL
MVC34BT2&/Z[4,>H0A_OIW=TL!?E0>(9Y)1H1X,!U:[,;ERFP;IU%V>@%U6>M
MUOGFRK3)MY+,@S/4\6GXF?8E?']=:_A\=C5?1.'6.]2N@3@2IV>6(29O9",H
M$AA)YZX0DH78\!P'`H$U8O362ZMC=BNS[9F]::A+57LILO5739AMFTH7#VZC
M-?JDDJB)W#;)S)*9*@3Q>R=C;?CSJ:N<U29.X`AK,RHRC<)C5&%`9Q<>WF&W
MF^+*XZR:=E_8+/R5);8XV;#SU5?:8UNM-RJP,VS=J7QC<HX>8D)2B."VQ1OD
M[HK#C``%%^WR!"N_8<49DNP\/IS;='/.XCL38QL5HQ;0:@2Q51U_Z?A4GM#A
M&I7=B!P<EK,C90EK`&II);*J:OCF')1K6PMQ*HLC(>AW,>.R/*5CJV8[NG0S
M;B\(NJ.I#1GKLC<%KJ"T]'4)QZ%ZOC9[:^[8;:MO9HBL2E107=]:VV`$.J\@
M*%J1Y4G8RG"=>D&_^H309K+H'!]J+2W7NT5?R%A4;$YCEGV=%+:E%1M2)=<T
MV=-@EJ%WK]T`WO3P3DXM*_N9+5AR0-_S9&,@(P[OLD[EM7^N-$;%GU%*+WV(
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M/QC(QH!J_(0)UF3!>N`A=2NJNUG:5(V&X[VNFQ7RETKL6_1R_II6!511AW:5
M!^5R9/UWZ6R0V0,U9QM6V+`!;;XMK,OL0X@(5$;0-0Q)W4D-DNCZ#IG62NT5
M:TK!V:OH2V&K'162E-6+7-\>5PQ*GN7S>6OJMRE$WF;\JR)2Z/CTM7.KBH$(
MY4H-,$(60B==O;EUE:[/:F+6UO!KLPS!&:`A9"&6PFJ>SM(I-P')"17!Z^%*
M96E6*,##DLHQ&$PS&<9"'/G@8?CO<UK[8P3E5'ZW]B-^,9:D:4B6U=HC?PH4
MO-`+(<?1F,YC$(CAY8_'G`OLXQ@/C.?&,\"2D;W>!)*QL>Q0ZC[Q,;G6Y454
M&U7)-?3VBSILEE;V6R$G5PA-DXXC+S6+V&K=4Q+R!8WHBLFFE8]BL&!__]/8
MR!T1T2_S:[G"UMG-Q[,IB_+JM2\[%U?)M9FJ:F)O*[;DRF1OR&U%=)1"N[7N
M-@:23BVQL0R23+TB-G3DHPE9)*+"$+?X93]55Q6;=3%=5U#*^J9G85<79ZY@
ML=:XA#6>/KBU!:QJ:&".IFUN:TJK"LT0\$%EY$88(><^XLBR&.*$T\U.U8)7
M$ZU:TT10F75,%&[J:BJB#U^XO24!H#PDOCI&&1M<GH`3BPCQ]HT[^8.,_OC'
M`D=P'`<!P'`@9,.K/K6L&Q'*V9SH1J%+['>G(UZ?)=(]>JM=W5_>SSA*5#Y(
M!+HR<0^O:A0/(S%BL!RDP?C(AYSC'@)KQJ,QN&,#3%(?'F.*1=@1$MK%&XTT
MH&)@96Y.'U3M[2SM:=*W-R(@/Z`*)+`6''[8QP*<.RC:]IZW8@ICVE6L:6Y>
MP_?.<2-15-8P6'GN3[94Z86QI12B[;L?6\)3DM@51,CLVD"-<5Q!"=,-*A)-
M1MY1QR0,/ZV]9SI$*$L&Z.RUR-MBP)FP&W7M)6S*^J)>*ZI7#(^K>L(-B+!;
M4<>/NV&PM(2H016K6="Q4_&VXP*3#$]K"_SJ@(4];JG>C>\$COZNJ(D.A^+J
M:DL,E>W]H0QA0RVGM8XTZ?-6VF'6QKW(&C#5%8/%6,PI2\6(_(/PKU,#5[D4
MU+LDMR9M#89K?K]T]K2DY1K\11$#L"N;&=`R2Y$]U,B*ZGZ_)IEQ+>%,^ON2
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M$5Y[S/I%F76:V'F!3(':,ZGT^^810Z0E$^R@I/,9-_*+`0*4&,8R$8=%CI+C
M-Z%'K^R;<_;[L'<7=*A`_P!=2&S7?6O5@2Q&$(LGL&M>MCC`F!&08>'&1%N;
MF\B-``.#1F9]Q#"Q^A-(].M62TV-<-6Z!I%4F1Y08>*SJ>$Q*1JDPP?&:%SE
M#0S)I$\&J`8\&F*U1QIO]8A<"47`<#__U-_C@.`X#@.`X#@.`X#@</\`C_8S
M_L_;^''G_1]CZ_N+U\_\GP_)Y\?T^WG^/`YN`X#@5T]D"?L@D]4LM7]:Q--P
MVT;'6.K1+MA[LDQB)AH6,$I4V0OT:AB&*S-RFLV>AJ#2D'LWGH4`R,F'@'[@
M]0IIZ[NIBBH`EO&,[`]IF-D[@C;HK=MVHKK3>K92+\IE*UQ>%KF;N1<==3C.
MX5@?*,I4$"*9RUK9D@<*RDK6G)&>6(+S-'VSKH980_M/76;J`=!6]VPEFANI
I;O4C^VF20HO`1"G;U5RUQ,<Y1DO']PYU/-7#_<8L\"<'`<!P'`<#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g285899img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g285899img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`T0$L`P$1``(1`0,1`?_$`.4``0`!!0$!`0$!````
M```````'!08("0H$`P$""P$!``$%`0$!`0````````````$"`P0%!@<("0H0
M```&`@$#`@,$!00-!@\```$"`P0%!@`'"!$2"1,4(146(B,7&#%!U5@*,E>7
MF%%A0C,E)E:6=[?7V#EQH209F=E#8]-4M-0UE:4VMM8X>+@1``$$`@$#`@($
M"00+"PD)``$``@,$$042(1,&,0<B%$%1,A5AL4)2(S,D%@AQ@=)48I*3E-15
ME5:6UA>1H=%R@D/3-"75&/#QLD1T=;4VEU-SL[0U=J8W./_:``P#`0`"$0,1
M`#\`[\6[9NT3,DU01;)F6<.3)H)D2(9P[<*NG2YBD`I15<NECJ*&_2<YA,/4
M1$<(OOA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%3I67B8)DK)3<G'P\<AV@L
M_E'K:/9(B<P$("KIVHD@F)SB`!U,'41Z!A%:/XL:M_G)H7^>%?\`VAA3@_4O
MNML[6S<"BXV!24`/U`@K6F#2`XAT$>P3OB@;H`_JPF"OK'[&U[+O$8^*O5.D
MW[DW8W8Q]FA7CQ<XB``5%LW>J+*F$1_04HCA,%7GA0F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%J,W=>Y
MW9>RIYHL^72K]:EWL'#1GNU6;1LE'NC,G3E4&TP#7YD_<('.*RR8""8%)^@@
M!E)5YHP%Y:KKUS+HN"M42NUVS%9Z+9<`?&6;I""ZJS5RWETU7`IM@.?H(B/8
M0W0O0`'"DG'JKO<ZI<F03.WC2(I)P'S:0>.&B_I(',8Z!@;]9CL+T="1),IQ
M.<RIN@A^H6%')0U/UI:/.FNW<+D4^Z.W7!RLS*<R9NX%6;5E)IN.X@@'14.S
MM4_3^H1*<@K93QDV+,;"UX=2PK^[FJW*JP#I\84_7?(HM6KEFY>`1V\,+T$'
M()JG,8#*G3$XAU$<D*TX8*R*R52L,_(3RS@^#G#+D#R?FA;+.=8T&1=U&+<G
M3`M@V)-J(US7=>*F<Q16"8N<LR15`O4Q4!4/TZ%'"J:WDX!:[?X>+GS=N>'`
M=G);GNCB]\@]([`LVLML663]BG-6=-VN%PHEM?-(]NT:H)R54GTV!3$2(4Z\
M4O\`#J`CA52-#7=/1;WL*VN8KS8[0\I7CPU9;^:7'_GC&634SK:D-6WW'[8W
M&_2[L-<P6PI8(^M%I=[CX1O.V=O7Y7TFIR2I3NSM5Q5,X4.F8#0KL88X\2.J
M^?C4:>77R(</Z/R\M_E3;Z8/MH;<6FZ]UWPVT%98RNLZ?;YRC@^LLI;(]%])
M/I20KCAP=LU%%-))1/HN)NXI2E_!IQC_`'U&6F_,MS#X:>2IKXS/*0.L-H,K
MK8J;`:MY4ZJJ@ZY6=_BB9JVU?/6^F$>*UT]9L,L<T5("T(T<PLH"G47C8GJ@
M0QM<WDQ=6$_/P=5@IJT6:7C:_6ZY$R,]8)Z9>MXV'A(2(:+2$K+RLB\41:,(
MV-8MU%EUE3E322(8QA``$<E6?5<M,+Y9^<?EGY)7/COX@XNG:2X[ZM,S+MSG
M=NNF*6]^BT>NET&:VM]<R/;!I2%D(S<C",)%%V_?MT1>.?E2``(E>X-8W+_7
MZEL6<>+WE,\JKI)SYF?(078KILJH:UL6O':.IR4PJ<5/<M]<M=.D%M$$,/:#
M%.7*($^`+`/VL*GFW\T86#7"S:WEFXR^6FL<%?(!R*9\B-&;<T-N"\\?MF,-
M;T"KLMA2]%D:U+'5=R4%6H6P0ESJ<$+Y*4@UG3Q))-R@NF==`Z*^0I<&%G)H
MP<KI[R5:6CW^($Y]V?@1P`L\YJBVJT[D%NVRQ.H-,3T>+12:K#^0*M-W.]1K
M5Z@Y;J*U.F13KT5%$SII2#MH)@,!NT2N1MY._`LVO&CRO:\V^"O&ODF#I)S8
M+[K>*;[`(D")!9;0JAEJCLIF=N@4A&I276#>G1)VE#VYTS`':8!$J7MXN(6=
M&%2F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M1B<>1QL"X'Z+J*&N=
MG^Z1.<KI036!^F5)N8JY5!$QA*4"&353$#"'P$0RGZ5=!^%9-$>-*1&08M&@
MNI5Y*NCU]O,QCUK(1"2+<IYOWB2;=)=XV<BZ2[$BF6(83F_DD]0#2J?7^12;
M'1ZJT`5W.J-)"%<&8Q;A@9LDBX2;QYUW,<@5^W7;M3,F;E<!,!Q,H8A0`1[P
M*(%!]5CSMVM),SN3*G>'<'<.4UU08+1T(D*:BRIVD>`!')+H-C`?TRF,F00[
M3B!B_'!535*7#M,J53NA2B(E-;$S_I^SW##,"F$@%$4R@;LZB`=?B(_$<!0_
MU68&2J%HDYQNV?,[R>\(_'JBV2G]5\?&4CY"^6L:H1H^AGR-..[I'&?7MB9N
M$U4'*,WLB76EG;%<#%<,VJ*G:(%ZX5QOPL+_`*?0+0]X@)20\6_GLY5^.ZT/
M5H_66_9.QUK7Q7A_2:.GL0B_W/QWE^I^@&<2.K[!*0HB7KZC]8B?4>T.D*X_
MXXPX?0N[S)6.N=S^*/\`^$;LG_3+H'_6+&Y!5V'[?\RN3^'UVYJBA^&[BB>\
M;0UU3BPT9N%W,C:;O68`(=J.]MFJ@XEOFLHT^6I"B<IP,OV!V&*;^28!$$D!
M+RM(&\=,V#S9^>BJ[<XKM)&P\0N+4CHBO;.Y1-6CQ+64FKI&UO\`8MCBJ%8W
M"2;&VS]@L$J,-%IQYEBJ$1/(F$&0%64*L'MQX=ZE;3/XJ_DQ:-+>/&MZAJ#]
MY$N^4NW(S7-KD&9U$3J:VK$'*WFVP@K)@!BIV1[$1S)P3N`%F"SA(0,4Y@R2
MJ81EV?J68_\`#Y<;*UQR\5G&92,C&K:U[SK'YA-ARR14#NIN?V@8):#%TY2+
MWJIP=%+$QJ)#&-Z9&GPZ"(A@*F0Y>?P+=7A6U'-KU'K2\W76.Q[=3(2>O>F)
M2R36J[4_;">9HTG<*T\I]I<P3LAR&;C/5E^JS<D'N352,'4O<4@E*<G&/H4C
M84+FSV1IR$\NOD7YSTJTBA)\=.#W%>Z<)*$X<$.XB"\N>4%;+,;@OL>0Z9DE
M)_4=2CHB($Q1!1H\Z&+T$P]2N@\&CZR<_P`RP!_A..1%DH<SS"\;>UCK1-UU
M;<Y+;%4K\AZB#EA)Q<NCJS>E?;H..AB$B+5$0SPJ10`1/(.%.@]3#D!53#.'
M!=I62K"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBU'HR1V.P+>=,Z[
M8S>[6-0[E,AP6;F"QO3D<()*&9IF%,1`P',(%'H(=?[K*3ZJ\/LK(N8C7VPJ
M[$?))`7%@A9=8(4MBF'RX6!N\;&-)MA($:V9QB)'#5%0IS`*)CI^F90P]1"5
M1Z'KZ*J5YA?5V*#6RD<UN,339JNI1=VP<D(W=.0]L9!A&^],HS6<%]('(@1(
MH#W]>O3JZID?1ZJRMLV;WQG#59680514`Z\<YE7$FR3,+42I.6QW"*#I03(J
M`<AR*+%.D(F*(?9`2D!25Q!6%Q6+NL83F$UM3**AR&+Z@A#1X]Q3&2*"A>A@
M^(&-T'X"`#^D%#_59/VFS0-*K-CN5IDVT+6*E!2]FL<R]/Z;.)@8&/<2LO)N
MU/\`P;9A'M%%5#?J(01R51Z]%RR>,OB-M7R&(<C?*S,\M.6G%*P\W=UVE77M
M<T-/:W@D'G&74+]QK_2#:P+7S6E]?NEV;:-?BD#<[1N)#`KV',J)\A7G.#<,
MP#C\:U5?Q`O"?:WCOW5PZ\AU*Y%;[Y$W!IL*(@I+86]I&G2=OKM[U,\;[&U1
M#I3="I-#8#7K!%,YML9)PV57`&QB^J)%`3*5<;@X%N,+NLX][JJ/(_1>H=^4
M-TF[J&X==5'8D"=-4J_H,;5",Y<&"ZA0`/>1BKDS9<H@`D62,40`0$,E8Y&#
MA:/?XH__`(1NR?\`3+H'_6+&Y!5R'[?\RU6\,/"GQD\A?@4U!:*WJB@4_FC+
M5W;MBH.^F<:C$62Q7>K;@V)'URL[)F$.@V&GST3$MX98'95?EZ'IN$.U1`O<
M^A5ND+9/[%2/_#">1^;C@M'B<Y(I.*GL[3K^ZN-"MK`V)&3'L*Y+OS[3T;,I
M&*D8UHUW-E=R,>4X&56C#.TN[L8)]TJ)6_ECT61?\6KHFT;&X#:LW%76[M]&
M\>=\Q4U=VS9`52L:AL:O2M"&Q.3E*)DFT7:G\4@<W\DI7HF-\"]0@J(3AV/K
M6QKP(;^K7(+Q2\2Y&#=M#R^JJ$WT)>(QN8HJPELU`8*H+9XD!C&15EJZVCI5
M,#?$S:02-^@V2J)!AY6XG"H49;6W-J[1T!#VC;5VA:+!6&[4O6\"_FEE2!-7
MS8EA956DU2*;MD7#M_-6*?D4FZ"*29C?$3F[4R'.4I`)]%"_.[E/6^$_#_D'
MRCM!D#--/ZVGK'$1[@?LSMQ61+%46ME+W%,<]BN,@Q9?9^(`N)OT`.%+6\G!
MOUK2MXU?$CNZ#XB:VV#</(+SBT9M[D@FZY.[TI&FK9J"%IY=L[L(VM<Z_.TM
MFFK?8#3WRE5@V?F7?JA[EL8"%3(!4RPKCWCEC`('1:+^4-$L7A`\^''3?<EL
M[9.S]6;R<PUPOVV-HKUU[<[E7-H2#S5O(!.W2%8KM3K+^3JLBNTL/W+%L8I#
M-#G[E.JAWTJL?I(R/J7^A6DJFLFFLBH15%4A%4E4CE43534*!B*)G*(E.0Y1
M`0$!$!`<E8R_O")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6H;=5*FM:
M[.GU7#%8T+8YE]/PDD#8ZR#QO(.SOG"?<PKXH'D8Y9PHF9)54QNSM.(=IP-D
M%7F]0O?7-A.(TQ78KF24]FJT;JNB.7KYLW62%(I4?49IIMR`W7.GV_9$H#T$
MO7ID90C/\JN61VLH]0(B604.!8I"+.D[9BNBLFB(CV?%D84&W?T,1,H&],P=
M2CUPF.JANRV=PN3T4TC]#=2@4B;U=JJ0#=I52F)%N5FR_4>H=0`QOT=`#KU*
M<86P[BE1I:G:W5>3;=1D_MDLI/@Q71(@X;,C-6S1D9TD,5$N$G3I-N*IB*$,
M)0.7X@(B`2%:<<E::O-)>O)GR.TOO#A+P>X)[<=PEX]O0M@<FK%L/2M/KUAH
M$@PCY*S0^HZ[(;(1M$JVM*#DT.]DI)*.!!L#M(C94RI%4Y5<88"'.*SP\5%B
MW!#<9];\<]O<*=E\0)?C5J'4FN.MGL>K;5KW84A&5M2(EI36DUKVXV%^[0*Y
MA0>ORR+-BHBM)$3`ZYRJG`J7XSD'.5@YY[J7R6Y@<>KWP<T+P$W!O&;EW&K]
MDU7D*2[:;IFHZ7/U^THR#T(T]IV!&V^;MS6#0>QJS(8YJ@*,H*@.#D`Q<*8\
M-/(E8U^&:S^6G@+IJC\/^5/CCV[?=.Q-Z&,UEMC7.TM#S=@U36[Q/B_DX:ZT
M]QLINI*4*KS$D\D22+1U[MFT5.V!JN!$``JI.#CR!ZJX_.4W\A_/O2-^X4\:
MO&]N%Q4(W<L`]G-^7W96B*O`7&*UI.*RL4_U=4U=DJ6"1@[6^1;+IR$E\O51
M:`=,S3UCCZ3U2/BT\B5*OA&EN>7$;0FA.!?*#QT;>H\+5I;8+&'Y'578VD[E
MKV.AY^QVC8Q'>S(&/V*>TUIPC(SBD<D>/0DR.C"B8$D_O1*42<2>0*P8\X7A
MTY72_-?3GD-\8=)DY/<\[:(>7V;#4^8J-6?U/;-!;$?U+<[=:TS=?AG,?;H:
M-"*GVYCF!RY;I&5*K\P<B$854<C>/%_HMWO&?<?*#F%09GC3Y&_&E<])M[YJ
M2Q0FS[0I?M1[(X]WQ)9M'P,[`M"UF^/M@523M"4NJY8,UF+GVA&Z@ED!4234
M-*MD!OQ,*TSZG\<7DI\&_(6^[+\>U<2YW<'MIR+9YL/C-+W&,IN[(!C'KG")
MD(->=6:UZ=O-8C'!V+6:8"HK,M`!*0C"BFBX2*X7MD&'='+;TU\NDFO`(G6\
M8/E<1OQV_IK4`.)ISI(S12&]6/+?U+HA05&!%2CT?^^*@9/H8`ZCV85OA^$8
M6MH^M?+OY)/(SPUW'R4XK?E'X`<6MPFW-`ZKL^T-=SUVE[A5:_-N*=<]A0U;
ML$I*6"X+6!5FU:-DFJ$;"-%'(D,JJHJX6*O+&-(!RXJPO+T7RN^0]QJ#4.H?
M&5M2%XJZMWK7-G[/A=G;<T)6[1R,5UI:@&)K"\5%[/D@JVN9!F@Y<(F75<.7
MBSALX.BC[8I%(4LX-ZD]5TQ\9-P7K=NLPMNQ>.&T>+-F8STC6G&KML/M?R<Z
M5.';L.D[#2.MK9;Z](51^NY418KBNW76!L8YFZ9!3$TJR0`>ARN7G^((XY<V
M/)XIKS5/'WQQ[H.MQLVKL1N3?-XONA*M7M@U*>B$X1ZWUU!J[24L4E5+2[BH
MV33>2*;!9(&94S-BJ'/V%>C+6=2?5;1O%-OGR20=#TGQ7Y[\$-H4BQ4^F'I[
M;E/!W_3=OUS,P-!K@I5QWLZ'A+^\MM;N<PQ8-V!E6;:30DI`_N!!L0R@)E0\
M,SEI6\;"MIA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$5&G:[`6=@:+L<+
M%SL<8Y%3,9=BVD&OJIF`R:@(NDU4P4(8.H&`.H83T48)\=M)(J%52UO7$E"B
M(E4307(<HB`E'M,5P`AU`1#X?JQA5<G?6O2IH+3JQ#)*T"$43.'0Z:@.SD,'
M4!Z&*9T("'4,C`3D[ZU[8'26I:Q()2T'KZL,))N8IVSTL<FNNV4+U[56IW7K
M^V6+W#T.3M-_;R5!)/JI2PH44;AV@.J*PTGDZW(VEY*3<;6XJ+CW#9L*TQ,J
M&0C4W"BHJ."H++AT,9%%<Q`ZF$H%`1PI`RI1;BN9N@9T1-)R9%(7":*AE44U
MQ(452)*G32.HF13J!3"4HB'Q$`_1A0K.K5T^H['=J^%:LT.6F2,?'?.)J+48
MQ%C,_9>\,YKCM0>V2:LQ#L5.7X%$Q?[/0"E7OA0O@LY;-S(D7<((&<*@@W*L
MJFF9=8P")440.8HJJB`?`I>HX1?81$`$0`3"`"(%#IU,(!^@.X2EZC_;$`PB
MB?4^SE-J,K/+HUQW7XF#M$C56!Y!X@Y>2KJ%[$I9[Z;0IV:+--Z?TD3)+KE5
M[#&`W3H&%)&%+.%"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PBP=W6YG-D[PJ-,KDBRA('2[!;8]YN#YBC(M*U*O6
M3@(4Z;*08+QSZ7C&")G#8HJ`5,Z_J*%$$NT2K'09^M21J^Y7-#CRK?+C-'4D
M"-;)/L)ZV,?;OPIZ<F\6@Y29BHF,C06DS5XA%R-DD4@7.9-/O#N]3"@XSA4C
M7^P+?2.-TMMK9<K)V>6<-9BZ1S61;((/D8V653)48!1",B8X4?<@H@<Y2MA,
MB+DQ2@8I"AA",G`5*I=MVC';1U+7;=89"8F=BTJTW*_5\&#5&L5!B@D@I6&-
M?(WA$'K)PP>',T76=.A.Z,(B<HF]/L(0,9"MC<'S?8N[W=;6L@U^LZ,HLAM$
M):$;@TE8NU/(Q5"%]Q(2\5+QSE5L@)W`^@"?IH#VCW'$1+'TJ1T'\JO:#VU<
M(KB*CM6X"9Q<AI+MVDJ9JH@L_DGSQ>,K3I5FVBFZB:[H'#950A&A?B(_9Z?'
M)48^+`46ZS@-M:O=\9JF-E72^IU+$XL]`:1K!.&9UY*,<6&<FYZ4-`(RKJU&
MDI5+O$ZC9$BXE13*82F,J4G!R5D-LG:ZL8]L,/!2K6`C*)'(S.S+N[;%='KJ
M+IHH^A:S5HUZU/'6*WV`B'Q3,<4V2*A!,1159-,"@!4+5\GL=IH*5O5OMACV
MRPM9F]$>V5`JK6G0;U,CIBQ)&,XV,$#1,$B#D&@HE*+Q04A$"?$"''+'T*RN
M.++>EZ@:GL:Y[1FFT",O,/HRLKP\(HZMM6?&7!NI:%CP,4O'.B.RE%H#8I03
M:E^'Q4`2D.!T^E4C96R-HL-TV1A&W8L%K[7U-D+#>E8Z':O&4!$R$<H2!%)2
M3A'!IW8;]V(J-V8."M$^J'W2H%7`Y2`,*R-76WD'/R6BHJ8OLN24L,E,W*5A
M743'=_X0LC)$2D[D]5K#%125G'ZAFD>@F#42I&*L(F/T[80@8*RRV+LY:*G'
M-,K[UC&.XNL/+A>[>_2.Z9Z_JR8*I,7B4>*`MINQS3I%0C-D94O:5,5E"*$`
MJ:DJD#Z52>-DE;[12I._6Z=FY8+S9).7J[&8!JB,-3FYPCH!!-@TBHA)BX?M
MVPNER@D`&.J`AT_64NQG`60^%2F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB810))<>*=,7.XVF4D["[BK^$,>XT07$:C4;&Y@6OLXY682
M0C$Y=\W21`!%L9WZ"AP'U"G*/;A3R*O79FLX;9U$?:^D7;V%A7YHD%#0B<>F
MJDVB)!F_19(HOF3U@5JK[,J1B"B(`F/PZ=`P@.#E?W*ZMITQKQ]K%W'"-6D(
MX[!9+O*J[]452NR2ON'*;@%99*1(5T590I^K@H&,`A\,)GKE4&&I%0UBZLFR
M;-.KRUFDF:+2?OEF",0?%A&9B?+X-FA$1\='L(QN*9.U!N@!UU@`Q^\XAT)G
M/0+&W2VM8[=$-?MBV:Q3C=MM6YR:EPH[`8UJW?5VO22C6IUR>=.H!O9VS4(L
MHBX136;E=MURE-U*'4Q5$XZ?4LMKCKBM7B)KT#,(K)P5<L%?L+:'8^V0CGBM
M95!Q$QL@V4:K$6AT'!$SBB3T_M)$Z&``Z85(.%XZ=K..J<Q+6-S.V2VV&3/(
MMT)FUOT)!Y"P4C*GF#5J%]NT9I,89-X)#"0"B=044^\P@F0"D)RHKMW%#7-T
M>WA],25K'ZXG(^S.F2,A'C%Q-@8(MFOSB,C%XI=FM(.&*!FYE'I78D05.5/L
MZ@(%/(J4)75%8E-;2.K?4DV==EV:S.4<MG**DP_*]>`^EG#MZ^;.R+O)E8RG
MN%#)B(@J;L[/L]I1GKE2#'1[*)CV,5&MDF<?&M&S!BT1*!$6S-HB1NV02*'P
M*FBBF!0#^P&%"A-YQWHDE$6J&DUYR0;WC8#78-M7<N(TSNP.X]T@YC:])+%B
MB@O6(\&J2:2'0%B)I@`*]1$1*KD5666EJJUVC+[777DWTY(-(5FPCG"K9.%@
M4H2-5C&WRYJT:MUENJ3A0Y2N5%R(JJG.D4AA`0*,],*S+YQAI&Q)Z^ST[,65
M,]^B8./?QK)Q%HQ;5[76IVD--E;GBU59)]'E.)D4WBB[5,QSB"7<)1(3D0IC
MHU(@]>UQG6*^5S[%IU,9P^7!R^>+F*0AG+M<I$DS*>FF0A2D(1--,A2$*4A2
ME`H)RKOPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%'VVK#)U'5>S+7"
MJ)HS-8U]<[#$JK(D<(I2<+7)*28**H*`*:Z9'38@F(8!`P!T'X#A`M8.D:'S
M2V%QEU%R#O7D[ME+;7C1-!W)<5E>-W%./J]30LNOXF[6%522EJ((,H&"3>K"
M*[E;[MNEWJ'^`FR%62T'`'T_A7Q*YOQVB+XOF[@!9.+J[UL@[#5W"+VZVPH^
MH!L&0HZ2WTIZ9[;'T0?G*\>`^Z1B_P#I1R%1^WDIT_-_&K;"]R(Z_3VM_P!?
M#0OPS5LB5.3OHT3@H%2-;%F"4NG6OGPUL(T)T898KX6HJ>N#$?<B4$/O,*?P
M<?QJMS<M<ZU<);7MB\XE:@[W`P!K3,TV6UEP@86:-KA:P6[#-.X1U54I%*.^
MC#A+^H*?:,8/N@^X^WD)_P`G\:^U$>WO:!*LIK?S>0-[)>+3,T>E&J>K.$D\
M%ON5<K8W*P5:K_+:FX&?GX*IE&2>-&GJKMF/WRA2I_:R5'0>K?QKR6.<MM0K
M+"Z6GSD5>O5"5:RKZ-M$QK3@\PK[]E!6<U*FWC28<U5-@NTA[@0T4Z4*H)&\
MB46Z@E5`2!"G_D_C5Y(U?=:]+I.QTO,F8:!LJ?K]5UW=#Z5X9I5>]6>V2AH2
MKUVHSBM+)'6*<L<P0S9BT:**KNERB1,IC`(9*CIZ<>O\ZI\Y&[6K+*?D;'YI
MX^!CZI/6VK6A],:DX41S2N66A5L+C>("=<.ZBDE$3-/J1@DY1LX%-9BP,"ZQ
M2)"!A)T_-_&JC(57=L3*62$D_,F,?,4V%LECML6]TMPQ;/ZQ7J=7ZK:[;.3[
M1:F$7B(BL5B\PLC(.5RIHLV4NS65,5-RB8Y,C\W\:^;^M[GBU+:C)>9A-@M0
M:A6K_>4'FFN%S9>FT:YF?DJ%PM**U.(K`5JTGBG(1SUT"3=X*"GI'/VCT)T_
M-_&KJM^HN3FOS58M[\M=AIIKS;X?7U++:./_`!!@C6V]V(KH\#3*V63HK89J
MT31&*PM6#;U'2X(G$A!`INA,@^C?QJ%QN,Y\WKM?)YUJ<M.6Z6D(&K1#?7/!
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MYUX8Z-VO,)2"\3YIF$FC$NJFRE%6&HN%+M..=WRRS%,I#9Z9O4%`:K7"VUY_
M&1A3]!?OF2Z"/>HDH4I.GYOXU'*6S3+5-Q?4_/7KTU(:3T=5G%O&B\%2UI.Q
MR[)>3C83YV>M%C32;R*:JNR(E4$_M$CK]/2(8X%./['\:O&1=WV(O,KK&6\W
ME?C-C0<&M9IBC2&K^$+*UQM>;U0+VO-/(%S5$Y)"-0HX_.3JF3`A8G_I8B#?
M[S(3IZ\>G\Z]12;)-'3$N'FRAQBJ]J:%WU/R?X4\)080>D;(W>/*[MZ8>#4P
M;QFM9UI'KJLYM8Q(YRFB<R:Q@*80E1T_-_&K;F[=/UJVO*%8?.G4(.[1\0UL
M#^IRNM^#S"PLX%["-[*SFG40YJJ;U")=U]TD\2<&("*C90JA3"4P")3^'CT_
MG58,^O))/9$,IYP*XG+:<%N&V8Y36/!]-YK474NC7D?KA`]5*>K@:P.",!%X
M"(%?'!N;HL/9A1T_-_&K\D]2<ME:MLB<J?E4MEF>:V)9HVPM8OCGQ)E"PEMK
MD"E.NJS/$840QXZ7;-7K91=JJ9)=-)P01`H'*.$RW/V?QK,'A_L2U;>XF<8-
MKWIXVD;ML[CUIC8-PD&;%O&-'UHN6N:Y8I]XUC6A2-(]NYE9%4Y$$@!-(I@*
M4```PJ2,$C\*R+PH3"+\,8"E,8?T%`3#_P`@!U'"D`N(`]2L'=1\UB[-FM<M
MYC1FR=<U/<=`MVR=47:PSNM)EC;*Y3V$',O1<PE2NDY8JV]=P=@;N44GS9+X
M]R9A*<.F=1L/&?D8IC':AFL5IF1RL:V0%CGES1ASV-:X<FD$M)^M?1_G7\.Y
M\/UVVEH>2ZC;;SQ_:5:&RJ00[")]:>T^:)G&:S4A@L,;-`^-SH9'=,/`+2OS
M5W-;Z\=5!6TZ)V5J^L[(TS;-[:UM$_/:RL+:VT>G,Z;*R?=%4RZSTS7Y=6&O
M<<X1;OD4>[O.F)BG((9-_P`8^4;((+4$\\%ED$C6MD:6/>7@=7L:UPS&X$M)
M^@^A4^:?P[_NS#?9I?)=1N=QJ/(*VFV%>"'80.JW+3[4<?Z2W4ABGB$M.=CG
MPO?C#7`%K@5_&O.;06DC9[=]$[*U7"SO'ZU\E*5+SD]K*S$MNN*:E3W<SZ#*
ME76=?0L][&]QJJ+5^1OZGJG*)RF3,&+GC!@RVK:@GD9;96>&MD;PD?S`ZO8T
M.;ECLEN?H^M5>5?PZG2N?7\<\EU&[V%;RFMH+<4,.PKFM?MFTV++[=2%DL/.
ME8:Z2$OX\6GB0\+Y57F^5['V23V'HC9>K&<3QSLW*"!/+3VL;2>WZTJ2,6XF
M"QR=+NLV:+L`)3C,4FK_`-L"@JB'>7L-DS^,%KV,IVH)W.N-K.PV5O"5^<9Y
ML;EOPG);G_?5>[_AR=7M5*?BGDVGW5B?RROX[,(H=A6%786C(V+N&W4A[D&8
M9>4D/<X\1\)Y!>Z!YG*@VV8?9>B=CZJ?Z[T$_P"2"$;+6#6=K4MNNXQ.8%W\
MG=4FYSK1A.`M$"F1L^,V[A5*/<``80HE\:ZP?)6H9V36Q6R&R-X2'&,A[&DC
MKZMRL;9_P^,,VG;XAY+J=W6VWE#-"9(H-A6%:](8N/=;;J0N?#B7)DA$F.)&
M"2,W]^;S37U#]&?,9KZT^D?K#Z:^1/\`U?8_AK^*WM/FOI?(O>?27V^GN?3]
M;[ON[LQ?W=V79^9PWY;N<.7(>O<[6<?:QS_!Z=5S'^P?W`^ZOW@[5?\`=[Y_
MY7YCO,QS^\/NWEVL][A\ST_5\N'QXPLH,T2\93")A$PB811)O_XZ(W6`?S2;
M(_\`HZ9PI'JM2E2WIQ7W/XI-5\<F?-OBSK>T;&X4Z;U/8']BW7K0[NM1T]J>
MHUJ_1[V%"YQ\@WF2UQ>09D3.9,R#LY?4#H4Q<@85>'!^<'U6M&9X&<:)F7V%
M+K>5'A6D6WO-P6*OPZ6QM=DBZ1?=_P"IKCJS;%ZB@)LLJSB?EXR?BDF:IQ*9
MDQK;5`@@#AP..BKY'ZBLOKCIKAG2+M'7_BQS_P"%S"U6#5FUM.;*L/*3>57W
M_-&CMG0.JZ=';/J+MYM:,`MVUQ0-3LZY'Q#@$H9W"*F;',@7UQ=.BIR[Z05;
MVE./G#S1-\I5X@/)7Q?N*-#L^UK%6Z5?^1=5EJ+"SK?1]5X^<6]F1E6:[.:P
M)=M:CU72DH26D%FJK648S,@*"+==)DHDZ(2XC&"J+%Z%T'7I7C!:Z_Y5^&3&
M8X=U71=*TM55;AI5[43,J+3Q9;HN$[,O;PZN\5=]YW6P2CN2/$/&;1:,CX=H
MZ(Z]NL<Y3DG/PGJK<UEQ!X9ZPUMNO5$9Y,.)$C2]K:SXT:LA8=_MW6AV]!KD
M!?8O8G-=*'$VQ%55T^5%M2D9<B0F(2+DI58Q_63`I<=$)<3G!S_Y865W.9KQ
MUYBW*E3<=Y/.(FLZEIF.K]CU)2";!T9:V3G<[2]P]JD[_<W\U;57<::*@JA'
MP\$O`^PE8YM*S8^Z,5Z5,CHJ6Y;]!6'D]PUX<7#8-NLMO\E/#:9H^\)B\VWD
M?J\VV-=A7;Y>=M<GJYL#;%I@U3[(,M#N[GQ5KZ6JUB&*8@LFZ#D0^!TS.BJY
M.QZ'/_E_YU^5_B[HZMP$A3Q\KW#*Y1NUJ+N71F][C<=FT138*^C]D;3I,@U0
MH#R-VFA&#?9#CWJRL4.5=2J:S831"4DD!A`[15T3)/Y)56MG'_4TM-;3V(EY
M4^"%NV!R`1IKW<D)=+?JF'HKI>C\EM3;QK]$@)*F7YA>Y#6<'0J"[H<<A-/9
M!Y'P2R(H'((N$U&0@)],'`63G--?4/-&C\<VDMY+>#^H=CZ8LI]D/;'1-MT2
M7B8[:R%AIC>"N-`;S^Q0?,7-6U\2T-F1GQE5"2DJV7^":)R'95+<MST.%B5I
MKC?I+C]8GKK6/D=X&QL3^#[/6U4>,^3UJIKNDOV<ENZ\)2#FF4C></KW:D6&
MS=SKO_;VEF_ZMVW;_?#F,+HJB2?H/JI]TI2.-]&XZZ=X\VSG]PD^F]9;QXOW
MN81C>5T_LJ*M6NN-#F!M474HZ+W3NNU-J"ZL%\J$6NJTA2-85-FDH3VQCB02
ME!R3G!S_`"*"UN(O%.=V-'[8M'D_X>%N[K=-=ME[=U_:VN&C2\:2L'([:/);
M?^EI)!WL=8A6FR[S;Z\9H[$I_8_1[(1(<ISD!T4Y(^@K*'B:&I>/EH9R5E\F
M7!JQUO5N@;II+2]>@-HZ_9MIFSVRYLK@]W]LPDYL655B-FV=:*2^IT8)<&EA
M?.%WKDXJ)M4D&0H.3]!]5A"AP8XR0<369"H>57AS!7^/K+>F6^4'9VO'%>OT
M#0>,4'KS0:TY&&V:"Z<QJ;DRVE]BH+D-U6-8GS7J!C@KCHIY._-.%EM;]8<4
MJ<&J6W&;R-\0&T?2>.NT.+RS/E#R!B.0C:B4[:<=K&'>[`T\VGMR%+`VBOP>
MM$F"<$J=.!?LG0HG%NF54CED*`3](/JH#5X:<.&4(I78OR><9)J!D)3:C!U6
MKQR,K<Q4X*!G=<T/CQJ:^U2L,MI,8-OO"@\7:@_I[V5<-U6<@2PNUTT4#HMA
M*Z*>3OJ*MW7G"KC/7ZQ8*+9O*_PY<P&QV>G8;:\U%VK1<U/6:A\>DKZ73>FV
MD)>[G8:6GJJNC8H!-RQ=,G/NT*>T`2@9X[-CHG(^O$Y62C;67&:7I#>IWWR1
M\*YYXOI?QT<>IJ=9;9UVV?.=7\-]B.=D[=09*.=B.#(2^^)A\JB4RGJ),4"I
M@L"_;TQD*,G/H?4_[ZAM7BWQ:V)2]4:CWMY$?'W8=1Z<JS32K6!H=]H]6FMP
MZ7G=P4#<6X)W<<R\VO).'NU-L3>HJ\#D&9@C&CY66D>J[A\D1HZ*<G.0#E9\
M\9-D\4^+7#&TZBN_D(XO;LVI(M]WW&_[4-NW5$5)[(MM\E;1+M)A_&?6SPY9
M=*O.(Z/5$%#`JHS[R]"F`H3E4D$NR`<+-WQY"!N`?!\Q1`2FXB<;C%$!Z@(#
MIVFB`@(?`0$!PJ'?:/\`*LP\*$PB_DY>\AR=>G<4Q>O]CN`0Z_\`/@="JFGB
MX.^HK6)HSCAR1A'W'"M;,@M25ZG\:=*['U9'6BH;%L]OFK^_MM<J%4C)52KR
M>M:BVJK1-M6CNUB#(OCE,J5(O=T%3.XVNYTLK;L])UA]B[9CE+7QM8V,,<]Q
M'(2/+C\6!\+?K7V/[D^[?M)L:WENX\/L[VUOO,/(J&R?6M4*]6*DRK/:LR1B
MS'?M.LN+K`B81!""&EYQ]E?FH^./),$=+U?:$!J*I5_0_%/9''J(L-/V/:+Q
M)7B9N<#JBM,+"Z@9/6E,1J\6U;ZW4=*I`]?J]SLJ1>O8)QG8;K2YLST7V));
M>PCL%KXVL#`QTKBT.$C^1/<`!PT=,J?.O=KVB[GD.Y\,M;Z]M/)O-J&\E@M4
M*]..G%4FV5A\#9H]A;-B1SK[8VN[4+<1%YQR#5\M?<;>2<S&U>N[0@M14B/U
MQPGV1Q7KTM4=CVB^N;7/WAAJF+:6J2C9'6=))6X:/1UH=55$B[]<PO"D+_>Q
M,:;>ZTL3Y)J+K$KYMG':<'QMCX-8926`B1_(GN8!PT=/PJKRCW<]HM?;N[;P
MRSO=C:V_N+0\CGBM4*])M:"F_92.K1R,V%LV)7G8!K7ED+`(BX_:`'PA^-/)
M:\P5CAME06H:`9CP5V#Q+J3BK;(M%^">L=T9U=JVMDVF]UE2AKT''C5BF412
M%^X/[GH7^]CW)-WI:LK)*3K$N=K';?RC:SBUA<2QN)'\B>70GB.BO7_>#V@\
M;V52_P"(6=]M!+[E4?)K3;-"M2[,%1UASJT)9L+??F?\R0U[NRP=OK]KI(FO
MM![@OUUN,OR-INN*E3IWBRWXRJUS7>SK->)&Q1DA+2SJQS#F5?Z]UX:N)J1;
M_P!!$B/N5@4.)P.7L#KB6]OKZE6*/3232667_F>4D;6!I``:T`22<NHR2<#Z
M,+D_*?<_P+QCQW7T?:;8;:]OZWFCO(1/>U]>G'!(R*)L$38V7KW?(D9S>7]M
MF!QXGD<0%_U8,A^87ZP_%S:?X1>G[#TOQTV1^)WR?\(_H/Y7\]]'U?9_,?N?
M3][T^5?=_P#B\VO[\,^Y_EOEX/O'USV(^WGN\\\?KQUSQ^WU_"O3_P#QE5?]
ME?W!]Q:7]^\\\_<]#[O[OWG\[W.SG'/M_'R[.?F?C_LEN#SSM?!281,(F$3"
M+Y+(HN456[A))=NNDHBN@LF55%9%4HD5252.!B*)*$,(&*("`@/0<(H3'C%Q
MK'XCQZT<(C\1$=34+X__``#"G)^M8_VVN\6JQNBN:7+Q@T`ZEIV'K$ZK)2,#
MHFL&28VB>LT$U)"5R?19V6WO62E4<*N$HULL)"G2+U$Z@%S;U]4^?6OV7(B-
MKG-P&/=U8UKCR<T%K`>0`+B/I^@+U'1^V5S<^WMOW"-F5E&M8L0B..G<L`OK
M0UYG&:>")]>JQXLQM8Z>1@)#ST:TE13"7OA_;ZE5;#2N'5"G)FWDK+=A3WVK
MM.UZ8CYZQW-[3`K\XO)(!'QCM@NR%Z*@J'1<1ZR"R!E"KI]<^7QFQ6L20V9H
MFQQ\B7CDX%K6!_)N!D@YQ]8<"#C!7;;'^'?>Z'>W=5Y#M=?6U]`V'/M,%B>)
M\,%1EOOPB.+G(UX?V>/$/CG9+'(&&-V+@<RG%L(P\O'<*J3),ZM`2-GW(F&K
M=,MGNHHF%MELI$X25;G*<EJE8J=H4X<[>'4=@JQBU5TCG%5HFXM-T#^YVWSQ
M!TCPV'[6)2YC'MP>/P@MD9U?C#G@$##BW5P^R%LW!0M[K6PSW;4=?5'%ES-I
M++6K7(3&X0@UHY(;M,!]H1\9K+(GM:&3OBH'UWPZ)([)9'XF:D=(Z]B]KRHK
M0E*T;//'C?45U0HL\>>AHXIY6@M921<E=,7,PDV;'CR*KJ*)>D)1N_NS9+87
M"1H,SHA\37M`[S.;>)+<2$`8<&9/+``.5M/_``[^0.J:BPV_`Q^UFUL>)H+<
M+6.VE1UR$0RR0B*ZZ.-ICFCJNDD$Y9&QK^8(J#6?XK.Y354$7B3H-O*[/:/W
MS,7R?&MK$`S8V]C4".JK-BZ.SV,C+.'Q73(L/ZZZK<Q"J)I+G!$*#X](V.>;
MN$QP$`XBE)R6%^'-XYCP!AW/`!]"1U6+-[$WX*6[V1V$CZ6F>QCN&MV3I>;Z
MK[1;9A^6#Z!B:PQS&UP8UX<6O?$WN&DN=E<)T8%I-)\3:"HJX#DJ9S&JZDU(
MT7B4^,[>6>3SB6<N4",V;6YLH]%>&4$XE.@\(=?T0(KV71XM<,IB,D6!\M@_
M$<_,D!N`!DEA)#Q]8(&<C.=#_#=Y9)LY->Z_KPQOW!QD!G<V4^0.B;"V)K8B
M][JCWO9:;C(?$YL7<+F<JH>W<.HQG57%CXK:9;#<J_M^=A'E5J&C-A5LZVH8
MJ"EW<`ZME3*]A&L_:FTNL2-0%00,X9'15,FJJ@56T/&[,CI!"\'MOA:X.:^-
MWZ8N:'!KFAQ:P@<C]3@1D`XPF^P'D-R>[%J;C'C7VM7#,VS6N4;`&TDFB;.V
MM9A9,Z"LZ)IL/#<B.5LC`]C)2R4Z/0M#W+9-HHBO"W5$#%UJ`@+']9/:3I=Y
M'R3"UFD1K16\/',G$ZW<2",.[.H59$GH>D4#"/>7,&UKHJU*.V)VO>][F\`U
MP(+,<NI''IR'H>JXKR3P/7>/^(T_)6;FO9NW+4T'RC(++'QOK=OYCE+)&V%S
M8S+&`6///D2/LE>VT4[B958[=$D\XR:F<I:2C6$G/IM=2ZT]262D*RA:$DX;
MU8M,HJ$:.`3-ZXI!ZH#T$2_'*8-9-8?68US0;3B&YSTP[C\73Z_JST6/I?;O
M:[NWX]4KV(&/\CF?'`7%^(BRP:Y,N&GH7-Y#AR/'\/11#+73A7&1VQ7/Y5M;
M#(:SG=OU^?BG^J=1PI_<:DD&#%253?R;="/2K5O2D2KQTBJHFW*1%P5<4E&R
MQ"["/QJX]\(YQ\)V0N:1R/ZT$XP!GDS&'-'7J,9#@N\H_P`/GE5RUJ8OG*?R
MNXK:N>&1G?E''9L>\1ED<1>;%4QED\#6EY+XC$'MEC<[(+5NG^-.RZ:PMZ?&
MSCY'I/W,@@DA$U33=X8&*P>+,C*(6.H1\G!NQ,H@8#$36,=$X"0X`8!#-1>J
M&E9-<EQ(`]6.8>HS]EX#A_N=?H7EGFGC+_#_`""70OEFE?$QCB9:UBF_XV!^
M#!:9',WH1@N:`X$.;D$%2'^6+C7^[UH[^B:A?L#,-<KD_6GY8N-?[O6COZ)J
M%^P,)D_6GY8N-?[O6COZ)J%^P,)D_6GY8N-?[O6COZ)J%^P,)D_6GY8N-?[O
M6COZ)J%^P,)D_6GY8N-?[O6COZ)J%^P,)D_6GY8N-?[O6COZ)J%^P,)D_6H`
MD*]Q99;V9:,2XIZ@=2:T0PEGLR.O]-L5&S:4:2[MK)1U5DFS2U66LLS0QFS^
M3CFSENP>KI)*!T]<Z&V9J7NU1VAD:&<B`,..2"T$%P!:UQY9:UQ!<`2/H!]0
MJ^V-VQ[:2>Y+[L3*;9WQ,B[5AX<Z-T371R68XG5J]AW=$D%>>2-\T3'O8<]M
MLEI1CSBG;*W"2&O^'FN[9:[/<K;5*]1EM7ZBKDD\:5)@-C4MSN6F6B4-&UB>
MI#N-EXU4ZHK.49IB0R:9E5!2R9-#)7G<RW-''79&Q[G_`!.`+SQX``9+FO#F
M.&,`L><G`SO;GLKL-'M[%7RC:4:.CIZ^M9GN!L\\;'67]@56Q11F62Q#;;8J
MV&AH9&^I9<'N#&<_E)3O#9C*76O)\4==+VO7-*D=C7RI*ZFU&SL%/I3#5\)L
M=*7L319$4HY:5?3R4`S;>H=5Q*MW9B=6C19R66>/67LBF,D8KS2B.-_Q%KWF
M5T>&GCUP&F0GT#2W\IP:JZGL5Y%9I:[:ONT6Z3;;&.A2LCOO@M6W[&:@8H'"
M++Q&R%UV63B&LK/@#L3SQQ&5Z3RUH:[:I5Q.C25;67V-!ZB+#UR1I5FK54;O
MJK7Y>$G?G=-FWM>)4&BUK@X54C<WN&,C*MDC(%1,"HU3>.6(P][)&.C;`91D
M/87<7.:6!KF@\L,>\9Z%K"0<]%D[GV#WNM9:M5;U::A7TTFQ8Z2*U4EF$5B:
M!]9E>S#'*+'"K;LQ\FB.2O6E<V0O!8+E?<HXF(B[5=9NB6:&U)7WSY@SVN_D
MZJA6)'Y%L*+UM9'T@BI-DD:Q%,IA^L[:N'R9"/HQ@Y<!Z?:D16VW12221UHI
M6.V#P"8@'\ARC,C0/APXEH`(;]ESFCKUQKZWLO>OW:7CNNV=.QYS:B8]^M9'
M9-B/O49+\#&$0F.Q(^)C8I&0N)AL30Q'GE[F3;KB\-MDT^)N\=%245"6(JTA
M6QE@;IO)BLJK'&`LP-4%ES,65FC/3?-45Q(Z3:KI@NFDMWI$U=VJ:5EU5[FN
ME9T=CT#ORFY^DM.6DCID'!(P3YSY;XW+XCOI_'+<\,^QJ$,L=KD616`!WJ_)
MP'-]>3E#(]F8W2,=VWOCXO=?.8JYM,(F$3")A$PB81<8_P">;;'[T-"_SS\N
M/_E<^E/W6U_]0F_N>I_X%_03_P"&[PC_`#,V?]Z>V/\`P*4-(<T-GS^Z=003
MSDC2)9I-;1H$2ZBFUN\IR[B3;2-LB6:\>@A<E1J"RSU)84RDE?\`!IC&`'/W
M'?F!M/&J,.LL2MI2M<V"0@EFK`!#"<Y9\?3U^'XOS>N%QON-_#YX;J_;W?;*
MOXCL8)Z^FNRMD=5]N0V-T=:5X>35'S0#".1-;]H`&8?TG%==&?/2_"A,(F$3
M")A%$$YJ-.5V>QVE'W:T5V32A:S7I>#CHVAR,)8(FJ3ECG8YN\5LU,GK#%**
MK6MZDNK%OV"IT3EZ&*<A3AL8M@8Z)HOBC>SDYP<2\.:7M:TD<7M:?L@@.:X9
M_`<+O-;YTZEX;)X7:UU*W3-BQ/%-))=CF@ELPUX9'-%>W#!*`*T3F-L0S-#@
M[(+7%JB,_#+6S1RVE:Q9+]3["SK>G*ZVGH61KKI<JFCW3M6H6)6+GZQ-5YS9
M7C!R1C).%&9BO631L02%,@F<-A^\MUS3',R*2$OF<6D.'Z\#FW+7!P:".31G
MX7%QSU(7=#^(+RZ>%]+<T]7?U4EO:SNAECG:W&W:T6H!)!8BG;78]IFKQME!
MBEEF<'$2N::RYXHTU6-2B&=TV3&L)6!>5C99&LW"J.-Q0<G:;!=9="_.WE=<
MKHO)>R6Z84<.H48A?V\N[;IF31.D5&V-_9$G<='"7M>'1Y:<0N#&L';`=Z!K
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M?./L@N```C`C%*6X5:C.-E41D+JU<6B%GX1XLE,QJ@,T;+5;U4)5W'-W4(X:
M(/G,9?%3J&.FH19:/9&5*<J)BJ71Y-L?@!$1#'-<.AZ\7,>`2'`X!C_!@.=C
M&>F='_$/YTT4V21:Y\5*Q!,T&*0<S7LT[4;9'-F:XL;)2:&@%I8R>P&.:9`Y
ME=M?%:H;$J$Q4-DVZ[7-*7IUSI(3)@I52EXJ-N,I3)T9*%^@J;58MA8:U.45
MD\C'H-3*HKB<5?6*)"DLU]]8I6&V*4<41;*Q^/C>"6![<.[CW$M<U[@YN<$8
MQA:S2>]F^\4WT&]\1H:[7O@V%2WVOVNS%))5CMP]N7YVW9D?!8AN2Q6(>X&N
M9QX=L\BZ40H"]?D;'9:0^:M[18H6DUYP:SMUY2!2C*0,T1@*4?%.(9X5XNA/
MN`4/[@2"8""!0`H@;!^;$S&06@3`QSW?#T=E_'/4Y&/A'T?6N,/E$6TJ5-1Y
M'$]^FJ6+<[17<V.8R7.R7Y?(V5A8#`SB.WD`N^(D@B.Y7CT-L7O[NUW^SH(;
M9K1(#8M2JK:LL*A)+MX%2M,IF(4FJ[.W2'?M8H$A`I9<S8ZR0&,D8HF*.9'N
M/EQ"VO$PFN_E&]W(O'Q<B#Q<UA!.?R,X/K]*ZNC[J?<<>K@TFKINDT=PST;-
MEUA]J,.F%A\4HAGAJ2L=)RZFJ)`QV&O!`(I-KX@ZNM<B\FEG]NBIU]7-MUAQ
M+14G&%47CMO[!_$V3.\8R$+(1,BZJEH5<#"&<MU0:-GKE%0%R+GZW*_D5^NP
M1`1NB#XG`$'UAC[0P000'-QSP1DM:1C`6=I/?GS/25(]='%0GUD=O66&Q21R
M8$FKH_=\8:]DK)8VV:X8+@C>TRR10R,,;HVJ3(JI[+JS&/B(6]0UD8H&76>R
M=[J46E.K*.'2BHH-4];HZ_K#9F@@8I2?X.%83]QE%#]0Z8+[%*=QDEB<QQ]`
MQYX_S]SN.)_Y6/J`7'7MYXANK,M_8ZVQ4LN`#(Z=F0P@-:!EQOF[8<XG)/Z<
M-`P&M;A>PK7=/:EWSNKQ."PBL):G:P*9OT2Z%2`;H82K=0/U,(B7H)?A\!ZT
M\M9^9/C_`([/Z"L&?V]R>-;<\>/3]IK?:Z]3^R=1Z=!@^O7TP,UW3VJ=L[J\
M#^L`I":IVL2@WZ*=2J%"Z`)EN[M^T`@7H`_#XAT<M9^9/Z?GL_H()_;W(S6W
M/'CU_::WVNG4?LGIZ].I].J_3-=S]%^R=U@`B<OMNZJ6L0(EW'[P7Z7,OJ'$
MO;T$O:`#U^']ARUO3X)_[=G]!0V?V^^'E6W.,?%BS6ZGIC'[)T'KZY^A?IFN
MYNY;LG=8@44TP;@:J6H3%5ZH^J980N90.F)04[0+VB`B7J(]!ZN6M_,G_MV?
MT%`F]O\`#>5;<YR>7[36].N,?LG0_9SG/T].HP]KN;K_`.W=8]OM@`/\5+5U
M]WZ8=3]?K+I[;U?CV_RNWX=W7XXY:W\V?U_.;Z?VB=[V^Q_U;<YY_P!9K?9S
MZ?\`5/M8^GTS]"%:[FZI=T[K$2@BH"W;5+4`F<#ZWI&2$;F($1+U3[BCW&'H
M;H(=0Z.6M_,G_MV?T%)F]OL'%;<YY#'[36^STSG]DZG[6",#TZ'!S]&C;<`.
M6`OYO6JC,KE,9,C2KVA%RJS!8@K$8*K7!=)NY,W[@*90BI0/T$2B'P&'.UV#
MQ;/RQTRYOK^'X/3_`'%1/-X$8916K;<3EA[9=9KEH=@X+P*H+F\L9#2TD9&0
M>JL;8''B%V+;T+7+7K8;!!J(OV-:C)*`-"P]I2K<K565PKCN5K<I9*M+MHN7
M,*J$<_:QSU=!%1TV6Z+`OE5-Q+3KFO'%"2>A<0[D6\@\L<`X-<,MZ%S2YH)#
M2.F.D\6]UMCXGH7:2CK-5+(_X'V)(Y^[+6-B.R^K.V.Q'7LQ.DB`:^>&2>%C
MY&PRQYC,=KL>(.LJF9-;5$A8]-O&;J'?Q"]`"LIMH>0CJD^HDH_:Q%DK=AAG
M#JU5)=HTD1<MUP4-$1ZZ8)+M@4-??Y%>L#%\,LM((/<Y9(+Q(`2US2`U^2W!
M'VW@Y#L+=6??GS'>`Q^;Q5/(*\C)62B[\P72LDLLNQL=+!8@E:VM:$LD';>P
MM%JU&\OCF+1ZI'B1K"00E`%_<6\G-QTI!3=D+.(.[/.UR<T_!Z8F:]/SLG'/
MG\_&24%68^3/[TRZP3K-)X50O04S0SR&\PMZ1F-K@YK>.&M<V9TP<UH(#2'.
M<WX<#@2W'TJQ4]]/,JLD/Z+7OIUI8YH:YA+:\,\.TFVT4\$,<C&021S6)ZX[
M08PTY7P%IR'CW7/B?IB](1[:9KB;=O`5"0JU.0AVT1$H45[)R4;,N[Q4&[2*
M(A$7LTI!1RY7X%.!5(]`03^!^^BMO]E5),;\E\@>_.3S`!`8_)ZLPYPX_P!D
M>JQO'O?#W!\:DEFU]LOEM7V6;3I72RNN,CCDB;3M.=(3+3[<T[##D9;/(.?5
MO'\7XQU9Z>88R=QOLE39"6>SD;KMR_KX4NOR4QL*%V=/J-(]*N)NYE&4M,(`
MII2R\BG'-'3ENQ!LDL)0#>3MXO9'$+(:&F3#N;@V-T3<GEAN&NZE@;R(:YW(
MA3%[R;JLVO9IZ_5P^010,ADO-9/\W/'%1FU\`<\SEL1CK3'DZLR!T\L<,MDS
M/C!-UUS7=JURQ3K&MYROH4A&0FI-A#VZ*E)A[7PG)B0F%:]77<3,0:#.I1"K
MWTHUHJDL=DV`$"*"BFD0EB:Y!==W[K7FT0T$L(`=Q`')P(=EYQEQ!'(]<9))
MTFV\KTGEED[GRZM:=Y&Z**-\M62.)D_9B9$)YVRQ3.=:E#.5B5KF"63,KF=Q
MSW.K1&NZ.B'J3NL!$%A%SV5.UE`S?[KM*AW7,W8L'0_4QNXOQ+\/@/6URUOT
M,G_MV?T%KG3^WOQ<*VYQQ^'-FMT=U]?V3J/L]!@^O7J,?S[7=7:/^'M7=WJ]
M0'Z3MG;Z'3^2(?6G7U>OZ^O3^UCEK/S)\?\`'9_04]_V\S_U;=<>/]9K>O\`
M>GI^#U_"OZ.UW/\`?^G.ZP`16`6W?5+6;L;]5>XJ_;<R^HMT$G0Q>TOP-\/B
M'0':WIED_I^>S^@H;-[??#SK;G[/Q8LUNKNGI^R=!Z]#D^G7H<_IVNYNJ_IS
MNL0*($]KWU2U&$@]Q/4]<0N104`2=W3M[>@B'7KT$!<M;T^"?\/QM_H*&S>W
M^&\JVYSUY8LUNO0XX_LG3KC.<],I[7<W4_2=UCT]N0"?XJ6KJ#KL3]0YQ^L^
MAFXG`_0H=#``AU,/01%RUOYD_K^>WT_M%/>]OL#]FW.>1S^TUOLY.`/V3[6,
M9/IG/3T7Y[7<_4G^'=8=/0,"G^*EKZBY[5.PY/\`'/[*`&$G4H]3"`#]H.H=
M'+6_F3^OY[/Z"=_V^Z_LVY^UT_::WV>F0?V3U]>OIZ=/KJ_H;)^GO3^:4?ZK
M][W>\^03WT]\NZ_WKY;]2?,O>]/[OW?I]?[C+>:7>SQE[&/3DWEG^7CC'\RP
M.[XC]Z\^SLON3M_8[T/?[GU]SY?M\/P=KE_9+G)_,5R%_>*V#_235?V9GLOW
M-J/ZG#_<W_\`"OUH_P!D_M7_`)IZO_)]G_I%?NJ]^;XD]GZWC9+?M[DXZ0OM
M/9/XUSL*L.F\@R=V&.0=,7#9*.*JX0=H*&3.F00,<IA`!ZCF)?U&JCHS/94B
M:\1/(/;<,$-.#G/T+F?-?;#VSI^&[>W3\8UL-N+66GLD;1L-<Q[8)'->UQD(
M:6N`()&`1D]%T8YXVOR:3")A$PB81:Z^+FS*K3[OREA;E93,)'8?D-V+KW7S
M-Z$H^&6L9=$:QMQ*]'F10=HQQ"0=<D70>J9!L'HG`#>H<I3=EOJ-BS5H2UF9
M9#IXY)",##>_*SD?3/Q.:.F3U^H+ZO\`>?P_=[_QSPO8^/TQ+4U7M50O7G,[
M;.U!]\["J9WY+3(3-/!&>(?(>;3CBTEMR\A^1&HM@\6=X,Z#?$)>5O?$KDW?
MJ0#%G/Q[F5K6OJY(T^U3K-PZCF0L?D-IF6C805.BX,HJ!TBF(`G"QIM/L:F^
MJOMQ%L<6PK1OR6D!TC@]K2`3GDT$],CI@K3^U7M3YWXM[T^.3^3ZQT%+6^<^
M/4KG-\+VQV+T\=JM"]K9'\^]6BEDRT.8&M+7EKB&F#>-FSZQK;<?(.R[%M"L
M-6PTCXV*ZW>/QEI%LG8]@P5_J%?:)-6:+]5)S8;1,LVQE03`OJ*%.L<I"B<N
MTW5&>[K:<%./E/\`-;)V!@'C&Z-[CDXZ-:"<?S#KT7I'N[X;N?+O`?%=/XG2
M;8V_[Q^?3N8SM1N,%&:E:G<7.+`6P5XI9`TN)PTMC:7$-,M[CV75;YR!X7)T
MBR&ED:ERTW+K>YI,RR;%)E;:MQ@W0I-5Y^FZ09DD!C'"Z)Q,0%FPG[3$.82]
M0U^MI3U-1LS:9Q,FOAD9G!RQUJ'BX8SC(S]1^M<-X#XAN_&/:[W"?Y'4[$E[
MP;57ZA?VWE]6SY%J1#.PM+BSN-#Q@\9`,AS0#@V2OR`U<\Y>U;?;6]D5T>U\
M=^X=CN[85O/%AR5FO[PUFO)V,\(9@64.9@Q9N/T,Q<B0IBD*/=T'*&HOM\=?
MJ71?]J'<0QAGPYY.@DPWEG'4D?3A=%%[7>9U_8B[[8SZPM]QW^ZVKH-K<H>Z
M;$^GV#8X!-S[8#WO9_SHCR07$8R+OY@[5IMJJU8J=0M`O+-1>6/!,UQCV))5
MBO$L;_O/7<Y74W+E5LT;NV\_`B904TE%0],1(L!1'MS&\<H6:\\EBQ'B"77W
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MWM+L[JS!XC8KM<8G/,.PLOL57L>US@P6()HGXY-<`X-D#2"!;:&_]71?+B[;
M\D;T1OH]SX]M';':6T[>>4AS5BR;KVLM%6(D(FQ/*IFD6;UO\/9@Y`ABE.4.
MWH%\ZB_)X]%J619V@W$\99EN>388LMY9QT(/TX6XD]KO,[OL5KO;"IK"_P!Q
MV>ZFXH.K!T(E^8KZC6B2`S%XC(C<Q_\`SICR"6DYR<U7W(/3L=.OZR]N[)"=
MC-K5?2#Z/-'39E&^T[I58Z[UBHF53C#MS.Y:K2S=V5<IQ:$(J!5%2*`8@<PS
M4;)\0G;$3$ZNZ<'+?U3'%CG^OH'`C'KTZ#"^=ZWM9Y];UD6XKZZ1VMFTEC;L
M?W(<.UM2S)3L6L&0.#8K,3XBP@2DMY-8YI#C@#R9V77-B;=T=9M>V=:7K1^/
M7DJKZSU@:5CFRECU]%ZXJ$^U5:NTF*RCJO6>&>-BJBF)0.F8Z)S$,!S==I*4
MU/76H+C.,WSFM=@X/PR&1[3D9Z.:6G'\QZKZA]GO$-MXIX'Y)I_*J;8-N/*O
M`)PQ_;D<(+TE^U`X.:7@-GKRQ2%H=G#@V1H<"T3AQQY$:BH'%71C.^7Q"*E:
M'Q,XLW:\`^9S\@YBH#9=;C:;3IIZX:QST7PV*UPKMJ`)'67(HD)UBD(8IS:O
M=:?8V]_:=4B+HYMA:8S!:`71N+WM&2,<6N!ZX&#TRO./=KVH\[\H][/);'C.
ML=/1V?G/D=2GP?"QLD^OGDMVHF-=(SAV*TT4AY!C"UP;&7.!:*9Q^V75:1M7
MELPNMD-&+7WG<VUK0F[TLF^+*6N0XOZ:LC*N1X-T':<<"\;`R#D!4]!L`I'Z
MF`YP`U>WI3VJ&O?69R$6J[DA&!A@LS-+CG&>KFCID]?J69[I>(;KR/PGP6SX
M[4$T>L]M';"ZYG;9VZT?D6UKOG?R+3)B2:"/#><GQ-PTM:2+7X,[LU[1>+FO
MXB_W,(Z>71Y?[.!*12FI)TK0=5<B;T2[SYG2#-\46M80L4>441/[@Y%BE03.
M!#`6_P"4ZRY:WLTE2+E$#4BZ<0.Y+79P;C(ZNXNZ^G3J0MU_$C[=>5>2^\^T
MO^+Z_O:QKO%M=F,PQM%W9:*F:<'%SF?%8=!.0\#@"PF1[2X9QIY1V]"R6/EY
M9JO//75>G=?^*&PUM\T=2+-!>)LO*NU.DG[-NH+9=F$O%KI^J`D3443$"*!\
M.T-WHJYA@UT$[`)F3;5K@0#U;58,$]<X/IZCZEZ][,:&34:GP33[FM&S:UMI
M[E06&.;&\B6OXW6:6/<.0?VI`[B<N:UV7,/7*VNM.0VFWT\C66MX9+3KC;TS
MH9&/".G"J'VW7Z2XV+,4T%3Q96X/&5+:*/A<"<&1B%["K&5Z$'@7:?9,B,[H
MB(A7;/G+?U3G]L/]<X+SQQZ_3C'5?$<_M5[@5M8[<3ZV1NM;H8MT7]R'`UD]
MMM"*W@2<N+[;FPAF.Z">1C#,N6&_"'>^M=?<0=2,=B7<L7,1FH-U[HE@DD)R
M3=):RUELF8;W:V+NFS)^*S:O#.,RG1`YG:@*E!%(X%-V]'Y/JKMSR*PZG%RC
M=8AA&.('=EC'!F"1U=Q/7TZ=2%[]_$;[:>7^4^_.]L^*:XS4)M]J=3%VS#&T
M[#84(G5*P:Y[,.G[,I#\")O$]Q[21G&O>=F&8V]RLEX.:?+PTEL_P\2,*NW>
M/VZ!XN?WJ1<RK5N<Z)VJ,LQ6+ZQ.P@JD'M4`?T9N]7!V]=KXY6@2"#;AW0>K
M8/I^O!]/J^A>O^VNG%#P3PBALJ\3=A#IO=*.8.:QSA)!IR,.<`0XQ/!X')XG
MJPCU67'$G9-7K<OO&K6JQF:V#8W/7DW5-?QSP)-ZK,R4!'?6+Z(8K)H.F[!*
M/K-?>N@!8Z"($1$I!$YBD-SWD-*>:.K/`S,,.IK/D(P.(<>`)],Y<YHZ9/7Z
MEX3[Y^([G;T/'-UI*@?J]3[9>/6;LC.VP11SR?*LE>"6N>7V)XHR6A[\O#G?
M""X4WEIR/U!LOAGR%::VV`C,R]VX7;GW)2ACF=@C'4EKZ/A7E96MK-T\C8\6
M*;:P2*"`)J'1=@<X&*GV@)@K\?TNQH^2TW782V.+9PPOR6D"0D.X$`G.6@GI
MD?A69[&>TGGGB'\0/BL_EVK=7H:[W"U.JM]QT$C8[TDK+`K/:R1_,N@C>_DT
M.BP""_)`.?\`51$U8KAC")C#`PXB8PB)A$8]N(B(CU$1$?UYR,_Z]_\`QS^-
M?+N[`&YM@=!\U+_Z;E7LM+6)A$PB81,(F$3")A%R*?E+UY_/#I[_`+&F^?L3
M/?OOBS_5)?\`*T?])?NO_MP\I_Q!OO\`ZJT_^F4D:;XN4*(V_JJ6;;8U.^<1
M>R:-(MV3/Q(7:DO':S*SQ;E)JTN;B'3;U%RX.D!$Y10Q2,#""YA`$QS#V.VL
M/U\[#5E:#"\9^](WX^$]>`=EV/S1]KT^E<EY_P"\ODU_P/=T9='NXXIM1<C+
MW>YM2VUH?7D:7.J-E+K36@Y-<`F8#M@9<NJ//#5^*J81,(F$3"*`4.,FFV]A
M1M*5;=EFF^]9/D@DZ&?G3$+MV8H"VL7]B%N,@+<S5:FKF;`Q$OLBG'U02!7[
M>;<[S9.A,!>.T:HK8XM_4B3NAOIZ\^O+[7T9PO4)/>/S^75.TK[C#KG^-1Z`
MM[,.?NN*Z-BR#EPY<A;:).]GO$?`7EGPJWF7#K0$?76-5:U%ZG"1VI-KZ/:-
M1L]E.=/6^ZYIC8-BPHN#RAG!W$S*1R*B;LQA=-`+VH*)E$0&Z[R/;NF,YD'=
M-B*<GBW]9"TMC=Z?D@GIZ'Z05M;'O[[H6MK)NYK\9V,N]UNX<[Y>N`;^HA?!
M0FXB/B&Q1R.:Z(#MR9S(UQ`*]C_B3HJ3+8BO*H\4"U$T*G-]+)8D_=%XT39;
M#IX""23*+?Z;E2`HKZ?;[\/LN?5+\,I9Y#M6<.,@_1]_C\+>GS+>,WT?E#T_
M-_)PL>K[Z>Y5,U#7O1@TCNC#^SP'C^\$)@VN<Q_%\Q$2UO+/9]8>!ZJM1G&K
M3\19(NV,*XZ2G(;<5XWS'NC3TXJ1'9VQ:I+4FV3AFRC\S=5O(5R;<HE9F*+1
M`QP433*<I3!;?N]C)"ZNYX[3JS(".+?U4;P]C<X^AS0<^I]"<+77/=_SV_J)
MM'9ML=K;&@IZ9[>S""=?0LQ6ZT/(,#@YD\,;S*")7@<7O<TD&RT.%/'5M5B4
MQ&FOBU]/0]PXU$9C:K08X:?ODNUG;-7/=&EA<BZ?2;),Y7_?[Y$"]J:I2B(9
MDGR;<NG^9,H[WS;+.>+?UT8+6NQC&`#]G[)^D+HI/XB/=>7='R"381':GR:K
MY!R^6KX^]*43H:\_'M<>+(WN!AQV79RYA/577)\7M+R\K8)M_67:LC9[9I6[
MS*Q;!/)E<V/CXYC7>JWI$DY$J3=.`7B$!423`J3WLZ."J`(]<=F]V<<;(F/`
M8R.9@^%OV;`(E'I^5DX/JWZ,+24_>;W"H4:NNK7(VU*5';5(AV(3Q@WC9&[)
MA)9EQF$KPUSB719_1%F`D7Q>TO#6*#M4?67:,W7=E[=VY$NC6">5(WO>\X^9
MB]E2QFZLB=NNC-LI]T5-L<IF[05`%`B8E*()-[LY(70/>#$^"&(CBW]7`08Q
MZ?DEHZ^I^DE+OO-[A;#4V=):N,=KK>GU>KE;V(074M/)%)KXN08'`POAC+I`
M1)+QQ*YP)S:P\*^.XU'Z&&FOOIK\OZ'&'V/U59_4_!EN^&12K7N_FWNO=E=C
MW?,._P!^(?#U>GPS(_>;<?,?-=P=_P";^9SQ;^NQCEC&,8_)^S^!;D?Q#>ZP
MWO[R?>$7WO\`O2?(N?RU?'WLYG;-CCVN/'CT[&.S]/#*NJ7XOZ8G+)-6R2K+
MM><L.T=3[DE71;!/(D<;`TE$0T'KF8*V2D"-T4(6-@&I%&I"E;.Q3$RY%#&,
M(X\>\V44#:['@1,@EA`XMZ1S$ND&<9^(N/7U'T$+2T?>;W!UNHKZ.G<8W6U=
M+L]5&WL0DMH[>66:_%R+"XF62>0MD),D7+$;F@`#YQO%O2L3(U^48UAVD]J]
MBW?:H54;#/J`UF^1+^0D]L.CIJ2)DW!+`\E%C))J`9-B!NC<$@``"7[W9R,?
M&YXXR,@8[X6]6UP!$/3\D`9_._*RJK?O1[AWJMJE9N1NKW:FHK2CL0CE#HF,
MCUC01'EI@9&P.<W#IL9E+R2K8>\*N.TA5%Z4[IKY2NN=$4CC8LR"U6<AS:AU
MW+O)VIUT'1)8KHKJ/DWZIS/@/[U<#=JBIB@`9?9Y-N66!:;*.\+;[.>+?UT@
M#7NQC&"`/A^R/H"W-?\`B']UZN[;Y#!L(AMF>37-^'_+5R/O2]$R&S/Q,7'B
M^-C0(<=EF,L8"25>DAQJT_*6.2M;VN.E9R6W-4-_/G03TXF17:-$IL70:S/`
MV3?E;IMF-7AFZ!F92@S6,05%$S*&,8<9F[V,<(KM>.TVL^N!Q;^JD>9'-]/4
MN).?4>@.%SU7W?\`/:>IATE>VQNM@\?M:1C>S"2-=<MR7;$/(LY%S[$KWB4G
MNM!X->&@`49KQ,T8R)`)MZJ\(2L--]LH8!L=A/[9OR8G?J3<1#B:2$7`V27^
M\2$_<+`/LMO2+\,N.\@VKN9,@^,P%WPMZ_+-XP_1^2/7\[\K*V$_OC[DV'6G
M2W8RZX_2OE_00#D[Q^'Y?5$?H_A[$7PN`P)O6;F>JI[GAQQ_=UQ]5%Z@^-!R
M.JM/:6=M0L]E*=37>AYM]8M90P."R@."+P<M)+**.BF!T\`W:NHH4``*V^2;
M=LPL"0=UMB:8'BW]9.T-E.,?E`#IZ#Z`%E0^_P![HP;:/=QWXQLHMWM=LUWR
M]<@7MS"R#82\3'Q(FBC:UL9';BQF)K"25="_&G3[BPGM*M<=&FC[R8\CC.OG
MTX4@[;C=>)ZL:6'VY7X(`U3I216HL>WV1CAZHI"K]O,<;O8B'L!X[7RIKXXM
M_5&3NEOIZ\^O+[7T9PM-'[O^>Q:H:5EM@UP\;?H>/9AS]V27CLG0<N'+D;9,
MG>SW0/@#^'PJW8[A_H.*AHF`95)ZE%PE%W=K>.0&S6-0R-1Y$V5K;ML1QEE)
M,RRJM@GF::J2YC"NR`O8W,D01+E]_D6VDE=,Z0<WRP2'X6_;KM+(CZ?DM."/
M1WJ<E;:W[]>YUW83[.Q>C-VQLM1?D=\O`,VM%7=5UDF!'@""%[FN8`&3$\I6
MO=U7VD.(VB)2,FXA[5'JK"Q5?1=.ED@LMB3,XK_'"R+6W4;,JJ<F51`]=G5S
M*JJD$JKX![')E2?9R&>0[5CVR-D'-DD[Q\+?M66\)3Z?E-Z`>C?5N%;J^^ON
M72N5K]>]&VS4N[BU$?EX#QGWU<5=F[!CP1/"`UK3EL)^*$,=U5:9<9].Q]C0
MMC6MNDYQMN^>Y%(NAGIPY"[9LNOW6L)BP"V/(&;F;.:8]4;`Q$OLDSCZI4@5
M`#Y:=N]D^$UW/':-5M?'%OZIL@E#<XSD/&>7K]&<+76/>#SZUJ':.:VPZU_C
MD.B+>S"#]V5[S=C%!R#.7)MMC9#-GNN`X%Y8>*M=KPVX_,ZPVI[>H/B0#/3F
MT]"-V@VBRG.36&YIAC/;"@A<FE1<F<3$G'(G(\$PNVH%[45"%$0&^[R3;NG-
M@R#NFS%/GBW];""V-V,8^$$]/0_2"MS-_$![I6-P_?2WXSM)-_KMTYWR]<`[
M'4Q/AHS<1'Q#8HY'`Q`=J3.9&.(!55><3]'/EY]RYJKPZUF7T*YF3!8["3W*
MW&B92G]/&(4DD!6X5N41*HJ!.T'X!VN?5+\,MMW^T:&!L@Q&)PWX6]/F1QF^
MC\H>GYOY.%A5_?#W(K1U8H;L893;NFQ?H(#Q'D$1AVN<Q_%WXR6MY9[/K#P/
M55:+XU:?AK)$VR/KCI&=A-O7[>D<Z-/3BI$=E[,J\O3KC-F;*OSMU6\E7YUR
MB1H8HM&YC@=),ARE,%N3=[&6%U=[P8G5XX".+?U<;@]C<X^AS0<^I]"<+!N>
M[WGM_43Z.U;8[6V=#2T\C>S""=?K[$5JK#R#`X.CGAC<901(\#B]SFD@V.WX
M2\<VM32I*%,?EKB.@K-QD39#:[090--V^5;34]6_=FEA="Z=R+1,Y7XG]\D`
M=I%2E$0S*=Y/N76/FC*.\;;;.>#?US`6M=C&,`'[/V3]2Z27^(KW9FWCO(Y-
MA$=L[RBOY"7_`"U?'WK5C=%#8X]KCQ:QS@8<=EV<N83U65#-J@P:-6+8HD;,
MVZ#5N03&.)$&Z144BB<XF.82ID`.HB(C^O-$YQ>XN=]HG*\4L3R69WV9CF:1
MY<X^F2XY)P.@ZGZ%Z,I5I,(F$3")A$PB81,(N*#\6:?_`.;<4?ZR'$W_`',L
M^CNU-^?9_N5K_"E_0_\`N1OOS_-O\@^3?ZUJ4]&;1J;O=NG&J+?C""SG:FO6
MZ1HGD%Q>DY4%%K;$)D&,CH?B-"2[^0`Q@]%%J]:.55.A4EDCB50N%LXIONZQ
ME]DCL/\`6.R!]D_7:(_W01]8(Z+B_<CPW=P>W>_FD=YCVV:6\X]S2>11QX%:
M4GN/E\GFB8S\]\D4L;6Y+XWM!:>PS/GY?@HF$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81<R7XB[M_R
M?DOZLE8_[N'/;_D]9^>W^^7?]XK]B/W4]NOZU#_I#8_U]5^:KOVXW.S];MG\
M'()L7%]IZ#U0W'.N114VBMACDW!S2B/C]K"L:4J)A$7!9*/,C_+!R@(>J3$O
MU-<*,SFO'(1/Q^T./7B<=/GW9_DXNSZ<3Z+F?-?&/`8?#=O+6LQ&RW66BP#?
M3R9<('EH[9\WL"3KCX#7G#_LF&7/!W1CGC:_)U,(F$3")A%K>V?RIVE3=K;+
MUS&EJ1C,=OZ/C*&H\BW1UB:RD&6N#[N4E!3D"$?2L5)7!F@T<%!(K8UB9@9-
M3T_M]I1T-"S0@NR=SK7G,F"/UH,G8QTZ`AA)'T]MW49Z?6_AOLIX7O\`PG3^
M6W/G@)-#N)+H9(T`[!C[XU`CRPED<D=65\K#R,@HV,.9R^'V\=^3U_E]>[.O
MFWC/%(^A:8USM15E,UBO4^T.7UJJ=BM,@6LQ-9LEG0G=>S+>/:MX)^KZ+UQ(
ME>M#D.JW,4E&XT=2.Y!4U^.<MF2+(<Y[0&/:T<BYK>,C229&]6AO%V0#UQ_=
M;V;\7H^5:;QGP0,%K9^0W]:'Q6)[5=K*UF"LSYB6Q7KNAO1.?(^Y`WE"R`UY
MVN:R4%U6B]^;9M/':(E&+B.C]ULMEH:NO#%.N-:C/.I1JHK,NRZXI&XI2J,%
M+5.TI5G)QT?-.FQ%VBZADQ44]`BEN34Z^#<.80YVL,'=C/+FT`_".X^(./%K
M\M<Y@."!G`R1@W?;'P?2^ZUBE89++[=R:=VQIO,[K4+8W`1-^?N:J.R\5H;8
MEKSSU(Y"R5C`_@SN.9$=FYK;#/%2@4F2@7ZKC0BK6KVJ2UG;HNM.N3)JB;8#
M*/DW3F07@HV.4JH""U>-)JR:3LI@*H=+M5-L8/&:?<;\TUX`MY<T2,+A6Y]L
MD8'(GGZ2<0TCZ`>B[K3?P[^*"["?(H;43&>3AUBM'L*LEAOC_P`U\D]\;6L;
M-)(+/V+PKMKNC()8U^6#S3'+K=]VNA(C6I5&\)-N:RVJ[.HZ_BKQ;U9!KKC8
MSV\,'K2RVZKPXL(_:=-6B5EC.&YFQ8Y4O<`J"HG,?CVKJUNY=ZRM#BXOD+&8
M,D8806L<[)B>'@8.>0^K!O4/8GVY\=\>-_R\A^QK,L.L/M79*=4,=?H,IO8Z
MO5L2\WZZVRRQ@8\2&=AP0P,?,LWO/=*^IZ:[1!E&[0F]^V'5EEC*-$U6QNHM
MM`);`.]CX!G>[=6*ZY6;/*DFD+IY()`HV*H<A3J&(4=;'J]:+\K3EU%E1LK2
M\N;GEV\%Q8QSAD/S@-Z'&>B\_P!=[;>WL?G&P@?W)O#:WB\&RKR7);,#9'3F
MB&/G?3JV)VAS+)=VXH'<9"UKBU@<1G!53R2M8KJDRLZ7EU(2+4E%GK6+9/5)
M$[%`STSQG"/I.&:NA<B;U$VCEPV(?J"2AR`4P\Q8#!.\1@"/D<8)(QGI@N`<
M1CZ2`?K`*^<=VVFS<6V:]K&4!9D$88Z1[!&'GAQ?,R.5S>..+I8V2$8+V-=D
M"O996L3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(N,W\
MH-)_R[\9/_O#GM_]]9](_O#<_P#LMW_:T?Z"_H&_V]>0_P"+?>+^Y^%_X&I0
MTAQ3I\+NC4,PA=?'.X7B=H4"310JK[F\:SKJL+7$NDT:X6PW5Q`&GE#I`5F#
MY,[,7`D]8HI]P#@[3?6Y=98C='N`UT$@^-M+CU81\7%G+C]?'KCTZKC?<;WN
MWVP]O=]0EUWNPV.?378RZRSQ#Y<!]:5I,_8J-G[(!S+V2)>'+MD/P5UQ9\^+
M\*TPB81,(F$6&^PM[:OI]HV`>V::E7L329>2@)79`0VO7T;*7=KJRK[F"N)I
M.K`2V(NI6NP$2DW?.V:+!23CFB!UR"DW.'24]5?LP0BO9:))6APCY2`AAE=#
MRZ-XX#G/):"7<7...I"]_P#%?;3S/?Z75MTGD$$=W8P1SQT.[>9)'3=LK.I[
MY+8#6+8IY[+GPQ2NF;7GGD;&X/E::&7D3J]0-?QRFEF[E_?"NJE#Q$1-:*LJ
M1:?0WM86(QC'T#>Y"%LIH20M2+EG68E=Y+$2;N'"3,`(GZMS[GO?I9!9(9%A
MY)$[?CD#NI#F`MY!A!E<`S)#2[UQL3[4^9M.TML\A>RMK"VS+++%N:Y^:NLL
M`OD9-39+7$S*SXY=A99%6+GQ1/L'D[A6%-R:KV@:2@`T9)7^G3LU$,]HRLC7
M=?R$#%SII=W7:T:RPLQ-?-;>^8M:PW?*J,FC]2)B#-'!Q(4IB(V_NV_1`E-I
ML5AK'&(!T@<6X#G<2&X8"7%H#BT/?R`^LX+/;_S;PQL.S/DD.KW]:O*_71QS
MWF320]IL]CY>6*'MU6/=8?"ULTL+;-H3Q-Y$ATEM1W)CC9*Z@:7*/U<\<TQ.
MNZ_OX4PFO:T65C)*QV*;U^E&*U0[@C="X41.FO#R($Z@VBV0J-U54P*&7WZ3
M=Q[$UGS@6><D?/N.P0UK9,\\9X2<QQ^MSL$`K<6_9[W=I>>/T%O=1L\@-N]2
M^;-ZQVY(X((;QD%D-+G5;IMQ"#/ZRS-QE8QY)5R+[XUO3;E9D9O2KZH1M&LD
M1"CLM%KK%U$*C=_G4]&SL7]/V1[:$8N6B9:1E%U#M$EBE=+@H05UCD-9&JNV
M:S#%9$CY6%W;S*#\&&EIY-#<@AK1U(Z#!P`5IXO;/R[R#Q^G)KO(H[]O95)9
M?N\NV#91\GVH9(9._797,D4L4%=C1*YI,<1:[MQM<VQ'VT>,[BS0L-M/C.RI
MUCW1;:8F!KKK764VK/M+LPN,G2;[=W\(]L";9LM-U1>+<@^.=_%RSUJ5=,B+
M@'&93*&[$#Y:%TR0UHW_`&))&\3&6!\;`0W)XO#QQ^%S&NP<MXKI:WAGO!%I
M[&P\*\PDV&I\>HVS^R7]A"('5'U8[=*HR9D!<X0V66(^R!!8K0S&-SI(C$IX
M0WOK>IZ]UG+P]:DXNMVNIQLU6ZS#Q4/'&KE4"4IU8;@M%H/6\<P;1\M>(IJ"
M#8QP*"PB0!*F;-4=5=L7)XY'M=-'(6N<23R?A[O7!))#'')^K\*\SD]L_+=Y
MY5N*%^Y#-MJ-Z2&Q8EDED[]GMVK#L2.8Z1[GQ4[,G.0#/`<B"X+T:NY&UG9M
M&M^R"0KVN5"HL74JX?OK'0YYTXC&#)_(OUG,;3;58WM=>LV3$#J,Y0K-V7U2
M@*?<4X%IO::>E:CI%P?8D=C`:]HR2`,%[6AP)/JW(Z>OHK7F?M-N/#_):'B+
MK$=O?7I6Q-8R"["ULCWLC8&R6ZT#)V/>_#9:YEB/$GE@M+K.:\S=9.%(9FO!
M7F+EIS5L-M%I$R\.P8.D4WUX=:]FZ._44EA:M+_2[$R5"48"<030165246*@
MMV9+O&KP#G!\3HV3F(D$D=&"1KQTR8WM(XN^L@$#(ST$W\/OF,3+$\=G6S4:
MVZEUSI8I7O:2RFV]#<8!%R=2MP/;\M,!ESWQL>R,R1\KMJ7)FD7&9CH>.B;,
MU$\TPIMD>R+2/0:4G9#\+0`ZULHI22ZJ5OCUJHH1TD@5=!+WT><%3)O43CCV
M-):K1.D>YA^$O:`3E\8X_I&]/L'GT)P3Q>,9:0M%O?9WR/0:^6_:GIO`KOMU
MV1N>77*#/EO^T*^8V@U7BRTQN>6/=V;32P/KR-61F:9>3)A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PBXYOQ4DO\@1_K4<0_P#:YGT7\F/SG?WK
M:_Z-?OM^Y=3_`!G_`/QORC_NQ2;I39D@\W+J1H:C&;E<[.H3<R_YF.*DOZ!5
MK5%)BM\JAMIO)>3](#=WMVB*KE;IV)$,<Q2C@[2J&ZVP>3ND+_\`U:R/R3])
MC`'\IZ#U*X_W$\0JP>W^]F&RY%FGNNQ^[_DD6<5I#CN2ZYD4>?3G(YL;/M/<
M&@E=9F>!+\.4PB81,(F$6'&S=#ZUGY[9[N];EE8.MV1M)[+L=%=2FOHB%K+]
MSJU+2WXDN7\C`_4I(J(@(P56Y7ST\0G*)BL=,XIE(3HZ.VNPQ0-JUFOF81$U
MX$A+@)>]VP`[CDN.#Q',MZ`]<KW[P[W-\OU>LTT'C7C\%G;4WQZ^"XV.]+-8
M8W8G;?(-8R;Y<RRSR!KS#$+3JQ[;7-#RYUBRVM=,V6J4B`G^5<'(URU3,DUA
M6C-YQ_AZ[L9LE)5]JO%UJ&B:JU@@MT!.L2(M9Z"21GXY5^HD1P4XMQ1RH[NR
M@GDFAH.$T;022)RZ,X<<N)<7<'-.2QY,;N(.,<L]+1\O]P=/N]CM-7X39BVU
M&O&Z9SF;N6>@XQSN;)8EELNF^5GA>724KCGTIVPL>Z(M$O<NV5X>:Q<R<!".
M+Q8&\>YL+&_/Z6[)0WZMJLE(LSJQ15KBG4S5WMDK4K!FL"$:]>PB[-5Q%E;M
MUCE$QE%;#/([X8^41,+@PQAXYCBU[0TM(#@UP=Q+FM>"`[)`^@:*E[]^8Q4[
M6QBUM5]IE1])EMINL%:O<KM@DK2MBLL@L1S=A\\,5MDK663++&T@!K/4GP9T
MH>?:R\L%BL$3]-Z_@YNES$@U7J-ED=;4VT42`M<O&H,&ZQ;"XKUJ5*\,W51;
MN5FS94R0'3$3TGRG9]DQ1\&2<Y'!X!YM$CVR.8#G[(<P8R"0"X9P59?_`!)>
MX;=6^C1^4JWOF[TT-N)CA:KQW[=>[-6BD+W#L-GK-,0>U[XVR2L#^+P&W6AQ
M1H'TTA5).7M,Y$D'69'I91Y'G7EF6KJP:H1#&17;QK=15.6A#=C]0O8LJ?J<
MATS#F.=_;[YL,;&R3]+C`/0RNYDC)/H[[/T#T.5I)/>_RC[X=O*<%*M>/W@6
M=MCPV)^QL?-2OC:Z1P!BFZPM.6-'PN:\!>!OQ*J4@Y0>;`N=WV:[:0AJ<T<6
MA2NM%"4%.HW:H-*JO]-P$(5RH5O?7KU>2$`DG,@F@H98"()I%K/D%AC2VI'%
M`TOYGCR/Z3FQY=\3CC]6UH;]D-R,9)*RI??/>U875_%]?KM/"^S\TYM83N!N
MFU4M.LCYB:8M'*E%$RN/V>.!TK!&72/>?LOQAB$Z_J.E-+#-/*UKC7:6LWTG
M,/45[?,1,5.ZVML+-N)!..^7O)U6>U@U*^$S=$BZ+Y<Y>PY2!D#>R=ZQ9<QH
MFFF[H`'P`ELC"W&<AO&4\>IP6@>F5;C]Y;[MIO?(9ZM>/;[;;'8,CB815BED
MAOUIH6L,G-L(AV,AA`>XL=#$T\FEQ5W(<=->-M.+:0;MEVM1DF,7%V9=DA%1
M\O;HMG(-'4JQL3MA'-DGQ;1'MU&$@IZ95E&CE4"G(<0.&.=S<.R^]"0;#22W
M.2&$@@%H)..)^)O7&0/4=%H9/=CRJ7S]ON/*]K][#)))7:\R/BJR.8YL;X&O
MD<6?+O<V:!O(L;+&PN:YH+3&3O@_I]=C88IHZM41$RENI5S@&$7),T2T24IU
MSG+VJUJCE:.7>(Q-LF[9,DEV[E1R1TTF'2(=A3E[<YOE&Q:YDCA&Z1L;V.)!
M_2![&LR\9`RQK&<",8+&GKA=C!_$=Y[%8JW9V49[T%"W4F?)&\_.1VJD-,.L
MM$C6&6M#6J&K)&V,QR58)#R+3F3'FCV*<@@:(?G3CI?>S?>5P*],E[E:4C8-
MNWCHR'!HR1*"'SV$C%CF<',<$$EB]YA,0"X+=HXL/<'QMJ=AF/3!=U)R?S7.
M'3Z2/PKCZ_N/9=5<+\0-N#QIVGJ\,\1'),YTDDO)YZ]F:PT!@`YNC/$8<3/>
M:E>8IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBY1?FNKOW6>!'
M]6CCK_OJY[WVKG]>VO\`?-C_``)?MU\EYE_GI[G_`.D&]_U24B:AD];'VSJX
MC3C3P@B71MBTDK:5KW'?0<5/QC@UEC`1D(.3C.8$[)1TPR4$%&R[=B\716*4
MY$%3`"9L/8Q6QKYRZYLW-[+\AUB<M/PGHX&FT$'Z07`$>I'JN4\[I^6M\'W+
MI_+_`''GA&IM\HY][NI()&_+R99-')XM#')$\?#(Q\T3',):Z1C27#IVSQ!?
MC@F$3")A$PBUP;YXX[RO-RVELBM.*E*+6R`EM3QM%D3(L'+K59J>T?1RZ]S5
M]PFV=#MAB+XL<9D*::#I0PKB;J0>SU.YU=6M!2G$C6QN$I>.OZ7F0?@Z=.T>
M/+.20.B^MO;+W:]M_&]!I?$MNV]#'1M1;.2Y'E[6[+YIS)`VH.)<W[L?V3.)
M>3GQL:(P,.%#M/'[=%BLFQK,CJBBMD=Z4W:=*>5=W=HL\9J5>XP^F:Q&7&26
M;UPQ+$_=_AX[F7J,4B*A7`H(E6.H)W);L&WUL,$,!GE)JRQ/#@PYEX&9Q8,N
M^$#N!C2X^F3@##5LM+[I>WNIU.IT\F\V;Y/&MAKK;++:D@DV;:LNUL258PZ?
M,#&_/158G67<2SNR&-K>,)S*D-6G/NG5NS6[1@[<U/6M_H4]9'ABA8736<?4
M20A6:7W9Q49+O8)XX<`4Y"@MV"(&'M[>;9?_`.S)Z))#9)XY&M'V06B0./\`
M+AP`_!E?/]7S1K?;S=>'2OECBO;>E=AKM'Z!KH67&2O/48>&31,C)!/'D`6]
M<SCFK7FZ81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$7'G^#VU_YU=,?]L':/_6L]_P#G*O\`5K/^33_17[U_OWX3_B3R'_Z7
M5_Z"DO2^I]GLMQ:F>.]F:B>-&FS*(Y=-&/E>LMS>NFZ%IBE5F[.GJ.13M;I=
M,@E3C3`(/CB"`_`^86QMU30G`KV&DPOZG7EH'PGJ7<?A_E^CU7(>X/FWAUCP
M'>00:??1SOT]QK7/]MH*K&N-:0!SK09FLT'JZP.L(!D_)76#GAJ_$-,(F$3"
M)A%K!Y(;OVS7+CN1["K7NO:J84::U'#6R(3KY(.'VQ'U-'9REO8*BLZMR$J$
M8N[@Q<F8#$).6J0`L*_4@]SI=7KYZ]9D@B??,HF<T\LF(O[7`^C,9P_'+G@G
MIA?97M)[<^#;;0>/U]BW66O-I=E#LY:TIG[TNL?9.O%5XPVJ8^XV*YVQ-\RZ
M.1^8^UAPC>T;:GF<Y8&<!O[9B],AJQMR0XVV1&21DY#<&Q(9KI):#JBQAKAR
M[:CX^^S\S$-$3)*BZ:F62%506X."9L&OA=$QTU2`67R0BPW&!%&>_P`G_:_1
M$QM8\G(P<'`S@];IO!M98UM2QM/%].WR"Q<UC-_7,9C9JZ,KMN)K(_3C[L>^
ME!4M2N#F]N01OX,[IB=F':KV\'D]J.B-MD/H&QKU5*RV_7SF3BFE/6KBL7<F
MIXV+CUFGS6X7>RV-!)=(R2QB0\97UEC&1]T5)_SD%1OW'8MNA#X0_BR0`E_+
M+#DG.&,:W(.1\;I`.O'+/!-+XU7'LWO?)9M1%9U+;IKU;S8Y76A.)*KA)(\.
M[=6G7@+F.#F`VK%UD8$G9+ZV8><XO`TPB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(N0+ZTV/_,-S%_H;W_\`[]N?1/RM+^MZ
M[^[5_P#`5^\G[O\`B7^<W@'^5M+_`*FJ2]+V_8"^XM3HNM)<LH]LMLNB).'\
MWJ3>3&&8H*6F*(J\EWLCS6L$>SC&R8B=PJNP?(II%,8[=8H"F;"V=>HW6V"V
MUKR[L/P!+`2?A/0`4FDD_0`YISZ$>JY#W!T7BT?@.\DA\C\&EF;I[A:R'9Z=
M\KR*TA#8F1^)0/=(X]&-9-"]SB`V6,D/'5EG@:_$I,(F$3")A%AGMOEU'ZXO
MVQ==1D+`3<Y2M1/;W'D>W%M&.I6Y,_;R1Z4[A4(Z1EV#).IR365-)$36(*)E
M$RI"=/[72:_QY]RI#<>][8I;`8<,SAAZ<P<@$\P6\>G7!S@KZ"\%]B;7EOC&
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M(2NI-N^>.)$OM&ZI&CH0U,.NCEHV+',BS7P2W`QQ+FL]>6227$]&EK0WXB.3
M5YCJ?!*.S\-WF\^<D;Y#I"Q\E81L=&876(*V>YWA*Y[I)GNS'7?#$R`]^5CI
MX09US5+S5,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3"+D'^AN'W[GO&'_.S>?^U[/H?O^0?XPN_VD'_0K]X/WC]^?\_?,O[V
MTW_=:DK3-+XHH;AU0O"\4..$+,([*HJL3,Q5HW0M*1,FG:(L["3C49#:KU@J
M_8.@(JB5=%5$RA``Y#%ZE'!V4V].NG$E^XZ/LOR"R#!'$Y!Q$#@CH<$'ZBN1
M]P?(/>V7P+=Q[#S?RVQ0=J+@EBDKZD1RQFO('QR%FM8\,>W+7ECVN#2>+FG!
M'5=G@R_$U,(F$3")A%AYN&M\33K[!K>T@;(3;:#D-^786CNZ)VQ"`>Q+G5SF
MT-96LF&=%J,2B:*2CV*IC%`J?IM^X4S#T>NF\@`AGH9,1<*[,AG#D")0TAWP
M^OQESA]>3ZKWSP';^^+8]5M_"^;M<^RS2U.3:AK.F9*W8MKNCL?H>7=(LNGF
M:`27<I<<@HGE$N#XHPZLY,;"]58=@(V<\J^Y&%FG[(TCKY+8*7((SDA9E*LD
M.G7"."W,48TL6+<I`"/,(#GQGRC+A$V''Z/C@5\`XD[?R^.G+]9CLY=RY9^-
M=O2?_$<'SLUL&JX-^2-<1,T)A8\1WC1.D#3VC8(-\L.IY6#8$I=^U#*RJM4!
MIP-PZVD[,]%+9LTA*_A_!&G[`FPG3TB)E7+J:"IM7OTV^D*A#VQX5)^Y;^HV
M+(]A3]YD`+H8)=E]W3,@'["PCN.XMRWF0`WD1R`>6#+0>O'TQE>*:7:>?GP'
M;T]/'R\.KNC^>F[$!?"+DL;6Q?,N9\PQEJ6M$70QR<9#!R+>(D)G'-6O-TPB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(N2?\
MLO.?^9OE[_7+X*?[.L]_^^?&/ZY0_O.Y_27[F_[8/X;O\X/`_P#13S'_``Y2
M-IWCIS1BMNZLDY_4O*MC!1VQZ._FGLSRWX53D.SB6EFBW$BZE86`H+:=EXUN
MS3.==JR43=N$@,FB8JABB&%L=MXX_7SLBMT72F%X`%2VTDEIP`YSL`D^A/0>
MIZ+DO/O=?^'R[X+NJ>KWOA,NREU-QD3(O&/+(97RNKR-C;'+-==#%(YY`9),
MUT3'$.D!8"%U)9X:OQ?3")A$PB818);@XC6W8MAV!>X;:)XFVW%67@VT3)L7
M#RBM=>OJ`SJ[6NNXIJLVEE9-.S1;::.[([*EZP&(5`!$#AU6N\AKTXH:LL'*
MO&`XD$!YD$A>7`G(QQ)9C&<?3]"^EO`O?71>)ZK5^-;#3"?14&Q3.DC>UEQU
MYEU]AT[9'!T0C->22H(S&7<"USI#CBO'/<7]PV"PW"W.+[K9I8-Q5._43:8H
M5.S+QD)6;C#ZQJK-37K-:RE5<S<16-=#WK2:HHN)!YZHI$02!L:J+>ZZ&&*N
M(IC#6DCDB^-N7.897GN'C]DND]&C(:,9R>2R-9[R^`ZO54-%%K-O)J]!>I7=
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M1BB)+FM,45%4\H;@E7`C2IJ"`BX&08>B`=_N$.GJEP=F;/W=/E_3LO\`^><?
MR3]'SKL_VI_D/HN/]P]7Y0SP#>.FNUW0C3W2X#?,D)'RTF1V_P!\I^YD=.'8
MFY?9[4F>!ZQ\\%7X?)A$PB81,(M8')"O<@)JX[DMT'2K/,Z_FZ+-:&CX6NS%
MD4M+R,1J:-Y0O$;1F$>C'F9N;V+Z$"31D/F"Z#@A`;^D!5`[G2S:F*M6KRRQ
MMMME$Y<X-X@\^';+R<Y$?%_$MX@@G.>B^RO:3:^UVOT'C^BV6QI5_*:VRAW3
MYIXJXK-D-DTW4Y+CWEX>VGV;?R[X.PQ['.,O,EIC:T:ZGG,Y8%Z]J'=Z-(D:
MQMQIQCA&\;=(^4UILB1;:20@+$]]:737U;%/+]%3<FP4EU&J+9D#DX)IHK@@
M?-@N0MB8)K%4VFR1&RXEA$D8,_)HZ?I2(RQK@P$D\1DD9'7:;RO60ZVK'M=]
MXX[R.*YK'>0S.DJ/CV%"-VW=-`S$1&QD92DJ5YFU6R/DE,3>3Y(C*W+RVURZ
M!RBU19T(NP6`6M5A("86<5)P?7T-%^QV4XMUKA[JUGB(P5O-)NXQL>/>,>YZ
MT50*@"P`JLPYVO-6^XYX"YC,O<X8?^D)S%P86%OQ,P''D'="#G'0/\(T>V\>
M/LQN]-)/5JA]V:>(-LM%Z63GKVU:TM1T),U7MML2">*;$4K9#(8\L99S,SFU
M\_)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1<K?X6ZL_=GY7?UI.?'^ZGGNG>N?UZE_<*?^&+]JOWR\S_SP\)_T=\+_`-95
M(.I-:ZT:[6UDZ:<=N3L4Z;;"I;AM*2_)3G!*Q,:X1LD:HB_E(NP\9(>`DHYF
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M"=HQ6S4Z;!:=M4753MTKT(TJ12;[%=1;YPW6?#[E-!P1`O4[4;T&HU4T$%@Q
M3`6Y8F-:)!F/FZ9A?]CXQ^C#V@AO3+<_E+::;VO]M-MJ-/NW:W;L9Y-L-=3A
M@;=:9->;<VUK260XT_VN,NHQV862,A_1NEB=([#9Q-\OO.WH\C:EKE.,6AJ*
MYA:3\Y=/:XU?G>678L-M&7B(A67^KXZ7A'3$NMQ*D9O#230QA<$=*H"=N8FK
MCU5<Z:2Z7<K0<_`#B,-C=$"<<"'`]SKE[3Z%H.#GSFC[:Z&3VFO>6.F;8\E9
M8M]IK)W,#*]"7712RB+Y62*9K_G\N#[=>4`1.A9(&RAV7.<\O"4PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$6G3F?_\`CCO[_P#9+8G^HR<ST?QK_P#6:G_L4?\`^.U??7\/G_\`;7B_
M_P"T*/\`\8A6NX?_`)#\=?\`I2W'_P#T!JS.O_\`6]O_`.SP_P#Y>5?5P_\`
MF?W7_P#<NJ_^";);AMJ?\1[C3_HGNW_H%_SSFC_\FW?_`+]GXXE\#^$__P"2
MO,/_`'W4_P#3I+8MG'KY/3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
13")A$PB81,(F$3")A$PB_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g285899img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g285899img2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`E@$L`P$1``(1`0,1`?_$`-$``0`#`0`"`P$`````
M```````&!P@%!`D"`PH!`0$``@,!`0$!````````````!`4#!@<""`$)$```
M!P`"``4"`@4)!`D%```!`@,$!08'``@2$Q05"1$6%[@A(Q@X>"(D-#:V-W>W
M>3$E=CDR,W.T-76U&;ERLD-$=!$``@(!`P(#!`0&#0@'!@<``0(#!`4`$1(3
M!B$4!S$B%0A!,B,647%")+2VD3.S-'0U=;4V=A<W=V&Q4G)#<Q@X8K)$5"4G
M>('!@L2W"=%3@X1%52;_V@`,`P$``A$#$0`_`/;NTGY[\/\`OFI[Y,B=GTP[
MN.FAQE'PF:NFG>/LVT:.6QA7^J#AJU;II)G)]#$2(4A1`I0`.YO#%YO$CBNQ
MR=('P'B#1K$_LGQ_'K^RL^+QGWI],E\M7XR>H/:"L.FGO*W9_;S,K>[[RLS,
MS`[@L2QW))UE;)K/9E;S0R*6.?4(?X\>CSTY3S,D8IWKON#UV;.W9BBY$#.G
M+98Z:B@_RSIG,41$IA`;:Q!"*LON+_&EL>P>P4[)`_9\==J[XP^'3MS)LE2J
M&'JKW>@(BC\$7M;.LJ_5^JK`,J^P,`0-P#K2S*P3_P"SUW^6]]F169=);2[9
MK#*/A5:.R]W>\K0KELH*XG0<%:M$D@.40,":1"_7PE*`5,\,/Q/%#BNQR0!\
M!XCR-(_YR3^,ZY%9Q>+_`+5/2^/RU?IR>HM97'339E^Z'9[<6''9EY,S;'<<
MF9O:2=4)D%ELBNJQR:EBGE$_V9?B%<"129DCD%>2VGJ8E)+B4SD0%:02<*%7
M-_M6*H<#B(&-];3(0PBLY")OYO*_0/HBN[?L;#;\0_!KIO?N'Q"=ES,E2J&^
M^'J>NXBC!VCQ/<QC'U?8A52@]BE5*[;#:U%+%8?V(.[+KWZ;]4TZ-]8G;5R,
MJ_%PV=N.S?:1!PZ;KBX\U%PN@W3(<Y1`QB$*41$``.0)X8?O#CQQ78Y*V#X#
MV"K6_P#QUI(Q.*_XB_3N'RM?HR>H_<*LO23BRKV]VZRJPX[%59F(!&P))'B3
MJ)8]9+&KV.L""M@G5$"N/A7\**DO(G2#W1KAWN@`F9R)`"2\TWJ/T?K_`!F\
M?B^H_65?AA&+!"+OPS'T#Z#9V_8^C\&KWOW$XE/2>K(E6L)"OJSXB*,'[-LQ
MT_'CO]GL.'^AL..VPUY,E8[$'QM]V'P6"<]<UZR?':X:O/=Y#U;9=[<[&5ZL
MW<^I\Y%5X4H`L8I@%4`^AOJ'/$D,/WNQR<%XFWDO#8;>$8V_8^C\'T:Q5<3B
MC\V_IY6\K6\N_>'?2LG2CXLJ5*_`,O'8A#XJ"-E/LVUT,OL=B4[6;BV4GYL[
M='8OC-220/+2!D4TG^.3RKY,B8N!(5-ZJ`&6*`?14P?4WU'GFY#",)78(NYK
MY'Z!]$J[?L?1J)WCB<4GHEVY,M6L)6P/J`2PB3<E,K`$)/'?=!X*?R1X#;4.
MT&S61/XP.U4@2PSI7[>C?&$=N^"8D0>('D,?R!1^9%SZGSDC/E%3&6$I@%4Q
MA$WU$1Y(@@A/>E)"B\#)E/#8;>$LVW['T?@UL':^'Q#_`#D=DU6J5C6?)>H8
M9.E'Q/#*90)NO'8\``$W'N@`+L!J:5>QV$W8_M2@:?G!1;]D.OR#=$9>0%)!
M!;I=VJ=+(HI^H\":2SINFH<H``&43*8?J)2B$62&'X13/!=S4G^@?][IC_-O
M^R?PZUW,XG%#TE[*D%6MU'[2S;,>DFY([L[;4$GCN2%9E!/B%9@/`G>/[59+
M&C\8G99^E89U-^AH/Q^$0?)S$B1X@1[U%ZO.'A$717(+I%=N'"BBH%,'F*',
M8WU,81&10AA/>U%"B\#'>\-AMX7;.WA_D]GXO#5MZ>XC$R?.1V?5>K6-9L7W
ML2ABC*$IW1W$JDKQXGBJJJ[CW5``V``UT3V.Q?BQWH3^X)SRV?;;;6S1,)>1
M`C5NET-[J/$F[<H.?"@BD[:I*E(7Z%*HD0P!XB%$,44,/DL<>"^-&#?P'_?*
M`_S$_LG\.H4>)Q7W)]-G\K6Y2=C8AF/2CW9CWGVDI9CQ\259E)/B59@?!B#V
MNQ]BL*'1O6G:$]-HNT^]?4EHFZ2EI!-RFT<]1L"<.&J:Y'`*D;.'*QU#D`0*
M=0XF$!,(CS%C(83W-64HO'X;9/L'M\[-_P"[P_%X:K_27%8J3YD,%!)5K-`?
M37N9BIB0J67NC-*K$%=BRJ`H.VX4!0=@!J!N;+9/>.[@?<,\`-.W7R1MFH!,
M2(`V;,>EN]NF3=N`.?U*#)TB11$A?H5)0A3%`!*`A,B@AXX[W%\:.-/L'TVZ
MP/[(]OX?'6SP8C$_#_3H^5K;OV+V"S?91^\S]V8579O=\2ZDJY/BRDAMP3JX
M.P=@GT.L3-PC.S22X_,-F$8*Z4J_36&-4Q:HJJ1WFE<`?T!U3"84?KY8F'Z_
M3Z_IY78V&(YH@JNWW><^P>WS#>/X_P#+K1/2W%XR3UCDBDK5VC_L$R$FQC0C
MJ#+6@)-N.W,`;<_K;>&^VL_Q5GLIJEW),-CGA,U[!?*B@V-[S(^)NC']?(=:
M/20-ZGZHIL5A$Z(%^@)''ZE^@_IY;""`3X_W$\:N,W\!]-AM_P!GZ==.N8;#
MC.^GX%2KL_:WIP6^RC]XOG)0Y;W?$N/!R?K#P;<:T9V&L$^AFN$G0G9E$Z_S
M:6F)6.G*/B'5BRVR6*6,4,5<#'CRE``!$?U8!_L+RGQ<,)NV@578=M(?8/;Q
M'C^/_+KD_I7B\9+W=W,LE:NRK\NM:4`QH0)/+1?:#W?!_P#I_6_RZS92K/93
MY+NJA['/F41T[Y*$TE!F9(3I$8SO30K$B9O4^),C('*OE`'T!/S3^'Z>(WUN
M7@A\[5'!-C%0^@?3YW?]G8?L#\&NN]PX?$+WSVTBU*H1L/V$2.E'L2\/=?,G
MW?'GQ7EO];BN^_$;:PV.>G4H#HP*4W,)B\^9G;8MV9.4?$,ZC$NS5V02C7`E
M7`5V"2!`(5$WU3*0`*!?I^CE!0BB,^2W5?#MR$CP'M\HOC^/Z=_P^.N(=@XS
M&OE?4@/6KD1_+]B)%WC0\9#V]48R+[O@Y8EBXV8GQ)W\=9-PJSV5;`$EEK'/
MJK>^]ER^:I,R1U?HAW/^/QJ@'F&<B?Z(M7BR9/T_R4UCE#]!S`-_?@A&4(")
MM]C]`_[KD3_[A^P/P:[AZD8?#Q^J#1I4JK'Y;`>`BC`][M3O=CX<=O%D1C^%
ME4GQ4;:TT:>G4WOQB>";F">O^27N"Q?^&4?%]:Q;=G+4@V9O/HN'J6C=`H)I
MIG\1"$#P@`%_1S7Z\41.8]U?##U"/`>!-/Q/X]_'\?CKAO:F,QK0>L?*M7/2
M](^UW3>-/<=NW:[,Z^[[K,WO,PV);Q)W\=9;ZBV:RN<.P)9Q8I]PJM&N1657
MF9)5180^47J3'@*IU')C*#Z!PHA]3"(^2H<G_1,8!O\`.00C)7`$3;J-]`__
M`*ZX?\X!_&!^#7:/73#XB'U([H2*I55%E&P$48`_\N^YG\`%\/?57\/RU5O:
M`1H*SV"?*7XAO#.S)?<M,[X)R/TE7X>X)M+Y/$:$??SC^=E:D*!4@4\0)E#Z
M%^@<ITABY9_W5]V.CMX#PWA\=OQ_3KEN&Q>,+>N^]:O]CA^S#']FGN%J4)8I
M[ONECXMQVY'Q.^K<^$:<FY9IB0RLS*R8J]2]?<J^X2+QZ"KA+N/:6J;A0'*R
M@'73;%!,IQ^I@3#P@/T_1RN]28HHUL=-5&V0B]@`_P"R*?\`/K1/_N+8['49
MNXA2KP0\>^<6HX1HFRGM6LQ4<0-E+>\1["WC[=?HXYQ[7\F=.--.--.--.--
M.--.--.--.--.--.--.--.--.--?EH:?W>=_/X*.\GYZNT/.[O\`OS$_RG1_
M0:NO[1S_`-*O2_\`Q$[/_4WMW64,B_KW0/\`3GZ*_G(ZX\M[/[UE_E6W^AVM
M=M[Z_HUD_P#%CO']5<]K3;+]W7Y!_P"!RU?GD[V\J9_XTQ/\IC]!HZX_9_O6
M]+/\1ZWZG]FZH#'?[V([^&#X=_\`.WJ/RTR'[VD_AF5_<;NNH=__`-"9OZY>
MJ7\T]SZM=3]QGO#_``)]7?S0]JN5\_\`2+'?RE;_`$2KK2!_S(>G'^)7<?ZN
M]MZB&-_O)V+_`/H^$C_NN%<E9#^*A_J9G_/9U>]__P!T=3_5]7/^MF=>5)_\
MM'O!_"_\<?\`;6R<\2?TPQW\,R7[FNL57_F]].?ZY=^?H=?70RS][/=?\9?C
M"_R8G^>;O\1U_P"#9+]U743O/^X[MK^0/4/^=H-0S1/^5KVP_P"!/BW_`,G,
M=Y)K_P!-Z/\`O,I^ZS:V'M7_`)S^Q_Y2]1?YURNIO5OWD^U_\2O7K\DW:_D6
M3^)Z7\$G_2Z>M;S7]T79']4,Y^MW;.H[MW_*Y[.?XB?'G^3_`*L\SX_^G%#_
M`'=[]-LZN/3K_G.[-_DKOC]:>X]=(_\`>WWP_B]W#\@O=OF*+]Y8[^`P?IM#
M4&/^@_II_43$?KIVAKM]E/W$]=_CSZA_E`Z^\QXO^E%;^3+/Z;-JO](O^97`
M_P"&?<_ZTYO4!<_^,]X_XP/DM_)+O_)D7U<;_`,;^EUM;/!_%_IO_4/T_P#U
MNPFKC[$?NNLO]93+?\DZ?RMQO\=G^KK_`*0VM"]*O[YY/\`,C_.]K6>HG^J'
M=#^(?Y7?R\0W+?\`V^._@N,_26UU*[_'WI[_`%5]-OY]EUI'L7_=E@G^N):O
M[6R_*?%?OZU_5F/_`*JZY)Z4?TO[G_\`3A6_1HM9HI']T.\_XH_)E_Z_TNY<
MO^_JO^ZQ_P#\]KK_`'%_3KMG^1O3_P#<>[-:VV?^K_1#_6GW#\SUXYK^/_;\
MG_5N']$77#/3_P#C7U+_`/3SA_U=IZR/@W[OB7_GW9W\Z_QY\V#(?QH?_P!#
M]%R.NZ^I?]Z3?P;M_P#5+OG6N=)_IOQ<_P"I?W'_`#0VSFO5_;F?Y'J?H>N$
M]I?M'K-_A!VK^KE;65NG_P#<5U^_\M=?_*CU#YL&=_C*Y_O&_FVYKM?KQ_>5
MW3_O5_\`IQW1K0UI_P"C\//^)_?C^WU@Y31_7[@_W5#]QURK"_6]>_Y&[+_0
MH-6_\&W]#P[^$78_SG6OE=ZF?5L_RA#^AKK0_P#[D'[=W'_7O%_JI6U^DSG&
MM?R,TXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTUZRT?C8KR4#ND%^+$
MZ9/<,;VG'WJXU>-`U>:;+MNE[0\G6J82G\_=03O1U(])`YDR+I-"JF,0QQ*7
M=V[UF:6K+Y==ZMF&8>\?>,,$<(7V>`(C#;^.Q.WCMK[#D^;O*R9/MK)?`ZP?
MMSN#$Y1!YB3[=L5B,?B5A8]/W%F6@L[.`Q1I"@#!035U5^(JK5><@II+<+([
M/!]?L3P,C<U,B42.&.,:[GFLL[(93WI4R;N>=9^1BHV`!(@DZ.H"AS$*493]
M_P`[Q-$:R>]9EF^N?;+#+$5^J/8).6_TE0-AN=;EFOGKS69QUG'OVY41;/=.
M6S1;S<I*OEL7>QC0;=$;K"MXS+)X%VC5"JAB=60A\9]=1S_>:#^+<Z='=,7E
M,;>R9JM&@M76<GM6V[,:<:MBRH)R#A%WM*T>"!S)%%)@143^)4Q219.]9I+-
M6ST%!K6!*!R/O$00P[?5\/"$-OX^+;;>'CJ4OS@9:7NCMGN?X%6$G;7<,>52
M/S,FT[1XG$8GHLW2W12N)2?F`Q#3,G'9`6@E1^):KU.TM[.EMEC>J-\UZE9P
M#-2G1*)#-^J5RRBX1<J*Q)DY@6N:V6)(.$O#X697IS$,J*90&58[^GGC:,UD
M'*6T_P!<_P#:5F4CZOY/6.WX>(]FYULV=^>3,YS#/AW[=J1J^7[FO\A:D)#=
MR5<E5DCVZ0\*@R3.C;[RF)0P3D2)0/Q>UL<3V?&/Q@GQ:;'B>:8N[L`U.,]5
M!L\WTO3M(;SS=@$N5!\YEG&EJ-%$#*)E23:%.4XF.(%CR=[S29""_P"74&"Q
M+*%Y'Q,L4<1&_'PV$8._COOMMX>-+_QEY?\`M#[?]0/@-7K8#N+(998/,R<9
MGOX_'T&A9^ENBQ+CUE5PK%FD*E0%!/)J'Q45FI:&_P!!2VBQ/5WZG3-0T:I4
M(I%)/]CQ*D)110<DESG,%[^RB"Y_D`+'U)O+\WPEYEG[\GGK"L:R`;6QOS/_
M`&LR$_1^1U/#Q][B/9N=3L[\[.8SG:L7:[]O5(XHAW6.H+4A)^])N&7W3$!^
M9^;/3\?MNFO+AR.OM<?%96E^N>S]>1V:Q`PV/->O6<.[0-1BA>03?`)F1F&,
MJVC0ERH/EK0:0%-=(ZJ96Q2_4AC"//Q^^IVRU?*^60-!+8<+S/CYA0I&^WAP
MVW'@=_IUXC^=;,1^J_;_`*J#M^IYG`9?.7UK^:DX3-FXHXGC:3I$H*X3DC!6
M,A.S`#7D5GXM*U6]2NNGI;'8'3FYV_K9;5XD]2C$D62O7*H/JE'L2.PESG72
MM*3X5ES^606IB^$@*`/UYYE[YGEII3-=0J1V$WYG_M#!B=N/Y.VP\3O_`)-8
MLO\`.CE\MV7CNS7P%5(<?0S]82BU(2XSMI+3N5Z0`-8IP0<B)`=V*^S7'GOB
M=J\[UGU+K:IM-B0CM/A.L\*XM04^+4>PY.MM0J52CEV\7[RF@[-:TZH1=<IE
MB`U,L)2"<"@(Y$[]G3,0Y<5EYPM9/'F?'S+.Q\>/AQY[#P\=OHU/QGSP9G&^
MK^%]6T[>J-;PUCN"5:WFI`DIS]JS9D#2=(E?+&R40A#U`@+<2?#LQOQ:UN-T
M74="+LEA57TW1:#H3F+&I1948E>B8WJ>/HQB+GW8RCM&2::>H^.J8A#)J,B)
M@42J&.&-N^9FJ0U?+IM%$Z;\SX\Y89=_9X;&$#Z?K$_0!JON?.AE[?:F&[6.
M`JB+#XF[163S4A,JW<KC<H9"O2`4QMCEA"@D,LK.2"H4^!<OBFK-PZT:1UN6
MV>Q,H_19_`YYQ:R5"+7?1:F$9+F64LFZ,6,PDV<EL;;-DWJIC*D].J[,F4#E
M(!C>X._)X<U!F160O"LX"\SL>M-),?'B=N)D*^SQ`W\#J7@/G:S&!]8,1ZN1
M]O5)+6)JYJ%:QM2!)!F<GD,D[&3I%EZ#7VA4!3S6,,2I8@?>;XKJT:U;?:/Q
MFL0*[5K%UU1XS"HQ7EP#FY87L^(*PS98983/V\>SV-60(L<J9CJQZ:0E`JAS
MAY3OJ98:\/ED(@A2,>^?'A-!-O[/#<P!=O'ZQ._@!K"OSJY=<+VYAON_5*=O
M82IC5;S4F\RU,QB<N)6'2]QG?%+`5!8!9V<$E%4^;HOQ=5O0L1M>*K[%8(QI
M:=PRC;%;`C4XMRZ9O,LR:AY2U@$V!Y9)!9K,-J,1Z=<5`.BJX,F!#%(`F\UN
M^)JV2CR0KJ6CKR1<>9V(DF>;??;Z"_';Z0-]P=1^U/G-RW:WJ+1]0HL!5FGI
M=N9+$"`V9%5TR.3N9-IRXB)#1-<,(3B0RH&+*S;#A*_$]6%7FTN_QKL91V76
M>QNJNR!3XD?8778?&[YC[Z&;&&7'US>JM+R=\@L8$S.5&Q4SE(4YCAF3OV=1
M7'ED/EX*T8]\^(KRQR@^SPYF/8CQVW)!\`-6<?SOYE(.WH/N[4([?P>!QJGS
M4OVRX/*TLHDK?9>XUEJ8A=1R$:R,ZLQ4+J77_P",JNWS-$<W7UV?CFZ/;RM=
MM`E4JK&.%QE*W3(FG)TGTIY5),(YTE%`X%YX_-(<_A\L2A^F-7[UFKW/."NI
M;X>:NW(^PR&3GOM[?';;\'COOJB[8^<3+=M=X-W='@:LLK=B6.V>D;,BCISV
MY;1M\NF3U%,A3I;<2!OS!/A`FWQ(59M%;!%%VZQB77+]VBO;M;[-B@-"K]FZ
M`TH<C'MR#-&!ZG44&@.4%#"F+LX^`Y4P_3R6._YP\#^60F".L@]\^/EI#(/R
M?#EOL?;M[=SK9I?GHS4MW`W3VY4Y8+&=NTU'FY/M5[>O-=C=CTAP-HMTW4<N
MD!R4L?#5AW_XT*[?:W1ZZOK4[')TGNC*=R4'2=6C7!W\O)RKJ4-1%$C2J)4(
MQ`SH2%?`)U1`/J*7(=;O2:M-),L"DR8Y:FW(^`4`<_JGQ.WU?#\>M4[7^;_*
M]LY;)96+!UI6R/I['VJ5-F10D4<:Q^<!Z9Y2-QW,/@H]@?5<0WQ&5:'JEYJQ
M-PLJR5VLO8ZR+/!ID012/4[$/<=>OVJ2/O)RN"5<V0I`B8QBBY]>H)@3\LH&
MFGU`G,T4WE4WB6`;<SX]#K[?D_E=8_BXCV[G6VW_`)ZLU?S>.S3=N4U?'5,%
M`$\W*0XP:9548GI#B;'Q1N0`/3Z*[%N;$6K</C>K]N88@P5U><8EQ7N)<^WC
M-5.KQRQI^5N6E3.CK4=T4\H0&$:Q<3!FA7I/,5.F3QBD!A^@0(.\IH'L.(%/
MF,<E0^\?`)$(N?L\20.6WAX^&^VM*P/S;Y3!6NX[282M(>X>P:G:[@V)!T8Z
MN/BH"XNT9YR.L0E,1XJ&/'F0-S5-'^(NK4JA$HJ.XV5^B1[I#WW%2F1""HFT
M78\"U]P06Y9E4G^ZW>#HL2#XOUJ<FHH(%,D0AI\_J!/-9-DU4!/#PYG\B*Q%
M_H_2+!/_`,`'CN3K=NXOGKS/</<Q[ED[;IQ2&.@G3%N5A^8XK-XM3RZ0/VBY
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M=;EWQ\\V9[U[BR?<,W;E2O)DGY%%MRL(_P#_`#V3P&P8Q*6^SR36?$#WX5C^
MJQ83^2^,^NR0=2@-KD\E^RC9-TL<8(56,.-T4V^>?3KQK(?[T*$.6NG>BDB9
M+SA<%+]3`41_1#'>DP-\^77\^6`'WC[G03@-O#QY>T^S8ZUBG\X&5J'ODC!5
MC]]ZF'@D_.9!Y08B%(49/L_M3.$Y,&X<"=@6'MEO2SX^H+IHG2TXC3IF]A3<
MHMN6(A)5MA!@^;6S7Y37%9E0&LG(&0<LG4F+$J("8ATR>8)@,/A"/W%W9+W"
MLBR0K'U)TE\&Y;%8A%M[![0-]_\`V:HOF%^:7)_,`V0:_AZ^,-_-ULB>G.\W
M!JV+CQ@B'*--U=8^L6V!#'AL0-]>Q#FHZ^4].--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--?F;B].TL<M[D/#:-?C.X7
MHWV]GH9R>Y60Z\1.0_=+LK#1$U&*GDS'82\5#1C9FV<I"19NT;)(IF*FF0I>
MVR4:1O8U.C%Q?*5%;W%\5:E6)!\/$$DD@^!))/B3K^P=WL[M#[Y]@5QB<8(+
M'J1VO#*HJ0`2PR]I]ORRQ2`1[/%++))+)&VZ/+(\C`N[$YCS;8M>=W.MHNM7
MTUPBKT8^/N?516OUL424G;'V@ZTQ=AFE$SRXD/+3L9(N6SUR(><Z;N%4E3&(
MJ<IK6QC<<L,A6"'<9&ZOU%^JM:V5'L]@(!'X"`?:!KL7=O8/8<';]R2'!X=9
M%]2.]H`12K`B&#M[N"2"('I;B*&2..2)/JQO'&Z`,BD:#'4M.+UZ[VR(:1?_
M`'"O]/)B;@7XW.R"]A)DO>#NA!DEHAV,F+B-DB0D(R9`NB8BH-&:"(&\I),I
M:J>A1^(XU1#%Q>_Q8<%V(\C3;8^'B.3,WXR3[3KEWW+[-/JIZ:5?A&+\K:[]
MBAF3RE?A-$>S^TYC%*O3XR1F:::4HX*]6623;F[$U'C&N:R]W5./>:GI3QA^
M`OQ'2'HG5\M;AH+^X:?U":6Y\+=:6.B+RU-99VE)*_3QOTW:Y5Q4!90#6.2Q
M^/6BSK!"&\SE!N$7V)'=*#V?DD#C^#BNWL&V\>H'8O8]?TV:U7PN(CL_>;U.
M3FM*LK<*N/[H:LG(1`\:S11-77?:%HHS&%,:;3935=2+T;[MSP:;HGOD%U-Z
MK3$)-#>+0,M#2TIV'[`1\I*14D,J+R.DI./CV[=RNB<BKA!!--0QB$*4(DU"
MC]X\=%T(>D]ZV&'!=B!6@(!&WB`22!]!)(\3K71V3V6?F.].\8</BOAMGOCN
M2*:+R=?I2Q1X+"/'')'T^,D<;N[QHP*H[NZ@,S$\C&=8U5[V)L<8\T_1GD:D
MC\0!DH]U>;2X9)C<8/'CV\2-5I4Z!?NL[I4TG]"_S\RR@K^8)S?7-D,?07&+
M(L$(?;*^(1?R'L</H_)V''_1V&VVPU.]0.Q^R:_I34N5\-B8[;'U1W=:=97/
ME9LJ*N[",'\V"J*_C]B%41<>*[?-[K&JD^.#N192Z?HP62%ZY_'9)PUA^^;2
M,Y$25A.T&PR$9+C*C(,'T_\`4?7*I*$4>?7]<)^?DF/H?>VA#T(>BUK)`KP7
M8A0>((VV(7\G_1^C;7F#LCLEOFT[`Q!PV)^$V.[.^HY8/)UNC+'`'Z"21=/@
MZ0?[%64B+_9A=>=G&L:HZ[-;;%.=.T1Q%Q^L_'JT81RUWLZK%FTL?7/1)*PM
M6S0\H9!!M/2+9-P]3*4".ETRJ*@8Y0$/RWCZ"X:O*L$(D:&^2>"[DK/$%/L_
M)!('X`?#4;NSLCLJ'T=[=O0X?%+=EP??#/(*=<.[09VA'`S,(]RT,;,D3$[Q
MHQ5"JDC49T?7=9:?&QV@M#74M';V6+S_`.,)S&6%&\VA.<C7%IQ'&GMG7CY4
MDJ#]DM9'KU9:0,DH4SU98YUA.8YA'-7QV/;O"E7:"'H-)DP5X+L>$TP7<;>/
M$`!=_8``-7/:78G8\_S<]FX6;"XEL/-E/4-9(#3KF&1:V7RJ5U>,Q\'%=$1(
M`P(B556/B%`$GA=6U-3L1VBCE--T0\=$]L\MAXM@:\6@64;$N^GG;2:=1;!H
M,KZ=G'.9B*:NU$$RE2.Y:HJF*)TDS%C&A1&*J/T(>;4923P7<D6J0!/A[=B1
M^(D?2=Z;(=D]EIZ4]FVUP^)%N?L?(RR/Y.OSDE7NGMF)9';I\FD6*66)78EA
M')(@/&1P>9N>LZLP^/CL!86.GZ,RL$=KO0ME'SS2\VAM-L6=@ZC==):?:LY9
M&5)(-6\Y+2;EV\(10I7+IPHJH!E#F,.3'X^@W=M.%H(3$T-TE>"[$K=G"[C;
M;P`"C\`&WL\-3?3?L?LFU\TW:V*LX;$R8N7!=YN\+4Z[0N\'<^=BA9XC&49H
M8HXXXB5)CC1$39%`'P1UG5C:AWB:#J&CBU@>W>]0T&V^^K3Z>%B&'2SNI.,(
MJ)1"5\N.C&,U#,GB*"($22=,VZI"@HBD8GI<?0\ICFZ$/)Z-<GW%\2;5!23X
M>)(9@3](9@?K'?\`6['[)'9OIQ.,-B>M9[$PLLS>3K<I97[L[2A>24]/>21X
MI98G=MV:.65&)61PW7[%:MJ<9T<O\[':;HD?.-_D!ZZUYO-,KQ9VDNA7Y/J5
MBLK)02,FA*)O4H:0E7R[I=J4X(*NECJF**AS&'%C*%%^YH8G@A,1Q4S;%%VY
M"[*`VVVVX`"[^W8;>SPU!]*>R.RKGS(8O&V\/BI<:_I=G9VA>G7:)IX^Y\M%
M',8S&4,J1(D:2$<UC58P0B@").];UCUG>(H:EI(%@>T'R+Q4&!;Y:BA"Q==Z
MA[5,UV-B?#+![<PK\PS1=L44?`FS<HIJH@0Y"&"3#C\?OCOL(??IXXM[B^):
MS75B?#Q+`D-^$$@[[G5Y7[%['\OZ<'X+B-[/9O8DDWYE6^UDG[GQ$4\DOV7V
MCSQ,\<S-NTL;LDA968&X^PFGZ9&]:6$I':/?V$F;Y?:I3S2+*YV1J_-4%Z(R
M66J@O$),C@:RJL<3F8>+T@G'Q>7XOT\K<;1I/F2CPQ%/N_SVX+MSZOUMMOK?
M1R]NWAOMK0?2SLWL^WZORT[>)Q<M,>@]FUTWJ5V3S0NN!9X&,KY@`;";;J[>
M'+;PUGYIL&N*4WMPN;5M+%:&W3Y18Z(6^_;6"L4PJN5Y<ZJ[*-4"6`[%K6G3
MI56/32$I62BIS(@0QC"-PN-QXGQXZ$.S5L:3[B^):>8,3X>/(`!OP@`'74IN
MPNQ5S_8L:X3#].QVWZ=R2CR5;:1[.2R*V7D'2V=K"JJSLVYE5563D`!K2V^:
M=I<;4L/6C]%OC%60^;*TT9^JTN%B;JO:2G=I5!.G.E$I(AW%421(!"1QA%F4
M@`4$P#]'*/&T*,D]D/#$0O;22#W%\'X#W_9];\+>TZY!Z8]G=H6\YW'':Q.,
MD2+Y=JUQ`U6!@ELU(R;2@QD+9)))G'VI/B7WUE"D['K[C(M#>+ZSIZSQM?N_
MS9N[5T"W'<MV]>OW2YK7T$%S3`JI(P3:9>)LRE$`:D>+@EX064\5^^.QPOQ*
M*\'$I2\.FOY2WN7T?3Q7?\/$?@&W;>X>P>PXN^\57CP>&6!\9V4S**54*S3T
MN[&G)'2V)F:*(RDC>0Q1%]^FG'7FMZ7I#-3H\#30[VU"=^7WL!3ISTUPL3?W
MFH1W9BS1L?5);RI(GN-98QJ!&R+!;QM$FY03*F!/Y/-=I4:3-D>4,1X=OP.O
MN+X.:@)8>'@Q/B3[=_'??7"NQ>S^T9U]1^OBL8_EO0?"6H>56!NE:D[?KR/9
MBWC/3L/(3(\R;2,YYEBWCK)&`;%K\CUZBY&0UC3GTB:0["D,_>:!;G+TQ(WM
M]T%AHXIG:TP=P8&$///VB/U-^J;/G*1?H1=4I]AR6.QR99D2O`$WB\.FFWC6
MR!/T?254_C53^2-NZ>I_8/8=3U4FJ5<'AHZHBPAX+2JJF\G;'>LK^Z(@OORP
MPR/X>])#"YW:)"NJ=`TW2FSCXL"M]%OJ`6OOAVV@+2"-RL:?W-`Q'9J:CHF$
ML/@DB^]P\5&I%;-FSGS4$&X`DF4J?\GE!7I4B<WO#%]GC*K+[B^ZQJ;DKX>!
M)\21XD^)\?'7$^V.SNT)H_6DRXG&,:/IIVS-6WJP'R\TO;T4DLT&\?V,LDA,
MDDD?%WD/-B6\=9PZJ:_K<M@^%2$KJNER;]\=@5\^D;[;'KQZ`_)EUBJX^L<N
M9=5=T)JS)N8X14,818.56X_J53D-=YK'8^/)VT2"$*&?8!%`'_A]MO#P\/>`
M;P^D`^T#76_6OL/L6CZE]RU:6$P\-:(/P2.E614_\ONX;'N*L0"_G$<<XX@;
M31I*/?16%[3NH::DP^(<4](OY!N%O[E(6XQ;I90-:T86S2)(9*RF"3^L\G$)
MI@5J#OS0;E#PI^$/T<JEHTC+G_L8OLUI\/<7W=XSOQ\/#?Z=O:?$^.N:8SLW
MLY[/KL'Q&+(H4>U#5WJ5_P`V,M=#*:_V?V)E))D,?'F?%MSJG^GNNZS-Y%U4
M?3.IZ3+/)<_7KW5U)7NU/G$G[A\GUCJ\A[BLYEE5'OKZPD6-7\T3>='E!L?Z
MH@!.6.>QV/BN74C@A556?;9%\-L8K#;P^AO>'X&]X>/CK??7KL3L?'=\][5L
M?A<1!7@&<Z:QTZR+'P]/(+"<`L0"<+!-A..W&<F9=I#RU8-QU746Z/Q0@AI>
MA(_=W6#N'*6P4[K9B&M$G"Y+8'D/)6(Y9,#3<A$NTRJMEW(JJH*%`Q#%,`#R
M)!CZ#2YTF&+[.]4">XONAI5!"C;P!'@0/`ZU;`]D]F2R>MYDP^*;R'>7:T=;
M>I7/EXY<G`DL<`Z>T*2J2LB1\5=20P()U"^K.M:O+4[J0O*ZCI$FO,5_J&K+
MK2%[M3Q255F>WG<Z(EU)([B64,^-*Q,*S:.15\?GM6:"1_$FBF4N?+8^A&UT
M)!"`OFMMD7PVITB-O#Z"S$?@))]I.MA]:.QNR*.=[YBI87$0QP6>YQ$$IUE$
M8B[7[3EB$86(<.G++++'QVX22R.NS2.3T=%UG56[+X[!;Z?HS<;)\7/8VU6(
M4+Q:$33]HC>N-_D8VRS9DI4@RM@CY%$CA!ZOYCE%=,BA#@<I3!YJ8^@;.6!@
MA(3-P(ON+[JFS""H\/!2-P0/#8D>PG4/M3L?LF6QZK"7#8EA4]9\#6@Y4ZYZ
M%:3/48Y*\.\9Z<#QDH\2<8V1F1E*L0>5@FMZQ(YU@;J0U+2'SF1JG45>0<.[
MW:G*SY:9;_(>,NJ\56ECG<GE1KL?ZD3B85_0-O'XO3I>#)D,?026P%@A`!M;
M>XOAQ^'[?1]')MOP<F_"=YWJ9V-V14[J[GAJX7$1Q17>YPBK3K*$$3=C=(*!
M$`HCZ\_3VVX=>;CMU7Y>3V*UK5XV0ZFDCM1T>/++?"U>+O+%97JTM0E+HVPR
M_OF]PD@0E4P?VI%\B1<LBKXW@+)E/YGB*40\8C'T))+W."$\>XU0;HO@AL0C
M@/#P7;<<1X;$C;8G6#TH[&[(N5N^#;PV)E,'S"U*<?.G7;IU&S%%&JQ[QGA6
M*$H8%VBX,R\.)(/LR^)*YW&WP4RK;;=:+2H7J[TGE2GLEAEYTQ)2<KNP*S<D
M091XZ\$A,*M$3.U@^BCDR1!4$W@+]-+[]K5JW3%>-$'G;@]U0/!3#L#L/$#<
M[?@W.WMU\??/-V_@,#D:Z8.C2I(>\^[8MJ\$4.\<,^+$,9Z:KND09A&A]V,,
MW`#D=_<ESG6O@+3C33C33C33C33C33C33C37Y8XK^Z3NW_`+W/\`SR=H^=WD
M_C#%_P`K4_T&KK^TUW^G/IU_B?VG^I_;FLJ9;_7BK_P`_'#^:[J[RXL_M,G\
MIWOT6WKMG>7]'+O^)_?GZM]QZT>?]V[Y!/X*9G\^G>/E1/\`QGB_Y1_^0I:Y
M,/[V_2W_`!#B_4OL_5.8?^\`G_#U\-G^:_3/ECD_XO;^%9;]SO:WWU&_NN;^
MM/JK_-O=FIVK^X-WO_@\ZD?F2[%\B2_TFQO\/N?HM?6M+_S.>FG]?>Y_Y@P6
MN-B'[R]G_P"P^%W_`-!Q?F;)?Q2OXLO_`->QJ?ZC?W04_P#6]6/W;+:^;_\`
MY8O=O^&;XU?_`+F?/R3^F6/_`(7D_P#,=>:__.+Z=?UP[_\`\SZ\_,/WJ=Y_
MQA^-S\LVE\7?XCK?[C(_I$6HW>/]R?;/\@]^_K!C]133_P#E=]KO\./BD_R(
MQ#F>K_3:C_O<K^[3ZN^S?^<OLC^5O4G^><OJ6P7[RG;+^,3)?R4]PN1#_$]+
M^`2_I='5'DO[H>R/ZA9/];>U=<G?O^7!V,_QF^/3\FW6;F7&_P!,:7^XO?IU
MC4_TP_YM>TOZO]\?K7W!KXH?WL=]_P",WL+^1CO-S]7]Y8W^3ZWZ9C]&_H3Z
M8_X?X/\`7#L[78[,?N#Z+_J,]9_R=X5S%BOZ50?R1/\`ITVH'I#_`,SN)_PG
MS_ZU9C4/=_T[OO\`Q7_)A^3'<N2H?;C/X#C?TNOJ_K_O;TQ_J1Z?_K7A]77V
M1_=;C_\`6?I_]@6'*O%_QV?ZN']VUSOTD_OHE_\`3Y:_37UG)C_4CN5_$!\L
M?^4>3\NE_?&._@N+_=YM=9G_`*1>G_\`5?TT_G3)ZU'V(_J=@?\`KMVO^W<O
MRBQ7[XM?U63_`*@UQCTI_C[N?_TTUOT.+60:'_<SI/\`B)\BW^8O1SFPR?QA
M#_J4?^K?UW;N7^\#$?R5V+^@]X:V;LG_`%O0G_6@[&?FEM?-:H_6R?\`5RO^
MAC7`/3_ZOJ=_Z?,%^KE;6..N?[ML5_YGV2_.A\>'-CRG\</^.']%R6N_>J_]
M[D_^ZP/ZJ=]:UQHW])^)'_4&[C?FFG>:]6__`)W^2JGZ'KA/:G[5ZY_X6]K?
MJW#K,?43]WS`/^U8?_*?U5Y>YS^-;G^L_P#-MO79/77^]+NG\3__`$X[DUH&
MP?T#X9/^-.[G]IY3E0O[;W%_JTOW,ZY;BOWU\P/\G]H_H\>J5Z4_W,]1/_KZ
MW_\`RM6;EIW%^_K_`/JV/YJ370_F&_O`[[_%GO\`Z;5]6/=_^J^'_P#A2[J_
MY.6/D*O^V]P?P^G^[+K4NW?K^O/]=NTOYUKZ@_4G^I/3?_AOIC^<SO!R1F?K
MW_\`]W^A4=;'ZY_T@[^_A7=?ZJ=GZZ>E?T+XTO\`2;[-?EET/GBG^^<S_+T'
MZ5#J)VC^^/5__'#M_P#6"AKC]=_[L^N__!_3/_NWR3\RY+]NL_ZUO_-C=3O5
M3^EW=7\/[K_ZW8&O+[,?^)=/O]#._P#^0>B<\87]LO\`]9U_2(=8/2#]Z]^_
M^I&G_/5#7M-^'#^KTW_"=T3_`+-;1S1?4/VQ?PZ[_G@U\6?/W_&E;^O'>7Z1
MB=>[?G--?SKUE2(V77KEH,V-"S.KSN.4_4ULAL\P]N+F+T9S*1:K%A<+Q7X!
M>&^VE:C29U\=HNU7D22;])B[7;D^I6R#J^DQN.K5%\W/(F1DK]90$!CV.Y1&
M;?ES=1N"%XJ64'\HKVR_Z?\`8>`[6K#N?,7:W?\`?PHRE>)*JR4%CD#O5ISS
MB7S`M6X4$J2)`:\+3012ML998>(S[#ZG:J_J3ZL9'#5.2SG8)>A2"VOWIG6(
M"NT*#RZOZ8IJ%Y=P#*R.XII--YM)LUCVJ;IPU*[07>&0*1R1+*V'HP30)/8:
M1)JPD'20LS2-*T720,5!*\22QV!V(7?=2;*QZ5=EX7*86MF<[8O5,M@8KJ#%
MTVL33W9LC/CQCJ:S/`LK1-"TDD\ACCD,4D=<2%H6?BUOMS*O;?E2-RIE;H-(
MUG,'.CQ19:\>JT6"@H7,F&CVF[V*LI0:$;'9S!/'IJ\9PJ\2D32A$UA:@V6`
M4\LW;T:U[!K2O+:KSB,[)M&S&4QJBMRW,C`=38`KQ)'+D/&PR_H52K8+-OV_
MD+>4[CP>96A)TJ?&C---D'H5J<%@S&22_,B"\$6)H!7+1]<S1[/7K_O=-^Q9
MQ)!1*A0'=_O>X02B>Q6VUUN/K56R&_P](92U@>5//;J>%F[(G8V+I=!^1G'Q
M(F62<O0.E]32U[5CZLR=62988H&^Q1&+--&SD*&D3D%XL`5W9_`A?'6U5OEH
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MT6:QO:S48MI9[&TDABUF,?(IH)`JNF?DJ3M:N4MR59I7BK.R%C&H56CC5F$I
M#GB&<F*,KR#,I)V!&MBN_+=@)*G<]WM[+9&W1P%FQ6-AJ4*5J\]*G#8G7)2K
M<DZ"6+4DN/H2U_,I-/`\C\(F744_]PRT^#T7V-DOW!^S_P#M>>V_C&MZ;\!?
M)\_[8]9]G>9^-7C_`%/I?*]E_P#S>K\'\GDC[GP?6ZMCH^<\IOT?'K[_`%MN
M?[3].^_/Z..KS_A5PO+S'Q+.?"_O1]U^I\*'+XUOQ\QP\UM\)V][J<O-_D=#
MEXZ\II\:;1K4]JJ_XPNU"[%@NRX>H\&DH%&`2US<-0V=2R$0"R_[Q4@CZ2,<
M5J)T0<%9@L*J8J"F3RW>K-/5G\L`:UN&?;G];I010\?J^'+I\M_';?;8[;G!
M/\WT\V;[=S/P",'`=SXK,!/-M]N<7A\=B17+>7^S$PQXG,FSF,RF/@P3FU5U
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M]TZH?MIL_;-@$O4JU8W9T9,706Q;^5>AR,J)TO+_`-W^O,8#N/)`IY-GOYK,
M!@\J!O+;??J;_OI9UV^I^1U]]_RN(\!OX7_<7SPV,_VP>VSVU'$#E.Z;G4\Z
MS?TFK9:N8^/EA^\_BA<-R^WZ`!6+J$KW3?%JS-@NZX?^-;SR]KQ_)<H4L@T1
MOXZZ3+='T30B3A(L+2!9,\V>_BT,W%=`$"M04!0XJ>`F)^^&?)ULCY8#R\\T
MG'G];K11Q[;\?#CT]]]COOML-M5G_&C/_:9VUZC?=V/EV]GLGDA!YQMISDJ%
M&B83)Y;[,0BEU0_!^9DX%5"\F\.D_%2SINDR>AEV][('D2=,R>U&H39L5+]D
M1A3&*'\\"U+"<+X%0`Q_U8>W>H$`]1X`\7NQWVUBJ*WE@`!;\>I_WHR'V<?R
M.I^'WMOHWU([B^=BQG^T8>U3VY'$L1[K^T\ZS;_>A[;GW/+#;R7FMA[QZ_`$
M]+D=OZO\5;-;K+M?7+\;G@);%FG6W.CVT:$W%2`+UY%$4I8D,%J*22-;/*_E
MHBY1!G]?T'5Y^-WVS9BOEO+`&"6R_'G[?,[^&_'PX;^W8\OP#7Y'\Z\Z>L';
MOJQ]W(^>`R^?O"MYUMICG0=XC+Y;>/RV_@_3?J_2J:\BL_%DRKFI7K2PVMX[
M/=KAUQMAH@:&W1+'CU]S2R9TDQ!]]U*BY"TEL(NS*>4F+,4O+`JWB\8?DW?3
M2T8Z?E@!''87?G[?,2))OMP_)X[>T[[[^'LUBS'SI6,MV7C>SSV[&BXZAGJP
ME\ZQY_&\A7O%^'EAQ\L8.D%Y-U>7/>/;B>79OB?8V/K%JO6\=Q>-4=.KG5:O
MGMOV`W64A@ZR42DTE%T2%^[$BOAN1:<#DY!=)>A%P)`%<">(V2/OUH\U!F/+
M#>%K1X]3V^:=W/CP\.'/;V'EMOX;ZFX?YW[&)]8\)ZMCMN-Y,/;[DG%;SK`2
M_>&Y;ME3+Y8\/*>:Z8/3;K<.1$?+8=1C\63-EI&KZ%^-CPYM/V"IZN>*^PVQ
M2PQZOB^P8^$&5Y]TF%\5Z36#/Q<>6D*8L`1\LWFBH3$>^6\G#4\L/LH&CWY^
MWE+!+OMQ\-NCMMX_6WW\-C"L_.E/8[1PG:OW=C"X?`V<:)/.M]J+&6Q>4ZW'
MRWN<#C!#PY-N)C)R'`(WBW[XJ65XZY:)U^-MSV-3O]RZ^VTUJ"A-W2L6;",=
MS3)$V)8@;4W(["S)YV#\R@N$_2&=BD!503\9_5?OMJ^8ARWE@3"DZ\>?MZT\
MDWMX>''GQ]GCMOX;[#/VQ\[-CMSU9Q/JB.W(YGQ>/S=45O.LHD^,Y7(9,N9?
M+,5\N;QA"\&Z@BY[H7XK_"?%.S):]YL_XWO?KM^R:#KBC/[!;?2N'OF';CC!
MH(B_W4/NA(LFT&D`<"1`51CBHBF4%A43_1WVPAK0^6'YO7CBWZGUNG-7EW^K
MX;]#;;QVY;[^&Q_3\[-@X3MG#_=R/;MS`4<8'\ZWVXI9C#Y;K%?+?9F0XD0%
M-WXB<R<STPC>9I7Q9,]$P:Q8@;;'D4G/]BLUWX;(6B-WBC53.\?HV3%JX18V
MEL19.5)2P?B[%<HHF<>5Y1P)XS>*O?+5LHF2\L"4J/!QY[;\YWFY;\3[.7';
M;QVWW'LU'[1^=*?M7U-J>HZ]NQSM5[4OX7R_G64,+V5N9,V.IY9B#&;?1Z7`
MAPG/FI;BO'6^)UDJMO"WXY/2_C=JW973E"A0&P_;A^Q&-7C(U88@C:_]YEJ9
M+H+\BX@@+P6P)"1+QBH7,G?S)Y;\U!\O!6C_`&SZWEY8Y=_J>'/I[;>.V^^Y
MVVU/C^>"Q''VS']VXS]W,)@,>/SUOMQ@LK3R8E/YM]GYDU.B4]_I=0N&?B$,
MTT?XS6F@Y>WS4VQNXLB'<N([=>\%I#=X8R\5`(07V'Z(;,V*"*P(>;[CYHF*
M(^'TXA^GD6MWJU:[YP5P?_#O*[<]OR^?/?B?Q<=O\N^M>[3^<*?M;O-^[UP$
M<Q;T_E[8Z7G&7PDG:;SO/R[>(WX]#CL1X]4:KM'XCF*,)L<-^.[X0UJ_=KKR
M=P&>M@&#-V?J54JRT:1,;<;W`*86L`N143(^N%82B1#P^(TP>H#B2O)Y4?F\
M59/VSZWEG=]_J>'/GMMX\=M]SOK:W^>JR^1P%_[LQ_\`@>,[:IA?/-]M]W;5
MFR)"?*^YYOS'`KL_1X<@TF^PM#0OC7:7V'H<2?7W<:%([T2O=4JX4I!V,BXE
M)UW-#G8I_<K<&J"`NO+"3^JAC>'Q>F#Z_0(-7O-JTDL@K@]3%K3^OML%4#J?
M5.^^WU?#_6UIO:WS=S]LW\G>7`I,<CZ;1=I$>;*]-8X5B\]OY=N1;CR\O[H&
M^W6^G50P7Q`L86FV2HAO;YP6PV'L1/"__#MLD9H.^6+$)]1L#?[O4!;[7'&2
MI%/XR^K]Q,82I>2!5+!O4)FL)/Y0>XL`VZGMZ(G'^A^5U_\`V<?IW\-ZR7SX
MV,AGZF=/;$:FK5P</#SS'E\%@S$(;EY4;>8^+%B-CTN@!N_4)6Y+C\;K2VFP
M<PZZ[8_@CW+T3MTG]*6@X^XU[_J,KI9J&?ZV1'VM&+/)^C"1#SS+%)YOIR"/
M@"M@[R:$V3Y<'S&.CJ?7^KTX1%S^KX[_`%N/AM[-_IUH.`^;>?!CN8#`I+]X
M_3^CVP?SMEZ`I8Z/'^='V!ZAD$?5Z'N!2>'58#D:>SOXA&-!SAIGQ=[?2A6K
MG1W'NHYVU:&/^(.S=>M=,4686]P!1BSX*5@`^9^N"4,M]">0":ME:]06LVS:
M\J!OP\.IO]2*S'[>`]OF-_9^1M].XW[NKY\+'<_=K]TGMB.$NM`=/SS-MY+%
M9S&?6\JO[8,T9OJ^Z:P3WNJ72VK%\:[2?4ZF*#L#MK^RWV`V'=40"E(+?>JF
MLZD^TL]95'[D3]B3@CO?1%=%]4+@I?,%),1\`5T?>31^>_-Q^>U88?K_`%.E
M#T>7U?>Y?6V\-O9N?;K1<5\W<^,7OA1@4?[Z=KXO#'\[8>4&,QJ8\6!^;GK&
M;CU3&>GP)X<V'O&L\D^)%EEF?T&B$W9[-%HQFYBR9L^;,#2?D=I,L[+?RFH6
MUV#43JYD6''Z*'^A7HN?]J0(GG7O4!KEJ:SY4+U2QVZF^W*M-7]O`;[=7E_\
M.WT[ZW'OGYZ+'>G=&4[E;MF.N<D&^S\\S]/EVYDNW_!O++RV&0-KZH\8A#['
M,BS^0^,IH^;]-D/QD=I_LCS.V2Z!_LAN8;V.QRCF2.@L'W,4*]]OBX\!3%]9
MZD`^H@F(_HB#O5@V0;RX_/Q#^7]3HKQ_T?>Y>WZ-O\NM7J_.'/6E[_E^[\9^
M_5?$1$><8>3^%1K&"/S<]?K\=R#TNG[`6U#,7^)MED%-R2I)[F]GBY6.<"1\
M:@-HX9O\/NU,GV;+XVX6Q[Z#W5:1]F'Z'5\DA/4AXQ'R0E9#OYK\\\QJA>L)
M!^V;[=2J*W^@-]MN?L&_U?\`+K8/4'YX;'?F>SN<;MN.L<V+^Z>=:3H^>[;C
M[>\&\LG/IB/S?L7D3T?=`ZFI'-?%VSF"=1"#M#M#]E/*MHS%$WV*@H-V)K]/
MD:F>:5#[H3"!/`ED//!`OJP<B3P>-/Z^(,$??#(^0?RP_/K$,NW/ZG2<-Q^I
M[W+;;?PV_`=5./\`G-GH-WVP[>C;[[9O$Y`_GC#RAQ=J.R(A^;'K";I\"YZ7
M3WY<7VVUPLF^*)EET+CL.3<7LT&31N-1Y%S4%LP]\_"/9-NUPBIDPM;OV_WX
M^RF8"`&6].6/!4!4%84T\MSOQK9G/E0O6ZO^TWVZL,$/^@-^/1Y?1ORV\-MS
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M?*R<?.LW3^)G`$C?RR\NC\#&QV7GYD^"=(<_MTKXI&6B.<@<'W!Y%?A1T>GN
MF)"EH+=Y[XA-T*PT<=".(VMM[>NW+/BY]M`%2F%(">I`#"8/RGWVU1IV%8-U
M\F+?[9MMM(DG3^H=_J;<O#V[\?#6/M'YV[':D6>C7MR.?XWZCP]UG\]9>BT5
MV"YY$?FS<PW0Z?F/=(#%NB=MM:DZ>=.D.ID>]8H7]>\@\RG#,P\Q:N)5_P`H
MF*QMSCDYD"IS,N)C6(+>)C("/T;>G``.KXQ$M'W!W$<]QWBZ7&>:3ZW+?K%#
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MU&AJM"A#E&7E([F16`.S[.R`[>`.X(;8BQ[(]:J?:UO'V\GAA=GQG;DV*JRQ
MVY*EBNT]ZU;>[!,L4IBM".W-51E7>)&,L3)-Q=/C<.IZ^KRT2WVO3Y32LZ9+
MI6)[G:E?1K"3B\*YNXS26>15I@9A&PUZBR3&1>200+<XJ)2KLYQ?*-OHUXKY
M\4(V.,@6"X1Q$G+E[G4Z@!5AQ9P0%ZA_(`'$-[VO6!];X^R*,\OIWAH<1W9(
MI@2\)S8*TQ?7(1))6FB,$]R-XXJ_G'79JT2J*RR[S:C:/2=*NT2PYIG6P76G
MTB^3VPKZ-"21%[\%FJ^S2S5W-13)]=)N4D8*T5^':FCHV9!5R!4G;I9RT<N5
M@53S'N<S6DNW*T4EJ)8>FP^SXM""`2$4!E9CR9-AXA0K*HV-M)\Q,F6[EJ=X
M=UX''7^X\96Q8H31E:7E[&*B98I'2I#''-7GE83V*G&,EHX8X9X88RC>7^Q@
MT!C>ZXGI4JTI<S1]PH6>5]C68AJ[S>([%69A;M1.I.`Y.YMRZTQ'$+%"NFV%
M@U,8BHNE1*N7S]Y6YQ3&!3966"21BQ(D-=2D7N[;)X'WMM^1]G$>&L/_`!!S
MFSC,L^'@?N&ODL/=O3O8E9;\N"KO5QP$/$+5412$V0C2=:0*R"%-XS-M`ZQM
M;I?6EHC[J[JU:?-,A97.H,:_&O%IE#";O(Z#FQ:S95UTGU(])/R:A'_DI.@=
M-"E*B#58#+FBU,XU:H8'B$DP,Q1RQ&W701R<E]C[J/=W(V/MY#PUKG:_K'/V
M]VP^&M8Z.[EXWRCU+3SR((FS-..C?\Q7"E+G*&-3#S:/IR%C)UH]HEH;_P!O
M*(]]^]/OZL_?GT]F]_\`P`R7VS[8]?[U[S]I>V^P?C;]S?[V^\O+\7K_`-'M
M_I?YKRU^]\G1\KT7\I];CUY=^6VVW+?ET>/N]'?V?E\O>UTW_BJO_#?N]\+N
M?=G]MZ'QO)]3S'#I=+S/4Z_PCR_YM\*Y;='_`+5UOMM>Q_FFZ^2=.--.--.-
M-.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.-
M-.--.--.--.--.--.--.--.--.--.--.--.--.--.-->K,O?'0H.HH;/:*?2
MG^1ZCGN[W3"X:"&>CKRW?Y"KYM4@M`F'[^3@I'\6(,AWJ:S!DR]C.0&YR/?%
MYY=[^ZE.6P<;!)*,A!-`DY;B4(F^NT8`##I-[NS,>?UAQ]FOM)OEF[5R6=;T
M^PM_(Q=]87*X:IF)9NC)39,H-K,U&)$CF3X9,1"R32R^<!ZJM7VZ9F;CLCV*
MA;4KUZG8O&ENPTQ?\Y@JM;XJ,NB63$I=]S[2=%DK/)U%Y93VU[(5!#&[#&>D
M2F6Y)%P9BX\QJ199!&,,+AY:_P`8B:R,0L,C,A*=7G')'&%#A>`#]:-M^!XC
MF-FV!.OQ>D?I1D<(OJIC9NX%]*J^+OS6:LDE0Y,VZ5ZA0CKQVDKBLB6FRM&Q
MU6JN8$%F+A,T<<DD3>=S-VF*W-N:=2<O1M.%Y?INE=B(F<7M3Z.G'F4ZA?<O
MD*/E3Q@\CG,$[N2V36"2CY.52D4V2)F**S585EEDI"]M8J.9%LRSF"U/%'7*
MA05$L4<H>4$$-PZL:LJE>1YD,-@#>0?+]Z:T,M6AS^1S+83N7-8_'X*6$5DD
MA3)8ZED4N9)7619EJC)TJ\]>LT#2N+,D<T82.-YJ'<&ZFN);P2(I(]9/QM0P
M$[H6T^&H!-N**C8"Z/Z\)0:R%7+<URP0Q`L/5^7]7WK?]C3D7[N5A7\J6E^-
M^5\QM[O2V$G'I[;<N7#W^?+;?W>/Y6M=_L%[=&`/;;3Y'^V+[NG-!>4'P[HK
M<,'D.'3\QY@U`;GFNMTN7YMY?_;ZA+3N?N</6H.0N%)S%>P;ME6<Z=UUBX->
MT,6,(]U#4,\R^,HVK/'[V15G'=77V"NR3Z2BB1Y':)7Z*35$445E91[:Q<D[
MI7EG$-6Q)%8)"DL(HI)2\0`''ET9%56Y;'@2QW(&QS_+YZ;9#,6:N`R.97%]
MLYN_C\[),M=WF3'8Z]D9+F-1$00K9&+O5X:]DSF)S5D>9P\D:2Y#LAV*E[4G
MUXAHW&6_8B*T+0*_8[?*1=U5R56DTC-\\TN-M<=4&ME2MS-_:T-=@(H69YER
M6/<E?.`5=$1215CG"X>.O\8E:R<0T,;*@*=7F\DD94N5X$+T9&WX#D."[*22
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M#HUYHSK,C$R!9RYV:\LVR3TRRB$:V0<+';.C^6B:CQ5#'RU9+^5:85$FBB`C
MXABTG,EB6!&R*C';;=B0-U&YUQSTR[*[#R';F0[W]2YLJG;-;)X_&QICS`L[
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M#-CD>_4%PR+VM2L3>0KR2B[!+`D[-Q*;3#=VC``8=)O=V8MS^L"OLU/B^6WM
M#-Y8=DX#(9*+O'$9/"U<S-.(7J&/*1EK,]&)$CFC^&S#H&.:6;S@(E5J^QB,
ML7[(=BHFUK=>)F-QI;L-*:%0*_6[C&Q5U2R4E(N^;:-ICVUR%.=V8]N=R%70
MR"?B09IS2!7[GT;GS6R:JR",<87#R5OC$361B%AD9D)3J\TDCB"APO`!NM&^
M_`\1R78D`FBC])/2B]@U]5L?-W`OI5#BKL]BK)+4.3-RG?H8]*R6EKBJJ6#E
M*5GJM4<P1^8AX3,D<CQ!WW0W.8K$Y)4^D9BWL&$95HFG=BXB=<VA\RFGF7ZA
MHF72]&REZQ=QJ\$[LKC';'(L9.51D$VJ8L4%FJAE5EDI"]M8N.=$L2SF&W8C
MBKE0H*B6*.4/*"#R"]:-65"NYYD,-@#?0?+YZ;4,S6J9[(YE\5W-FZ./P4L*
MUT>),CCJ.1BN9)'603+77*T()J]9H&D;S,J3($CC?<][W*A9W2JQ>)U6??,[
MN[AHVE0-6K$Y;[E;YB>BW$W'PU<J=<924S*R'LK%R\6!-(4VS1JLNL<B21SA
MJU7%V[=F2K$$#1!B[,RHB!2%)9V(4#D0HW/B2`-R1KYM[9]-^Y^Z^X;G;>-6
MK'8QR2R6YK-B&K4JQ0R+"\L]F=XXHTZKQQ(6;>262.-%9W537A^Y?7I)A"R"
M]S>MPLM:8V6ML'-3MC>8L(/-";Y0O6X>&6A22;V]PFCOFT/)P)4O=HQXZ1*Y
M02*<#<F#MO,%V01`\'*L0Z$+M'U>1/+8(T8+J^_!E!XD[:VM?E^]5'M6*L>/
MC8U+CU[#K9K-%!PHMDA8EE$IC2G-022U7N%O+6(HY##*Y4C7?P'=@V]78TAJ
MLW6!RK:;ODY#2L3-L6\ZA4'23-*;8O)6-CV[T7J@',H1L*I&X"0HG$3`(X<M
MBOA@K'J*_7K)+X$'B7&_$@$[;?03MOXZJ_5#TT_LY3`.+M>X,WV]3R9$<L+M
M"UI2YA=8Y'9.`V"F3B7/(A1L0-"<J-<KTXTTXTTXTU2O8/39?),MEK96HF.G
M+:\G:11Z7%3+EPTA75STN[U[/:L>;<,R'>$A&,W9D7+T$?HL9JBH5,04$H\L
M\11CR%]:\[,E<([N0-V"1HTC<0?#D54A=_#<C?PUT/TL[.H=]=Z08/+SRUL%
M'6N7+<L2JTJU,?3GO61"K$(9GAKO'%S]P2.I<%0=911[(=B92UI]=XF.QI#L
M3%Z+>J[8+A(Q5U5R52D4W,<_U*/MK"GMK,E;VDA9VVL0,09D:9<%CW7K'/FN
M4TDD%;\X7#QU_C$C63AVAC94!3J\WEDB*%RO#9>E(^_`<AQ78$DCMTGI)Z44
ML(?5:]+W`WI3-B:<\%6.6H,F+EK(7L<]9[35S59*[8R[:$HJ(9X^A#PA9WE2
M(H]YM+M%7)J].IM&8YKF>?8==-X@;`I/R%R6?ZO+OF5OKV>S4>^C8:.'*H:.
M/(&<R#%X6<,<K<A&7T,OR0>UJ4%CX?8EE-V>:=(&7B$VB`*-(""3U6/'96'#
MVDM[-7TGRV]GX7,GLC/Y#)2]W9C*9BIAIH!!'4"8V)'JSWHG2263XE+((!'!
M-$:8!E9K&XBUVYGNIH=)]RU2X56D/<!G97L[6,^95]2<:Z4WFNM<3HLRF_L\
MM(/'-:D([4&>0SYFK=LQ9JQ'B9`HJ[%584<47;-.SM0KR2C+(M5I"W$Q[63&
MNR@#D#$9H]R6(?WM@NPWKL?\O/:O<71[)P-W(Q^J%:#MZQ>><0M0:+/RT(BE
M>)%6PDF.;*4A(\DTJVMK!1(.$?/[G/9[L75I$N.W6OX\;>;J^PA3-I6`:W$,
MXC8?:E=%+-&MD(_G3V*8?94EDDX=06DBQ)/%.S\!8\5%@2_%P>'G3XC6>Q\*
MB$_4#<.H3#T^/`A>($O53VJW3][Z^PWQP^C7I/FJGW^[>M9_^S+'1YD7XYFJ
M^?DEQ(H]'RTR0B"),D<G3"]6"8TB+'(V@L?/GJ=MM_L31[3J+5LF'7<LKV^V
M794YU.WKTR;'"KTUI$97\\292[.9@G.N@X&0:/9%61)`($%)9O('$#\]CM[$
MPL+-J2Q\/L/76'CPYKUT+EI-P0W2^J0O'J'Q!0>&I2^AGI=BIX\_W+=SGW$S
M5O"U\4835%N'XS3:Y)/>+Q/%,N+XB"2&!8#=<\XY:JCCKN1_<6_66:C-)K5?
MI'[-B&G8;C\^$F$]^*2TYN=.SFP,+G&R+=\6L,H"I3NO0,8YC5F*[AX4CUP1
MVCY:"*N)^VZL,;4IWE^-=">9=N/2XP/(I0C;D6=89&#`@#=`5.Y(K;?H%VQA
M\?-VCF+61_M=;#9C*0]/H_#A#A[5^!ZDD;)YAY[4.+NV(YUF1(B:\30/RDD2
M7=?NR>I:';\U)HE?HD52.QF77/8,3)5@GBV>LP-/G*@D2LZ(YDWSV*GYJ<I^
M@1<F1Y'HQR#9PD[:B@J4J3A2/E\)1IUYS3>5K-.=(9N7'BS.K^]'L`557C9=
MF+$@JVX\0*+U2](NR^U<#F&[4M9.;N/M/-5,7ES9Z/E[$UJ&T38HK&B2010V
MJ-BN8IVG>1&@G$B$O$O)D^V&@1&BR<^]A*0GUSA^P+_K5(*@A/FU!&T1U24D
M76AA(A*#6#58E[2-`^T^@!V*7\_];_\`J<R)@*DE-85:7XPU,61]7I<2^PCV
MVY<NG]ISY;;^YQ_*U.I^B':]_M.'%UK&1/JS8[63N!!R@^'&O)9"+1X=/S'F
M32(N^9ZW2Y?FWE_]OJNF?<[=(>MP;ZXTK,%[%NV5YMIO7:,@U[2Q80CS4M0S
MW+XZC:L[?O9%:<=U-?7J])/I**)'IO$2OT4FJ(HHK*S&[:Q<DSK6EGZ-6Q)%
M8+!26$44DI>(`#B'Z,BJK\MCP)8[D#;)_E\]-K^7LUL!D<RN*[:S=_'YV285
MG>9,=CKV1DN8U41!"MD8N]7AKV3.8G-:1YI!))&DM;]D.Q4Q:D^O,+&8RW[$
M1.@Z'`62WRD7=5<E5I5&SG.M)C+5'5%I9$K<S?6U#7X"*%H>8<ECG)7S@%'1
M$4D58YPN'CK_`!B5K)Q#0QLJ`IU>;R21E2Y7@0G1D;?@.0X#922112^DGI/0
MPA]5<A-W`_I3/BJ,]>K')4&3%NY?OT)*TEIJYJNE9L7=LB458S/&:T7"!I'D
M2*-N\VDVJN(ZO3J;2&.89U1L"M>Y0-@-/R%W5D=CDE&]L@J!,Q[Z-A8X<FAR
M`^.L_8O`G#G].0K'P^>,ANUJ5>?X?8DE-Z:6PD#+Q";0CW&D!!)ZI]W96'#V
M^][-7<WRV]HX3+-V1G\AD9.\LMDLU6P\T'02F(\5&&K378G22:3XG*3"$AFB
M\F!U6-G?IBV,Z[+:?9M0HYYZ"H9,2VC1MTRS+U84M@)H$).XFYN16T[<G[Y^
MM7IB(T2.S2==-V[-FR6B@!FF=5V994R-?<PE&"C*(GE^)UH8)9=^/399@FZH
M`.0,9DC!))#>\=EV&^D=U^D'9N'[,R2XRSDSZB]O8G#Y+(B7H&C-#EUJ\H:J
M(@GBEHR9"G&[RRRK9_.&5(!&@>[+WV<R/.+XTSRSRD^28\-6/896*IUJG*?G
MY+U+K0%&4TFYQ,2[K5$)<)INHW8#(N4/&)?,/Y:(@H-94P>0NU#<@5.G[_$%
MU5Y.F.3]-"0S\%\6X@_@&Y\-<Z[9]'.^N[>V7[JPT%4T/SD01R6JT-JZ:<0F
MN"A4EE6Q<-6%@\W0C?;?@O*3=!6.F=W<GJ.>ZG8Z@M(WB[YI0]HM[[/6<#9$
MIF/<XK+DJUB8V]!&'</*BT5M3I!%NNZ2*#YF91XT!=JDHJ6=2[8R%BW!#9`B
MJSRPH).2D$3#FI3Q]\\`20#[IV5MF(&MR[/^7/OC.]TX7$YY8L;VYF,GB:J7
MFFKF)URT1LP/5)E5;3"LKO(D;'HRA:\_2F=4.L*M.IVBM0%D19R<<E/0T;,)
ML)J*?P<NS)(M$796TE#2J+:3BWR`*^%5NX3(LD<!*<`,`AS7YXC!.\)*DHQ&
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MKF;QUNMKO.'='H><ZAG4Y`/="<T=O/1TS;QV>>E&RY8!RE'G08-U`7`'"PQ%
MS&&BJ_!8O,'%O#*K2%$$@>22*16$8<J53HQJ1S!;=R-O`:UJ#U4]),;V_P#V
M1X]\])Z9V<7D(I[\E6LM];EV_CK\,Z45N-#)%5^$TZTB&[&TX>U*ACWBCU$'
M73[L#`UZRI5"?RN0M/8#*]2S7>Y"7D;3%QM*E]5U71-14O.:IMJ_*.KDC2B:
M[.Q;>,D!AC2!6\>N=PW^CA/DE>X\1+,AL).*]2Q%)``%)<111Q<)/>`3GT48
MLO/CNX`/@=7L/KUZ6Y/*4WSU7-Q87M;-X[(85(HZTDEN+&XVCCA3R!:>-:AM
MG%T[#V(/-B`O:C6*7[)]3,O4._$M?X;E<4L.M`[FAV`&3":F_P`2Q=H45*$_
M"\U;^WO8!C37M$LS[Y[MY@,OYGZ'S/YQR,>XJAK^=VE^-^4\OMLO3VY\NKRY
M<M^G[G#C[?>Y;>[K7SZ[]L-A/O<4R']L'W:;"=/HP_#^)N&;XCYCK];J"D34
M\GY;CUOSCS/'[+4);=.NP$]5ZPRMT_E4=9NOF49KF6!/HF0M,K$W.7R[5<TU
M!I>M*;N8"+<TU*VDQN!BW,;'C,F8@XD%R.%P%NER2>X\1%/(U=+!@N6))9P0
MH*"6*2(I'LQ#\.M(P9N'+9`0/$ZV*;U]]+L9FKEG!5<W+A^Z<YD,AFTE2M'+
M4BR.-R&.:GCV6>1;9K'*W;$=B?RHFX58VBC/5?4S0Z]]C8:ZI]E(=KD#S>)G
M0="FK%FTE<+:USIG0[OF>:9K#5R/T5O1W4Z^FJHICT'+N'!J^V1?'</VJ940
M%!<(QS&&EJ_!938&*6&-5D"(9#(DLDC,8^84!NLZ`=0E=D8[^(UK\GJIZ2Y#
MMX^D-]\]'Z9U\51B@OQU:S7VNT\AD,A+.]%KBPI%9&4N54C%V1H0E69C(1+'
MJ%-^CNK52J*X]5;#19?-]7S_``2H[=;IB0G8>VP<ODTDLK?)RCUEI!R\;8D-
M3@5O1-D'<E&C"."^>8[PAO*"4W=%"Q8&1G25;E>:=X$`4HPE'V:NQ8%>DWB2
M%;F/#W?;K8IOF/[(S>;7O[-5<E!W;@\IFK6(JQ)#+5FBR<8%*&Y8::*2`XV8
M=61XJ\XMH>D%KL.9T'J><=CY.]06NYRUQT;U`P6TY&WA;)9;A&P#K,=%F*=-
M4NYNI=A4IA\E=*G+T5FXD(E-J+-Z@Y<(HO4CD24&GH7<-'5;'7#9\J[PRDJJ
M%A)&'5T`+@<&60A6)W!`)4[D:Y9V7W;Z24^VK/8G=CY_[M6K.)RC2UZ]62=<
MA1BM16ZBQ/9B0U+,5R5(++2=6)XXGDKNK.@I:#Z7:;1FD?CE5FJ++X599'JS
M8;_99I[.Q>AQ4GUKB<XAY>,KU791$A!S334V>10A0<KRS(T,*[XWE.OYN7EG
M+W-1M,<C.DJY1%M+&H"F,BR9"I9B0P,1F?P"GGLGBOCKH62^87L[N2>7O[-5
M\E!ZE4XNXX*5>)(9*,D>?EORQ23V'E2:)L<^4N'II6E%KA6'.#[4ZXSOI#K-
MNJ@9%;+!0H?/<JH.^U/$+7"OYV7LT]+ZU)I+4.>O=7=041&UU'+H!#T+INTD
M9,9M=0RY3LRE!(V5>Z*%>Q\1KI*URQ-7>=6"A5$0^T6-@Q+=5O>!*KP`VV;V
MZL(/F-['P6;^_>#JY.?NK-Y3"V<O6E2&*O#%C(R+L-.PLTLDYR,YZT;RP5_*
M(HB*SDEQ-'/7OL=,70>RDLUR!KO,/H6>S4!FK&X6QUG#FA4C,M,S.7KCK17%
M&;SK";M!]BG9=NY+7UT6)TF350JP`NN,5<QAXJOP6,V#BFAD#2%$$G4>6*0,
M(^94JO1C0CF"V[,-O`:U^+U4])<?V]_9#1?//Z96,5>AFR#U:RWUNW,AC\A%
M.M%;C0O#7&*IU7C-U&F#6)D,9Z<>H:ZZ=;_!5JS,:E8,KDK#V#R;2<RW^2F'
M]IBV%,F-0U;2]1>WG-&[:!E'-S0JH;/8(UM&2)H8S[R(]<[A`/4)<DKW)B)9
MXVL).(:=B.6``*2ZQ11Q!)?>`3GT8V++SX[N`#X'5_#Z^^EV2S%.SG*N:AQ7
M:N<H9#"1Q)6D>W%CL;C\<E/(,TT:U#9^$T9Y+$`MB'G:B6*3[)]7UVFZP.];
MIN*,*>QB)QUAER:3\=3+->KSF\7<:^:@V7.Y"$5T+."*VVJ3#>.L17C-X@@Y
M047:^G<(F074$E3@LXN/LVGL%E%J,J75$D*-U%D!Z<GN."5XD$@['<'<#7,?
M1;UE@[&[@[BM9Z6>M#W+CV@DMUZ=._)5G\[7O),*-\BK9B:2`Q2Q.\;JDG5B
MD66)0V?4^D.OMH["7T(\QJGSG6M_8]9SJMPBEVG:O-[7H^B2LO?HFVV.\H6>
MZK4LN7OW,,E*D6-)R$]++32C5L=DS:\MSW-C6DM+,+,D5P+%(QX*RPQQ!8RJ
MIQ3GU-G*$<51!&&;DS:ZF_S&=A36^Y:V1C[@OX[N^*#&7[$HJ0V(<30HQQ4I
M:T%-J]06_B*1VFK%!7@I5H\<DTRV+$VMHX+FMUS&6W1I8QK3FN7?:[5J-'D8
M:1DUYE2-O2#"0EXRTQ;V)9LXM]"S2"J*!FKIXFZ;>!0WDG\2?-:RUZM>CJM#
MS$T59(G!`VWCW`*D$DAAXG<#8^'C[=?/7J;W?V]WC1[:GQ/G$RV-[=K8ZXDL
M<:Q"2F72*2M(DKO(DT15W$D<31R<D'479M:(Y3ZY3IQIIQIIQIJD.Q&9SNL9
M7*5>IR,3%7*.L5"OM*?6`CL\`6X9C?*WHE;:3WMY%7Z4)*RM82:/%4"*KHMU
MSJ)D.<I2C:8>]%C[ZSV`S5BDD;A=N7"6-HV*[^'(!B0#L"0`2!KHWI1WAC.Q
M^]8<SG(IY^WY:EVE;2`J)_*Y"E8HV&AYD(9HX[#2Q*Y5'D15=E4EAD]'KWV-
MB;J3LK%,\A=[Q+Z+?)VP9H_N-L:YTVH-RRS.,NB*VQT9"BNIUY.5D^1PDPX<
MC7VZ+TZSUJ0J(>0OR_.8P\E7X)(;`Q2PQJL@1#)U$EDE+&/F%"MUG0#J$C96
M._B-=PD]4_2:]VZ?2&])GD],X,32A@R"5:S7FNU<C?R,MAZ#7%A2&P,G<JI&
M+SO"%KSLSGJ1:A;7I!K-2JBF0U2PT.7SS6,[PNF[A;9E_.P]J@I?+9=\ZOL]
M1:RT@Y>.L;?4("0,Q;-GDE&C"KD!<QWA#"B$INZ,?8L#(V$E6Y7FG>!`%*,)
M0!&KL6!7I,.1(5N8\-E]NMAF^8WL?.YL=]YRKDX.ZL'ELS;P]:)(9:TT61B1
M:4-RPTT3P-CIT$TDD5>QYM"8@L#`.>Y-],=/O362QZUS=$B<+K<SVDM-`L<&
M\G9+0)64[)PVF0L3%V.K/8>/@H9MEK789T!=(RKXTQY+$?):CZ@.88NY:-5A
MD:Z2ME76JLBL%$8%9HV)5@2QZIAC\"J\-W\6\-5V.^8/LWMJ>'OW!U\E/ZE6
MZ_;E:[!,D,=*./`2X^:62"RDKS2MD6Q5/[-ZT(J\[(ZDWV1UY3WK;V2MLPAM
MMQ4Q]IN-">X$CG]4@;);75`L$1BZVE_=A[!;'U.9S5<>:FAK\T5J1&(D2P0(
M,A.=Z/GASRF:PU>(XRL+!Q<PL=1F5!(IFZ?#BH<JPBZ*;[NO/=MN/AK!7]7?
M2/!8]O3K`+GG]-\G'FC>LS5ZRW8)<L,?Y805DM-#.F-.+J&0O:@-PO8XK7'3
MUS1ZK=B:PG)7JD/LG<ZOKM;[!5K764W8+4RJ5/7W&]M;M6;#1Y1K4I"4MQ<C
M10-'G8NVD3]P)F\X%V!@\OF3X]AYRM2T+`Q]=Z[1%50NX@0HRN"X"=7ZVX+]
M/V;/[=2_[:_2C,M#VUW''G$[(P5O!V,6\,%9[-H8>DU2Q!<C:RD=7XF2)Q-%
M):\D1TS':'OZ[<5T_P!(JTHQRBNR5&6ZXNM3P;8YJ;DI&=2TQK(X73LR@2T5
MG66\*M`2<?<;'CT)(FE#RS8[%!=\AZ58P-U!Q2=QTIT-^99?C(KSPA0%Z6T[
MR-S+;\@469UX\3R(4\AXC5==]>NTLU3E[WRT.27U:3"YG%0PQQPG'M'F+60F
M\X]AI1/&]6#*VX!6%:03.E:3KQCJKKHY-UW["9ZM21D%LDE"]9L2T/'NO1R3
MML33T%>W2E.-"6;4D259(]%3AJGGD7'.&D::;%=VY>.2*D3*@B;QD,QB+@EX
M>87SUJ.:Q[J?9A`_)8O>]_=Y&8%N&P"@@G<ZB=\^JWI9W5'D147.PGO#N*CE
M,X##6)HBK':ZU?'$V2+AELWK$Z2V!3"11UX61F,CC[9+JMI4SH$M49!U21Z\
MS?8=_P!F9"52F9L-(/-2E25:O<Q+6AKH0/M(Z*L::+-^Z^8#'Z,O0^9_.>?B
M9ZE'46P@E^,+3%8#9>GL'W$O+ERWZ?N<./UO>Y;>&O%/UL[0Q_:\&=J)D?[5
M:W:B=OI&8H?("*.R&3(>8Z_6ZOD`*AJ>6X];\X\SQ^RU7C7IYV!G:Q66ENGL
MJCK1U]RG,LSP-]$2%IE8BYR^6:KFVH-KUI*#F`BW5-2N!,=@8QS&Q_O)F`+R
M"Y'"X"W2"8>X\1%/(U=)S!;L2R3@A04$L4D7"/9B'X=:1@S<.6R`@>)UM<WK
MYZ6XS,W)\%5S<N&[IS>0R&:25*T<M2+(XV_CFIT&6>1;1JG*W;$=B?RHFX58
MVBB^U?4R;]>^QT+=4^R<.VR![N\UH&BS-CS>2M]M:YTSHEYS7,\VA:['Z(WH
M[J=?S53/CD'+.'!H!LB_.XD&R940%NL$8YC#2U?@LAL#%K#&%D"(9#(DDLC,
M8^84*W6=`.H2NR,=_$:U^7U4])<AV\?2+(/GH_32OBZ$4%^.K6:^UVGD,A?F
MG>BUQ84BLC*W*R(+LC0A*LS&0B6/4-9=(=7J%9'(:I8:+,9OJ5$Z_P!7VNVS
M+^=A[;"3.0R1U;W-TFLM(.7C;$AJD$)6;=!W)QPPC@HKF,\(;R@DMW10L3_$
M;"2K=@EL-"@"E")A]FKL6!4Q-XDA6YCP]T^.M@L?,;V/GLQ]^\W5R5?NW"Y/
M-V<35B2&6K-%E(P*<-NPTT4D#8V;>5WBKSBVA$8$##F;<S?KAJU<TV@L;"\H
M:>+8?IF\:KFS^&E)UW>K7);6XN_M%=M-?>P3.%KC/.8S39MN9VWDI`\J)&*@
M(M1!<HU]W-4)J,S0B7XG:@@BD!"A%$/#DRL&+,9#$AV*KQ]X;MX:T3N[U;[(
MRW9V4LXJ/)GU#[DP^%QM])8X5IUH\0M/JSUITF::=[\F/J2")Z\`K<K*&28&
M(ZK3>.CMBTG?KGH4;!9S;:MK@9.%E>WV_P"PP"V=GSTR,5/F99E09&,I^O-;
M)5F2'MZ,L]C!C98IU%3N6I@1+,Q7=$-+$Q5'::.>OU>(C2)NIU/>7>20%X2K
MD\B@;DG@`&\=;AZ9_,?BNT?2_']JV[.6HYK!?$_+I2I8N87A>WD@YY"ZDEK%
MM!9=^N]:*QYBJ51%AF7J'[GW378Y&5[66A:UY^2;[FYMIM.TV,*1\G%4V6AX
MA[3^M+RJR#:LH2<RQA:$^59V_P!4"*CV04*[:!X4_*/^IW)C4CH0".;I8V>)
MXCX;N"0]D,"Q`+2`&';?9?=;V[ZQUO7_`+!JTNR<+'2RAQOI]E\?:Q\FZ&6W
M%+*EKN!+*-8:.)Y;J++B^F66*!3!.=VYK[%*66RDJ%7)<F,+&6TD!$IV6.KD
MF]FJ^RG",4"2;:%EY*,A9"2BT7@'*@NNT;*J)@!C)D,(E#3;/0\Q(:Q9J_,\
M2P`8KOX$@%@#M[0"1_EU\H]Q'$-GKK=ORV)L&;4IKR3QI%.\)<F-IHHY)4CD
M*[%T2615;<*[#QU)N8-4VG&FG&FO6@CWVGXF`6U:V9U!!C-\H6W7C"'$!9))
M6]SYL47`K>#O,=(P:$)$/-8BP/(PRC)PZ(P23%%T!U#`<-V/:<4DWD*\S?$8
MI8$GY*."];VLA#;D1'W7W`Y'Q7P\-?8$GRQXN]E%[)P>6L_V@8S)XBGF5GKQ
MBE#\7'O34Y(YFFE3&R;06EF2,S,W4@*J"NI(KVEW2*EW6)3V;YBEV6?WV@5:
MK-XRWV5UD3JN:#1;]HI+E)RCBO-;<FE4HC*;&Q=M$F@F>/F;8R:J23S]1@&!
MQ<D0RD,T_P`%$4C-NB]4-')''P`#</?,L;`D^"EMP2OC4)Z+>FUV@GJ+C,OF
M3Z018R[9LM)5KKE%GHW*5#RD<:SM5)LRY*A-%*TH$4,LP='>O]K&I#N]J3^M
MNI.FY'4GD_DF;Z+IW9&OS5TE$$X=IE6D73,+'3<ODF%=<>^V.PR^96%[$N9)
M%DU]&S;%7(4[SQ(9T[7HI.$LV)!%8GCBKL$'CU8TE5Y06]U5$L:N%+'<ML?=
M\;BK\N79=;+I3[@SMZ/%YW+T<=@)X:D9,K9*A4R->WD8WG7HP019"C%9CKO-
M)U99C&S+!M+.?VQ)XU])-DJ=7'K6;7D,#->AGI<-`"\N*.E;4[D%=]E&`'/?
M?EBUT4_6^X^L^KOP^1^KY%^[D0J](R/\:\MU^'$=/@'X<.6_+J<?M/9QV]WV
M^.M;_L#Q@[9..:]=_M>&!.:\GT8O)>36X:IJ=?J]?SW1!O<NCT.E]AOU/?U!
MF'>#4&%<:2UQR.IM9?7,SH6I];(.$NDFO[VST[1Z-F%<IFH/W]>;A`6.%E]3
MKCV3<QJ3YJ#-XZ*B0QV?B<2F[7HO,8Z]B0QUYY(K+%![IBC>5GB`;WE812!0
MW$[A=S[WALEKY<>S+66>C@,[>>C@LQ=QV?FFJ1KT6QU"YD9[>.1)VZT$T6-O
MQ5X[#0R=6*$R,%L;125/M)NLG+-\1A,YS`_9ACH%YJ=D;R5OLS?(&];HF?T7
M2QNL?*-JZYMXH6J&U&O1[5FJT\;.1=N3**+)-/U^`X+%I$<I+-/\%,,;J0B]
M4L\CQ<""W#W6BD8D'Q4+L`6\*=_1?TUIT6]1LCELR/1^7%T[-=HZM=LHUBY=
MN8_RCQM.M7>M+CKT\DJR[2P10A4C>?[./CWQLL]",-.IF;P)\DI5&Q"Z;N-A
MLTDA>J\;:Y)=@[@J,SCH-Q!3+[)F#<9&84>KM22")RH-0(H`GYF^ZD,4IHV9
MG^(2RSI!Q4<&Z(!#.2W("4GB@4'B?%MQX:M1\LV(QF2E[-[AR]D=\Y')9BIA
MNA7C-.?X1&'6:X\DRS1)DW;H55A20P,#)-R39=:)WG8=/J-JJ&;8G2JA=="L
M-.T+37Z%YL<K6J^RI6:K52/?L4'<+#3;Y2S6R?NK!C'B9(&K<//<+"8$BI*T
M^*QM&Q7DNY.62*FDL<0X*&8O)R(.Q*CBBHS-X[GP`]NXY1Z9=@]FYW"7^[_4
M3(W\=VK5R%''HU.".Q.]O("RZ.5EEA05ZT%2::?9NI(>G%'L7+I1<=W>LEL<
MPN@4O/H!;K]'.NN,+HM@G[*]9:!'3G9>.I$G`J5F%8Q+V!>Q>=M--@%)KU+M
M)9R5TY!L!3-`]1:/VO#7#4[,SC+$66C55!C*UBX;DQ(8&0Q2<-AL-EY?6\.D
MV_ERQ&#AL=K=PY6TOJE*F>FH00UT>C)#V_)<CF%B9Y4F22\V/NK4Z<3+&8XC
M,2)STN8;O;9Z[$2&D77-H%/*+I1]PN6$C7K-(K7FP*XG)HL&U?O+*1@T(.'?
M:O'KA)0ZK%PZ38(D,@Z`RGA..0=J0S2"E6F?S\4L"3\E'!>L-RR$-R(B/NN"
M`6/BOAX:F+\M.&RU^+M+MW+V3WOC\EAZF9Z]>,4X!EXR[3TWCF::5,:ZF"TL
MR1M.Y62`JNZCOJ=I-TC9=UB$UG.8$[,/-!H]3K:,;;K.XR!S6KWGU[TQ.[R$
MFYKK:XIMZS#Y=8(YRS3:"=W(LVYDU$D70^1A&"Q;Q#*133_!1"[MNB]4,DD<
M7``-P]XRQL#OX*3N"5\:Q/1?TVN4$]1L=ELR?1^/%W+-@R5:ZY1;%.]3QYJ)
M&L[52UB7(T9XY6EVB@EE#H\D(ZL8?]X-0?UEW,T[(JHZELBS2]ZEV4@IRZR3
M?V1IF6CWG,+-3,OD6-?7)/625E\LLCV,<R:3%J9HR;$6(0[P3-\Z]KT4G$5F
MQ(([$Z15F5![QEC257E!;W5`EC#!2QW9MO!?&XJ_+CV95S"8_/YV\E'.YBEC
ML!-#4C;K-D*%/(U[>1C><&&O%%DJ$5B.NTT@EEF:-F6`"7;UXVG-LXI4-H%Q
ML)HVMV-Q!L:X9G#SEAFK')V-`74+#URKUN-F++89A\T(=8K5DT77!!)14Q03
M24,75ZN-NW++5*R<ID#%MRJA0O@Q9F(50#X;D@;D#VD:^<NW/3WN[NWN*QVM
M@*@FR]1)GGYRPP0P1P-QFEGL6)(J\$2,0IDEE1"[(@)=U4PP.U_7@T4RF@U&
M#]NDZ?#7R,5]-,@M)UN>N2.=1RT:R&,];(2OWZY1AG$8BF>39R;A%NX;I*K)
M%/*^`9CF8^@_-9"A\1X,J=0[G?8#I[N&)XE06!(!VV$^B'JL+LF/.%L^;AOR
MTI!RBVCL0U#?D$C]3@D?DE:VEAF%>6NDDL4KI&Y7R\+WR"W1;7$(:(E8=7)=
M?N.2R)))C,MBR3BHN4V8S+1Q)PL2V61D5@4$$FYW((%*7QJ?4P<\Y3$RXL5S
M(RL+%=)1L1X<QOQ.Q)\/#Q.V_P!`\-8/4GTQR7IM'@I;\\%A,Y@:N3C,;Q-T
MUM*6Z3+'+*P,8XCDXCYDGBNRG5]\J=<QTXTTXTTXTU3V\Z@[Q_,9BZ14$E:+
M$:5J%1J%<<2`Q+2;NFA7""H5082$H5L]4CHD]CLC8SQ<B"RB+0JAR)J&*!!L
M<317(WEK2/TX>+N[;;E4C1I'(&XW/%3L-P"=@2-;[Z9]F0=^]XU^WKMDTL2(
M+5JU.J=5H:E&K-=M.D?)!)*(*\@B0NBO*45G526&5D^TFZ2,NAB$/G67F[,L
MM$N=0L2$C;K0AC[:M4K.J3J(WAE*-JZYN(M[-":9`1S9DHT\QI).US***HM0
M\^^."Q:1?%)9I_@AA1UV1>J6>1XN!!;A[K1R,3OXJ!L`6\.UOZ+^FU2BWJ-?
MRV9'H])B:EJ`I5KG*-8MW[>.\F\;3K5Y5YL?=GDE67C+!%$%1))CTH]^W?:+
M!!L-,I6:P*F4TFB8K=]Y^X;/(H7>O#LDL]C'T!1&L=!KP4T_R=C'*24NJ^7:
MIR"!B(M0(H)CAF^ZD,4IHV9V\_++,D'%1P;H@$,Y+<@)2>*``E3XMN/#5K_P
MSX;%Y*7L_N++VAWMD<GEJ>%Z%>,TY_A422)/<:299HDR;NL%584D:!PTDQ9=
ME/8DN[=FJ3Z8OETSZ`1Z_23_`+&UW/+#`V1\\T)_8.M,9>Y6>4LD$^B64"UB
MM#9Y=8%(7TSM19L5HV!R!A=CZ?&G:\-A5J5IF.75:S2*R@1A;)0+Q8$L3&98
M^>XV.[;?5\8-/Y=,/G:U?MGM[*VF]4H8L#/>@FKHE%(.X)*<4(KS)*\S246R
M-%;?4B5)#++TB!`.K\3=L]P@3N,TNN6YU'=@+0_Q3\,8:&N=@D<\<Q&XK7M-
MN[MTNYKC.P-G.7DR^>/,$9M5"R)6S<6HI"Z$K<.W\9,!>K3S-B(Q/U&**)`8
M.'@@#%?M>K'PW/N[MRWX^/ZOH;Z<9-5[O[=S66F]+J467^(RRU(([RRX<4RR
MU8EG>!ER)R-(53+(I@,DO6#B$&7PW/<C7Y>+-`47*Z'*:WGD%N-FVZNS%TGV
ME7:M,#NK6C24'G4RTJ[B1D9G4WCGUT`M)-FK=BR((/0,K]"\]+VWCXWZUJ>5
M<?,\"PL$4L3.A<-(I;8"(#C(%)+-]7PUGA]`.PZ-T93N3-Y.'L;*V</7Q$\5
M2%K+-FJC7(YK\36%2.+'(O1NK7DD>:4@UR$\==]KW+LD[9XNVUBCUQ[UM#0L
M:R.>N3ZQ2#70TKAN%1H=HK=@BZZG%*P!Z?`/M2K\5($6?%>'<.7*R7ZMJ4CC
M$W;4,4+5YY7&:Z,TRH%!CX0.ZLI;?ES812,NR[;!0?%MQ63_`"_8C&X:;!9G
M)6X_5SX5E<G#42!&HFKA[5VO8@DG,HG%J=,==LP%(3$$CAC?WIBT4FP3L_?-
M.N%(9W>A5JJ4O=\YMNMX))0MCD9:PK5&G3E6CW45HT:\B&+&.LLQ7KS$S#;V
M]=PV235<-5#"HW*LO@RV"JT:\K597DLU)DBG!4!>;JQWC())4,CH>0!/NL/`
M["F]3O1KMKL[`Y*QVYD[E[N'MG+5<9FHYH(XH!:M0V762A(DKO)7BGIV:LG7
M1)&98IE`64I'SY#MM:(O37ZSVG5A#KU%[<[ZWO[F:>EOQ!;Z,QJ*E@<VP:\$
M,-?-GR=F2-6Q)ZWW'U@>K`OD?J^>T[>ADI`+(YR[519"<1T^F7XA.6_+J<?M
M/J\=O=]OCJ75]#,+=[.BCKY"XWJK-VXN>2IT8O(M0>T(%K=?J]?SQKD7]^CT
M.E]AOU/?U7<?W?U%C76LI<<CJ;2:US-,_P!2ZVP<)=)-<LTSU#1Z/F%=IFH/
MW]>;^P62"E]1KCV4<QJ3YKZ-XY*B0QV?U7F/VO1:8I7L2&*O/)%98H/=,4;R
ML\0#>\K"*0*&*G<+O];PVNU\N79EG+/2P&=O/C\%F+V.S\TU2,=)\=0N9&>W
MCD2=NM!-%CK\5>.PT,G5BA,C!9]HI*EVEW64EF^)0><9@?LPPO\`?*I9F\G;
M[,WR%O6Z%0:)I(W2.E6U=<V\R%LA]3KS!JS5:>-G(.W)E%%DF?Z_`<#BXXSD
MY9I_@IAC=2$7JEI)'CX$%N'N&*1B0?%0NP!;PIW]%O36E1;U%R67S(]'Y<72
MLUVCJUVRC6+MVY0\I)&TZU=ZTN.O322K+M+!%"$2-Y_LN"3O=9K%$1NETK-X
M%3)*?2L,M^YFL-FDD+U7U-ODCL7$%1V4=!N(*8>Y,P3"1F5'J[4D@B<$&H$4
M`3\S'M6&&4TK,S_$))9T@XJ.#=`;AG);D!*?=0`'B?%MQJS;Y:,/B;\W:'<6
M7LCOF_D<Q5P_0KQFG.,/&'6:X\DRS1)DW/0JK"DA@8&28LA"ZLW/^T%YM.JU
M6.F:+5X_&=9OFT9CDEJB[')/KHI:L/=6I"4>W.$<P[2'9P-[:T"==Q(LW2RS
M5%F@5P!CN_U$&W@JL%"1XY7.2KQ0RRH5`3C.%V","26C,D8;<`$D[>"^.G]T
M^C/;>%[)NV\?DKDOJ#@\9B<ADZTD$:5!6S"UC&E2996E::DUVG%9ZL:I(TLI
MB*K!]I=UT['8OGE[A\UN%V0B;A-!7S),`AK'(Q\26W3"U>J1[;8XJ'?5JD$M
MD\W4919IEXP"1=$,DW\PX"`5E;#9*Y5:[7B+5UY>.Z@G@.3\%)#/P4\FX!N(
M\3MKG/;WI+ZA=U=M6.[\#CFGP%?K[OU8$>4U8A/:%:"25+%PUH6$MD58IC!&
M0\O!2#JO=,[E8O0<YO\`>(FP)727H])V.X?9,.UG"S[TV'S253O,9)-DX-X]
MK`Q=T>-HQ5=\W3("BX*$!1(IC!+I=MY*W<BJR)THY984YDKQ'77FA'O`/N@+
M`*2?#;P.MI[/]`/4+N?NS%]N7JK8ZADLCBJOFY6AZ"#,1&S3DC8S(ECJ5%DL
M*D,C'BG!BCD`Z2J]A8VVM0%HC/4^W6*'CIICZQA)13KTLFT2>(>HC9AG'2K!
M;RU@\23E!%=,?T'(4P"`4L\+UYG@DVYHQ4[$$;@[>!!(/XP2/P'7(\UBK.#R
M]K"W.'FZEB2%^+QR+RC8J>,D3O&XW'@T;NC>U6(V.N]S%JLTXTTXTUZAOV)]
MIL^>1/7Z;3J%;HF&9OOM1R/1265>8<Z'.Z8(LLKE)RI-H-LZJ+"A5Y11*=(=
MP[.]?&*9F`I?4P=#^\^-@N-EXNH]JU/7>6/CMTUB\90KEMG,C;&/P'%?K>.O
MN_\`XB?3S#=U3^J6.-^WW-W)E\+:R=`UQ$M&''^_DHX;33,MI[LX5J9"1"*$
M$3[/L#83[&>RMAOQ>U$GGM(B]9K=^S-[7\11T<L@QDZ!2LTU[.[0U-HWVZVB
MV5CGY#<)23C@.R\@B$8S1<*)*.%O(AKD\+#3^`QRRM0>&4--T]B)'EAD7[/D
M2540*K>]ONS$`@#?5:WJ#Z0XKM<^BE/*Y&;L>WB\@D^7-#@\=VWD,7>K-Y#K
MM(\$*8>M7G(EYE[$\D2NL4?4AB_5GLI68"X*5>'SR=M?9C)]8SO81<7)[%1>
M0VC5-<U'3HZVPCA:O.G-_KM(CMFE(YPV228NWZT8T43*0CA84)0SV%GFC$[3
M)7I6(I(=D!,JQ0Q1%&]X=-G,*L#NP4,P.Y4;[!'ZT^D.8R=!,S/E:V#[/SF-
MO8OC4263*5\;B\=CGK3*)U6E/;DQ-:=)&::*%+$ZN6:*,234G5'326,<8+%5
MX.NX[XW[`CHOW4;[K-&H4="/'+C4GV;S/>S:.@#[W7UPLO9?Y`D]5_(&*<_1
M,/Q+D_QCRAK]/C[F_4WZO/?ZO3]WCQWY_P#1\=:\WK=V<V)_M!,UK^U;[L-A
M/(>6_-A(;A?XCYOJ[='R#&'RW1ZOF_>Y='WM0=#JMV4LU7IJ-GA\Z@K1UDR3
M+\XQP$+B]EH;7;1ENN9/IJ]OG%D:\V<T"O7&-Q**CDFRB+YXQ7E'ASE.1NB9
M>4<]A8)Y3`TS07K$LDWN`&)9898N"^\1(R&=V)W4,%4#Q8[;')ZU^D.'S60D
MPUC+6<-WCG<C?RN]5(I<76R.,R6/%6$&=ENSU9,O9G:16ABF2O`JE6ED$4W:
MXSV3@M!+VKC\\I4MK$_H.BO9[$5]()'LXK.[CEN3YM7&:&CC7'<2[LL')XM&
M2L@!&0-SMI-VB@HJHW1%:*V3PLM+X"\LJT$AC"S=/<F1)99&/3Y`A6$S*OO;
M[JI(`)VUV;U!](LGVL?1.UE<C!V/5Q5!(<N*!=I+U7(Y*_.YH==95KS1Y:Q6
M@WE+B2O!)(J)+)TX(TZ8[=3*8_Q"OI4^RTW;<\P&K:[HZEF<0SK/[!F;]Q^*
MDG"U1Q!N'ENC;Y75RH01".6JC)\41=@5$0,$MNY<99LC*3=1+-6:PT,?$$2+
M(!T@S\MD*,-Y/`@K]7QULD_S!>G/</<,7J-E#?IY_MS*YNSBZ`KK*MV#((OP
MV.:RLRI5DI3@O<)CD66$@0$R`J=)ZQ5>QJFB5_:,XSNAS-K@*UMV*%JDOHZT
M0U?4>\SM'GJ!IIIPU37(S=QLM043RT*"*JI6KX_IUUU4"D5I*%C#"F^,N32K
M7=X)N0CW(=%=9(^/,;@B0\'W`W4;@`[CD?8^:])D[4M>GO=N6R=?"6KF(R_F
M8J`E9+E.&Y#=Q_1\RI=9(KKBM;+*IDA7JQ1I(62A:YU`V//HQE@T"TJ-CQZY
M274VRW;3'%C<0T]5GW7.$RR%NL.TIAHIZXGC:*TQJ,"+7(\338GDG0N0`K=(
M'%M/W%CKDARLID3(QK;5(^(96%AI60E]QQZ9F;F-CRXKQ^L=NFY;UY[`[IN2
M>IN3>_4[]Q\/<U>ICU@66&RF>FR4M25K?400^0;*V#90Q,9A7A$)WE<Q<A]T
MTVZ[TMMBEA0IE8J&*Y_V`K&0W]*RN)E30[!ITBC^%DI.U1O!MG=0C*+7$#(3
MR9W#M1X^5`S,!1*)QR+W+C*MHY.$RO8LS5VECX@=-8A]J%?ELY=O&/P`"CWO
M'4ZK\P/ISVYW"_J)BFR%S.]Q93"6,I2-=8A1@Q\9^)1PV6F9;4ERP0](A(EB
MA7:QM(>(G+S&>R<[H`=JY#/*5&ZS`:%G3V#Q!/2"/V4AG5.RW6LUL+,VCA7&
MT2TL\S)[9*RS`#LO3E;,&J"ZB:JZHH15R>%BI_`4FE:@\,@:;I[$2/+%(IZ?
M+<J!`BM[V^[,0"`-]<K^H/I%C.UO[$ZN5R,W8]K%7TFRYH%'2]:R.,R$#>0Z
M[2M7BCQ%:M/M+S,D\TD2ND2=2$K]5NR=:K=R0K41G<_9>SF1:AG&RK.+@^B8
MS(K3J6NZUJ"5M@U%H!PZT"N5!CN,PP4;)IL';UQ&-%"%33<K"WE#/X6>>(SM
M,D%&Q%)#L@)E2*&*+@WO?9LY@1@?>"AF!W*C?8H_6OTBS&7Q\F7GRM7#]G9W
M'7\4%JI+)E*V.Q>,QQJS`3JM*>T^'JS+(S311)8G5BS0QB717:?KM:+W3<&#
M.4YJ9>X'=6LXG58?5K/BECM=>5S:UYF[;P6GU$Z4G6K)&M[,F]2$YDVCY)!9
MFL=,CCQEIL%F8*EFV;G%5MQ%>1B695;J)(.43^#*>/$_2I(8;D;:Y1Z*^J^&
M[9S_`'.>[#7KU^Y\<T)LRXVOEH*TXOUL@K38ZT#'8@D:NT+;`RPL\<\:LT7$
MYI-TVW`C/K]-P]:S2!F.M$Q;-OK%7E;U:])/>M9U74Y.PW:C671=!8SEJ"-C
M,_656-."(>LO#UM)I-6[:+12/=?>/%%[<<KSM'=5(68(D?"**((CK'&57<R>
M'3_)A4H6+.2.O#U_].&L=TX[(7,Q9H=X05L18L1TZU`4\9C<;'!4N5Z%%X:W
M4DNA5%/;[+#PS4WFEFNR.NYNOE!O6=2^^QMKBXE*!M6Z6_3*+/1LZ,BO-P5^
M1CY5VTEH<\:S4KTC795-5H)/.=)N2%*J0Y0$2AJ^7MU;L=1X&;JQU4B=2NVS
M1[@$'<\@P\?8-O8=?-OJGW/VUW90[8MX2:=LE1[:JX^Y#)#TUAFI%XU:*42.
M)XYXRLH/&-HR2C*2-]:2Y2ZY'IQIIQIIQIJANRF<V;3\FD8*DFB/O:#M.<Z-
M3F\^Y790<E9LKT.KZ/$PDL_:MGKB.C[`YJX,5'1$5C-2N/-!,_@\`VV%NP4<
M@LMKEY5XY(WXC=@LL;1E@"1N5#<@-QOMMN-]=-](>[,/V;WQ#DNXQ/\`=RS2
MOT+30*KS1U\E1L4)9HD9D5W@6QUEC+H)#'PY+RY#(3;&>R,+H1>UC#.Z7*:Q
M.Z-?Y"<Q!;2$V#6-SFV9-E>7P#)#2!KCJ(<VB(E,9BY9^!&0-C-9!T@B=15!
M(5]A.3PTM+X`\TJT%AC"S=/<F1)996)CY;A2)F1?'?=5)`!.W=YO4'TCR/:O
M]B5G*Y"'LBMB:20Y<4"[27ZV3R61G=J'765:\L>5L5H=Y>H)((99%1)7$4&9
M=--OI-,?8K7D:;9JEM^;X14M?T-2S.89QGU@SJ5D5-4E(2K.(1P]M\5>:W(^
MG@2$<M%F3Y,1=@")@.66W<N+LV1DYNHEBK-.\,?$$2+(!T@S<MD*,-Y/`@J?
M=\?#6R6?F!]..XNX(_4/*MD*><[<R^9LXNB*ZRK>@OQQC&QS65F5*LM.>/G<
M)CD66%MH"9%XGM6/J'LF@QLA@\^TJ%;QVGSG;&VTK26EB<3$W:GO8R!UF$ID
M,^I98IBM!J9TWVN4]T74=K)/CQS46X"#A4&^*'N+&TY!E8C(^1D2HCQE=E45
MVB9R'W/+J=!.(V!7DV_U1O7XGUX]/^U;D7J9BWOV^_K];MJM;H-`L4-9,#-C
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M9^?NY.MV?VY<P5BA92D))<BF)HM4O0O!YA?*29"0B>F[R2I`@,=@[GEKK0W4
M_6J@\889!1]6D<#D=:Z][++Z6[LJS2TQJ>&T[)HF2H8T@L4HI(2-LM>*QKIL
M_(^*V;,))R54/-;)%<8Y.X,?84Y24R+EA7L0B,+NAZ[RD/SW\`J3,"O'<LJ[
M>#':%D/7#L;/02^I.2ENP^I\6"SF*BQZUPU:0YBUDY8[OG.H`D=:ME[$<D)A
M,DDU>$H>$SM%U\=Q/L70G&=C.4VA/B=3L)T?(<;%K?W#=+;I6T2%&0KD]-F+
M5W*F:Q;*GYLR;O$U4Y%8)*17%(IT&Q%'&/(Y3#VQ,(I)1\0MQS3;Q@]$*'+*
MOO?:$O(Q7;B.*C?8L0('?_J+Z3]SQ988W(9.-N^.Y:&4RO*DK'$1UTN-/##^
M<*,A(]J_*\3*T">7@C#E9966+YRW6;6)R^36;/HFN)X-/]E)+L\_T-*U#]S^
M5+U94[O*RTCV4%/=RZ<N+TLMZWT0P@>`2>J_D<1YS'Q55NJS_%4HBL(^/N^#
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MM8L&@:.\G\27T<L>SB<\N689-G%;9H:.-<=Q3RR04GBD9*2`$9`W.WDW:*"B
MJC=$5HK9/"S4_@+S2K02&(+-T]R9$EED8]/D"%(F95][?=5)`!.VNS^H/I#D
M^UCZ)V\KD8.QZN+H)#EUH%WEO5,CD[]AS0ZZR)7FCR]BM`3*7$E>"214263I
MPF.Z:;=1JBZQ2O)4^S4W9Z%U[KFMZ.I9G$*[H-@RU^?\4Y&&JCB$<O+;&WZO
M"5&"*1RU48O@,+L"HB!N2G[EQEJP,G-U$LUIK#11\01(LH^R#-R`0QMXOX$%
M?J^.MBM_,!Z<]R9U/43*F_3S_;V3SD^,H"NLJW8,B@^&QRV5F5*LE*?=[A,<
MBS0["`F3<:N3,<"V*!T[-JW88>J1V.8%JF_ZO3+I'VA62G]`/LJVA$J-9=5,
M8=D>LK46)U>41DW*KI=-VNP:';`8JZP(5U[+XZ6C/-"TAR-NO7B="NRQ]'I\
MV#[GES,2E0`-@S`^P;Z!WCZG]@9/LW+Y;%6+TO?W=&$PF-MU'KB.&B,4*)M6
M%L]5Q8%R7&UGKQK&C1)-.LI!CCZE:[_T[T:^;YH=GAX,]RH6Y!CI)Y5WV!U7
M,*O11SDR,78B77*J')13+76+V"9HO(0OJ45DY8547)DFHE6Y,Q/<5*KB88)'
MZ=NKUN.T$4K/U-V7A+("82&)63P(*;$;MX:V_P!+O7SM/MGTPQ6'OV1C^Y^V
M_BO1"X3&Y&Q<\_O)`:F2NQR/BW29VBMGILK5@DD(>8&/7CO.HFXOIKM_</2Y
MXVENZF7ZI4K1#(.TFB>93=:B'U/Z^FCIMK#&=6!C<J>]46NAQ+XD)L4U6Q5D
MBF^OI>XL6L6.K;S&/&3Q.AVWZJL0]C=2VRE'`$/X4W#;'66#UV]-Z^.["P'/
M*O1]/,UC;-:4J6.0AL2I:SG4A:7C`]2TBKB1OL]/FDQC<C;V9TE>PN:=5E[;
M"-ZU:%:_$'L->:3)+$UA)H6"'N46VGDV<<2909._&F1R#=$%RE`_@+]?H&D6
MA"MF05V+P<SQ8CB6&_@2NYVW'T;G;\.OCSN./%0Y^[%@[+W,,MJ403M$8&FB
MYGIR-"7D,1==F,9=^!/'D=M]2CF#5-IQIIQIKUVM^_*#&+D-!M69GB\=L5&V
MN\XK;8BVDF+-H;7#70-Y:*G*DYK\0UJ$G?6GB?UL$Y*3(X9D-ZLS1;PI#N)[
M3+R"G7GY9%)84F4ILL9G&X*N&)<1GW9-U78_5Y#QU]6R_+#+8NQ=K83,";O^
MIDL13RU66J8J]%LPO**2&TL\K6HZ3[0W^5>N4E(Z`GCW<=X>V^F,';S+YW$8
M&.[(KWRATRMY^UU-21SV4CM$I5PT*,N+W2`H;:780U<KN<6-*433K[A<)"(\
MIN"R;I!;F'[O4G47H;3-AA#([2&+:0&-TC*"/F02S21E3U`.+[G8J1JM'H7V
M?9@C[SQG<=J7TC7&7;<]YL<([T<E&W5HR54H>=:)Y9Y[]!JS-=C3H6N<IC>&
M2/4>D^]=C5K03=2P]2;DZ#G=^T_L-7)+0&<2\S2"R_0;1F5P@*@\;UN5::)<
M%;'0;"M%(J^RM'S"(\P[ANHZ13YF3M6$3]*Q:XQS31Q5V$9(D:6-949QR!C3
MC)&&(YE6?8`A2=6E/Y:L2F8^'9SN05Z>3RM+'8.>.D\JY";(T:^0JSVD:Q&U
M&J*]VBEEU\W+#-:XK%*L,CZF_P"V*8=%(B6BL38(;54L+'8OO`P2X:4O14[L
MD\^PQK?DCGHN52P8R7N_K0F!^GH?2AZCD7[N?F>_5/Q7R_7Z/#PZ?4X;<^7[
M9M[_`!X[</RN7AK7?[`A]U"YR<@]3AA#F/A7E?LOAXN&H5\[U]_/<0;GE_*]
M+RO_`&CK?9:A$;WLL"5<]\MN(*PKV_9O2-4Z[P,9?FDN]TV!TC0*GF=1K]N<
M.*U%M\ZN);'H=<6DD$O>FC)C,>,CA=1HNGR4_:L1FZ5>T&2&=XK#&,@1M'&\
MKL@Y'J)QCD"GW"638@!@=;'<^6G%/EOAN#[C%BOB\O<QN=FDI-$F/FH4K.0M
M3U56Q(UZKT*-]8';RDLLU7BT4:3QOJ1!VWTQZZ;9?"8C7W_9-OH%VI-@SYUJ
M:C#/(Z/H-$J6DR%S9:2%"=2[R#L5:T*O(QB:M?;K^Y2WDN`13:KK<P_=ZDJ&
M_+:<84PHZR"+>0F21XPACY@!E:.0M]H1Q3<;E@-5)]"^SZT#]YY'N.U'Z1-B
MZ=N"\N-#WI)+MRS02H]#SJQ)-!8HWGL,MV1/+UNI$9'FCCUPE.^I9.,A[Y3\
MO4F,EA*5B=VVFS2UN3A;/G;7<I1:,C(J#JC>OR[*XRM`10,^L93R<:1!D)?2
M&=K"*09AVF4D:I8G"Y!Y9TA4)NLA@&Y+-R!02?5C]UMS];B/'5DORR-3N3]L
MY[,B#OFSD<O3Q->*J9:]YL/&))))K+3Q/5CNEA#0(KV"\N_7$$8YF^]TV^Z9
MY8:I1,MS)EJN@V.K7W0EX*4NI:'&1]$S7[;0GW(37VY:5'%CFYBW1T=$,S-D
MVZSA<ZB[E!%`YAJ,7BZUR&2U>G->HDD<?()S)>3EQ]WDONJJ,SG?<```$G7,
MO3;TX[>[KQ5[N7O3,283M:I=I45FCJ>=D>YD.N85Z/7K!8(8JL\]F42,Z(BI
M%#+)(H%-M>\`6&2@[+3,T/,X61QU]B;[I,G;4(6Q5B<[*LJK(45&)HQ821;6
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M\K6HJ1!AOEH*[)-MT%GC/,=H>VVF,WCS+IG$J^Q[)JZ!2Z3`4!KJ:S_.I*.O
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MA(/T'Z:S6Q]VY9-.K&SV1ONH'L"_6)^@`?23X:^?.W>Q.\.[NXF[3[:Q]B[W
M"G5YPQKN46'?JO(Q(2../8\Y'947PW;Q&H\3L7A"D2G.IZU1#PZU,@]$;R)+
M"P,V=4FRSIJM!6-FH54?5QTG9RA')BEXS"_.1N(`J<A#9CALJ).D:\O4$K1[
M<3N'5>3*?P$+[W^KN?8#JU;TG]2UO'&M@\F+ZY":BT9@?DMNO#YF:!AM[LD=
M?[=@VPZ(:4$HK,/$Q/?J7NJVJMJD94KC)-6M>3V%!<X'5-+51P1JM(D*0A2I
M,Y!<%/)*(F/X$_J;Z"/A#UD\39Q0@-C;:Q`LJ[?@;QV_&/#?\>L_J)Z7]P^F
ML>$ESH!BSN$K9*`@;`165+",[GQ9!QYG8#=MAN!N;SY5ZYMIQIIQIIQIJJ-M
MU%/',WFKV$"YM<DV?5FNUJJLWR$8XLUQO%HAJ33H$)-RDNA%MY2SV!HDN[,D
MJ#5`QUA34\'@&PQE`Y*ZM3F(T(9F8C?BB*SNVP]NRJ2!N-SL-QOOK=_3KLQ^
M_P#NZOVT;24:CQV)[%ET:1:]6G7EMVINFI4R-'7@E9(@RF1PL?)>7(9C#MMI
MCQVWRZ'Q.OO>RB&AW&C3V?.=3699U'Q]'H%6TY]=6FE%H+J8=P4_5[[`HQJ:
MM>;N/<Y3R7!4DFRR_+O[O4U0WY++C"F%'601;R$O(T00Q\P`RM'(6/4(XKN-
MRP&NQGT,[/KP/WG?[BM1^D+8JK<AO+C@]]WN7;./2HV/\ZL2S06*5UYV6\Z>
M7K]2(N\L<6N&?OG[K&0]ZIN6JS&50E'QB\[78I:W)0MGSEGM<P[AX^)@JNW@
M)=C<IB@$8JO[$0\E&)H,0+Z0[M8WE!E^Z?3D:I9G"WWEF2%0G)9#"H8EFY`H
M)-PL?NL2WU@H\=6*_++Y*Y8[:S^:%?O:SDLM3Q$$54RU[[8B)97EFL-/$]2*
MZ76&@17L,\V_76",<SV'G=X:[+35ANF:'AL,5>]@(.B:3&VU&9L=EL/6MA;9
M.]-Y:B&@XY"!C+*SSVP'K[A*6?*.RQ7U<)-O5(AS&O:_618:TX;*;5V>,ILJ
MK9*!-GY'D5,D?4!5=N?@6XG4"O\`+E\6HU\5V]F!8]25CPDUS'R5C%!7@S[U
M8Z;1W.M(9I*[WJ(O(U:%8C9^R>;HR'7T%[BZ)&(/*=;\+C:[NTP_QE+-L];Z
M<$S5[)&;JO;DJY(6&\)TED^K9Z.&?3XV5)"'D00",`S([P'*0!^_=RI(19KV
MB^*43=23I;,I@X<@J<R&Y]2/IDNN_+WN/$ZRGT"[4N21Y_`]RS6_32O%EC?O
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MBTL#-6RV6,'J@N,R>2BQ@JEX7I8FU:K6P]T3`QVF\C=GKPBK)&\-<<YT>:-1
M(,-[3S6L6ZK15AS(E&JFO4*U:E@ME+;T[!(7*D4ZP5Z%DQN$![!$!2;(^C;?
M$S#-H@ZED3Q[XQ%'";ALHF;#E,#'CZ\DD4_5GKS)%.O#B$=U9AP;D>:@HZ$D
M*>2@@$,#JK]2/17']CX*[=Q68.2S>!R=;'9JOY4P)4N6H)Y8_*S]>7S==)*M
MJK+*\=9Q/"&6)HI4<>`\[=.X_47<2\S]HAB##87/7M[K2EO$)MMJS2G'MCA1
M2A?;GD?8"4@08$9()<7OO(?3T7I?YQSVO;RO1$BS$Y,UO,"+AX&(OP^OR_;-
MOM./#;A^5R\-2:_H3!:[,2]7RCMZC2X!<XF,%7[%L:UH5E`N]??SIC(N^7\K
MTO*G]\=;[+4`C.]EA2K@S=LQ!2%D+]G%%U/KO`1M_:2[S3('2]`JF95&OVYR
MXK46WSNX)V30JXM)H)!--&3&7\9'"ZC5=/DM^U83-TJ]H,D,\D5AC&0(VBC>
M5V0<CU$XQR!2>!9DV(`8'6TW/EJQ3Y;X=@^XQ8JXO+W,;G9Y*31+CYL?1LY"
MU/55;$C7JIKT;ZUW;RDLLU7BT42SQOJ0E[;Z8^=-LO@\1@'_`&3;WZ\TJQ9\
MZU-2/SR-C\_HU1T:1N3+2@H;J6>PECK>B5U*+35K[9?W&6\ER"*;5=;F'[O4
MD0WI;3##&%'601;R$R.\80Q\P`RM'(6(D(XIN-RP&JH^A?9]:!^\\EW':B](
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M72.SCQ<F1!^\(9!OYBI1(%97Q62MU7NUH9'J1[\F`\!L-S^/B/%MM^(\3L/'
M7.L%Z9>H'<W;5SO#`8B];[8Q_/KV(XR8TZ:"678^U^C$1+/TP_1B(DEX(0VH
M)IO;+%,VS2WZ0I<H2R(56GZI;D:_"2;96;G$\;DR5R^1C)N81,V=P%O<MXAV
M9<I"-)!RFDJ)3&`.2J7;^3NW8Z739"\D2%F!XKUAR0D_@9`7&WM4$C6R]G^A
MWJ)W=W?0[17'V:DEV_C:IGFC80PG*QF>E([?E+-55[400DRP1LZ;@;ZOFKV.
M)N%;@;7`O$9"$LD/'3D2^;BH*#N.E&B3QHX1%5-%44U4%BF`3$*/T'](!_LY
M53PR5IWKS`B5&*D?@(.QUS/,XF]@,O:PF3C:+(U+$D,J-MNLD;%&4[$C<$$'
M8D?Y3KN\Q:K-.--.--?G>DV#.8ZWY)2)V9C*EDU&QOM&UPS:)`LQ)0NW/Y-D
MLGG$DTJ,#"R=_I<9`505EK(6=C(]<'H%2CDWY!%4O84=H\U8M1*TF0ELU3/"
M.(:$`_:`NS"-RS;"/@S#;Q<H?#7]6J5FQ0]7,[W'C*\U[OG)=P=NMF,2ABCE
MQ"1N#?C:U--'2MR36>"T#3L3H8MWM/68<#HFPV&\2'9^&U&:SY2`W6-T3$DJ
MQUE6LT'(VRP41GAO::(G'K;0HY17'FL[)?=-GE8Q!Y.M4SL:L1-THS=2+=OR
MFABJI@FHQ2\\689^5GB0BN9ZI4=,_;%1QB5B$/O2[J&5&.N48K%=MU?1JQV9
MCLH+7IK+B<N;'<`KS)6@NOF.W)84:C(!E&AC\MCZUAXJ<C";(L\*3P5)9=50
MQ7ML1"=B5ZG&0]LMNEX#V'B]]CVLNXC&/7";G^QO9"6^XIM].0\:&AU&BJV>
MR1<F6KIRTF\>U<JC%HX:R*#CE@XKR2TQ8+1UX+=<P$@$V%6M7'%0K'IN_&-E
MZO!0)=G960C6[V8L%?R':D6<FL4<%A^Z,')A7:)9'ST,.!P,70A2&63R-JX*
M]"S7.1:M7BBR)2S/%-5EBU+$D(;V8V?INP'K1^V,RMQ][^KOP"Y+16?ARH:(
M,?\`B`%Y/I)2%]=[=]O>S&\X9`'("UY@)EZGFR/_`!OX:4Z'A[.H?M>IOT^'
M2_)Y=3GX<./O:HWDR'Q`=T,G_F_]P'JC"^[OQ\XW_B7G>?D?)BAN>CU_/>;'
M3%7I'K:AK]>U2]2ZXKVJ-A:G8\TZ^8!%=?F#N7=2<=V0FX'L9UBEFEDA'T%#
MR)\[J5Y4JU8BV!+2E$RC-Y:3J/6B#6.<.>2$$$=BZ("TD,]RP;!``-=6KV1Q
M8,PZCIRE9ND64B+96+.HUL%6/"4,[W;'A)K%[$YCNG-R9MUB6.3`PS8'N&)J
M\R32QB]:IBSD;$QQS6:\L6.5:\\LUN*'5O0UANT?VDD-2BL^6G]UDM'V)*P]
M94;-!1]OKV>N\#ZRP\.]6T&051QUW8(X]8K<M)(-)YRD2/LYDFRKMY'KMN5T
MD55\"M&27ABA##QL\6*-(+%DL.F/M@IY2*I*`\HMV"JX;6AY#%=NVO1>+LN]
ME5J^FL6)Q1@[@->9ZL]Y<UW!+*@HH#E5@D%B_6@>2E&QGQRO,D$%J*75"UAF
M6$PS4:96)2,N><7?(^K;?<]BC_=HJ&Q65C'CPND/7=4L,+%7JY1-@K!O'7`@
MHV0<"^*9.038)>%8;:=NKE(+,ZM'<BL6NA"=B9@0.F`RL40JW[9S91Q\4+GP
MUTW,V#D?4G"]PYB";']VX[.]Q-A\4_2EERT<BKY!%LP2R4ZDL%CPO^<G@3HD
M/5>R^\>M_P"P6K48OL/3+12\J"SZ2UQ_LK2&>9_>M>CGLKG*MUR)>J[0E8Y4
MK*IL8!.TQ#!O*0ZKP9]!M+E5;-'8MET^:ECH*+X>2"S/PI&S6<R<&($G"8/#
MQ&[%N)8JX'3)0@LO(:^7NPL)V9=]*<AANX<WY/M!\]@+;Y#RD\B1WQ4RBV<2
M8(^=EYC6EF>O:6+R3R52DL\`FC?6(\V:M8+)'N?U*0C;OA,_:?CWD;SO3,\O
M"1U#DZQ4.M:3V`>T:P0K'0YI]HT/6JVK`+1L8[:-3V8Q956/&/<?79[K-+D1
M;L*T652/(!(#Q8N&>SLP=6,:B,M()`S`GI?9A^:Z^B^[YILEWS'W1G8IL=ZE
M5:7?"4\*PBF>['8M9\I,ER"9Z,24);%];JV+$4L@QX-)+0M1:X%N:A.8;F]0
MM4A%TK.J/E':EOA^LOC2TO![9+23Q$,[?-*Q78>5O-,B(*JIF/8PG8Z/<%?*
M%3CDWR8&6#-7;I96>Q`K2W);%7KQ#8-"`/M`69@CEG_:^#,.(W<J?#5I@ISC
M?4G+Y["13Y'NS)9SMMLQC$Z44V(BC1O/(UB>6.G;EFLD"AY.>>,PJ7MO6<B,
MWM.6&[ONT<5J4MGRT)NS#2,:2KO61>RP3ZWSF?-<"[1P\J];Z$P65QQM89`U
MEM,M'-W4\W2/'5HJ3I5H\D&S8*F**LF!:C'+SQ1@FY60I"+(;%4@=,_;%1QB
M1B$)Y2[J&5&;7-<;BNW:WHO/V71RJV?327$94S]PBO,E6&\V;[=EC1J+@95H
M$\OCJT[QTI&$^0+PI/7JRS:J)FM:H>K]CSUB/A;;8],Z\]@(OL&W:RSN,8=;
MIJ=[)=HY5_8YMU.0\:IHE1H[RTVN,?%JJ4M*/'M5*HR:+M)%LYY9.*\D](3E
MHX8+E<USL";*K6J@*`K'INX2)EZO!0LNS,&1AK>K$>$OYGM%<Q+8HXG#]U82
M3!LT2R/GX8<!V[&D$*PRR"C:N+6QMB$Y)JU>*+)%;$\<]2:'6K>Z\>Q;9_TS
M?U"9U67"N:;&C38#'#S4'JF@1[K!-'B!/2)0M:FXF(L\35W*\N+>8"/;NX]L
M\;%<HN#I`.O]LNQMY)+"P+S@/-IN+11D3QGWQR4E2P";IR(8JVQ`.N(_+O:L
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MBW\S&)1RQ&TM'.ZE*&.P<&51],Y4)YK59=(WB#0>X0I2@^_VAH1`KMX@#<*=
M_$$./$>.X]C`'7Q!Z[1533[+N)*!?D[)QJRURI#0B(2)%(9`6BD6S'M-&%;J
M1J>$\<;C8['YKFN`Z<::<::<::REW02,?#A<,W#$EBB]6P.<I4=)'?(,;/>X
M+<,^F*=2%GS%A)#$&O,^R0B$WRZ8,F*KTKAT=-NFJH6_[:.V4V8'HM7G5R-M
MUC:"0.^Q(WX*2Y4>+!=E!)`UV[Y>W"^I'2L+*<5-A,U#;DC"%Z].;#WHK5P(
M[Q]7R<#O::%&,LRQ-%"KRNBG"D38;JQ[32&I1F?KSF[2&FZTE8.LB-E@F-P@
M<]===^M,-%/5=!?+HXVZL3'[<K,O(-VL^X2)&V0R395T]8.&W-JDBK/@!1>7
MABA!#QL\6*-)YBR2.F/M@IY2HI*#WH]R%5PVOI2]BNWK/HM%V7<RBUO32+#X
MPP=PFO,]6:\N=[@ED044!RJP/YC(58'DI(QL4`\J0U[44VJ)J;3V/#]0IU5D
M8NZ9Y>,;ZRMMTUR/-+1,+B<G'2<U^)+]Y5[%#15YN<--U=8YJX$#'2#HSY$R
M;])BD8BXVMANKE8+$ZM%<BLV3!$=B9@0O3`96*(RM^V<V4<3NA8^&NEYR?XC
MZCX;/YJ&;']U8WN#N!L-C'Z4LN7CDCA\@BV()9*=26&P`+_G)X(Q"P:J]EPT
M>I-I+9"=R9K0;>_C:/A%?O'R#R5(W=T>6G(V^R]GI?9]%G7VE'K\,^T*%D,Y
MB;-9U9Y:2C6;)T:LE+%+/S2#8`P4F,61-NNK2Y5XL>'@&RF,*];=B[,(V$A6
M(1A6)'5^T"<&U3]HS2XWOE^Y\#%-DO4RUC>QX[F&410R4HJ]OMTM.UR>5*,R
M7Y:^.6DL%B6:,9`F['5%68ZG=TG+[-;?2-!NM&0IFYUEQU';4+`S66-FY;2(
MN''LW]WR45>(<CG.(+[H:V2R!6TYB5CU1-6@&3+&^O;AR)5CJ18N6I5E,N+<
M6^I/Q*B,GRW`%#M(W$K'U."L/M/<Y\&UK7;V-[8Q_IQDNUNW<DV0]-KB]SM=
MS0KR0Q4))?N]Y6.2G*5OS>7:O0\^U6M.NU\^3-ORLIU':Y)7.%N.KVBB5EG<
MM<O5'[@LM6S$LZWB#8@[L.NL9&HRTY:)IHPK%Q@J,B`Q]F"O.)1ZH\$%8EO)
M-_JIS/,E:6M7@MN8\=%+3,4O'?KA8B'"JI+(S_6CZ@4;>$A0^&K;+5.W\A@,
M'ANY;DF/[%QN2[6?&Y`PM+\76#%O':BAKPL]BI-<.T^/\]'7A6+=+TM279=?
M.C(,HVC(9[5';2Q]<GO97IA99;L!YDC&MX>1@*%UA)&9T\H,C%-]#<6J\VBL
MUHT>\:QR\*U8683/WK5:/<HC^6F=[1N6`4S(I7%$'@=PTEG>02`]/BBM)R!8
M.6B]U6#J=>>Y9;-SN1NZLXCU/5J/M#NRO%A-HY&ECGN]PF2^EV.5J*UJ=>QD
M!/%).EN2;'@5J\T=J&35A==)F[-''53ZTQK*_A5U*V*)Z]`SLS-DEVD9JKXV
MG%VBN*O&7F9C!HT6!B%G:5N2AY(DC/`BDU729+K\AYB.LPR'VA7KY"$V-U)\
ML?MMU;8_:MU&<`Q%UXQ[E@6`UJOJQ0[=GB[W_P#$'@.;[YQ4N<YUW<]N.!E3
M)6G"/MD)C<FM)$V+:U`8*1D>:-[$4>N/:P2<2]SH\UY<?@J_?2Q76>VQ-95=
M%E8UH)TK*XX6E(,E;PM=V>LF,@$DFQ-6CPI?/"2%<?3#EK[B..U'XY48E46'
M\*\AM-SWX<#%X\>74Y^'#;WM3\&7BHX_N/';R^IJ^F4%2'$$!2\`F4194VRX
MIBH^,`<P-,,@+9Z1J"+[;56OU[7+U7KDXM<9#5.RYIU^Z^Q?7^.=S#F3CNQ\
MW`]C>LLLWLD(_@H>1'/*E>E*O6(N/):4XF49O+0=1ZT;M8YPY&<@@CL717+2
M037+!L$``UU:M9'%@S#J.G*5FZ7)2(ME8LX&MTJQ82AF^[8L)-8O8C,=TYR3
M-R+$L<F!AFP/<$35YDFEC\]9IBQD+,YQS6:\L6.5*\\LUN*'5NPM@N\?VDD=
M1B<^5L&[26B[,E8NLJ-F@XZW5W/GF#=8HB%>+:#(*HXZ\GXTU7K<K)(-)YRF
M2/M!DVJKMW'+MN5TL55\"M&27ABA##QL\24:03V2PZ8^V"GE(JDH#RBW8*K@
MZT3(8KMRUZ+Q=F7LHM7TTAQ.),'<!KS259[RYGN&69!1C!RJPR>8R%:N\M*-
MC/CE>9((+<4NJ+I[/V/%-'IE5DXRZYS=<LZI([=L+`96)AL9EXIXH&BNWE4L
M4+%7JX15CK/A/6_8XV07];XDY%-@E]%AMK+=7*06;"M%<BGM="$[$S`C[,!U
M8HA5OVSFRC;Q0N?#72<_/\2]1,1W!FX9L=W9CLUW*<1BWZ4LN6BD4>15;,$L
ME.K)!8W%_P`Y/`G1V>H]I]XQIO%5I)?0>M-6<,6S#**7V,[=SF7:>+\SM#8Y
MV=#>O::5$5A)D2U526ID'8;'[TZG6L;&JN:\0(]P^*^1$*/)A!4O3@DY"2E4
M66+;;HJO0Y.6WXN'98^`0LP$GOA>!UQ[U#CJ1=K=X9J*1Y>]\CVGVQ#D<=P"
MMBH8?@O5MRV"YK68K<T%#RD=*2Q86.\WFHJQK2;Y_P"X+:)8]F^PH3#C:;'3
MK0AU?-?U*'.WJL9AF:;=TWC(U/9$('/+'-V)DX32+*UT]:5?+.)55=BX*P.0
MSD;;MUI'PE/I"LEE#9Z?-4:23VD]'E(JJ?R)>H``@##D#MKJ'H+-=L^CO:IH
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M14,7Q$$0$.<MM)''9D2)Q)$'(#`$!AOX$`[$;_@(WU_-[N6I1H]Q7J6+M1WL
G;%;E2*PB21)/&KL$E6.55D1779@DBAE!V8;C4KY'U2:<::<::__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g285899img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g285899img3.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.@`Z`P$1``(1`0,1`?_$`(8```,``P`#````````
M``````@)"@0%!P`&"P$!`````````````````````!````8"`0`%!P8*!PD`
M`````P0%!@<(`0()`!(3,S<18Q0T%C88(3$U.#D*82)B)&0551=765/#5&49
M&EI2HL(C0U9FV#H1`0````````````````````#_V@`,`P$``A$#$0`_`$S1
M['O$[5'B>X_+8VQX_'U;F8+<O:VC;75UMVTE2""B&!`TKZMQ$VV1&YJM(9KT
MUOKI4#&`"I7.NQ+80383<7Y`;/Q[0?07XOON]MW*25:<U5/BKF;D2;;Z8KEG
M9_SJ8]&@F)W4RV_OHOO,<$L#VYH<\:_-2)7;JFL!B9%[+3?H`S33SG6WXW';
M<YB3#5=7C'F7F\C%27,%OE&1XT<32$9S&5`UZ!,@UJ0V8Z89(X3J\N()$VV(
MG-#!L<Q@^=SL;TR'J`E\8CLLQQ9V'N#%T_<BC'X@)E<R#!;A=J/)E54BXHTM
M%'$GO%]MW]6>PX;P0F1AN(CS!/"=0QIL:U6PPMM<;E=]-`;,'QD*LC9)R-RH
MQ,J<=W"/Q^CFI"BZO+Q>0$WN5^*]I.NARRNASO!+H$G)(#6YZV0G)H54"A[4
MF75]$PIH"6!&WP!%6/D:NO/"\?N[RG*L(K+8KO8*8^29BK42YDI<,JHB+"#"
M3T1OFM9`;!)D+X.JBLQP34>J%H7%T#VR7$W$QU]MP3_Q_@\"=\+XQ+1U/X@)
M3C)0E5V/MK!2,=Y!IR=95#W8[+>;Q$.#-<N30A#^%#1H;%\!ZJ`799'QOUM\
M:=78)F/8!J_L\;ZQ7L!Z\<]U?V?WO?>?[[\KH%HD'\>UO?@&JS2.[GW>R9K5
M_"FY)V<C%?3;Y%(G@HMZ3.T@#O1P:;M]ENH8R-V!4`@4_.SQO7K%=A`\!=KO
MIT`_JH51N!BX'$`T&AP_R1Q_T^X_Y(N"\EE:>5P(OLEC&+)1>OA#;[C!KV'Y
MY,/SY,8Q^L?I'7774$$'.>@!CP32U<B9*X..I]69X8[[=R\]I!`<CV7H$CMQ
M'^*@N',,G/-$?$F[280+GKC%K=DTHXE(Z<04=]F1C344;.---`N@::$TP.W_
M`#;\3/+TIZ)Z&B\@$CVGB;:ORHFE7$/'QVD5;G'`RJX%!Z8T3DAT@2.HI&5@
MN5"12.$?434#M#.VG;=`#EZTT=5>+W!6K@N5SO&LFUR5C:]<Z(9?)*=VB?&J
MW9'8YMF09(TC*3E<B\AV:)W%4UH8XCI+<(*`S+V5P<'<`Y*:B:`\1V6-M3R'
MMKA.Y8*24!79K2*Z2E?+>0(*;$S17'X^@2JC@5^0US1XO-/:"84#=ZFB'EG4
M`JC&MBVH62XODSMH/L`ZULID\ZE6*9EJX*^ZX3^U)OC]9<2^UG2=Y9F*Y29!
M4=:"NMI;,"-UR+ZHWCVII'<AP/&@Q830/(F-]<8VUUS@)U_\O[S<?R\7GXQ?
MO4\::[]U^P_%#O/TCYO-]`?9R$\*<F\5O"785:A^X)M0<PJ0@[W?73;'<1P:
MTK9!L,S=J_-]EA.F2'5K7D>(AG:-Z>;0>L,YM?Q#F<:>3&H8O.Q:/-O^.8$B
M]:0R4RKCTO:J6LSLC)UG\EQ./M`FIU12F0\_I`#:Y9OL>QQ>T[$0M=DQ/3-U
M$PU.UVV.8`&ZW7`NII.W&Y5;1\;4O\4[4`A"K]=C<O#H7*`7(1T]8Z=:T\(:
M264]B*E55^8C]_G_`&%D)HJ[0QLHDS80QTWE1+=0OIJ+N!@?>,LQEK66$Z\R
M]R2QOQVQY,V7REO$=7JFXIK4)M,,Q2BEV>1FJ<>@A.&'A&HX0@C1T0D9+950
MU;4#?;<,+?78%L6/NWR'OZ2W;2N\G#Z^)8K?R.MF/(\J36=&M+!$8/94.U@:
MB)(\MK1^=X]2O;!8#<QM(3'""673R7A*+!Y(E]Q\;BZ9!$DI3IRGV=Y(ZR\?
M_)/7%QV*<<**KZ.MBB$6OJ&ZM.1<2I(AS+Z))W[\(0PD((.2#<;J2O9',GQ]
M]PD\4O\`\H4T-KD.5GN76E"T>.P5.''Q,#VIA"ALP)4&MB7=^0F8[:]/!YB[
MG['J;MG9O-C#]G`.4'P1+'B!=<'%`;0(&Q8CC`0NWE"VKX2^:O\`F^QEX3^U
M7U!XO\+OX;^\WTA_??K_`.3T".J@7(GQ9\=E=Z5V8<5?'Y<3D6(NNPHDM)F;
M(S)'R%$R6`X%]K1B>766Y&V[H9>X;SC%U9U+A%"H^Y(8CZ08ZIK;3.H/<1M)
M'G;E7F/F1J+QGOKDT@"3VO"!"JTMLZS[3KBSVRZHSA<Y!\[DEV-Y0V2U&0]2
MSG],1P?UX@!%B9I(W-DNTU&#&P&_KCR-<IG(Y.C;68HM`Q^(JO-GE-99U"H<
M>=;H;MT:G%]0<CKA"TZ6C/-*;[356ONP7*TQU,P*XPD\L:PKZ%T_8Q@OMML'
M#.-_DI2RG#"BT0J-,S;D;F@P^)OT@V&W''&72M+*V;LTY9!=!@NLRTU#$&E]
M#4"DU94QHH+.@0((>H>GYWH$%D.X\25E.,>0XI<<2\=4HYXZ^6"W9P1J%&?+
M@DSW?/,)PPJ[7BX%!5(9E!%+0[G#RC,BO&L@DSJ<&!HIA:"9'&)@AY`=W;/"
M'5#F];$8R?1QV\I7-$S\(QU)MJP9_)U#:TJ:.&O!I904Q.K?LGK$+-+:.Z_J
MF40<8P;W_6@Z7N?SU30^NN`R^4:V%!Y?'EJV5(XL)W-KLZ4IEI_.5&[/<#HA
MP_JR&>`UF/2M+1'W(S52EV-QTZ7BRCN;-QJ1V,K6$S;17V]'%#$R'HW^'DU?
M],3;7W3]K/MG#WNK_;/?/NOT?OO-]`(N7:KR<X.3:N=KG]"16E%_>3Q3=K!J
MBCN<^SIO0>.=9I]#'L_)+S?+/;9W6(+7!VAB??LTXB;*).K.&/ZF.N9-@^7`
M!;QYHL0T*Y;;0S'8;CZE.J4&T\3X/=#N=3@MZM26VZ(#S5&#V;F)(>329AAQ
M'+`$[4.UR%M$Y)(E#OLD(?QMOH'H#MOH!`;1-2FR9U/@ZY%<W=Q=4SX1%1;F
MV<XL=<ZOZPCDEI$Y)!C!YB'$R4X@,D7]'7HK[(IJUOH4'7A1P%C4CL$3"!&Z
M`;EK^+JAG+/>/DC@2.XF6:Z7*KS%=)UAJW5*25(SG:JF0E>/$151_0Z\([D8
MK93A$>,V>*AC""FA1#HYS)W?&@VF<;AM;,G^%:M-X>2F.^0FYK-(;6YBJD#*
M>U<T2)Y^9;LBX*`H\1UE&6RDPQ`E*FPNTD^F)RMN$E#IX@!?;)4UL/C;?'0%
M^.>\-J8YYPFS='C?B'XP*7<DJ>THVB-%2CL=,-4M(;I=6PRRWZWF<]YK0MY!
MAPQ$3U,*`Y\X;(I&JYHG[!!B&PMP]\`X'DO9==H+B'F4L58GC,>*O#S^B:BV
MDH/!'M**S4NX.K<=+,14MG-1`9^YU5@DU7UTK!<)04`28?M1N%MM^/IOG;H$
M6'^:(Y:OXW-KNO97P7A#PK_[(\.O6O[R];_*Z!5[Q?<C]D/@SB,?COX`9>>E
M5$U8DD6*G0L<A45N)2U533]<@4@Y*K4TH&9$UZCSU4`-NWSKIC0/J`^4'&G0
M/&>\&VYN:BH\OW2X3Y4J=:NWZZ^FO'\\N>^23+#+/#P=7553U'12@V.P16$L
MZ);#U*$--3Y<KKJ8.ZG`\B&`ML]`1S+/#X<A#B'Y!)MN;024H)MM"`++<3$L
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MD81@D?`2"$$,6%`V,G-Q,;_*`CO&4SE:^$3BWMDQ[<)D(V4K3-G(X8KG%KVB
M]4FCXC3+JL.7C-WH@AIP!+;!1,QDQ%,10P,Y"9P,?(VN"O9F=-=\!29\&/-U
M_-YKIX5?O/\`LNZ]]S^R?7OG\_\`/YKH$O0/'_?*]_`IQ`$*.1*[I3/QI*'(
M.<D<)JOYF,;**3=<ZD`&N(>V>+T9X:I@^.WC^`^PR8V![';K]3&^O7!L],ZV
MV+J4\_NN$%6L9BTP)O:D_P#+*<=+6<#C076J)Y1RL5?<;<$'7&TO.1',ZG6Z
MIEA]-0C@F0]-\:;XUVQG7`)GYG6E':9#:]>29;0YY/9#Y'5)8CVN4_QXU7G4
M5BUQ5Z>N5G,J1=EN$`#YAOR[AV-\8!OAZFT],#(FDD11TW-"&<"=`<%RP\4/
M*?RG7^B:"DE$)1-QI-=H-$S'T\)39AL5$8RDY*^L9;D8TYF@W7HRI<D4-6EA
MH:IA4%0P(&G"F>V+8T+8WVW#F]-.66U7'G>)U\4;0XO7RY="A5HAU-I<LV=B
MU4D6(7`K,)PS%,CM.60<S7=8[W+S*44A'(7)**T$$WB>N$\#Y,8"P&;47C5X
M?N4>^+Z9-)V^^V16.F&S9=]B316<K(+A2W!ZP[(<NZ<SVMHY'0RW)!!B`Y7:
MZCZ<>)X.Z.;/EUTU"+]3?8%Z\+1"Y%+JYW`L,`S@*_TWL&H-IK-;DJD(I'<X
MQQ4+2$IAD)L+JV=K`JB.61)4VDQXK(;*[,J1)[$SQT-2$V'!`SMJ!^?X?FO^
MGHM-\WMK]K-GYOXU^^GT9_XY_N=`B.C_`-UB'UB>].^'_NMZX/ZAYW^F\]UN
M@.I^[^?;<\>7C%[Y33XJ=U]7:4_H3SG]H_!V?0'1\?'NQ]V4]T/K8<U7OY[J
M>L/GZ5_J/TGL^@=]^YZ^,_)=XO>KP3XF>H^]<Z^[_P#6_D=GT"T@QXI`>$/_
M`$_6/%+Z&V[C_A_0_+T#X=R9XAREXM>]:MX5]]].+'TUYK^@_#VG0+=HJ_\`
<B(E/O.]>W?=[]H>F][YS_:_#T"SW_P!0^@?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g285899img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g285899img4.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`(@+&`P$1``(1`0,1`?_$`+D``0`!`P4!`0``````
M```````(`08)`@,$!0<*"P$!``("`P$!``````````````$"`P8$!0@'"1``
M``4#`@((!`(%"`<)`````@,$!08!!P@`"1$2(1.6UI@961K3%)=8,2)!43,5
M%F%QD3(C%Q@*@6)RLC4V.+'!0D,D-"4FV!$``0,"!`4$`0,$`0('`0```0`"
M`Q$$41(%!B%AD1,',4$4"")Q@3+14B,50C,6H;'!<E-$&!?_V@`,`P$``A$#
M$0`_`)6O'^6.C+D[NSC7<4R=3U<'-P7U(+B[-4LBJQ6<IJ276LVI6I953>4/
M13HIJV3FLGR#@%U_M@8QZC.4'99E[[Z9.:?(.`3VP,8]1G*#LLR]]],G-/D'
M`)[8&,>HSE!V69>^^F3FGR#@$]L#&/49R@[+,O??3)S3Y!P">V!C'J,Y0=EF
M7OOIDYI\@X!/;`QCU&<H.RS+WWTR<T^0<`GM@8QZC.4'99E[[Z9.:?(.`3VP
M,8]1G*#LLR]]],G-/D'`)[8&,>HSE!V69>^^F3FGR#@$]L#&/49R@[+,O??3
M)S3Y!P">V!C'J,Y0=EF7OOIDYI\@X!/;`QCU&<H.RS+WWTR<T^0<`GM@8QZC
M.4'99E[[Z9.:?(.`3VP,8]1G*#LLR]]],G-/D'`)[8&,>HSE!V69>^^F3FGR
M#@$]L#&/49R@[+,O??3)S3Y!P">V!C'J,Y0=EF7OOIDYI\@X!/;`QCU&<H.R
MS+WWTR<T^0<`GM@8QZC.4'99E[[Z9.:?(.`3VP,8]1G*#LLR]]],G-/D'`)[
M8&,>HSE!V69>^^F3FGR#@$]L#&/49R@[+,O??3)S3Y!P">V!C'J,Y0=EF7OO
MIDYI\@X!/;`QCU&<H.RS+WWTR<T^0<`GM@8QZC.4'99E[[Z9.:?(.`3VP,8]
M1G*#LLR]]],G-/D'`)[8&,>HSE!V69>^^F3FGR#@$]L#&/49R@[+,O??3)S3
MY!P">V!C'J,Y0=EF7OOIDYI\@X!/;`QCU&<H.RS+WWTR<T^0<`GM@8QZC.4'
M99E[[Z9.:?(.`3VP,8]1G*#LLR]]],G-/D'`)[8&,>HSE!V69>^^F3FGR#@$
M]L#&/49R@[+,O??3)S3Y!P">V!C'J,Y0=EF7OOIDYI\@X!/;`QCU&<H.RS+W
MWTR<T^0<`GM@8QZC.4'99E[[Z9.:?(.`3VP,8]1G*#LLR]]],G-/D'`)[8&,
M>HSE!V69>^^F3FGR#@$]L#&/49R@[+,O??3)S3Y!P">V!C'J,Y0=EF7OOIDY
MI\@X!/;`QCU&<H.RS+WWTR<T^0<`GM@8QZC.4'99E[[Z9.:?(.`3VP,8]1G*
M#LLR]]],G-/D'`)[8&,>HSE!V69>^^F3FGR#@$]L#&/49R@[+,O??3)S3Y!P
M">V!C'J,Y0=EF7OOIDYI\@X!/;`QCU&<H.RS+WWTR<T^0<`GM@8QZC.4'99E
M[[Z9.:?(.`3VP,8]1G*#LLR]]],G-/D'`)[8&,>HSE!V69>^^F3FGR#@$]L#
M&/49R@[+,O??3)S3Y!P">V!C'J,Y0=EF7OOIDYI\@X!/;`QCU&<H.RS+WWTR
M<T^0<`GM@8QZC.4'99E[[Z9.:?(.`3VP,8]1G*#LLR]]],G-/D'`)[8&,>HS
ME!V69>^^F3FGR#@$]L#&/49R@[+,O??3)S3Y!P">V!C'J,Y0=EF7OOIDYI\@
MX!/;`QCU&<H.RS+WWTR<T^0<`HY7ZV.\0,81,B6^V[]?*`/LH`,V*0PZ,DR.
MXLL*+%R&'Q>VT/DTAGC\E`/\HCDS<80$714=*]&F4#W5A,]WHT*.E=MG`RE:
MT\S#<CK_`"TP*RAK2O\`+2O\%]-*_HU%!S5L[\&]0J>6U@9ZE^Y)X"LH>YFE
M!S3._!O4)Y;6!GJ7[DG@*RA[F:4'-,[\&]0GEM8&>I?N2>`K*'N9I0<TSOP;
MU">6U@9ZE^Y)X"LH>YFE!S3._!O4)Y;6!GJ7[DG@*RA[F:4'-,[\&]0GEM8&
M>I?N2>`K*'N9I0<TSOP;U">6U@9ZE^Y)X"LH>YFE!S3._!O4)Y;6!GJ7[DG@
M*RA[F:4'-,[\&]0GEM8&>I?N2>`K*'N9I0<TSOP;U">6U@9ZE^Y)X"LH>YFE
M!S3._!O4)Y;6!GJ7[DG@*RA[F:4'-,[\&]0GEM8&>I?N2>`K*'N9I0<TSOP;
MU">6U@9ZE^Y)X"LH>YFE!S3._!O4)Y;6!GJ7[DG@*RA[F:4'-,[\&]0GEM8&
M>I?N2>`K*'N9I0<TSOP;U">6U@9ZE^Y)X"LH>YFE!S3._!O4)Y;6!GJ7[DG@
M*RA[F:4'-,[\&]0J^6]M]DTJ<[[IVX!%VTO\RM^E^$^2$8CC:7QX54.K\[1%
M.VM:4'XB-/,`6"E*U$*E*<=*#$IG?_:WJ%-ZVO\`ET;'7FA;1<>T.ZQ>^Y]O
MW\)@F:9P,B)2B..%2:T"H()=&F?J4X%B4=>4Y.94!Y`_RF`"+HU.48JAG<#0
MMXJ^O;`QCU&<H.RS+WWTR<U'R#@$]L#&/49R@[+,O??3)S3Y!P">V!C'J,Y0
M=EF7OOIDYI\@X!/;`QCU&<H.RS+WWTR<T^0<`GM@8QZC.4'99E[[Z9.:?(.`
M3VP,8]1G*#LLR]]],G-/D'`+D$?Y8>,%%K`^8MD\+YE)1/6M8NS<2^"U$JZP
M/_W:OYN*7E_F%73)S3Y!P"R>[N>X=,]O.R\`E=I;:L-XKRW1N,Z1^*6\D`GZ
MJ%1"X+#GZX-UI485&5:)WK2+QMI*K0=#*$E54]890005#6Q-%CC8'FA-`ID-
MF6-@!V2LG?\`E=TX1;RW%_6.!.5O7^<2)NCS4[NMP8K_`!8T1HAS<#2$57@*
M`A5S@$,-`_*&UK6E`5X34>JIE=4M]PNGB6<&',\M.^7XAF3EEI-9>,RIM@\D
MN<U3=L/A\?F#TY-[.RQUY<Q"+HVN3TYNR4I&$X(`JJJ"Q%"&`5!:5"%CP:$&
MJ1+.##B>QB\4UA.3]DI7$,>Z*1WQDK#/&=R9;6)T9BDE2X2]<G-$2@:`'(C@
M46AJ8C,,)&$!HA`%2BH4Y'@@$&I7JI-[;/*)A"+?$7.A1DYN5;Y==BWT4H^I
M*/<RM@V%I#G*?Q]&(01+HF@*7DB.64K0HL)H:UK2E=*A1E=2M."\#BV?.)-W
MT%ZFO'3(^R5[+DV:MY/9N]P>%S9"^N"7^#&-Q7"-5)4)I1[@Q`=DI294J0#.
M**ZVE.L#40*UBH]E)8X4S`@%<[!+(R3Y7X3X[Y03"/1^+2R\EIDUPGR-1<;F
M.--#D>H=BA(&@;PK7.PD%`MX:TJ><89Q%7\WX:D<150X97%N"PU8W;Z5S+L8
M#YS907`L[;&-7CQ?76^(MI;J/*YB**W(2WB7DQ:V"ET_>;RLD%?WI-4RU,=\
MFH*YBB*4!RCYJZJ'<*K,Z$!X:#P*R"8K;G%L)?@%8W-'-">66Q<K=IUFD>4)
MG22K&6(TD48N#+8BF9HU21+720NBT;;'`J50`U/J140QBJ`JE.$@\*E4=&<Y
M8RIHID70RXQ;LG:R+WPNUD):.`6>G%6JD)N5()HTEQ*9_OM)\^U5B3FD.5AD
M@5B#B?2J,)U`$TJ,=0AI6M)J%0-<30#BHT7YW/,;+&WLPIM$LG,`?6K,I:Z.
MK5<TBX+$5#H?;<ME55ATW"H3?/4D9%TIS\O'V'J3"TYRWKZ",ZPL)0X)`*LV
M-S@30\%<UG\TXY_#=TY#E#=#%RUZ1@RVNWCI;ASA]V4KC'W1)!BZN#%'YV[O
M;@)+'+VEL:):I?F7K"2V\*?CRAIQTKBA9QHVIX57LL(S(Q-N59N69$0'(ZST
MLL3`S'$F;W9:9JU#A$0.:0IC%Q$C=SS2`M!X"UA(BP'!"-2$\JI-#*&`YIJ/
M7V52QP.4@YES+*Y;XNY(*OD;`9`VHO&O#$4<]-;[>RYOD*]+#5[TKCB.1+T2
M4553<@.?T!R/@H`6:!04(`@!KI4'T0M<W^0(6/K*C,G/MHSP1X3X/V*QHNH\
MEXO-.1[POOQ-YM!U5$BJX3I`5S2U.,?<26DX0584%2"C20#K4XT0S:!!2FH)
M-:!9&L9DSO)`K17KB)NIV?N]C&@O5E0\6WQ%G;1=R\E@I]#YC/$A<7!=.Q"4
M3S/4T*D+G4HQY;4T7X.-2Q5,.)"`T%!G<H!F`>%2H=&0[*WB*`]5)R79_8/0
M`BTBF<Y96'B">_+"T2JS9LBN`T-5+A19_K0+')V,*LPL94==ABY$ZY71,E,'
M2H:#Y@BI2:A5#'FM`>"]0?<DL?(M+IU`9->JVL>FUL;:UO+<.+O4J;FQXAUI
M*`+,%<M[3*S"OEX0$!H>+B&HT]*BI3FXUX:5"C*ZE0.!7'@&3N.MU53TAMO>
MRW$U6QNWL=NV_I&&1)E*EGM9+D)[G%KBN!!E"3$\-D+:F,/2.%:?+G$@J((N
M'"NE0A:X>H5TQB\MJ)M:E/?6&W`C4MLTKBCQ.D5R8VN`[19RAT?3N*IXD+6X
MD<"W!O1D-*FO.7QH.I(J!K73FH((.4^JP70[=!W)I]$()FE#<!X7,MOBX]QV
MZ,Q2,0R32V49JN%KGB7FPQKO61!V@*EB5(%"TH2FK<4B'4!']88"*T6ZK4^M
M."S&.,'*7?G3]EEZN1FYAU9^[,=L1=+)RR]OKR2RC0*.VUE\V:V26K@R$8`1
M^BEM5&4HS'/8C`T2EKAIAGU$'DH*@J5K:H]%B#'$9@#1=PZY=8ML=WT&/KOD
M#:INOFZ3%%;YOM&IE:(,_4S=QCI4M01D,<#42XIS61D\M:7080EU),!^;F&$
M-51Z)E=2M."A3<W=/LR;D3A]8O&*Z%A;_G7HRF>,>K]%QN9BD,BM$C00%\E2
M-T;$L?<B$]7!:[,IB0*A0!6VF4+,``530UX145H%81NRES@1P65_4K&FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HBC7F#?Q1C#C3=J]K6Q$RN51-B0MMO(BH&(I/+KIS=^:8
M':Z,*C`5H8!"\SZ3-Y2FH?S!2U,J'II30F@5FMS.`5JXF8B1W&IG72Z5K2[H
MY7W)+3/F1F2TB2$*I]<6<J"@FNC4S.AP#%,/M3%E(Q((Y&VX2=L;FT@JG5".
M$8:,!3]5+G9O3@WV"L[*#/MJL-=RRUB(PC4S2YER;GVPC,P2*1/I#';F#7$>
M@-*)]<W=*$"0<G>JC$-J0]8*AA9!IAU*!H`)FY;?VC/K.G76K3O[5C;VTKV4
MH72/C%2`#QR"E'.Q(`]R/6_@CZGZWY:\=;G\LZ[<G2]C:)H6IW-F]KH73ZC?
M:="9GP10O)>+:&@%W/E!:Z2-D=27EENY-YM7_LY-KJ);:8]J)_:['J&QF<WG
MN#+I<ZPD"]OD?_J36NU77(1-\G7L+76IBPT(U0"SP&%"+`((.MR:'MG2]2M+
M>2^ONS?7DCV0QL:'T+.%9>-6YCZ`Y>!!J03E[KP9]:/%?DK:^@7&^-['2-^[
MRU.YL=%T^TMH[XQR6WXB75<L@DM8[B7\86D1%S',D:]P<[M]9D#GO>JV*95<
M2W&/3O-<?H5;"U]VKCW-F$J70<Y<PW3,;C&YCM@2H3C;)+(X^@="1.`>L/H4
MIJ(D0`<`#-R:1M/3[UPL[Z^;%J\D\T4<;&]RCH<U724_)K7%IR\&U;0@GCEY
M_A_ZI>.M]31[-WKO:/2_,&J:[JFDZ;IEG;MOFQW&E"023ZH6O$MM;7$D3Q;G
M*POBI('.JYK+ZS>SQ28FVB@TV8T/\83>ZCDR%0"'O2YR;RQQ]24V.,AD\@`@
M.HX(6YB;G5,0+EK3_P"06DEUK4-!ZXVT]IS;CU.6SE<8[6W![CVT/Y5(:UM>
M!)(<>/\`Q:?<A:E]6OJOJ?V$\BZKM?5;J33=K:!!.;^\@#)"+AIECM[6W,@[
M;Y)Y(I9!7_Z\,KP*Y5/0+BOJ$`OGEGY@`%_[D[HJ(%!5I_7_`$<=:?[KR40`
MXC`D="H+Y8Y;7DLK<2SEI[)VN8;P3RZC%<"3GMTLN4GMTWLC%!ZL9?S?[Y=5
M*1JJ-Q4.AI80G'EU$82$!=!C'PUMFW=OZ?JME<ZAJET^VM;=\;06QF0N+\U>
M#0X\*#T'H:F@"]6_7OP%L#R?LS<OD+RAN._VYM+0+O3[5LEII[]1DGGON^<G
M9B#Y:1MB8XEC'`->7/+6MJK5N=F-DG%#K,VIB%A6.0937!MG)[MS^VKO<VB*
M&6SB436'-QY-94C--_?[M(W,`$C<$LP)55`N`A"Y@TUR+#;FD7+;G4+B]>S0
MH9VQ1RB,YI7N`)_$C\0P&IJ*D>@%"N_V+]=_#FX(]S>0-Q[RO[/P'H^N6ND6
M&I0Z<Y][J=W=L$C3\5X'QXK:(F:Y+FEW;%6AM"5U-Y\QLR[?V\8KN17$=(.W
MQ%GTUQ;I'72NXD@$CMA)4A[P"4P]P8EQR-Q<2FM,@3FI%!:?K5U%A80E4-KU
M>LNE[<VW>WCM/N-3<+PW)CB$<1>V1A#2QX<`YH)JX.&:C<IXD<5V/C+Z[_7/
M>&\KOQUK_DFX&\7[D=IVE#2]*DU"VU2V>V$VMY'/'GCC,KI)&31NDRP=E[G/
M+/S702#/+)?]P6*98?CU'SKV7/L-,,E)G"YE<ERC4;A-LHJM/"D2(70],2N<
MI8_-(2E%4YW5?("."$T%:<]2LL.T]',]T^>^?_K8+MELQ[&!SGRN`S$@5`:U
MQI4#\J&A'`'M]'^JWAG_`&^Z]4W)O;4&^+M"W;9[:LKVRT]ES<WNIW3&YWOB
M:\QQ6D$N>/N,S=\,+HW`Y`^>-B;STOM9BV-Y6HAW8D%RH>U2HED7KC%"II,6
MA&4L;C%(*$@5@2+B#0%GT`"AY5`F<H>;EIJ&JV#M*U*?3GN#S#(6YAPS#U!I
MQI4$5%30\*KR7Y8\>WGB?R;KOC34+B*[N]$U*6U,\8RLF#""R0-))87L<USF
M$N+'$LS'+4^)Y.9.73M;,+/V;L;;U)=F^%ZZS5RCC%)Y<?$HFSQ:WC22[21X
M>7@(NM&J4U4`3HB`C*H,SFJ(?0$`^VT+1+/4+6ZU/5+AUOI=KD#G-;F>YTCJ
M-`''@/5QH?4</4CZCX*\+;,W[MO<GDKRKKMQM[Q9M?X4=S/:VWR[N:ZU&4Q6
MT,,/H&MRNDF>0XAN4-;Q<YO@M-QF93BTV.#E96U@)%D#D?-9Q;QKM-,)J<R,
M4,DEIR%!USAOLD)+*.4M[7U9(D5:!3C.)5!&/E$`18NW.S(;74+YFI7)9H]C
M$R0S,94O;*?\5&\:$\0[^0#A0<#4?6__`,<:)M7R'O6R\G[DELO#^RM+L=1E
MU:SM._/>VVK.:-,$%LYQ#9):O$PK(&/B<UN9K@]O8NFYO$6+#AIR6?6-[;+@
MR(4ZAS#95.K='MP6W=M\)>GDT<$YMR?F(BC)\E1Q6.)H2JD-0N/`1_*"M8]C
MW<VYW:%#*'63"QSI^#1VI*92`3Q>>+0T5J\?V\5P;'Z1;MU7[*7'A#2K^&?9
M]D+&\GUIV2"-FD:@(W6USVI'_E=SY_C0VS2X/NQ2HBJX7C(LO+\++18GO%GK
M+_WD7CRDC#1(26A2^2!EM1;U.*&()8_+)3,J$*!H4E1+J)VTI0<G-5U`96@A
M#!0LSC1;=TQFIZE#J-V8=-T^0LK1IED_,L;E9[^E7$`@5'``DC7-%^OWC"V\
MC>0M-\D;KDT3QKL*^FMS,V*&?5M0=\R2T@9:V>=HD?\`X^Y<OC9(V+,P%K6N
M+V>S8FY*.N2]H2[@.4>7P*5,TPE]N9W$*/9CRC9)K!W$+<]$-3P"A07-J.ZT
MLPDSEY@\]2ZU%4'.+J=PZ.-#U+X<<G>MWQMDC?3*7,?6E1[&H(Y\#05H/F7V
M$\.1>#_(QV?8ZB-7T"ZTVSU&PO.T87SV5]'W('2PDGM2MHYKVUH:!X#<V5O>
MY%7?NG:N`H76TULY%>>XLEF$:@\7B:)8XHV1"MDBHPD4HG#VC)5"C\,8RB:B
M5*A4`"AAA8!&%A%4P./1;"SU"[='J%RVULXXG2.>:9B&_P#%@/\`)[J\`*F@
M)`)H#U/AC8FR]_;NEL/(>X;?;.S+'3;F^NKMX8^>1ELT.%K8P/<T7%[.2!%$
M"7%K7N#'EH8[RK'K,=3<:TUZ9Y>=H(M"_8USJ>P"]J1NDXY-$FUPM\@3NKH[
MQA^I4`G)N5-ZD(2R1<QM%-.KH(?.76O8:UMMUCJ-I9Z9(ZYBOH8Y("6Y7$2&
M@:X>Q!]^`IQ-*&GT#S']=I-E^0ML;3\97L^X])WOI5AJ&B/D@-M=R1ZA(Z**
M&ZM^/:D;(TESQ1AC_,AN5X$=(ON6S.3843?+!);1)_$3=?*EGX);-5)G5N"]
MC<Y1$V1A"_NQ]33$+Y1%(CC502@A(H:FX4Y`U%6G=3[(AM]TP[=DN7"%UKWG
MRY:Y:->3E']I+6TK4C-[T7V?7?I5HFA_:#2OKY<;AN/]--M7_<7^IM@CD[`B
MM;N><V\32`^#/;L;$7$R%LM3F<`#,S&^Z&1=R(Q(G7("T[!9QS3/"='%VZ)W
M.;+F-<F9!)#*N#J-X9'!P0IQ)'$%4_5<]>?IKPZ-:QKEEI%C.R+2+J2ZC+27
M%\;HRT\*#*YK3Q''T7F?S9L[Q#LK7+/3O$.Y;_<MA);.?=27>G3:9+;39QVX
MNS.R-[@^,]S-EX<![J%.3<`8,(;E1O.^R#8D@4-DES+>6\SKM?&4Q;3`KJ6X
MNA*FJWC)?X<60A)9FF]-E9C(VY8:])225#U'S5B5<(ZH"1AZ,\.(7QQI+QD=
MZTX+*T:6(DTPH7"HBC!EBK2O&E:@%4-:TK^FE:TU*Q+1HB:(FB)HB:(M0?P'
M_LT_WPZ(OFNR[CN8&8>[3+&O$=ML"L:<`<;5%L9$HRB13LZUB^<9@,ST1<5,
MP)H8D&J=I@DMP(AO$9U@24A)9W-S#$`.JFI=P]ER&9615=7\C[<EC_B+3+3<
M+L3-O;(2+E2.:8.[VUBL=9XP":W1ZBDBM#(%LXEL07(3')O*$]V^6HW9Q0DG
M'ET*&WD%`.H'FJ'4>U#BKU&8R-/JPE7MG1;QL9(__F$8;%H0!EB+QDUMAJT<
M9C,;&UL*NKTNAQLF4,S2SHB$'*I-5'#5"2E\`C&(0^%>-=#[J&&IC/O0KWG-
M:PQ2')[>!MC8>U29F3RS8XMXE9(;;N(E,[4_/[)/')*2D;&EA;TZ!P?D\<8@
M%`**`-4,LH(>%:UIQ$<33!0UWXM+C_S5HV^RN@>0.5>']RK%6^EU\FJR.R;D
M[`I)$W:`S6-QJ?78C5OHJIDMBT+@^,C?_$BP)Z0ML=/W=\P56JX)))AAM:A"
MKQ_926D-->!+PHQ8:SUGN7E=BM.(Y(K?KV]9MHYR0MSMY8_%!RQQL]CG+16>
M<'L.-#5(EZ50]7?FD63!$<Y+'%P6GDCJ3U7+\S6@H'K^RLX4:0?[AZGUYKZ+
M]G-,I2;2^#B56F4HU9.-;>6<D5ISDJH@SYR2_P!F<F/`6>29TT_*(-*].KM]
M%QY/^H?U7RHXW6'N*]2;:9MRUL+J5:[->,L+C?<@YH<2BNMP0RUOU==$%UH)
M.`I()1&G-$77YF@:FE<E`\::H!Z+DN</R/N/3]PKW@1<LMK979UOS<2:QZRM
MA8S;#/:!KKK7:QA<<I+76VO#+K^SYT2I9K9^JMMJD<[CPXD"!J=CN-21DC"`
M(J5$(#V&"@TS.:.+JCW5\*8&^8]0#:/O"_W8=X!BFR0_-1/%KRY,X.*+@PVT
M,HO%-%<KB#3,<6DD^EI<89)M&!J$<2<S7$8B4/(,!!=*\H%/3!`:EP`_+AZ'
M_P!5ZO;>)V<QT:-ARZ]V$$JDMAAY$9D_+3.[>,=(2[LD?NV`QVLI#EMK6]UN
MJM8H27<=Y4.40).6"`0G447%$)N00Z3Z4P522XO`_E0>ZWS(`FF$:@L.FD/,
MD4<??\TE<\$FC[VQJ'!J=XXH,<?FA.Z-2F,3+H\MY.4T9M!)3P5J$51!%6E7
M]5-:5(_^-;N5MFWVOG3MMN[2/,@M1;;<PV^;Y77M';Z)GT32VQT3A!<AO`7'
MXDSHTZ-Y0`4JB5[@G2EU+Y"!F&4I0L5:"/7"JACOX5_D6E3DVZKJV%OCO)9P
M79QHMVZ6\M!,\),?5S#^\K7KK.ES94DG9+4OGK5`G%J9%C>S.8T`4!*H:4FB
M\38,\/.`01BD4S&F"I('")H=ZYBMS*O%9;EAO:U@_P#?CD?CLVMFVFQR`Z?X
MW3$RWLG>QI;^.C8;"W>3#:W),I8%A3O\T<C#0)M3TQ)G&E`=(BKOV4M=EAK0
M'\O?]%U^5.!&/./4@V3,3H+`U\PLN1N#SR3SM)<2E)^NN"_/-L'*2OLGNFL5
MM]&U[-?GIM344!.3E(A$DED4+H`/+40!0>R->YV=Q_E11BRM<<8L8,I-VV$Y
MAV%62APRDQXM1$]ODEJL@Y3QEDL*8[.KX$T62LNL88\Y-EO'Z(W0JWFU3IJM
M_P`M\G0R@Z<I03(-`352W,YK2T^AX_U47\^;.W/EUFMONQ-;+3>[>4V#N`$>
MN?N&J6*0/,?7+,6BE$)6J<6I2\MQ1HY9+WI.A-4T;NM.4)"B##`ECZT7(/L/
M>BNP@%SJ_B7</UQ4NMU>X2B,#QNS+PJ9#U$,W(<)I3MN-"1D;Q,W\/N5QS8V
MY8^C7M02R1-;G"D#@]LM4E0T,2C;A$AZ"]#B/=4C%:M?ZM-5]$`\86B-X3K,
M,X*>F9FMLQ:=L<(RNI7J4J509:M9`$KN<,'[,I4ZGU5'C_&O6#%7C6NKTX46
M'-^><XU6`;$S=7=\:</<8-O^%8WW2FFYC:)VAF,#SC))H-.(U&2T4>EY[3(+
MGN5S4#8H9D<&'!>*TA<6(X(#Q]::75&`1HZ@T%/=9G1YG%Y([9XU4+]W&Z1<
MQN'N7VM61ZW5DIM$;G8_K6ZVL+Q/=Y]?/+J,1>D(<U.2DTR77HG`JW]KX.U!
M-*3"9RD`S"B$Z0\T=3S`#J[W5XA0-/J/U].5%E#M%8AONSFKOL3)@@[&\WO'
M;BQ<6Q[N&\1Y&J?(U(YKAX_IT*ZWDG<D8U#"XN[VH2EG+$!Q1HJ4``P?+3AJ
MU.)Q6(NHQG]OOU6-/%^>8X2Z7?Y?"UEH+.O\2OWC)>%YMSEBY'V7D4*60>=F
M0-[+>X5/YLNCC<DD\DE$P9UKX0756L&F2EB&9U(C*%U@4X8K(X.&<D_B?1?:
MKJZXB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB*#.Y'`)G<'#:Z5+<L:J53VVKQ:W(")Q!"7
M4U=,G3'>ZL-O.=$$!(>E0Y25IA2E&D*Z:FJC2P4Z:Z@^BO&0'BOIZ=5*RV%U
M8'?2W,'O/:Y_1RFW5T8TV36'/Z`VAI"]E?"**B0&\*\R=Q;S1#2K$XZ!-2JR
M323`A,`(-)52"#0^H4$=QQN1DMN)"]*WI"E[EGOC'5T7)D1!:YP`W+GXA#^\
M5915%"PMO(&(!/6B%0D`JT#PI6M*[[L61YDU-CG$L;HUW0$\!4-K0>@J?6GK
M[KVW]++RYEOO(EI/-(ZT@\1[G[4;GN+(S(R!S^VPG*PR.`+\@!>0"ZI"BMN*
M9@VKDE_FW"^Y]Q'JV>/\9HTRO)*11Z/R602.X"RM&Z2L%E&`$=;UQ[0TJTRA
M*I=5HJ!"(8N3C42>A1_?;*VQJ,&BNW380-N-7D#FVS7.:UL8XL=,[,0'&H<&
MMP_]]6_?_IC]<-_:)XAG^S>Q=&M==\OWQFM-MV]Q<6UO;:>S_);7&M7!N)&-
MFE8YLL5K"*D`9J`3%\7/W"<AL<YK;5VLU)&.Y$/E$;MM;>]6&"YK:W<R+7AD
M\E:6O^!&UCBR%J<D;BFBPSDZ):UOQ-`ETJ=RET,+#S8]G:+KEK?MU.!\,D+Y
MY8;T%S<\+6%V<EY<TU=0N:Z,FOXU-#PXGTZ\-^9]L;VM_)>BW6B:EH-[K>I:
M+O..66$76CVMM++\^2>Z?+&^-UT!)-!=6#R7?X\SRQ[J1TSTM]FH;!;M7WNW
M;FV3K&9):;&:WQ#^;+:II;:U.FD=N9/-&:,P1$;0E*MFEZ#!`=S3`"&6C)"$
MOE*!2FN^V=>[7%_;:1IDTS9H[F[DRY?QEJR5L;G/+>(9#_``BIXFI7V?ZE;Q
M^L,>ZMO>)O'FM:[;ZY9;AW-J#K<6F:TU1SK;4;6RFNK]XS.99:*`;1C2&NF>
MYS\TCR5]$,#53)="(BLN(T,L?GJJ.M1\Q8XXX&.K`T2(Q*75R0,SF<,PU>W)
MS^(2C1"%48>GC7\=?$[QMLRZD;9.<^T#SD<X4<6UX$CA0_L/T7XT[MM]M6NZ
M=1MMF7-U>;2CO)6V<]S&(KB:W#SVI)H@`(Y'-XN8``#[+%SN#&X0$78BO^,J
MWDU4?-V&GZ6VUS3%LC-MP%W3K'!2.$-[3%5-5X;I45'T5HE"@JB6@#B`CJ+\
ME0;_`+,&ZCI[_P#MF>$`7D9EBHWN4.7\R7BG:-`*#\N#J4XU]Y_3R/[2R^/;
M_P#_`#3K.EL[>[=/=J6F!EL-2,+F1M%])+=-[9TK*TQ31QO,M62EH'Y9L<JZ
M`Q*-5PIN+N')IF3:Z3X23:WIKBK_`(V*/03F,RJ7R:U;#+!QKD>BGC^!WMK4
M-Z=7T5<"2!FAX$&5!N\=]=3?[.QV48OGQZI')3_'Q8]D;)7-S_B1W&R!Q;_Q
M+@/Y"OM*TW=N'6QY0V9]-WZ8[?MAY2LM0$;/A%LEC<VMI;:K<6@N:PF'YT%U
M'<21<1;OE;&?\S`Z8]*W/GV%^VGCU=T3L8^Y#7?A#5<<J0T5C>W2SEMW)[N`
MB:I!556BL2EWBK:R4,Z^M3!E@IS\1<VM8)TZRW3KFLZ;_P!*SMGF(MH`V>1H
M82*<.#^X#3A4FB\UTV+M'[-^</,?CH6PTK9NW+Z733;Y!!%K.I1P:>^6WR_A
MEANI;[+V_P`0XG+047+W+Z6D=LC[7L^5SI(H'C>EQQNZO@<PAR!>D7+[Z+EH
MDAT062%C:7%T"DI%$B<Q,TCJ6@5'C!0ZE0&#U78@U!FASR;>#)=<-]")&/<*
M"``4>`7-%<Y(+OY4K3B`N/\`1T^0]/\`"NO:E]?H++5O-<F]=(CO[.\DC?''
MH4;,XO&6\\L<6?Y;Y&RW8#IXHVN,9#F-60?!%PG[IAUCLLN>U!9)C6V[8F5-
MP6DAB&6RH%:Y!$#SV9*G2)FU2NAZ9`>86`HJE1&5%RAJ*M-:9NYEFS<UZVP<
M7VW>)K6OY$`O%:FM'EP]3Z4]EXZ^V-GM"P^R>\[;8EP;K;0UN5S).ZZ<&:1C
M)+QK9GN>Z5K+QT[&N+W&C<N8@`J/.X<ZVS@\JQGN=,+K7.QRF$<D=P6:%Y%0
M>#M5P(O#4+U&4]91$)^PN8S^MI-$!%`,XBTBJH%91@Q!H`(Q![O9;+ZZMKZQ
MM[>WO;5[(R^VDD,;GD..1\;AZ9#Q?5S:C**U(!^R_3:PWSNG0-\[$VWM_0MZ
M[;O;+3YKW;M]?2Z?=7DD%R[XMYI\\0;3X4CBZ\#IH@Z%S&@EQ:#C?L0T5QCC
M^W1E'=P4JCMGT%\<LWB1R62M+DN>H[&KTQ]$U6RDDN0M*%0K+.EQ4;&JH8`B
M@3`G4$$/`8:5W?5IO]Z_7-O:=VWZD^UM`UK"`USH7N?*UI<0/PSAI!/`\/9>
MUO+&I#SIK'FCP-XZ%A>^2)MJ[3AMK:VEC9#<7.BW#Y=3MK1\LC6$6AN6Q92\
MEI8035KJ2YQZB2A+M7Y"S-[CYB)7<"-YD73A='IJ`6^-L3GK,_)6M6C^9)JM
M;0R-J:PG?V50?,I305KS`%3CK>K7`_\`Z%96D3ZMAFLXGY3^)<QX<0:<#E+J
M<?1P/N%YU\Q[BAN/OULW;.EWC9;?1[W9NE7O9E)@DN[":W=*Q^5V23XTLI9^
M5>W*UX%'-*Z.\692S%?;WPSB,2?"XK<V^%E;:QEFF:MN<G1';")H(?&4\PN2
M<U-:1:O<G1C*>"0-R<LHPRJD8C:`'4BA8^1INUAN'>NJW,[.Y8VEW*XL!`[K
MR]Y9'4D`-=E.8U`I1M0'5';>-OK3;>??N+Y,W%N*U-_L;:NY]2N9K)DD<3]4
MNY+RY=9Z:V65[(XXIS"]US(Y[6B,",N:)2]L[<`E>/X\98DT8V21\F=O8RZO
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M',X'DE4)&=2@!E@^EW]_INF:I!?;C>Z'<3M,R/,/Y]F0C*UX`+FMD#,U`/QX
MDT-:G]+M][X\9^-_*.B;Z^QU[=Z+]B+KQDZUO9-)A;?'2-4G>ZU@NH[6.26V
MM+V/3G3!D<=+>-[S*V,ES7NZJT[JU&XIWU'FG8Y2^6!0Y]/CO(#+12ES&;$Y
MVXR5S(N"ZS=O0JR'!19Z!JS$2=.-'UBE?1=PI2@RP#IR-1CD&OV?_:]V&:P=
M':&]YH_.,!IC#"103/\`R)S4#0VIX$A=AY"T^_C^P&U&?6/=4=IY>E\100VX
MU>UB`N[".VB=I\5E(]CHVZQ?L$TD@FRQVY@XDM>YIG9MG)HP6[Y?*K(%N)&(
MZV]C0+'D"@N0%,AQQ,9$7<Q7"P2>E';^%37ZJ8)0A?EK4%*?M`F4IJ&^C.8M
M-;JN4[C%J?D4R5IF':#LGXYLN:O.I]"%Y/\`O)/KK].\<6_E-T+_`+$Q;7F&
MX2TVYG`=<UTQEZ;;_%\H0=TO`XBI/\',5U;GKJ3,+(P_$2/F%K[LYJ76MS:2
M%1XBM#7!)!H[.XQ<.^%SUB<',:DBELK:1=8H5K1T"2!:I2$4%UIY8:_/3Z47
M@F/@<WL`LE2@8##SAE\>K$:8(OF_K<E15J#F_P!;E_'^74K&MK1$T1-$31$T
M1:@_@/\`V:?[X=$4$EFZ-MN)E:M,?G1B^0>G5*"%!`[JQX!A2@DX91Q1H>NX
MT-+,!4(J5Z:5IJ,P5^W)@5Q_--VUZ]-<[,7*UX<.-;K1SCPI^'3UO'H_1^K2
MH3MR8%/--VU_OLQ<_P!-UHY7C_/Q-Z?].E0G;DP*K3=.VV`UH(.=V+H1!K2H
M1!NQ'J"I6E>-*T%0[FI6E=*A.W)@5I+W3-M4H`"R<Z\6B2RJBJ4`FZD;)`54
M0ZFCJ6`LP(2ZC-%45>'#B*M:UZ=*A.V_`J@=TO;4`"A9>=.+)9=###:%EW3C
M18*&G"J,XV@`&!#0TX=:U&+AS#K7C6M=*A.W)@5J\TW;7^^W%W_1=>/4I_10
M[AI4)VY,"GFF[:_WV8N4X_JNM':</YN!O1Q_3P_'2H3MR8%:3-TK;3.+&2=G
M1BP<0;R]:0==.-&D&<@J#!UA)A@BA\@Z4%3C3H%3C3ITJ$[;\"JG;IFVJH`8
M4HSKQ:4%'<M#BE%U(V>2=0`J"!0THXT99E`"#2M.-*\*TIPTJ$[;\"AFZ7MJ
MG<.OSJQ:/X&%FAH?=2-G4":5^Q-!0PT5`&D_^`5.`@_HK32H3MR8%5\TW;7^
M^S%SZK1S^G]K^/\`+^.E0G;DP*CME5E_M>Y6V2DEF'G<NM9:<;NO8'YAN99K
M(%IAMQH3*(NYE.S&^,3PD4!">66>6(I4C44$F6)33"ATIQ"((D'W5FMD::Y:
M_LO$,0[O[:&,5P[P7QGV[I;[*W(2]K%!X9+[QWCN?;-H<TEOK<46BB,(CT<A
M:1O9&MK1JEXSSS:]8:I.H$5>7@+G@4'NK/$C@`&D-"GQYINVO]]F+G\_]Z\=
MX_T]=QX:FH6/MR8%/--VU_OMQ=^J\=K_`$<3NC2H3MR8%4KNF;:HJDB%G7BT
M,28VIZ80[JQP8DQ]0\E3TXA&U$0=4'1S@X"X=''2H3MR8%5ING;:X?ZN=N+H
M:UKS5K2Z\=I6HN'"E15H=Q%6E/UZ5"=N3`J!]X[P;7M^<M;&9,7*W6[9O,'Q
MV<FR;VSQ8+NM;U-95#>9H0NS<@O"Y&@)K(W*0D)W,(PI1F?+@/3%C"((1'%F
M1PK6JN!(&EH::GW4\/--VU_OMQ=^K$>^-J:A4[<F!5/-+VU>NJI_QU8L_,B(
MHE$J_O4C?S0DM*\:):J>LZ^J:E?_`"^;D_DTJ$[;\"JTW3-M:@ZF?XZ\6NMJ
M31,(W^]2-]:)-0=3:)A&];U@D]#:\W5UKR<W3PXZ5"=M^!5/-,VUN%*4SLQ<
MIP_5=:.T_P"PZGX:5"=N3`JM-TW;6IUE:9UXM!J:94XVH;J1L-33Q!"`1YM:
M&TJ8>(``AJ,7$5:4I3CPI32H3MR8%4\TS;7^^W%WZL1[XVE0G;DP*>:9MK_?
M;B[]6(]\;2H3MR8%/-,VU_OMQ=^K$>^-I4)VY,"GFF;:_P!]N+OU8CWQM*A.
MW)@4\TS;7^^W%WZL1[XVE0G;DP*>:9MK_?;B[]6(]\;2H3MR8%/-,VU_OMQ=
M^K$>^-I4)VY,"GFF;:_WVXN_5B/?&TJ$[<F!3S3-M?[[<7?JQ'OC:5"=N3`I
MYIFVO]]N+OU8CWQM*A.W)@4\TS;7^^W%WZL1[XVE0G;DP*>:9MK_`'VXN_5B
M/?&TJ$[<F!3S3-M?[[<7?JQ'OC:5"=N3`IYIFVO]]N+OU8CWQM*A.W)@4\TS
M;7^^W%WZL1[XVE0G;DP*>:9MK_?;B[]6(]\;2H3MR8%/-,VU_OMQ=^K$>^-I
M4)VY,"GFF;:_WVXN_5B/?&TJ$[<F!3S3-M?[[<7?JQ'OC:5"=N3`IYIFVO\`
M?;B[]6(]\;2H3MR8%/-,VU_OMQ=^K$>^-I4)VY,"GFF;:_WVXN_5B/?&TJ$[
M<F!3S3-M?[[<7?JQ'OC:5"=N3`IYIFVO]]N+OU8CWQM*A.W)@4\TS;7^^W%W
MZL1[XVE0G;DP*>:9MK_?;B[]6(]\;2H3MR8%/-,VU_OMQ=^K$>^-I4)VY,"G
MFF;:_P!]N+OU8CWQM*A.W)@4\TS;7^^W%WZL1[XVE0G;DP*>:9MK_?;B[]6(
M]\;2H3MR8%/-,VU_OMQ=^K$>^-I4)VY,"GFF;:_WVXN_5B/?&TJ$[<F!3S3-
MM?[[<7?JQ'OC:5"=N3`IYIFVO]]N+OU8CWQM*A.W)@4\TS;7^^W%WZL1[XVE
M0G;DP*>:9MK_`'VXN_5B/?&TJ$[<F!6H.Z=ML@$$8,[\7PC`*@@B#=F/T$$0
M:\0B#6AW&E:5IT:5"=M^!6/!YOC@G;":2VX6#&[CC'C&9<&0.$PN%8F8.<.O
M/BO+)J[FU4/DV9K;'22'R>T4MD:JM3G11%7I"A<5`JG'(A'"$8*.'L5DH\BC
MVD\_=:3MQ>9FUI0>[/LGJ`%F4,)JIMW=\0@F`K_9GA`+(0T))X?QI4-:U#^B
MNI#B/0T5F%\=>WW6DBAH:5!]0:4J#[@\#@N,9N&2DX8C3]UG9!/-'7B,T^V5
MV#C1UX4IQ&89?T0QUX4X=-:]&K"60"@>0/U/]5F9<WD3!'%)=,C'H&R.`'Z`
M$`?LM9FXA+CAHS3MU[9%.-;AU-;C3K;W;-,;C*AH"IC>89?X0T)E0!I3F*J"
MO"E*?HU`>\`@.H'>O$\?UX\?W5637,;9&1ON&LF%)`'N`D'K20`@/%>-'U%>
M*W3-QB;'`J6?NS;)QY8JTJ(L^WUX#BQ5#6@@U$6;D",`JA%3C3C3HK3CJ`X@
MU!H5C9GB<'Q=UCQZ%IRD?H10K7YCD[]6O93[!7D__0>HKS"ID']K_P#P_HN.
MJW$9>N+`2NW7]D9>24<6I**76WNVM**4E<:E*2BU-_S0%J"JU_*,-*##^BNK
M->]AJQU#2G`D<,.'LLT$MQ:O,EHZXBD<TM)C>6$M/JTEI!+3[M/`^X55>XE,
M'`NI+ANP;)#@14TL^I"^W-W5I'7E"J,H_J55_P`TOKRA5XA'PY@UZ:5IHU[F
M&K'932G`D?\`DEO)/9O[MFZ>&7*6YHWECLIX%M6T.4C@16A'J%NCW&9N:,!A
MN[/LG&FE"J,HPVWUX3#"ABIRB&28/($0RAB#T5J&M*UIT:@.(%`0`L;,T;2R
M,2M8X4(!H"!Z`@<"![`U6RKW$)<O*"G<-U[9&<$X#2U`$Z^V]VUQ`%!5:U*4
M`)57_-+">56OY1TIS!_16FI;(]AJQV4TIP)'#]BLMO-<VDAFLWW$,Q:6ET;W
M,<6GU:2T@EI]Q6A]PN37<>G@JUJ+=LV4ZUKTUK6!WDK6M?Y:_P"(/5:\PL`C
M:!0,?3]OZ+C*MQ&7KR!)%^Z_LCN"08@#&D7VXNXM2C&4+G*&-,JO^:2(90Z<
M0UJ'B&O33IU9KWL=F8[*[$$@]0L]O-<6DPN+-UQ#<`$!\;RQP!%"`YM'`$<"
M*\1P*U*=Q.8K4YJ1=NP[)*Y(<$(#DBVW-W5:0X`*A$`!J51D`80:``@4J&@@
MUI2M*</PIHU[F',QU'#W%0>JK`^:UF;<6IGBN&FK7L<6/!/J0YM'`FIJ0>-2
MMP6XS-Q`ZH6[1LGB*J"A5216_O#4FI5`T!0JI5<@JEU*H"G+R\.7EZ.'#49C
M6M154`<U_<:)!)6M:\:UK6OK6O&M:UX^JXYFX=+#@EA.W7-D,X)(>0D)UM;M
M&A)+Z/[,D)E_A!)+Z*?E#PIT:D2/'HZE>9_JLS)[J(N=$^Y:YQJXMD<"XXN(
M(J>9J5ND[BLS3@ZM-NR;):8OC475IK>7?3E\U>'$75DY`@!S5X=->'&NH+W.
M-7.J>=2L<CI9G9YS,]]/5SBXTPJ:FBU&;C$V.+-).W9]DX\@\L9)Y!]OKPG$
M'DF4Y3"3B3<@A%G%&!Z!!%2H:T_&F@<0:@@$*K,T;VRQ"5LK7`M<TT<TCT+2
M*$$>Q!!'LJ$[BTT3$DIDN[+LF)4R<L)2=,EMY=],F3E!XU"4G3D9`EDD%!K7
MH"$-*4_5H7.<2YQJX^I-23^ZM*9)Y73S]Z2=YJYSG%SG$^I<YU2X\R25I\Q2
M9=4<1YL6R3\NHH;12G_NZN[\NIH?3@?101_B`ZH^A].@?/2O/^GCIG=4'-Q'
MIZ\/T4YYNXV6L_>93*[,<S<O\<KO5N7_`(T(I[452=PF5G)0M/G`[,\.04*H
MF)<HC:*X#LX,Y%:UXC:&*09$)(X(XKFJ(L!X1$<W]8%:<::%SG$N<ZKCZD\3
MU*B5TL\KI[CNR7#S5SGN+G..+G&KG'F22O5L>\C=K2R\SDUZIWN967R-R;G+
M&3%Y9D%=:ZT%3OB*&D*Z.)-M[60J-$M\+L[;`IQ#10)H9DX1K%`0G+E"LT(1
MA`C'BL;FR$4#2&X*7GFF;:_WVXN_5B/?&TJ%3MR8%/-,VU_OMQ=^K$>^-I4)
MVY,"GFF;:_WVXN_5B/?&TJ$[<F!3S3-M?[[<7?JQ'OC:5"=N3`IYIFVO]]N+
MOU8CWQM*A.W)@4\TS;7^^W%WZL1[XVE0G;DP*W"]TG;9&$ZH<Z\7Q4**H:96
MEUX]6@"^O)*YQ?VW0'K30AX_K%32H3MR8%?F=2[_`)ME?_3G_P`S2#]I^T_X
MNL_:?Z_Z_P"76(+G]5;WAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3
MJGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3
MJGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3
MJGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3
MJGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3
MJGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3
MJGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3
MJGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3
MJGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3JGAPT3
=JNQ0_L'C_IR_X2'\/P_XVR_UO]7_`+^&BGJO_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g285899img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g285899img5.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/P+&`P$1``(1`0,1`?_$`-,``0`"`@,!`0$!````
M```````("08'`@0%`PH!"P$!```'`0$```````````````$"`P0%!@<("1``
M`00"`@`!!P<)!04$"P``!0(#!`8!!P`($1(3%+5X"3DA%1:V-[<*02*S=+1V
M=SAY,5$R(Q="LB0V.E(E&%BA8M+35)0FEM:7&1$``0,#`@,"!@X&"`4#!0``
M`@$#!``1!1(&(1,'(@@QLK,4=39!4;$R<S1TM!5V-W<X.6%Q(\.U"8%"4G(D
MA#46D<$SQ!>A@D-BDF,E)O_:``P#`0`"$0,1`#\`_?QQ2G%*<4IQ2J-??(?:
M1[L?VVJ)Z\J7.G=.OBF9]&N>(Y7TA[@7JCUB^[J;Y&57+H]\6_WIOZKI[U-%
MY#<WJ%A/UN^ZM2]X[\#'1;^_E/*E5)VU_C]0/;1U!^VTGG3<?]DY>CW?$.OH
MELC\L!W[OLIXDNN!/X_;?MM"/6T+D&_LH7T>ODUJ:'^5^OW=N^2.I*;;^S/\
M0[_&_1/WRG>8.!\<VI\E?^;!7(MC>M_=5^KF9_A+%2$!_P`_WN0?87#?<Q=N
M8Q[U6W-Z3/R[5<LR7X7^\;]Y+O\`%H=1`_$@_P`TVC?9^:^\6[<V#H[_`*!+
M^4EY-NN\?RD_L6W)]:%^80ZTQ[\/[1^FOL.:E]<V[F3Z:?$<IZ2?\4*Z#_+C
M]4NH'WCY/R46K7R/Q<.J?],YWZK[-YH2>H<[TR7CL5XBB?@7WM]\"?.<?56B
MO@E=?_ZAN/4MRYO"?:5,]%_O0KV@GYBFZ/NK_?1:MS_$9_R::J]I&L_=OM#F
MA=&_621\C+RK5>%OY37X@,W]49'S_'53#N[X'73#VJMJ_I=L\Z1B_M1R7R%O
M]U7T%Z<_F/\`4+ZDXWW,94B0_P`./W./MZY^^*\<PLCUQW#Z*3R(5RG(?BSZ
M^_=DG\*AUN@U]I?XA_\`AE"]57'F):^)[3^&_P"05SO'^I_=4],'Y2+4RX?_
M`$^JO8^G?IY'-<7[54^7)XJ5Y_D?FDI]?0\4:I9]WG\-;WN7[A:=_3[`YT[>
M?KE@?A7_`!6Z^AG>K_%WT+]*97Q8-=+HU\*[WL'ZEH3ZR%.-V^O.$_S'DQJX
M[R/XU.B'PF:^;M59CISX@GN9OZ;0?[J-G<TO)^JVX_3!^68KQ_O_`/"YW@OO
M<=_B6.J27N)/LM[A>VALGZOU/F$ZH?'<?Z/'QSKD7\RSUSV%]WT#R\FJ5O<U
M?%;>_4^P?[&8YTOJ-ZB)^MKQQKZ&]_\`_!(/PF$\=JN/N-_B/F?X9[K_`&D=
MR;JAZG!\,W[M1_F/_A*C^F,3[AUQ@_"QZM_U1IGU:(\IKZ[S_0W[Y*C)_&EO
M3[F0^<!5V_7KX[7>GV:-;^K-#\YME_LNQ?RP_&DU\ZNJGY:?3;ZX3_*9JJ2^
M_/QR$>T%U4]3ZBYT_:GV7+\DD^,[7T4[L/Y;R_5;<GE<I7R[G?';;]J/JUZO
MT]R;;7V5_P"1E>Z]4_=^_+27ZE[C\?*5-C=/VW^__P#X$ZQ^K`;FI8__`$O:
MWRASW2KSKT\^SGNO?67(?.':Z0;_`)[_``[O[D$_]RD<G<^*;M^%3Q7*NLAZ
ML]ZSTBW_`-Y6/_B5?M'ZI_N1M'U[4.7/1CXED/[[?BE64_E#>J>]O2..\C*K
M]4^NOL^HG[FUCU)!YPF;\<=^%+QEKXI;M]:LGZ0D>6.LRY;5K]5K;BK['9?N
MRGK'LHA8/]!]==:A&Z3&O`EA-52'MB[WG9!^EC%7.?79PPP;I]$%5!UQL8F0
MW%?(D$N24NX9:1S=,<ZN%VS].0D'Z5>FJRCA")<H`;$UT(2*B&:GQ*UT$;):
MZK7KS8.4<Z0=W9>L>T&HO_DS+;O=Q+4YYAF26-APX#$MSS0'P<:9E3')0B4A
M0)P&&"!E04S*I$:#ZZ5WKG9KX#UU?+"G5=C@UHK5]%&RTRQC-4E(F2L.P%Z2
M9/%BEG@UFZ+\PI8MQ2H,2;$=<C91YYQO&'RV8>S#+3LQH//@4D)\405=1;**
M&@H@J0<>TG:5%1"O9%KE/4_JQENK.'QF2W9C(J[UB.2&Y&99:%AS)-ERS8:E
MM,M-QSD1$UHD@41YQIT!>U<L#7I=T`6U3V@=@M:OVCG4GS=3;P;N%F%U]HS=
M)5;$4P[.R#HY";-:&5(T6(LLMN%G8TUZ)%\YF,VW)RT^S-MMR`WEF?/F/.-3
M@"`J5@0B,4U&B(JFB)=4&Z(JVU*HW1;CN^9+9.,ZH8H]YX7Z=YN0ALQ8[CZM
M1!D.RV0YTP`!7)+33:F0QA<9%US1SC)E#:/4U.ULSNGHKU-'V_:)_7U!@Z=T
M+>=PR!IN2!>OU$"ZF&D3U+LEZ07%&JM63,YQB46GQY;<EV)$<86XEI]U7,A*
MFKC=TY`X[`/2EDO@S=$+EFKJH)B%E$B1+H(JED545$NB5O&?W<YT][RF^)6!
MPL7*[G<S^:AXL7&1>2%,=R;C;,N/#5IUJ3(:!#;C,FV38NNBX(J;8)6H^K>N
M".SZ+VK!:2O6U-1]2]D&*8#ZOV:.8+3[0.&C@V8>Y[UJ&5>G2Y^OZYV"4\EB
MOON.^"5HDDQZ&6WXZLY#.36X4J`]DVF)&X&1,I(V1!556[(.HW82<;3BXEN/
M9`[V6MZZS[MB;-W+LG)=1<;A<[URQ#$M[<4<FF@CN...ZL3#R@PT:8?GP6[G
M-`1XHK,.43A-NHGAZ#M5)ZU]E^R%:G0;SUKT%3.OT'9<+7.WK0:M[-U<I%NL
M,79'8NC%)%EOT(.`;$SQ(XB/24P7G27HTF5`9=4G+M3+,R<SA8;PJU,RKDM6
MU=:$0T(8"K<<T0055NAD)*.D40D0E2LEU.PNXNKW1_:68C.8W=W4_(;I/'G/
MQ<=F*L1)D5@H&"F-C'A&Z^KH27V'UC^:LM@\RS*<!%0.AUFV[;-D=^,WR^WV
M!"C;<ZEF3U!TLS:0TJ'K"M1-Q`6:9724$:3E,3=M'ZRETU8O'RWH<B4J`UG,
M>"E:ZN<QT>%M/S6(T2K'R`BX]I5.:7))3)%5$5&A*P-^PJ"AKQ*U776'8F$V
MEW8O]L[9QCKCV"WRTS-RRQG1+(R"Q3ZRWVS<;%0QC$C3$@^`'0;22:([)41U
M5709_5NR7>Q/;+KGND:(LW;0\N#N!OM%:<#M<P;?N>16="Y,]>JU=8U;QK%A
ME\)!DNN^DOJ<E*<?@.1E>5F]>>9G0DP^WYD97`@#=GS4;N*#-W[2"!2YBV,D
M1+(B)P)"1;;KE<EB]Z;1'I3T/W9MYV?#V,RAXM=NQN9/.+B1D9KE9R1$)_Z0
M)1EO-B/+!!;06Y(NI9,0V=;RNT+EW(W+>M9]C+0%ZX[PMU$%[JU)M@92%=6J
M'J8!6)3UDU'KF>?B1=G6YEYV=9;7Z7"=;DCY3,'&9"&LQ4W$..W!C8[&Q'XC
M;LR*!JRZTI^=..D79=<05Y8>];:LO`A4N"K=<]L[!0=F[?V!T_VWF-IPLANW
M;D68YB<GC')G^XYN3?D"C&3G@P18^*J(S`QO*=$FWVW)*HT1\Y98]\M8:HM=
M,IUYK;%PMW8#L05U_I?1109N3<]-JCYZVCI,V)L,O4:#>JW7U`*%2H9&RS_(
MA(]*:'X8<SXNISC`[4G3X\EV,\K;>*ABX\^BLLF6D%MRT)P"+49J+8]KAJNG
M@KA_=FWEO?";AG[;RY0(/2[:C$[+9EMS%8F7)1F,X(%!:E38<A_G399,8]F[
MR\LGE<!.PM\/[+:ZA:[(=(^L$.#N#LQ0P-4V@[?]#UN\%(>U-H10`2MQ0NZ[
MS;B-GJ`:96*;;B+R),`H>&19!,]$]$;D*AHCHKX26LL,GFB6/"E$XURWR!%:
M:NI79`4$RU&")8A`E00+4J:KKG^D&ZY&ZXO4;K(^Y@=G[FE3L<D+,R(;9XW'
M$\]()[$0XH1Y3HR)<5L%;>CPI#@1X3_/)I'R=+4D*WVPST\Z_P`79-IVG(T?
M7^U^PZ1VT$!"%]+;8U!J$*1V7]!M)[<L0B,QL,@+H)]RL!;<4B>+DD<E+B)+
M\%W,EV_*.PUN&64-ME,H<!LXJD@(TZZ2-ZWFA55;13'F&T*\$*]T0DLF]2,#
M@\?U[W2]M&%A0ZC2MD09FV77@A-8S*91X,?YYE\8PZ2P6W)K*9"7C(SO9;?5
M0)EN2",AXJ-Z30="[DZCZ\W+85>TO$VKTEHVCK48?MC1VB5+M/<`NO=H3-:F
MKTE=NC5",Y"(2*[)?RI$.;*<>@J]%Q%SRO\`18.RL;D<NVR>25B:;XIHTN'&
M!7&D<0.PI\11Q$\*(B%VM59`NFT;);GZ?[ZZJX_%2^H1X3=TS,1FDC*S,E;<
MBO3L<$]J':*4HD-@)S8(BNM-@W)3G*\E3GU#3A'7'NX]H'5SQ\=IW8W5TIM^
M31BUIL]P@5W9%#VG7J=+M`:7;C!PH*<NP&\-H)-H?PS+DC&G\I\]EU:]7R$A
MS,[8^EYR`619G(SK01!2;-HC050$%%T$'9X71"5/!:O-N_,_/ZM=W0>J&\QB
MN[^Q.\V\6,QJ-'BF_`FXU^4$=T8K3+;B0WH9+')0UM-R#;1>6@"-C_-,KR33
MBE.*4XI3BE.*4XI4%O>/$B(GJF>FBB$X9-3MGK0PF8.ER(,I+,OLGJ>)+93(
MBN-/8:E1'UM.)PKR7&UJ2K&4YSC.U;,`',^`N(A#YO)X*ETX1G53@OM+Q3]-
M>E.Z3$B3NML6/-:;>CK@]P+I<$3&XX#)D*Z214N)(A"MKB2(J65$6OY[S*9.
M@=$.RLH<1(B)J:&TTR2$3'H!.%Z38@<9Q^#,CK;>CR$M/*\E6,X^7^WY/'')
M=EM@[NF&VXB$"NK=%\'O2IW/H\:5WE]H,RVFGXZY-55MT4-L]+#Q(A@2*A#=
M$NBI_P"M0DV-N'90+4L#JYN*RSW=_:$[1],(J;JR^\)?WIH.S]D:$'HFWH>&
M76E2I)>`RZ$M<=I3S<8[%>PYGS<IE.=GA8Z$]D"SF.!$Q,J#,71P7DOC&,C:
M7VD1>VTJV505+)V;UZ+VEL+:.2WR[UGV##:'IAN?9F["6(HHZ.'S4?`379N+
M*Z*@BT:C+QID@$Y#<;4$U,N*EN&X=*:UWW5&:1M0%,L-9CF(9]J!!L]LJ;R2
ML"/,BQ)&2E-.5\LMMM@@[C+*G\LKRK&5(SE*<XY_CLG-Q,CSJ`:`^HJ-U$#X
M*J*O`Q)/83C:]>%MA=1-W],<V6XME26XF8..;"F<>-)3EF0$0\N4R^TBJH"N
MI`UI:R$B*J+7![M#K9I\?6S^YV05AD;(J/8/M)0J_82FQ]EFVX%2K6V[Y000
M?((Q;YU<F-C:E%;B-NOQ'7_!&',KR]_F<W+>F:R)O!C2,/,G(D8R%&VTN9-`
MX2ZD!"2Y\>"HGL6MPKUKWO\`J[OV5EXO3YR3%':,[:VW9K[#<#'LJ<F1C(<U
MYWG-10?%7)1$Z0@Z(<5!!1OLU;ISGU>%*<4JIHAU-WB?FM@B\(4NGCMBWTX'
M^=B8:T0<!-P[XKFT+MDU5B4Q$$Y`$1ZQA4:`^K*'&)KL?&$_*GG0!W!BV@5U
MM2\Y)EL5LBBNIE@F@L2)<552XDGLBBU[BB]<>F^+CKDH#CZ9]W$PF7>4V['/
MG8O#/XZ'RI+8*;)NE(5''@1%$V0=55X+6VBNCMZLZ8U+KZJ1ZT-/ZKM5QV-+
MD29B8E?-VFG6DB5UN!JHH(2@-UNH6Z295*A0)/GH@`=%:@R4O*;2I>/;RF*7
M)2);ZFK+[8-IPN0@8(CA$JHNHP1+$265PE4AM?AH\+J1TU/J#G=TYLY;V+S<
M*+`$1!2?9C2HS;<]Z2X\V:R)446D;>>;T.S7W#DLJVA*@_7;>GMK6#<MFN-"
MHK+1*XTQNDNW>S%*N^-K@`_5,UPC($$Q)X-L09*KY(@Y)E5M48H`(X8^<8LF
M*35A/(8_(P&<:$:6ZNAMS7H%"N1">I+HHJVJ$B61RXN#?00D%4]B[^V3BNG\
M/;^YLD11,?D%EI#CMR$<??9D\]L76W678+@OM@+;<]'(TUC7YH\R]#15K42N
MLO8[$@B'5"@*!O"M-T^;,@6]J(T7"];+T2LFL"XZ),)S2,)9X:3;:(IDNYDK
MS$\'E.^*<JR*9S#:4<NO.0GC1%"]BD@@NHJHB(NE451MPX\+5O@]8>DBM-3T
M<=3)"_E90`<525IW/PVX^1:<(&P;-&7&R)A6QY:([=M`LJ)FNLNM&P='B:XP
M'KV;-+MNGKG3[<,HL>FT6K42YG`.K!HTHZ&GV]OYSD3WZS/69,PG9DN:^TTY
MB.G'DXS:S<W#RCAJX>@6Y(&"GK,C`2=54N@<+:AT`J(B(J\:US>/5_:W4>?+
M<GRDAL0<_%E17)A2IDF9$9>R3CC:.A%7EB`R&4BQ71:;:`C'FJMU3-=8:I+Z
MYZ[5ND2-?9J/D;%U8O8(1BI:W!8.!$%J/!M4Y8_59RRB3(]S$/*9LN4MN;)A
M,O8>;\WA.56LV>W,S!R1>YG[%WEEK<+25C4$NZ(J*\>RB=E"5++>M>WEO>#N
MSJO+W&UE?/KXG))!>*5/>Y+RM3#C`AY)F.ZT::T5IIM%9;>(.6>M5MB$;J5;
M:E\XL:H#U_5XR>SO-1T751E0:C7%%CWQ"L>O1!#+Z<+&H;UM`;;:DL>0]!90
MF-Y2,H0C%RNX(\C24\C?<16-*DIW#2PHN*GM_M%XHO`EX_IK//=<\%G>4[O>
M1*S4QHL/R7)+DI2BJQAC8G.A9;.*L\R(FSN+Q*KMB0B*O<TYI?9M"VX'N!*@
M>==C4LD*/6*89J9',B*T!B("@ZM8H1H?<8:Y1R&A$H"4@D:ZRK"RD69'F.N,
M*I9+)09>/*.#WA<11%!-..I=1$*BH+85X."0N+[PA441:QV_^H6SMS[%D8&'
ME-('D6W&6`:DMZ25XE=>DL&R<4D%DE5N;'>8G$FF&]'=8`7$U&2ZF]@K!`3!
MM;%),2!D;8VS(!##(\LI5\VI)UT9M],KDJT%ITRB7!JP5TW*$6J(VN(+?*-9
M:8PTVMKF0#/XAH]3"NB*JVVJ<4_9M<Q`,D%$0PTD"&TJW)!6ZW5%K>8G7#I;
MBY/G.$+(QVGC@8\PN;7^"QHSVHLM\8[0#,BJP_$;E8UTD=DA&-#<4R$Z]$;U
MHW"Y3+I4:Q3AFO[5<]FE;W8+\>%:^@MD&JY;+[?M=X?L&M;E*OEX(8NDP#+6
MZ91'\PW'>0M+B'7&\R'F\=YRU(?<)YAIA`%L5<6VH&VW.RX"-@FA'$L%[JJ*
MEK(M6DSK!L(=P8_/9C(/93"X_#MPV(3+DXU!7XT*%.LQD(@PH8>:!,;08I'K
M)QLA4"`338G833FU-FDV;0WKC)J9)JNLI,2NY.TTH'#7X,*VMB?&L`:P&`31
M`,'(6^*U@T(*0#@IW*)HQ;RVW48L\1DH$)OD*]I%''+EI-%)M2:LHD*%950%
M708D!)<31+HM:ITKW_LK9T,L*>6\W8"=D!)_DRVW783KF-T$PZPT\H.NA%<+
MS25'>AR10H\P6Q("K^=H=&;,V+<Y)NH41HX4G:=,TE)V:7JKX4=\YU?88XG`
M#S2Y:N76K'),ZQ1VO-MI*`+$R\VDFU%S#1(2P64@PXR-R7=`))0[(A:EL3:H
MJHB$!#857^JXVJ+H4M5JCT9ZD[/VGM\,=GLF4:$UGVI?)!J2CSG+D07&S=!I
MI^))9$&#+4JQYL$Q)89OI()I<FUSUCK$&Y:/N4C2U7K\C7</9K<B80I.JJH9
M#D29&ND*A,'AM;F;$`9RV_\`.*V78TE3K2UK<<PVMW/E4)F<?.-*C)),T>5J
MR(;I(J(A(:*KB"7]FZ*EEX(E[5A]V=8LS)P&X\`UN&9*:RSF/40"7DI+3K;;
M;X2@-V>TP\MQY"$+C:"2((@I"WPPO8'7_:FS)0RDS:<(BU>L[)V`;F6*[8K%
MWIUN`W[=T;9HQZ/1466&2*1JZ"A88F1B7S>MN:IOT7$EM&5\N8F6@0A*2+A*
M^XPV*"&H#`FV.4O;TJB*1+=%'5V;ZK+PK8=K=4=E;/8>W%'GOGF9F(@L@Q$\
MXARHKT+$%CW$*8L<VVR?>/6TY'YZ$RA<Y6C)!K86RNJ48T&T8-!#0]CM>HJI
M::T"V;;&!Z['7IS6M+`+HQYB5YEV<SD7?G($YE$5*U0W64.HQXM85RTA9]6G
M91NJ01Y#@D307TDBN"K@V\'%O4*W\*+9?#6J[0ZW/8[(;DF9)Z1$PF=G1I#V
M/C*?(?!<@PY,9(;H"\R$C[)*XJ(Z)$!+8U2L?$Z3OF=6[9H]+UO$T^`VA]`:
MBBB$;&,(10\%V*V'W3>WWJD??:PNV5U]4-K,2:V3FR(:9SR67WUYQ5/)Q//H
M\J2\LAUCF'K05156]V0[8_U2[2W'2*%I2Z)64G=1-L_[TP>X]PY=S/9/"^>R
MO/&V'`)TT)7<3#%)+*+:,^B.ES6BCL@ZL9M7&VA2L-<T;N8@).-6C6D*P;=D
MUN-7P^YX=\A!(0VG5[7K5**T<>IHN_;(2=CF1,L@F&J.H<SFS>F2)*)P]+>+
MI,IC0<!6'U#'(:DK*MJ2J9.:T->&E>6BH-[ZEY6E!TG>M@'J1T^BSHQX;,.1
M=B!+)]W$G"-XW)3\Y9;<P[M)&/S!IUIA74<1\_H_S=IDHTI27TRFB+%-DCG*
MKU^;HX]#8]G3T3%QJJL==;-'OSQZS;"?%03TD8`S<1ST9_T&L.%,*2+]#?2V
MB<_X4V\JR`JC\OFGQYRZ"_Q`\O2+=U%%+0MTU.:??ZDOI2K.%U,Q4=ET<WNE
M<E*537*%YK)__>QRA(Q'@HZ;(N/>:N(X'.R`QK+)\X;4BC-WTF,ZI=E0T#6<
MN*)C22VEX=;;HL!^^1,,3F:7.5M$:,,O^G91A)FW'7ZM(7_F)P/&-OYSYM>,
MYRAY_".F^)$J-R5+6O+7AK3E*J</8`4=3P=HE3PI719G6[I!D)688>?,(.X7
M)"S#&$5P66'T<XXTFB_[**R&1!.RO/D&VB:Q6LQ9ZN;8&@BH-RF9L-]E.DY5
M%V^[;`:<Z[&$+E?K!?:^ZB65:-M*V:Q8'O\`+A1Y$:6DVEJ<J.@<C*;9<[CS
M>%U'-$1$1#:T%^T5`;%LN"6_9Z4\*HJ<NXW4ZU]SK/LB9DF<D&0\UVR`MC,Q
M:1GO\<X$6$Q"?11;5E?H\F`[3Q@XVL-3C(Z4LK^B)Z\;GAPJW'HVMJ_K2C4N
MQ@MCCM6%S@9;9:S`JG5J79`<:+3K),JX1G8X*;967$NORA_E2FY4AM,EYSS=
M,\QC2(UE/&]*=`FU=05X"1D8DJF*$7+)&U2R(7!11=*)>UG=5>GS\B6[N3+R
MLQN3(1'H#F2:9=16H[TF3+CO$4J.$EY8#P8\Q40;?LV;+1DRV.ONU#J,U0-H
M:O-"]*5QBLUXQL`BXJO5349AH(4)[NFV"JFGE6@^&*UYZ/K]D>E,X(U,(1VH
MR(_D84RTC,LG<*RX+[1R35XQ;3M&ZET1A!(>R*H7[35V3L*WO[*K5MG>NI[H
MV;F<?,W%++,2H\)M.?)R;2O-MX@&)+2>;,.MOH4U7U5F633!DX3NI4<,DL\Y
MH]>-Z<4IQ2G%*<4IQ2G%*<4IQ2J-??(?:1[L?VVJ)Z\J7.G=.OBF9]&N>(Y7
MTA[@7JCUB^[J;Y&57+H]\6_WIOZKI[U-%Y#<WJ%A/UN^ZM2]X[\#'1;^_E/*
ME5)VU_C]0/;1U!^VTGG3<?\`9.7H]WQ#KZ);(_+`=^[[*>)+K@3^/VW[;0CU
MM"Y!O[*%]'KY-:FA_E?K]W;ODCJ2FV_LS_$._P`;]$_?*=Y@X'QS:GR5_P";
M!7(MC>M_=5^KF9_A+%2$!_S_`'N0?87#?<Q=N8Q[U6W-Z3/R[5<LR7X7^\;]
MY+O\6AU$#\2#_--HWV?FOO%NW-@Z._Z!+^4EY-NN\?RD_L6W)]:%^80ZTQ[\
M/[1^FOL.:E]<V[F3Z:?$<IZ2?\4*Z#_+C]4NH'WCY/R46K7R/Q<.J?\`3.=^
MJ^S>:$GJ'.],EX[%>(HGX%][??`GSG'U5HKX)77_`/J&X]2W+F\)]I4ST7^]
M"O:"?F*;H^ZO]]%JW/\`$9_R::J]I&L_=OM#FA=&_621\C+RK5>%OY37X@,W
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M`/!(/PF$\=JN/N-_B/F?X9[K_:1W)NJ'J<'PS?NU'^8_^$J/Z8Q/N'7&#\+'
MJW_5&F?5HCRFOKO/]#?ODJ,G\:6]/N9#YP%7;]>OCM=Z?9HUOZLT/SFV7^R[
M%_+#\:37SJZJ?EI]-OKA/\IFJI+[\_'(1[0753U/J+G3]J?9<OR23XSM?13N
MP_EO+]5MR>5RE?+N=\=MOVH^K7J_3W)MM?97_D97NO5/W?ORTE^I>X_'RE38
MW3]M_O\`_P#@3K'ZL!N:EC_]+VM\H<]TJ\Z]//LY[KWUER'SAVND&_Y[_#N_
MN03_`-RD<G<^*;M^%3Q7*NLAZL]ZSTBW_P!Y6/\`XE7[1^J?[D;1]>U#EST8
M^)9#^^WXI5E/Y0WJGO;TCCO(RJ_5/KK[/J)^YM8]20><)F_''?A2\9:^*6[?
M6K)^D)'ECK,N6U:_47MX=:<[0NE-V[0=FVO1V[Z&&,U0-LBHC:[8&C-'L4N"
M1,T.\U"UCR(&W59XJ-8FQVW,,R8,YK#T9]I2G,+SF,S7F,9S'RV&Y6,=)#5L
MU(;&**B&!@J$!6545>*$G!46NS=..K_^S-O9#8FY\/!W)TYR<AJ2[`E./L*U
M,8$VVIL.5&-MZ+)1MPV3(5-MYDN6ZV:(.GGHCK4WJ6U7S:=TV1:]U[MV;$`A
M[9LVWP0`3T:J554]RM4>EU*KP!U?IU0%RBLJ4J.PAU^7-DN/R7WEY3Y$,KF?
MI!AJ%&8;C8UE246P4BN16U&9DJD9+9$NO!$2PHB5+U+ZO%OG"XS9>WL1"V[T
MZP[CSL;'Q3>>U29.A)$R7)D&X_*E."VVVAFH@TT`M,MMCJU;SOE4C7RCW.C3
M9<B!#N=4L54ESHB6ERH4:Q")@=^7&0^E;*Y$9J9E:,+QE.5)QXXSCF,B2"B2
MFI0HBDTX)HB^!5%46R_KM7-MLYQ[;.Y,?N2.V#K^/G,21`KH)DPZ#J"2I94$
ME!$6RWLO#C40]P])VMI]:=.=8X&XKA2JEJ>'K`=.GPJ]4+#_`*EC-5`80D$$
MO]=L@R=6S5;($!L>?/&N1U0ICS"&W6U,XRC.P8_<JP<W(S9QVW7Y"NJB*1CR
MU=)5)0(50A)$54$D74B>!;UW?87>)/975_/]8Y.`@9'.9QS(N`!ORF/H]S)/
M&Z\]"?CN!(:D`#ALLR!-'6@,B`D-=29"UU<O%EU5L;4^Y>S.R]FC+I$K;-8L
M`>KZWU!9M73JN0^>1A>G3]7U@`R[+9,Q(#Z6YS4J-C$%+*FE,.OMN4ESL5B>
MSD,;"98-M2U"I./"ZA)I5#1TBX64DN-E[5[W1%3%.=9]MXC>V)WQT_V?B,/-
MQ[DA9##LB?E(^1"0'*<:E!D9#ZH*M$\"DR3;EWE<0T<!LQY47J9Y%Z-[-[!;
M+G=E;D2UO.T\.9N%&I-:HH36IDN./V8*W0``[(0L3N1@/#=*S9N9'GT0V666
MH[",MJA*SZ+%&%B6!A1Q>1U=!F1JXB*(KS"74B"BJ@B-K75555XU#<O7'5MJ
M/L[I;AVMH8!G+AE7%BS)<B8]D&FC8CNK-?/G--Q6G71C-,Z-"NN..&ZX2&G8
MK72#KS2^P8?L)2]::\IYH#K>=0A5;J^MJ*`"P",^QLFW+[">%`XDZ'<4P$.#
M,26UI5F`^XWG/DJSC)_=&8E8@L/)?><:)Y'%(G#(E1!T\M;DJ*%^U;^TB+5+
M+]XWJKN'I9(Z5[AS&5GXZ3EPFNR)$^8^\;8,*RD(T<>("BJ:C(Y9(J<X`.UT
M1:UW'Z)+<="TD_O_`&=:^M]:V?%VT#T,?A5PAC)\9<,["K]8L&T),)Z]6;6U
M9O'D$((F2[EW&([$=Z4]&92SR[7=5D*4U$8;S)L*T3XJ2=E0Y9$+2+H%P@[*
MFB6XJJ"BJJUM3O>6$0D;BQ>U\/"ZMS,,6,>S+!OA^Q<B^8OR&,<)I#CSY$.[
M#TEL=/;==;8;><5RN]LCH]]-#.XH56WEL#6>INR)!)7?^IZX&J,Z%<B,T`,J
M5MF56U%Q<FP:\D;$J8:-`.JB*?\`24(4ZQZ-(6MW,D/<_FS<8GXK3V0A)9AT
MB-%!$)3!"%%TN<LE4@O:W@6Z<*M]H]X[_;V/P$C-;;Q>8WQM%KEX3)ONR@.(
MV#SDF*$F,TX+$X8,EUQZ&CB!RU5`<YS0B";WLO7ZKV+:'7K9""$X3&ZX#]@P
MZ93(#$/Z/2G[W41M'8GS,O-+F,2*M6XTJ/!\RM./(GO87X_F^&+8R[[,&9"5
M$(IJMJ9K?4F@U.R>QVB5%*_]E+5S3$=4LSBMF;JVB333[V[78)RY9D?/$8<I
MR8H!94%1DR";<>U(O%EO3;C6/[HZ[3]B7RD;AUWL\]IG<5$KUEI,&XB`%?MX
MD_0;?,#%#E.MU2LK"X1<<DU784^&\R_$E0Y;'E)<4A;C:JN-S`PXKN/F,#)Q
MSIB:@I$"B8(J"8$/%%L2BMT5%1?![-93I[U7C;4VSD=A;KPT;<&P<G*CRSBN
MOOQ76)L4'6V9465'5#:<Y+[K+HF#K;K1V44(1),'&=.,5?5D>HT;>&TZIL[_
M`%@*[^-[LBOA73MUVM8U36[1,O-.8'P*38:0=&3U0%5[T1F%'AL1?,9;?C-2
M,71[C5^<LB5%8<A>;(P+*WT@T-M*`=U,3%4U<RZDJJ5^!*E;),Z_+F=Z%G=R
M;<PL[9WT`WA&<02.HS$QK&A8PPY2F<MB8RX"/).YI/..F]S$)IXVE^;722G&
MM6;KH^R[S<M@W?L(;"VK9>X%H"UFW)M%-;!HUH0I0\(/0"J$#5SM9@/!(:&9
M"&I#*W9"I+C[REQ7<\EJ=&E0FFV8T,2%MKM$&D]7,0U)=1J[J)#6Z71;):R5
M,?>+S^/WIMW<>S\;C\5MS:L9Z-C\6BNR(OF\M7ER`2S>-7I1Y%)#PRW5(%(#
M$&D:%MM!S73G7(M0]BV7<^SML']W;=/TP+K2':R]9K%*&5C78,K-L"*Z`JU2
MBQQ[$HY8IZYQ6:ZMUV8\TPE"6&6&VL6N1S+<N&&-A1PBX\'5<44(C4G"1!U$
M1K>PBFD12R(BKX555K7M_P#5F%N;:</I]LW!Q=N;$BY!W('&:D2);DB<\V#"
MOOR9)$9"RP",QFA01:`G5)7''3-91<P=<8IQ2G%*<4IQ2G%*<4J`%UZ'L738
M-G(R=Z['A:0OVX*=OF_]?$#*C/K]BV72I-5)#WH=W)"95VKM0)FZ.*G3P\20
MEEV3'7EIQA#RT9VR-NI8T0`2*RN39CFPW(N:$+9ZD5%!%0")!,A0E3P+Q1;5
MZAV]WF'=O;6AQ6MM8ESJ-B\#*PL+.<R4#[&/EC);-"B-NC$?E-LS)++,IT%(
M6S'6+A`)5);L3I43V+TIL'29TV4K@C80=H-..!6H;Y0<TT2@DL/0VB#3\-;N
M7(.$YPXA6/)5G\OAS#8;)N8;)LY-H1-QDM2"5[+P5.-N/LUR'I1U#G=)^H>*
MZB8V,S+G8J0KH,NJ:-N*K9MV-05#1+&J]E46Z)6K^S/3;6O9X]I*WV><8K5S
MT3LFL7ZKV>N>B-SR@X#80UFGT*P)E-.M$:B?+UV!)=:SCSC$J&T\RI*L*PN]
MPNXIN$:DQV$$X\ID@(2O9%(5'6-O`2"1)[2HJW]A4W+H]U_W?T;QFXL#AFX\
MS;^Y<1(A2([^I0;<>8=CA-8TJBA*9:?>;$D[)MNFV:*BBHRYYK]<*K26@](!
M]`TTY3`ALF>B'=F;2V:],+-1&9+!':=[.7PF-:3";;:S"&3CJV&%9QYQ32$Y
M5G*O'F2RN3<RL@9#HH)"RVW9/:;!`1?UJB<:Z+U.ZC3^I^?C;@R,=F*_&P^.
MQZ`TI**MXZ&S#;<5355UN`RAFB<$)51.%;MYC:YU3BE03V?O_;M`,31,>OHL
M/CV/K5-:GUJB6LT,%:T)A-538M?)RX"R&(]XLI*^*::GR/1X*$-R,H;\IEI+
MFU0<1CI;:.$>C_!$=B<`55Q"=121%MV!1NZBER\%UXK;TMLWI=L3=$!N<[*6
M+_\`R4B6H2)L9IQS(-O9("?;$T#5#CMPD(F0UO*I-(16<-0Z0?>ES*ZOK),K
MM&JUV">V?"J9K>'S,`8`5P--U&UL9]"62DU^H1I<&_O*IZ9$M3C2'6O-NIS/
MSR=S%1FYQMML.&8,*:,:BU$2/<OV$UJBM_MK)QLMT[%7$_IMMZ%O.9#A86;+
MDQL,<EK#\U]7GW0R:P!6[8)*(3A(F45MI$)1+6"I%2L/E]H=RMCIZ(@J&2:)
ME;K4J#=1M>2EFWVJ17J;%H2(&NIA'Z5P&F;#9USWV9;B<NPHZFLN8\4KY<#@
ML:IHI$HJ(@;@*7O!0C5R[B)H7LCI14\!+>WL5GV.C'3\I;1/ON,FRQ$E38CC
MZWBQA?EE-4YX-^;&JL1T9`VA72Z8F@+Q&O`A=M-M13K-L-P23%*&,IK=@K\L
M!6H$#_48/IF<?.:X:0F:[L&'LXQM2$J$+:<;R'>CMN1_.9EY82Y5+;\`FUCM
M*BR2[0DA$J\M7D$7/!RU;1I=1K[]%LMM-[9.1T-V,]C2P>.<9+<+Q><,/B_(
M,_,'<L##,]5T)!/'M8TT>DD)>=`X0.Z>0CBAG.O]][$MI&L5>];($:GN(*'6
MZJ;`E-?L-E]J;!)W>R4^QY!5XC/DE1S(\!"#&HC,'+R1V#S,DEEV`CR%VLO$
MPXX&_$8*1&-2(21S@TV@"8ZB1$1;DI@JE;5H40L?%-;W1TQVI@XDW,[:Q#^<
MP$ER1)9>;G*K6-@MPV)3'.?;`6W%-\Y41TGM*OK"<9B($HM0X$*WGNL18:R*
ML^WHTYJ;6[S8L9FA]/U)9B?7]CW&FC`^19=V"<-Q'8%59<6T!;>(>>E*\<I2
MN.G%TYBL8XR9L1U14,!X$Z=D)L#4KC<16YKQ.PV1/TULTWIMT[G8N9-PV!-L
MFY<-CL.Y24C0/P(LMQWF-(;+)(<DA0II"QH;&R*HNDOE"^SF\!08"Y=[9#`3
MHQNNSRH8X(UPWL0\(+4>B61OYF$0BD"DV^JE9I^8B&.#$H]QE)0I$=#LB#+C
MYJG@\6XX?FK:F*B2(HJYRQ5#<'M*J*8$B"BJ1BK*<%*R&*U?3>CG3B=D)([<
M@N2HQQGP;=9=GK!9=:F3(Z\UTVSEQ9+0,-*Z_*CN8IM5$G2!J2PZFX=H]BMJ
M4MC5DT.T()1S;W8:F61E`5V:LI;Z?;H&K=1&83D=Y'S>.-;"GP43&\8RWE@E
ME6,I2UC/,=!PT"2KXN*0D*1S'M6L!@KKPK[:BVA6_2/Z:T'9G2C96X7,U'GD
M^R[&'!RXZJ\@(W%E13R.4:-"1=;C4$'E:*Z$AL6LJG6/:.[%[:FGGBNV2./H
M4C7FR+2_,=!U@8'+2-;L4]<]-"2%ER;0@G#9GS9)*(:2C#C#K+D#+C;3^6ZN
M4PV/%KEX\?\`$\YL4342JB.:[:[H@V6PH*A[**A6NE\KU'Z3[&CXP86QVO\`
M^B7*P(R`CTAQUH9ZRD#SWG",=6S4&FX[L1543$QDH!&WJ$>Q^V6-"QS=C(P=
M<;0`[,E5>\,V`,`JA%0R95">P:[!K@^^D&Z9'+N`R(MK+94C!;*HAS68LEB<
M['P@&%@+E5:8$GH)L(0:5(DNAHV2DH)KMJ0O>B2AJ%2%11;HG238SG4X\=B6
MG,MLR3AQD0U8=?DM\P)+<%\WSA`LLFD>;D$A1F'BC*[&<>9=C`[JQBQ=R-EC
MB:SC$-<2@R;U2S0*:1U^2@JL6GZ;!,0>Q.0JI!)^3(-B)HI)*(G.,O1&9*(Z
MO.Y3ES-PSMN$8<I5O+1HQ)$<1=+QJ*Q[\+:51=*^PJHJ\/!69Q/0#:$N&F-<
M<1S<X8V6T\#<YL^1E)9M'@N;I;019=!U8[B^]=)LG4T704\.#V)[6R!VPK@^
MH5%"ZY%&25J5,K]1A4L`,\]L.2PAV1(.HODJW!D#A+&/(C+#+8;D.R'&W%?F
MU2PV`0V8Z:E<>(4"Q$IDO[-/[.A`*YKX==U1$14\.2D]*.B+,O%8%M'CR&6?
M:;C(#\HY;[EH(DJ"+*PABN\R4?%Q)2&30-`0IVI(U7>DJR=C+L$:V9796L``
MV%,`#Q![54@<8'YUZ,L94Q\I%_8Y=J$2DR5^E#V\C6T1E-K5Y33WAA'\6+.'
M:=5DTG&JH2J+MT7F**)X.6ET1.!=I;W3PI7(\UTV9Q'2?'9$\/+#>4ITP?-U
MG)"XT?GSC#37_32`TIMBVG+?)'R5Q#%+&W>/"^Y.[(D*44(UK`^,*K.UKI9!
MA*ED8!\32+6K74GK_<A\'TQ]1,542MQ?#'L^3_QS,&5.QAKT?+><RFV\81(V
M!W(G&@%4-%%3#F)(!5MP4T!#;_LJ0CQU7KJP]`.G;\@(429S7GYF-B1W&Y;9
ML.S(WGXYN*9Z11MR4W%"5"2_[$GF8RJ?-0DS(5V"V].H6\YU?O=6N=J!:LV'
M:@RFZV+5&U+L(1<[-6*C3+*T%EX:*1B,."B3Z)-\V22D>^MQ:D2&\-VQXC'#
M+BB\TXW'.0V!=I;NMJ`D9C=."HJVNEQ[2(G%%OK\[I;L.-N;;<;*8R;C\+)S
M4&,[>0YJR<%V)'D2I<=7ANV39FK?-9U1U5]L1%":)3P4[VLWX;)V,S4V7QE5
M&!C-F@18M9KCB08^KB]7`#Y/8+UFE-EY5&"WXK8'R:@C:C38AA+D=M>6L^7=
M-8#$M`#3ZZGR,155(NTI*Z0HWI2R&3:-H.OL:ULJI?ALF-Z)=,<=#B8_.$+V
M:>D-1S(I#Z<XY#F1?9;@I'%6AF.PFX01TEDD0I1J+I"AIIE2YO>SHW]::1B"
MIO7D6GSP5>L3E:)S`S^X*Y6X^Q"T/Y^&NNODXLVEF<X3`88S(0Z$DY0M2W,(
M3@4Q3'T2W*O_`(Q7$(AU(B\DBY:+I7P*AI[Y5M8QNG"N*#TSPZ]+X6XU<1=U
MG/!Y]A)#8.CBWY!06CY+B(+9!+:15>,]"C,9U"@AJ6.=/[>;!Q!I"9Q%J]($
MWE)'<5EKU>!'ZX+UE+$TX2Y,%6BE%%!DA8ECOBC#,V1%ADXHT&^/GPDR<+DN
M9F1MZ'J=THK2DU9D2)1)7$(ULHFE[Z6]"BBJ*D:&!6L*=:SW0?:RR<BL9I<:
M3^-5O%1WWWF'W,@+LMU`=C2V^;S28A)%-EMQV.Y(F-2HLA65%D,.K?:+LU=6
MM85Z)E:+$2#!*]=%4VG5))HIL'$4I:RDZM)V*>%T^(%DT8E79:D2)"<-XG/I
M:6IU"$\N'\%A(W/>7_HB2D&LRLC=T%$+EBIJJ&CB<$_JI?@M9[+]&.CVW3S.
M5?LN*9D//Q/.Y4KE-P=3<9L)'F#+DHG1F-SFD4&U5>2VIB@$2UL:R=EMD0ZE
M6@9C8-%K&T(NZCM%V3%KA;6H]^OB!5`MAN,AI.T2K007"GV,*TEB5-\'9;'Y
MK'E*7C/+)K"PBD..M-.G!\U$VU)'%U*K@#_\2:E5!);HG@7P^"M2Q'2#:,C.
M3,CC\7DIFS3VZS,@$^UD#1]UR;&9)5^CFU><,([I*;;/9:/BY9!5*RC?79+9
M5(L1X)1%Q5"86JGPHZYEZJLQ5F-^6&OR;I24F#(N:S$>%IK@AM,B!&3C,E9R
M,IIU/DI2JCB<+"E,@[+OS%D:E!#L7($D`[(J7OJ5;$O@T%=*PW3'I'M#<>)B
MY'<R'Y^YFT=<B-24:DKA6'QB2^4TX"FCG/=)0><7]FD-U#!;JJ8J*[1[(L%_
MFQ\V,35)8.W52J1M*E08EP[<B\W9KVO=A!!Q!YZ/8)ZJ<U!DS(A(<E4-45")
MLE*HB^5W,%"9B(N@G!)LS5Y"72"(TCC9*GO4U71%$N-U44[25FIO1C:6+VNV
M[YH_-8DP),DLLV\ZC,5H,>DZ"\8(A,`DI3;:=COJCJ.*4=I4?&K,N:37CZG%
M*<4IQ2G%*CJ]V_ZEQWG8\CM%UU8D1W7&'V'MV:T:>9>96IMUEUI=F2MMUIQ.
M4J3G&,ISC.,_+Q4=)>TM?/\`\8O47_S3]<?_`-X:R_\`R?BFDO:6MOTC85!V
M:$^DVM[Q4-@UO,R2.Q8*190MK"9(0LHQ,@_.P&;/@>F1,N)\ZUYSRV_*QY6,
M>..*@J*GAK+^*51K[Y#[2/=C^VU1/7E2YT[IU\4S/HUSQ'*^D/<"]4>L7W=3
M?(RJY='OBW^]-_5=/>IHO(;F]0L)^MWW5J7O'?@8Z+?W\IY4JI.VO\?J![:.
MH/VVD\Z;C_LG+T>[XAU]$MD?E@._=]E/$EUP)_'[;]MH1ZVA<@W]E"^CU\FM
M30_ROU^[MWR1U)3;?V9_B'?XWZ)^^4[S!P/CFU/DK_S8*Y%L;UO[JOU<S/\`
M"6*D(#_G^]R#["X;[F+MS&/>JVYO29^7:KEF2_"_WC?O)=_BT.H@?B0?YIM&
M^S\U]XMVYL'1W_0)?RDO)MUWC^4G]BVY/K0OS"'6F/?A_:/TU]AS4OKFW<R?
M33XCE/23_BA70?Y<?JEU`^\?)^2BU:^1^+AU3_IG._5?9O-"3U#G>F2\=BO$
M43\"^]OO@3YSCZJT5\$KK_\`U#<>I;ES>$^TJ9Z+_>A7M!/S%-T?=7^^BU;G
M^(S_`)--5>TC6?NWVAS0NC?K)(^1EY5JO"W\IK\0&;^J,CY_CJIAW=\#KIA[
M56U?TNV>=(Q?VHY+Y"W^ZKZ"].?S'^H7U)QON8RI$A_AQ^YQ]O7/WQ7CF%D>
MN.X?12>1"N4Y#\6?7W[LD_A4.MT&OM+_`!#_`/#*%ZJN/,2U\3VG\-_R"N=X
M_P!3^ZIZ8/RD6IEP_P#I]5>Q]._3R.:XOVJI\N3Q4KS_`"/S24^OH>*-4L^[
MS^&M[W+]PM._I]@<Z=O/URP/PK_BMU]#.]7^+OH7Z4ROBP:Z71KX5WO8/U+0
MGUD*<;M]><)_F/)C5QWD?QJ=$/A,U\W:JS'3GQ!/<S?TV@_W4;.YI>3]5MQ^
MF#\LQ7C_`'_^%SO!?>X[_$L=4DO<2?9;W"]M#9/U?J?,)U0^.X_T>/CG7(OY
MEGKGL+[OH'EY-4K>YJ^*V]^I]@_V,QSI?4;U$3];7CC7T-[_`/\`@D'X3">.
MU7'W&_Q'S/\`#/=?[2.Y-U0]3@^&;]VH_P`Q_P#"5'],8GW#KC!^%CU;_JC3
M/JT1Y37UWG^AOWR5&3^-+>GW,A\X"KM^O7QVN]/LT:W]6:'YS;+_`&78OY8?
MC2:^=753\M/IM]<)_E,U5)??GXY"/:"ZJ>I]1<Z?M3[+E^22?&=KZ*=V'\MY
M?JMN3RN4KY=SOCMM^U'U:]7Z>Y-MK[*_\C*]UZI^[]^6DOU+W'X^4J;&Z?MO
M]_\`_P`"=8_5@-S4L?\`Z7M;Y0Y[I5YUZ>?9SW7OK+D/G#M=(-_SW^'=_<@G
M_N4CD[GQ3=OPJ>*Y5UD/5GO6>D6_^\K'_P`2K]H_5/\`<C:/KVH<N>C'Q+(?
MWV_%*LI_*&]4][>D<=Y&57ZI]=?9]1/W-K'J2#SA,WXX[\*7C+7Q2W;ZU9/T
MA(\L=9ERVK7Z<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4J"YGO121L*.ZU33&9[MIV;5YK)HS7Z^+!2
M]<[6K.K8A2Q')<EZ,,"V]RS,EH$CR',H',.Y<2EQ'D9VIO:LHR5%<'0C;1)9
M")21QHG5013BJAI4"3^TJ6X5Z3Q_=LW%+D$!Y"/YL,+'R`5II]]QX9^-D9$F
MV&1%"<>BI'.,\W<;OF"`JB6JMA-=F:(Y2=.V.>`=9&[GNJJ@.AM3`$\7"849
MGAU7=!)$I`RPT0@=3!S#(P_.8FQS$.2A'FW%939K@Y:2I+(G^TC-:U6Q(JKI
M1=%K7%Q!U7%;:5`A7BE:J?1[<P[BS^)C2A*9M['>=.$H/`X:\H'?,U;45<8F
M`SSN:P[IY)Q7V2+4"(OQMW:0%3[7M:LDJ83<D:QK"[!$;^>JW#/7(@ZU7&1$
M"O5DI.@DW!MH-6J,*'%T^='K)-OL27(RD-^>1\$[)8CO@Z-GSTKP)1!.U=2)
M$5+B(*9!P+2J**%=;5,%T7R6>PF$S$3(,HUF9B,$O)D&Q$;19"NF_(;`VT<C
MLQG)+\5=+Z1R;<:%Y"/EX6<[Q:X%-V1R+4K*9:#%M;MP'(2@B6;&(V-JK.VQ
MUL'+>G)\@4&'QG(<M3F,.-SD(PG&4N(5FZ:VM-<4$)P!4A<O?5V5;=Y2@O#P
MJJHJ6_JW]I:V'&]V_=LTX@O3H<<Y#$]30^==AV!DOHQR,XB!Q<=,A=:0>R3*
MDJJB@2)Z=4[>56U5G8%K73',2-8:YLVR9L@/9:K;*\6A@Q$<A(AU.[AI3H@H
MZ[$DIC27DY;1$EM/QWO!3*O&F_MY]AYEA'>R^\+:7$A)%);(I`J73BET3V45
M"3PU9YOH1F\)F,7A!R"<K,Y:/``78\F,^T3SI`)R8;HHZVB$*N-@NI76B;=;
MX.);)9W9.J"=5UK:]M`"4PS-W@5.'&K-KK=UBPF7YSJS5A388WH(Y4.K5T;/
M+D&FO&0B,/=2A*W?)3F@&%?=GG`CF6H6E-5(2!5LG9'2MUN1*("O@N27LE8B
M-TBS<_>LS9&"E/J_'QIR2*1&D1"-1!$98Y!:W$*2^XS%8(NPKCX*2B&I4QIW
MML"-SHU?JFM35FNV-CW+7[57)DZ_7W8I6BV>8$8.9)D'9$5L-8Q#2B@B2C"O
M/,KRSGS;Z74(N/\`;SS0*\^^(1N2#FI$(KH8H6FR<=0KV33V%X\4LJY@.A>3
MQT8\IF\Q'A[=^B(DY9#;;[Z$W,CB\K/+!!)76'52/*;6V@T0TU-J!$(]JM9Z
MZK-1^;Z38XX0OHG8VWZ^.B,BV7V7M=/5],O6SS2R#B?IQ8)QQY$96'78KTB"
M^I;^?%*U`P,Z8^YK=!71EMLDJW_^359SP>\%!2_!%1"2R>Q4(G1/>&[,Q/\`
M.LC$+(L;E@8M\R5Q45)R/Z<@BH"?X-@&15Q%$7`!YI!;2Q"/N:O[65#9%@NP
M589@'!HP:X6$N439`)[YD%4VS3:H05=18M>9E(GF5P9$L6S*POYQ@19+B%8R
MPXC%&=@)$)IIS4I&Z0"B:2'4IBAIH5>!H-T0E3WI**>RE8W>?1+/;2Q>.R`R
M"DR<E(BL--K'>9YSDN.$D/-''$T2P:0VVI)MVY#SC($B\T"KJ&>UE9:TY1-L
MXHY"2,O!Q\$1#G3%7"1J>6"N&,$AUMLI*<NJ"RC)4`Y"@ID2FHTHDXPUZ0SA
MS#F)F\`^N1=Q_-1#:%"110BUH6FR@*)J5+%J*R*J#=;+:U7&/Z)9@]_Y/8WT
MDT$O&QD>;=9:D/%*:>1KEN18[8))<;5M\7GE!LG&V!</E.**@O9G]N=?0K>Y
M5'0IAQ43=->TY*+X=#?-\)RS5:UE&[J_G,_+S-8AVZDE*Y)4I*7T$8BU^1F/
MX.9@&WIA1_.$(>,8GD3C==)`FCP>^4#%Q/8TJB>'A5&+T)W3(P*9P)$=$/;S
M^5%JSNLTCR8S:Q![%ED'%EQI[:(J@K#HCJ1VX)K*O=]J=8Y$=I.O#$:(22&9
MQ`=LM0D6^.L]%BSH\\W169ZS0VI>A34-K++\N+B>XB)GP<<3GE\]M.2S?]L*
MD.I;Z3T=E52PG:RG=+Z?#IN7@2MPRO=CS^):(URL<WV5=76D>4,4D9(@(&9B
MARG).L%)(R6<Y(D^EP%:WS7-QACF[+IJ2'6:_!7K]"(LXT_:ZZT=<4]5ZQ:%
M.0J4VSDVV!]&MS;.9:G$-^=0O\WR<XSG$/8YQK&M3R,UYW%$TEI]\0\3\&JX
M7M[5JYGE]@Y#&].\=OF1,E.#E%U`TD9]64M(D1['+5>2KVJ*1HT@J6E1XWNB
M:R']W-;$6JY)37+$RU:A>RI`Z2ZH.Y&;F4`S7V15?(2H\YYJ&3V)5+*P="(5
MGR'H7BTYEN3E#*K\]L304QU@JMDVBIQ\#B%<D2W%&S%6S]HN*7&ZUN,KNZ;N
MB'+967$(X3T`7!3FH2A-:?5Q\!($4FX,F.<.6J<0=L8H3*$XG>;[7CANMMD[
M`,ZLL8G-.UU_K`+K@XE7"\^_4V;),0(4D5(ARF8L2QR)@-33\*9YM3*GF/!U
MS"E>1(N`,YK,1M\"YCW)4E0D1LT1%6]TNHV*Z*GALO!/9MCZ(2Y>[\1M;'YJ
M(^D_+?1;C[C;[00I8"T9BX)"I$P(O(0.M:D)`<[`V35CUI[RT4!=IU2@U669
M9A&,B8Y95BKHEZW8^:M5S\QM=AIS_P`X74_(F[29@L"VO,R),H?(2CQSEKRZ
MS&UI3L9)!N(*J-[:271Q=2[BIP`41I24ENB(2*OLUE<+W;=RY/;K6=DS@CN.
M,<TFN0^ZD7]ID@U3G031$8$,<3QR"U-MMOM$5K'IW_\`ZU5C&U[5J)@83EGZ
MG0VKVMV`B%)03=0XW\Z5@3!3)20>L8H86$REH4VEIQDS'PA>5><PG$_1C_T>
MWD5(4:<=T<;I;VB5;6TJJ&GMW!;IX*Y=_P"/,RNR(6^W'F6\9.R:PT0U,5;1
M47ER'34=",..-26T5"4A**ZI"B:%+4E/[<4<V/UPN76L@G=DWXI26XD,_5C$
M>ONM#1D[).R9@S&98Q]=IM8D#-'OQFB,,T3PEQE4?'I*\A(V]*:-Y!/4C#2'
M=1)-7%4L-TLO9`W$)%45`>"W[*;UG^A6X\=*RPL3/.0Q&,;EJ1L26B?17'`Y
M<?6"BXB1HTF:R^#A,.Q(ZJ+B.KR1UZKO_2'@M"*CZ-.B/76G5RUK3<K?2Z*'
MJLLY)N4215;#9#1'(N'81GT'D?Y>,Y;?R_&2VO\`SDYQ=KM*4+CH..HJ-.D'
M8`S4D318Q%$NHKK3]*6*Z<*VE.Z]N-O(9.%*R3;C>.GOQD\TBRYCLD61BD,E
MB.TWS#8<\\;XVU`@/*0_LU1<VL':VIQJ)4+TQ04I^GE\+42,/OQRMT'T&8!K
MQRQ/2+"4,XF1H;^8P-;+47.%O>?7A/R8QG/+9K`2%E.15>_Z32&JMB3ET(A&
MPHEK\2NJ^"U:[B^B6<=W+/VV[E%7Z,QC4PCA,R)NL'GV6$%AMK01IJ>0R<X!
MH15XJJ)68;4[-U35)8M72-6-6`N)U`9VSD977@LIXDX&RXJ#2!#,F;%<F6H\
M.%$9,'&4HCK9&N>4XC.6\9MX&#D3VQ>!P0;*0C5RU):_A-;(M@%5%"]FY)P\
M-8'9/1W-[W@L9:)-CQ8#^>:QG,?1T4;1VR',=40)`C,N.,-O<5<0Y`6`D0K>
M$QVNK96SX2"I!(]31CM3;-[$BE`3:`T2_GX]7K9&.#E/-&B$!95]*2"6_(D0
M6TJRII:TY;Q57`/ML?M71"26O2VJ%Q5L=1)J3LHMO>^P7MI>]9)SHCEX6&OD
MLBS&W`\,E68)-O*KI0F2D2&R>%%:`T;1584K@\2I8Q$D*I><UVN$4XI3BE:^
M.;;U56;M7-:639NOJ_L>XL>E5'7YRYUP3=K3&\N6WZ17*I/)1SIQCSD!]/EQ
M6'4^4RYCQ\4*\%++X?8K8/%*_P`3+98^!G9.QLY@P\YS?[IG.<QF?E_^IBG_
M`*G):OT\%85\W#__`(&'_P#+,_\`L<C2O]*O\**TTS[J5E#+3;2/_$OO+/D-
M(2VGQS(K/CGR48QCQSPE6KWO_P"A*_2OR-4JHU]\A]I'NQ_;:HGKRI<Z=TZ^
M*9GT:YXCE?2'N!>J/6+[NIOD95<NCWQ;_>F_JNGO4T7D-S>H6$_6[[JU+WCO
MP,=%O[^4\J54G;7^/U`]M'4'[;2>=-Q_V3EZ/=\0Z^B6R/RP'?N^RGB2ZX$_
MC]M^VT(];0N0;^RA?1Z^36IH?Y7Z_=V[Y(ZDIMO[,_Q#O\;]$_?*=Y@X'QS:
MGR5_YL%<BV-ZW]U7ZN9G^$L5(0'_`#_>Y!]A<-]S%VYC'O5;<WI,_+M5RS)?
MA?[QOWDN_P`6AU$#\2#_`#3:-]GYK[Q;MS8.CO\`H$OY27DVZ[Q_*3^Q;<GU
MH7YA#K3'OP_M'Z:^PYJ7US;N9/II\1RGI)_Q0KH/\N/U2Z@?>/D_)1:M?(_%
MPZI_TSG?JOLWFA)ZASO3)>.Q7B*)^!?>WWP)\YQ]5:*^"5U__J&X]2W+F\)]
MI4ST7^]"O:"?F*;H^ZO]]%JW/\1G_)IJKVD:S]V^T.:%T;]9)'R,O*M5X6_E
M-?B`S?U1D?/\=5,.[O@==,/:JVK^EVSSI&+^U')?(6_W5?07IS^8_P!0OJ3C
M?<QE2)#_``X_<X^WKG[XKQS"R/7'</HI/(A7*<A^+/K[]V2?PJ'6Z#7VE_B'
M_P"&4+U5<>8EKXGM/X;_`)!7.\?ZG]U3TP?E(M3+A_\`3ZJ]CZ=^GD<UQ?M5
M3Y<GBI7G^1^:2GU]#Q1JEGW>?PUO>Y?N%IW]/L#G3MY^N6!^%?\`%;KZ&=ZO
M\7?0OTIE?%@UTNC7PKO>P?J6A/K(4XW;Z\X3_,>3&KCO(_C4Z(?"9KYNU5F.
MG/B">YF_IM!_NHV=S2\GZK;C],'Y9BO'^_\`\+G>"^]QW^)8ZI)>XD^RWN%[
M:&R?J_4^83JA\=Q_H\?'.N1?S+/7/87W?0/+R:I6]S5\5M[]3[!_L9CG2^HW
MJ(GZVO'&OH;W_P#\$@_"83QVJX^XW^(^9_AGNO\`:1W)NJ'J<'PS?NU'^8_^
M$J/Z8Q/N'7&#\+'JW_5&F?5HCRFOKO/]#?ODJ,G\:6]/N9#YP%7;]>OCM=Z?
M9HUOZLT/SFV7^R[%_+#\:37SJZJ?EI]-OKA/\IFJI+[\_'(1[0753U/J+G3]
MJ?9<OR23XSM?13NP_EO+]5MR>5RE?+N=\=MOVH^K7J_3W)MM?97_`)&5[KU3
M]W[\M)?J7N/Q\I4V-T_;?[__`/@3K'ZL!N:EC_\`2]K?*'/=*O.O3S[.>Z]]
M9<A\X=KI!O\`GO\`#N_N03_W*1R=SXINWX5/%<JZR'JSWK/2+?\`WE8_^)5^
MT?JG^Y&T?7M0Y<]&/B60_OM^*593^4-ZI[V](X[R,JOU3ZZ^SZB?N;6/4D'G
M"9OQQWX4O&6OBENWUJR?I"1Y8ZS+EM6OU5Y[UCM[V,ZA=;[E?>M^E6;S8@U2
M*6VQ[7N94-`U1IRMAS=;%S9QD.LHS;+_`'LX@\I`$$/C)BO.,NOSIL9AC#<A
M4X"A+9:L_95E;+2U?*I3:%*SC'AXY4G&<_)^3Y<\5)4&>A?8/8G8FC=A;!L=
M8%9'6O='MEHJL9`"G!+":%IO;1NFTM!%IR;.S,-I"P&\2Y6%-ID/>*\-HQGR
M<*F)++P]I*^_NV-_["[3='NON_MK+!.;"V36396S+K0IP("5+@72S`H^1PIV
M:1<AM>@"FO*3EYSQ7Y2O'Y?#"AHB$J)X*KJIW8;O9M]GN/M`3WJZA=?:9U^[
M3]G]/5/7^W>N39H:S4-%VR8(`%+_`+(QV'I12+!,0V4^G3&!:%LHPIQI*\^"
M>0J?2*62RJJI5A?7/>.Y>YWN\]5[^HC`#0>]M\]?0]YJOTF`SKI2J1L(\"])
M%SY@&7(#%K%0)99*9#*,O1YCXB0A6%I>SA7(U(J()6\*(M1%T9[P7L)VUO>K
M.MVN-9Q=/=AM0GTO^\XE6ZOE+!3NN$>FDI`M.M-<RI#XN!=[7VC(0,DZ,21(
MDQH%$4\8E-N2,1HSBIE%!2_A3V*NGXJG3BE.*4XI4"F.QVZYW>.FZ)):Q;H&
MEC>NMXF0UAL9`20NFS#^KCVM!*[(*$AR$Y-1H#:;DK`_,U>");RU.KCQ6FVL
M.[46&QH;8<R@/\[(B\RA"**@-HZ+BZ55436?8[5NR/!$555;>FW>DO3R-W;\
MAU+B9E<IU"C9;#M.L,`Z$3'LY%G(.I'<==`/.IJ^:)S^4G(C6$!=>,ST3UYJ
MM>9*J\[.=ANR^BK`3NLBV:0#"9.SJG0]"]6Y`IZQ;8[.!"1:HA;`5#VR-;AQ
M&O6]V79)*X$*&#G0A;,-IPDM:)"EM;QA,1A<HT,9&Y)&C!&_*OI:C$B&0HH*
M"H0V%+JIHI771:UJ]F='.E?1_J5BV=O-0=QR)H8>3-S6XQ<1C&;>>;:E/,-.
MQBBN-OQ4&.VCSKLQEV0;IC$$2:03M#YH]>,ZJ?[9=S+3K;LG)TP`W_IK0%8J
MFFJIL*U6;9FH;IMZ5//W2W6T/"@)B5"XU-NJUT`!JN)A`G.7Z(QZ:QA:T85X
MXWW`;<CS<-]).Q9$M\Y!MB#;P-6$`%=5S`M2D1*(B*772MO!7M_H=W?L)N[I
M$'4'*;7W!NC,SMP28,:/C\I$Q8@Q$BQG2-2E19*R7WGI*M,1V4YA\ES2)*-E
MLUH<R:1I%0($K-7[K/GU@%-F7&IQ$P*M:I,H9&?>L5<A(+'D1`1I;F9,1O$Z
M9A##B<8>=_QYTJ6(A*<``-H$,D0#6Y`B*O9);#<A\"]E.*>!/!7CS<T>/$W'
M/BQ(<K'16ICP!%DEKDQA%PD1A\U:94GFD3ENDK+2J8JO+#WJ0%[Q=K;1I#9&
MC-7U#:6N=0N;"`;4NEMN=_UG;MO9@@J$FG0!`H#1:38*^=($SQBUK4IQ#BT,
M1(#[BD^2A7-KVO@8^3ARILAAZ1R3:`&VW`:NIZU)5,Q(404%/8XJ2)[->G>[
MAT2PO4;:6Y-Y9["Y;/#BI6-B1HD+(1<7K>F^=&ZX],EL/L@VRU&%$%113<>;
M!%N25+[KU:YUZTY2+>0VG0-U/V&!+)-[,U@"<K-(L\-\I.]`=#`GK/<7QRA\
M/"(DEMP@\YB6P[Y:6E>+2->R[`1<B['!AV,@*B<MTM1BMDO<M(7NO%.RG!4\
M/A7A'53"1MM[^R.!B87*;>;BNBVN/R+R2)D<T;#6CKR1XJ.(9W=;(6`'E&&E
M32QEJ/M%MW9=3N/7?2>HB%6JEW[%WJV5UO9%V"2;.`HU>H-$,7VQ/P:Q&+@,
M6.YFH@Q,43$>F-1_*4\\[A:&<HSD,'CH<B-,R>00W(L-H"Y8%I(R<-`'M6+2
M`JMR5$OX$3PUO/1G8FT,Y@-U]1-]M39VW-IXV,^L"(\,=^8_-F-0F!.033_(
MB,DXKDET6B<L@-AI)Q"3M=8-SW2]63L!IS9I*JV/8O6_8@.E&;K21<D#7KL#
MM]$KU^JQURN2RIU=9LL>$;=@%8")LIAN;#4XTM+;J6FY<YC8L5F)D8*&$.8R
M1H!JA$!`9`0ZD0=0K9"`E1%42XIPNM'K+T^V]MK$;6W_`+.:FQ-I[NQ+TMJ)
M+<%Y^&]%F/PI+*/BVRDB.1LB]&>5ELR:=03%2!3.1.P+,5IM,L-F!4NQ;$-"
M("GQ5(J:P[-@LI!QUN/$&#Y-@)A@D/+K[R<NORI+++#*5N*SX)\,X>(PW)D@
MRZX#+9+Q,KZ13PJJZ455_0B(JJMDKE.UL/"W!N"+A\ED(F)Q[[NER9)1U6(X
M(BD3ABPVZ\5D1=(-MD9FH@B<;I&?I)NK:V\M<['L&Y@M:K5XJ/8'<NL95:J<
ME9(/7(5`LZ@<,&V=6EI5EDC<-*;>)89CHFN8RXAEI&4HQF]S8R#BYC+..(SC
M.1&74(N"ES!U:M/]6_!=-UT^"Z^&NO\`>+Z>;)Z;[LQ.+Z?2)DS;D[:V*R(R
M)(HVZ^<V/SB>5E+^;BY="%C4:M(J`3ADBDLEMA6<O3*78+,`I-BV.<%0L.B:
M/5'0T<]92+S[,6(.A2["3#A(*5/OX4](E26F8\=*W%9SY/DYPL1AN3)!AUT&
M6B7B97TBEKJJH**J_H1$NJV2N0[5PT#<&X8N'RF1B8G'/N6=F24=)F."(I$X
M8L-NO&J(*H`-MD1FH@EM5TC9TDW1M3>6L;Y9-RAZS7;U5]^;JUG.KE1DK(A*
M]%U[=)M;AA&#CB6E61X:B)EIPEYJ.F:M.74LM)5A&,SN;&P<7-:9QY&<9R(R
MZA%P4N8&K4H_U;WOINNGP77PUUWO%=/=E=-]XXS$=/WYDO;<W;&)R`/RA1MY
M\IT0'R>)E+^;HYJ0A8U&K*+H4S5%)9B\UVN!4XI3BE0N>`=-:S,:O2SM3A39
MUK+%(Y1JXE9+T^U:NV/&A'VHD-@G(7*G578Y-B%-C--*RF6ZU'<1G\Q'-E1[
M<CP+%T.**-HBIH1+`ZVJC=;<$)M%)%7V$54]FO0@93O`9B.6VQC3G([4)ILF
MUBMB@1LC`(V5(B;%!"3`;-YIPB2[0FZ!)VBK*WJ!U<LU6IKDOZ)EZK;)5NI>
MMG)IUU^&DQ?C4RV'@E#S*F>6#LC1:M/+B-PO,31.!V6(WF$,>;3027G6'W$'
MF"^V@&Y8>-FQ0!([)VAL27U7$]5RNJWK"-[HZSX?-9`&//F,W!"++GH#*"?*
MA,A&9>FZ0L\PK4@4<5[6U)Y_->YI.ZU\BV57JH0V';R=YL8J?8J-!D;&ME9L
M]X,2:C5(X>(")';3(J9$FJK0,-PH0N242EGS:,9COOMI5(\X]/'?SP1&VXH$
MC+JHV!""(9W4D$=:)J7BIH/&_A1%[-DO\'F^MD7:D"'MN(^UBLDX,"-(CPVA
ME22=)YMF,,EMOSD[F<AN,JGJ7]JVV:HUI;QPAJOI.#^D."$JFBDAIC=4--+O
M)&*V`?O@.K6\36FXZ#26Q34ZJUH?(%QFDH2P,0I,;"&''<*KA/W.[HT(X6I-
M8]A%U<LB!2][QL9$A*OA+WUU1*RT7>O>)R7FBQ0R#ZR&UDLJD-LE>2$])BNR
M%+E7<4),A]N0X2JIR%17E)P`5,G*-]8MMC2%N:V`V^#K^KK*`LZJW?SU=')U
M>B,_\^LV\4.(05*'P&)*WDNRFDO,X=PZA6,+2K-!M<YCS%A6;.F^)#J;$EYO
M]70JHO%;6LBV6UJPT(^L>QI;6"/%J.1E9J._'21"9?/Z14AY*Q7'`/MFHH"B
MV2@6E0)+BJ)Z#-?ZX737]>*V:PM[$H[1^=5P1?:5D-6!A^R[!DPJ2V+;>N#V
M'9)@C))('#LJ3EYE4Q:(ZDY>5XR*]F8TLVV`Y,K0A$C0B/9;N=^Q["6U%["Z
M4OX*M3RG5K;VZ)4+#15Q.Y"BA)>:QT=IA4CP1.6KBI%2PM-BVK[]E021H2=1
M4;&VO[#1.F==%@K++MT:LO`U%J0'N@#9EL@V=$NK[!L*3P;Y]#FUEY98%?3I
M6-+RO*Y,9V3(96I*?*3B\:E[D>,V1;4T.QJ!-@HV-L=*Z5&R(38BJ>PJ(BUM
M.+W+W@<K,DXAB`<QN2C4QV(]CXQQU&1!8Y+O)=91H&GH3,9QI$1&W!;:,45;
M*N>6JE=49@RDQ;)+IS(>GZL)72E)S;Y,:%%U-3,!))BX19+!=*2E;#)+07)9
M!U;Z<XE(4ZXKSGCFTCRL^)NJPCBN./H!]A%573U((+PX$MBL*6\"V3A6LX7<
M76YB9D7L2WD"GS\TW$E_X42,LG+YPM12$FOV<AWE/"TP*`J*V0@*:+)RJ59Z
MP79T[1J:1#F9,&KWFGV,,,LAG$F=4[3=73%R'S\YFMK.#8]P>D-*=PI](UR9
M(C(6RF2ZVY"0_G(NB5)$A17`,541LAB%@5.'950LMN&JR$J+I14ESN8ZR[="
M-N3<#3\=EV;#E,.N1VM(28T1&HC@=A49<**@$@V!9`M-/$+BL@0^5:*YU01K
MD8?D68)4M9WJQR[$&+TR[E*G6STBRUUL/88P]=6)0H*ZM8*\*<=*QD)P/_->
MFO80]A<A-1A[/^>$T@$Y-:!!5#!#(=)7&^I%74)*B"OOO`*73A5[ALMUO+=C
MV,:AR)V\,9$%AUJ7#;DR&1COJZP1I);,TD,/N",9Q55_BW';4FU%I>F3TGTW
MD2H]4E0:9$(I.2-3/C(-JF#"I6WVFI&;RQ6S;D`M'GF;B]4#T\K!7*6[.8C2
MG7F%IPK.>3AD]R"*R!5U0T<VZBBH@":!J&Z*B!K$1*UA541%JXA]1>O[+)9M
MES('$6,.31PXPN-MQ8TEJ&LAE#:(&HJ2F68SR-H+)N-@VX*V1*0"G3LB'M^N
M`=\J;,*]R(5A--!;M/B2I$U$D7@7*!GHY!"X,V+('176&83Z5MX;PYA&$>*N
M##<8.MS'6G-;2*(W!%LEENA"J<46ZHJDGLVO>HRH77V+/@;MR6,G%(Q@FPRK
ML0"$047.8+S)`J&!";@F;P*A:E%2U62LEK]7T@QL.[:]&;!NA6[EPS\.^5&3
ML:\%$2?3J8`#.EB[+LYP?&LZZ@D=E,E+C<Q*,M.I\%*\K-N\_E%B-3#9:&*)
M7;-&P2UC(K)PNHZ]7"UO"E8;*9GJ,YM7';JF8K'L;<8D(<*4,"&VHZ);SJ--
M*@(91TE<]%;42:5=8+=$TIC:]8=,2R"2(K6OVH%F"3Y3HH'95B@[P[3]VI8<
MV=$B@Y*)"ARZ7>:H#AD)T5M#K4N,PT^O.5>2JOY]N5O3JYVH#1+D-UN\!J(J
MJHJJA@9J(KP5%54K,#O+O!0B9)XLHLJ'(`4<>CHXZAY2)+=99=<=;(S&7#DS
M'6&7%42:<<-L>%T_M1@]28]!VH0$7<48HXH/$&[(,V#8)TNQ4:=7Y98F*$9G
MG"KCU7I(V6[/=C)C99A.*\^K"G/)5Y*0>X5EL`XT0RB)5;06Q369(B*MA3M&
MJ:46]U3AX*AG9/71[<^$BSL:_'W&_()R`TQ!9:*5*?%IMUW0RTB2);@HR+BN
M:W13EHJ#J2_0GU?IA1"92BSS-8KY>3$?I9(2Y<3:)XC,UW7MO1F1*P4<=K9.
M'(D5LA%(..QWHCC\5QIU&7$YS.#^Y98#*`7#;1=:+H&RVY@>"W:141P5&RHM
MB146U7,7,]X3<L-G<L:/-E00,9;;J165!W0DZ*ND>6B2&R$9[#C""8.B#X&!
M("VW#(UUH=W81Z5*A5O.S&H$^\VB0Z54U:LUFZ`R%`?EFW_2VR&:9/&5QR*S
M'=5Z`T\-0XVA+K"5IQJ3,JD,!%3\QN@#P[.H"1RP\+:T4KJJ=I4)47@M:$UN
MOJ8&U8K+#DO_`&>3H0XXHW>-YQ$>":(LII4/.P<?%PS%.<0OD)D0.D*Z?K&L
M^GMI@Q)L(R*O<R\&W::%LEIOAZSV^;9@0>':XXZNG+"6D6"!9!-6I\*;'?BK
M;F+&#HS^''&\(<5D7IVXV"42$FA:'60BV(@@D2@JD(H@J*D9"J+PU$J61>%;
M[F=X=>\+)<CR([^,CXV.DMV/&A,QXH1WG3C$X^RPT+!QW9,IUIP'$)I)#[K2
MB)J0)UQ#72+7"Z=>1-HI`WTV**OM/)L7`D6:*CCP!=.$V.#%01GI("IX@`\V
MVYYM3'G&'WOD<\\ODSB[HF(Y%<!U;*K9IH1+*):U%5LEE123]/%$\%DJK//O
M&;M&?MN="R+W+-R%*;6*VTK;C+Z2G6#)0!0<!U\"(=2'I-IOB'+&N_;`'60;
M&1L$CM2Q!!EAV,9*@RM8VQ<VAC6P"0BP*LN*E&KY60S%?*"9D]V8S%1YA:/*
M<RG'DX5B2.[G#+S,&`(P9%"0F@ORT4=.M23V%0415X^Q5M@\GUBF/+M:)A(D
MF9%Q+3;S<C&Q%<6"VZQYOYR3[8J0MN@R+1.+K1;"BK=47*MDT7J[*FE"NS9-
M7AGE5Y.SREA.V5\39HM*J`:%2IA]XVJ?%+#J5!'F4L3D><;@*>GN./)RZ\M>
M:$*5G1$0@HXK6OE((C<5,U4T'3944U5+C_6L*(G!$2L)M'<O6=B.S"V<$US&
M)*7'-L,QT=CE+E.G+%A&=!-.2S-I39723R`R`-KH;$4QC-(ZC5[:<80W8!X.
M[V&X.V-^CQ[]8X(.R7-^XR[I#>.5A!=-?(3D7P@].'Q)"/-Y(.?Y#2E82G%?
MSK<+T%7%`CB@WI0^6*D(:$!=)6U(G+1!)4XZ?"M9A-Q]=<KLHYY179.W(D!(
MXS"A,&]'B)%&(2,R%:YX`L(!9?=;74C"?M#1%55F=S6J\^TXI45NQ/>'J'U(
M)58/V9[%:JT>4NT$H3J4#8MJ@UV381X21"BEI8MN6I.93`^0180ZI/R)4ZG&
M?[>*B@DO@2OR(^\![U]+=E^_Z]UKV2HW9'3MMT=J#7KHS96VP]I'SZ;1)_SW
MN>2F'83K?E,#'UM'H><)5G'R2F\Y\,*\>0]FJXB7+5+<:_3,W[Y?W53J7U-]
M^>LJTQF?2'\IV6&SAIC+[$7#J_\`,_-1Z1*;1X_]I>,?EY&J6@_:6O\`)OV5
M]I.Q?W_NGUF*<EJ\3P5A7(TK_2C_``I/PIV?:6WE^GK/"5:O>_\`Z$K]*?(U
M2JC7WR'VD>[']MJB>O*ESIW3KXIF?1KGB.5](>X%ZH]8ONZF^1E5RZ/?%O\`
M>F_JNGO4T7D-S>H6$_6[[JU+WCOP,=%O[^4\J54G;7^/U`]M'4'[;2>=-Q_V
M3EZ/=\0Z^B6R/RP'?N^RGB2ZX$_C]M^VT(];0N0;^RA?1Z^36IH?Y7Z_=V[Y
M(ZDIMO[,_P`0[_&_1/WRG>8.!\<VI\E?^;!7(MC>M_=5^KF9_A+%2$!_S_>Y
M!]A<-]S%VYC'O5;<WI,_+M5RS)?A?[QOWDN_Q:'40/Q(/\TVC?9^:^\6[<V#
MH[_H$OY27DVZ[Q_*3^Q;<GUH7YA#K3'OP_M'Z:^PYJ7US;N9/II\1RGI)_Q0
MKH/\N/U2Z@?>/D_)1:M?(_%PZI_TSG?JOLWFA)ZASO3)>.Q7B*)^!?>WWP)\
MYQ]5:*^"5U__`*AN/4MRYO"?:5,]%_O0KV@GYBFZ/NK_`'T6K<_Q&?\`)IJK
MVD:S]V^T.:%T;]9)'R,O*M5X6_E-?B`S?U1D?/\`'53#N[X'73#VJMJ_I=L\
MZ1B_M1R7R%O]U7T%Z<_F/]0OJ3C?<QE2)#_#C]SC[>N?OBO',+(]<=P^BD\B
M%<IR'XL^OOW9)_"H=;H-?:7^(?\`X90O55QYB6OB>T_AO^05SO'^I_=4],'Y
M2+4RX?\`T^JO8^G?IY'-<7[54^7)XJ5Y_D?FDI]?0\4:I9]WG\-;WN7[A:=_
M3[`YT[>?KE@?A7_%;KZ&=ZO\7?0OTIE?%@UTNC7PKO>P?J6A/K(4XW;Z\X3_
M`#'DQJX[R/XU.B'PF:^;M59CISX@GN9OZ;0?[J-G<TO)^JVX_3!^68KQ_O\`
M_"YW@OO<=_B6.J27N)/LM[A>VALGZOU/F$ZH?'<?Z/'QSKD7\RSUSV%]WT#R
M\FJ5O<U?%;>_4^P?[&8YTOJ-ZB)^MKQQKZ&]_P#_``2#\)A/':KC[C?XCYG^
M&>Z_VD=R;JAZG!\,W[M1_F/_`(2H_IC$^X=<8/PL>K?]4:9]6B/*:^N\_P!#
M?ODJ,G\:6]/N9#YP%7;]>OCM=Z?9HUOZLT/SFV7^R[%_+#\:37SJZJ?EI]-O
MKA/\IFJI+[\_'(1[0753U/J+G3]J?9<OR23XSM?13NP_EO+]5MR>5RE?+N=\
M=MOVH^K7J_3W)MM?97_D97NO5/W?ORTE^I>X_'RE38W3]M_O_P#^!.L?JP&Y
MJ6/_`-+VM\H<]TJ\Z]//LY[KWUER'SAVND&_Y[_#N_N03_W*1R=SXINWX5/%
M<JZR'JSWK/2+?_>5C_XE7[1^J?[D;1]>U#EST8^)9#^^WXI5E/Y0WJGO;TCC
MO(RJ_5/KK[/J)^YM8]20><)F_''?A2\9:^*6[?6K)^D)'ECK,N6U:_4(O>1:
M+V%V9Z-]D-#ZIB"9VQ-F4+Z/U2(<*M@Q+Y+Y\#S_`")Q9UF0W!9]&A.9\O*%
M8\<8Q^7BI@5$)%7P5-EE.4--(5_B0VA.?#^]*<8S_P"G'%2U2Y2:+[PCI;8^
MT&N=!=8M4=E];[O[$[C[&:?V>7[$#]/KUR7WV5S;;)3=RTLW2K`:+#*=?)DM
MZ-/KKTYX@'<;:RQ'D(SY4*J=DK*JVX5/7HIUMG=0.H.@.MI>RQ+D>U1KX<!L
MUI'PWAXL[;)DB6=MA$/!D*5)B!7[(6E9A-NY\ZB+YO"_SO'D:E)=1*M0GZO>
MZKT'`L'9K8O:_JAUIV9M/9?=GLENBD7>X:\H>S;([JR^7QP_K1)$T?K\R5"E
MPA;F<_-ZU+Q"7GR<9\?EXJ8C7@@JMK59%O8AN"IZ2O+W6FAU*Z[E@UE8S4]/
MMA]JET)%CD89%AI=G*LQI#L*I5G#V)LN/$95*DQ8JH\;"77$*2J1+7X^"JK:
M/[N7<O3R[:*[)]:[F[N/L.<,_1SWC2M@6/-:B]SZQL8\X>MVUFW)6)0:J;.T
M/;"#DRAQ$H9BL5/#U<R\EE3"T*G4T*Z+X/8_15W7%4Z<4IQ2G%*BO==37$YW
M"T'N<>Q`51]>Z:W[2;)(=GMM$FCNPCNGB%;;B#LHRY+C.QZ7.RZYC.,-92C&
M?\>.9V-D([6WI>-._G+TE@QX<+-BZA77_P!Z5VO;N^<!C>@FY^GTHG4W)E=P
M867'%`56U9@LY0)"DY>PDA2V=(JERN5O>K4J.8*N*55[V=U;VSW36MW]?R.J
M=0[`J^SRDZ'J#L).L8VM*T=2K"P+SAZQTEX<0MY;8NLRT1^:(G!7_,E7DPU/
M+@J;=SS>,+.V_CGHV5"1(9?9%.<P@J7.,;^].Z`C;B*B$)I<4U6U72O9G1S>
MG0[I[E]N=48F;SV+S6&9`\I@P8<D)F);"N<&):.!%:@Y!H@:E,RPU1@5]&QD
MH859@&@.BA`H8_/E%'APV#`>)SLX5-(NPXK4=R?+4GY%2IBV\N.9Q\F5JSS2
MG#1QPC1$%")5LG@2Z^!/T)7C[(20FSWYC;0,MO/&:-A[QM")20!_^D472/Z$
M2H>[6D=JZELG8,W6VEM5[QU_L6C5\16TSK.%UI8Z1;!3!D>5A[0G%AI5S8&M
MS""C,J.J#A9`=A$J.F&\EY#N-B@)@9$)D9LE^++9=)2L)."8K945M$5.6XEE
M1;]DN"ZDM:N][(:Z)YS:.*C[NW#F]M[IQ.2?=?4([N08F1G":-L\<#3C:09[
M2MDV:/*C#]V75?;5L@K:O5;2\SKMURTUI`B>19R6M*&$K!,XRV\S#GDHC&7"
M"A;$C_B(X9B8\MJ$VO\`/;B(;2KY<9Y89W)#E\Q)R8!RVWG5)!]I/8O;A>W%
M?TWK2NM?4*/U7ZL[@ZC1(JPXF8R;TAME513!LEL',4>R3J@B$\2<"=4U3@M8
MON:5V*J.S:C?M2:RH^YJ3BF6&J6NE2#8.@;/#GY9085!6>LWRQ,OAR%4?9A.
MQ"@9Y<1Q+F6);*WE-J9Y7QHX>1"<B9!]V-)Y@D)Z2<;4414(2`>*%QN)I?V1
M5$O>LST_9Z49W9\_;&^LQDMO[B^D&),:6++TW'.L"VXT]'D0F%%T)**8NQY0
MHZBCS6'!;0T<KY=.=+6S2&IRXJ^*`QKIL':NU]T6:MU&3(F4VC%-LW8K<%T6
MI3)4,<]-#5=@@B/F1F/'3)E8>>2VA+F$XCN+)1\G/%R(A>;,L-,B1)8S1H$'
M6:(JV(E15M=;)9*GZ^]0\'U&WPQ-VRDH]O8K"8W$QY$H1"7,;QD1N*DR2`FX
M@.R%!3T<PU;;5MM3)15:\_N-JZQ[4H]-%B-/T'>H4'?QEAMNO+78B-#MSXN&
M,*L0+#J#94`B-Q1-CUH[)BR&WW76$2QWI<7$B.IY*^3[<G,0)+AN2'8KI-*(
M.`*&"*JI<76U1=;9"BI9+V+25EM:KKH#O/$[*W'D)D_/9/;60DXMQB+.C,-S
M8J.$XTIL93'FVYYY`D,BX!`(F33_`"'N4ZC:C6+=)>MY/1D/<5OL%-K.M#FZ
M[V*LC&L:D=DVL?K^I52HAZ?6`QFX3&T2+E>2JA\LP>*9R[B02)N)2Z\EO#SE
M?<V9;RA1HS+AO-1FE%72%!5PS-3(D!/>`EQ`!]@13@E[)FN\5U;A]29&`P.*
MR$S,8W;N,<CKD9+(QCFR9,IV5(=:BBJC$AM:VHL*-85;CQP50;4U;"<O-7KS
M=45.IVI;GJ$'N^!=8XZ/(O7:7L!M>O8'$$$4.T[8=YE'JS(EK0VUZ(0>'.IR
M]'SXY97^;G.>9_<&0C9%V*<525&H$=HKI;MM@@E;VTOX%]FNV=<=\[?WWDMN
M2MNFZ;6-V7A,:_S`5M4E088LR!%%5=0(XBH!\$-.-DJ5?,!7$ZBIU)U+<]/U
MC<0J[1QT:9<^SW8;:8)(T@@BV[4-C;'+66KR)3B&FL1B#PJ8A3\?.,Y97G*<
MYSX>/,_N'(1LB_&<BJ2BU!CM%=+=MMM!*WMI=."^S7;.N>^=O[\S.`F[=-TV
M,?LW!XU[F`K:I*@0&H\@11574"."J`?!#3C9*E7S`5Q.G%*<4JOIGHXY](%%
M).PW,C,7F?<(8X7!+`9XE-EV<)V3>&!%@#V"&6%D+/-KT#QEQELO,2&//)SG
M.?#&WKNE.3RT9_:<I`555"1=+2MA<5%45!0BX+=%1;5ZE<[R`?1:0V<4GGGT
M:$4G'#:>!WS?'NP(:NL.L$TX$<'WK-.(8&!\M4LEUS,KU/,DJI0:RQL\F-<U
M7,NMDIQEB"F:4+WLI>8=MI]OOTPR\3F6(L.8B.-FI+3L6::ESYDCS['G\M\M
MF\^T$AU]6!5'T`3&]D1M`4#!M$L@HJJB@BHJ`@BEEM>M?A=;\?$SF4S+F&9>
M#-MQ&)31'H;:AMPSBRHL(6D;%AIPB$HC9"XU$:9CM<MWEH=+SU=M5XV!;2ZM
M@0*S1KI,'2+.(K@LJDM98+$BHR)$`R.+FBNOL%6VZBF)@RP&;GSADGT.;AYM
ME.7(1<ZQ%B-M\E3E-(NE25+"O;XBJ"CENW?0IZ1)-0V5>$=M]9\+MO:\&"F+
M=F;DQ[9C'=?<:5J.:C*$3:<:9;G<M5E*YYH<HF69#?G$=6S<5`U8_P!"#$EL
MFS+VNU.1,AB8F')E8RY+G2*330>MM;GS4ADLPB4?`T))B++=:;:1*D$DNI2U
MAG"%9!-V-"HJ,>UE5>!<$0S)QP1X<!)S0J7O9!MQO>MT;[SF/9)EQC!JV3;C
MI6"180&9+>GSV6A5HE%EZ;YJXV)$2MA'4%4U<4DV>>ZJ%HK5I'4&SCV8.Q=0
M6766P#%_F7>YW(B2,B_FN%:X]EG6=PC)?@0V8\9$=]WR&(L5M#"F_#E@SGFU
M5LY8*I,R1=;0-``B(MU!10;<5NMT3BJJJWK3<9UL@OG"E[GANE)Q.>CY"$U"
M"'$BMMM.<PXQ1PCHV*&:N.*X`W-QPR<0[UZULZVV?9.MZUKZVWR176`1>RGW
M9E4*6FTD91B4#(B*E(P>VL6N1ST>ORC4B:II;JE)DLQ<QG(^6<9Y3CYIB%-.
M9':0R(1&QH(HB(2*::6D`>T@H-[>!2NBWJQP?5W#;1W=,W3@\8,MV2Q'90)+
M<:,V+0O-NRAY.-:B,ZGQ9;90D%$5LWD=%W7:M?BNH5_JEC!WJK;'JB[-",F;
MF9"EZF613B>P[-:#Q6SVR*P,L;!4=DZ#*Q(LF.EU27GA;+^5>6Z_Y5XYN*)(
M8.(^RYR%$0$D--:-B(H(+<;+I)%5%MP0E3P(E;1.Z\;8S>)D[:S.)FIAG([4
M1IUJ2TLIN#'C,M1XQ*XPK;G)>;=<;<4440DFVB:0;MZ]SZ99M`/6P2/?&X:*
M3K0_K$S*=KWEYLX&Y2ATFZP$Q6BC;0@18,CD)Q%2I[##;;:,*7A&,YIQMR\A
MUYU6K\U\7435[T@14!;VXJ-_#PNMUX7JQV_W@DPV2R^1=QBN%D<PQD&A1^WF
M[T07!B&I*VJNNL<Q5YBH&LB,K#JX>S6>J1FH0[3D+LB?\\6Z@;3ID@B2R?*Q
MZK.V#?9MNC']>BR%ADCZ8IN$24T4B0VVHY68/'R5X0J.M+M)_/MR";YK*<MM
MYH[)I34C;:`HN*@HI\4N*JMQ0C'CJ2V/S'6W'YZ1"^D,0UYA`RF.EBVWR6RD
MA!A!%)B<X#`G+N;:%&<=(CC-/RF14D=%0ZYCJG88NMAVMZ??8J85;O-EL%*,
MV*`6A66H!;:)DMRV0U@U^8IDF*5!V`R1?CMH;2*GBW\#ID5QO.7L1;S[135F
MR6EUFT(F@JBB:@26U"X)HJ$(BB_UA)-8DB\*JP.MN*>W<[N[/XPUD2\;'8EM
M,&T<>4[%=%15UB:U+$FWF&F`,E)9+,@%EQWA.S=8:7Z36N9,R<A;IE)LTZQX
MV*2+$:L/?8@;3#9V`JFVFLP1KXI4"$)1L%V/(C27I;CT*''80\TVVE.+IO<\
M<1Y1QDY"!RT1"7BT7+UB2K>ZKRT5%1$L2JJHJK6P0.\5A(\?Z-D;>#Z':B>8
M-M-R313QKOF*2HT@W$<UFZL$7`<;%M`===<(#,E5?4&](1P&GV8,*M3LDPDP
M&+ZX8*RK0JBU%X!$##H,B71XEB:"3CT@0->@O%4--S\1)2T(6G'R9IGN<W9(
M.FW9O2HN6TZSU*2K8U'4@W5"0;Z;HEZLI?>-EY//P\A-A"$#D.M3U;&/YY*1
MXG7#$9A,*\#(NN"\,92)E76Q(A5?!LZK:AVL#O&R;J_:JFT0V)#?G^(R9LOY
MM`6OZ`U.H0Y$>F3+@ND$($8A5&Y:I"X+9-;;N6?/8QCRLV#^0@.Q6(R-N:&5
MMQ1NY#S#->V@:T54-4M?3=+VK3<UOO9.2VYB-NM0IQ1<4X@?M!Q_,>C>>R91
MB4L(J3`,@DDT@(\4="%'.6JK9-)JZ&2(3+<$)M<@E@!!RFC%30&%/L`&6=?U
M\WL6!.D#'0@XE6[Z)I<IF5'Q';<Q(+.2E..2&6E\RJ;K0EU.QTN:]M!)4$D'
MF<M4OJ5";4T5%NO`$&R(JI714[S34AQ9.1P;2NRG/\8VR\8,/"RDY8!@+B/&
MV_"=EMDV>LAT1A900:<,:S^%U8/E*!>J5>;;7""+)JP+I83\R5XE&A-4<,7.
M%79=B01-37RQLND\XRM#66(L5M'^4E7G5\LRSS(2VI,5LT4)!/+J)%76J"EA
ML*6%--^-U5?#X$K5Y'6K&0MT8W<6VX,MHHF:>RSO.?;(UF.M,MH+"ML@C3+7
M)$T4M;CA+VU30-80WT:(NR#!8IM&61/DQ<U3\MN*>%#+$><FZR<CM7T**M$6
M)<Z9."ZT8%$1$S+C,F$]GR<MN)2KETNZ001;;806A).%Q51&SO\`TR454#0G
M5(33BBIQNE;&?>1B`U'@PL*#6,9>#2*DRXXPR@9!"6$ZY'(HDL'<@<EB4UI)
MMX$U(8JHUN]WK\87MZS;?3?GOG&V0+)5"5<F`1A.LM40G4@8D*+:@RF_2Y9(
M39ZW')N9D2'83R94UE,=OTC+G,6F7;3'!CN3V&U$T)"5"YB&2DMTX(BB2BED
M0DL*W6UJYR'5*`.PX>PUQ8^:P78\EM\7G&Y"S6Y3SKKBF*Z1;=CR#CBC8"\"
MMQW%=+E(-:<'=/+VI@')([;0(GT0FQ8=;!:U`-D:K63L651LX:==OAZUVYZK
MRX=#0T@:P2CX&QBDN%&>Q$\A&<D>XXJ*8A'U`ZBBX1**&0KS/[`@&I%<OJ45
MU*(D2:JWZ7U\VTCLEF)@E?BY-E6)[T@V6Y,ADAF<42$S&BI($YJDL@V'/.'(
M[$AX.?J).G2>B.*N2I;TK9AC(RG)B"X+53<L%$.Q*G``FF8E9$6>MV.(9%PT
M6NW&IR\M.)\Y&G^C9QX)RM4TK=7G`.H+`ZW+JNO28J:D-R42%45=``/'V1O[
M-JN-Q]Y?Z:AY!MG#Q_/)ZDX:R48F,E)-YI2D.QY#!-.&L:+$91"%=+C/.1;E
MI3(I_5V^1&!(*IV"D"*A2]G62^T47$>V=4RL479J[9J^NMDS]'N8,JTR&8/M
MX87&>2B2W'\E]O.5>.*(9V*2D[(!TI+K`MFJ\HT51(2U()@2=I1XW3A?@M8F
M+UGVR^X_D\Y%R+^>R&&CPICA)CY+9.1WX[Z2&V9D1YM5=)DM:."JMJ=VR2UJ
M]S;W54QMBQF;;*V%Z"0+5Z)0%UZ4$CEJ@[KB55RPRSU\E$E+29(S#%CL$DAA
MU4Q,?*8\5MUAQ367,TL=GV\>R,<6;@)JYJ0K'S$)%$D5."((B@VM?B2HJ7M6
M.V'UL@;'Q$?!,XKF16)134?%XFI23QD-.1WVR%.4V#3##;&E&E<13>('00T!
M/"K_`%*N%=,%X#&R!!.AV.QUF>3;+5XH]<QM7H&Q7KY1JN&*HL&!STD;!3%#
MN$Y;#LCT:+A]*,R%9SRJ]N&,\V)JP0RP`D2Q)H4G&^69*FF]E6YZ45$NMO!6
M2RG7/`Y:`Q*=Q#[.YHD20#:M/MI$<D38"0IDEUI6-:"X?,E#';,6^8XK2ERD
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M$B+>E3)CZY,J2\OSOYSK[[JEJS^56<\5#F'[:UU?_P"*?NGO_(+UN_\`L*)_
M[WBG,/VZFMH+KAHGJQ0<:LZZZKIVG==X-E;)BGT86V'!X/&\L*+E<0VU*3Z8
M0S&;RZO_`&O(QQ4JJI+=?#6[.*A6KMCZ4U/MZ;2".S:#7+M.UM9HMRH<H_!3
M,>JMIA.QWXIT.K*D^C$&'HC2DK^7PRC']W+V)D9T`7`ANFV+P*)Z5MJ%45%1
M?T65?^-;GM/J)OC8D?(Q-GY27CHV7AE%FBR>A),8T)"9=3^L"H1(J>TJTJ^E
M-3TK8-ZVM5*#7`.Q]G)'IV!<1T%+!RV)$MI:&X,R\*SF3B&VC&$?)CPQCA[(
MSI$5N"^Z11&;Z!5>`W\-J9GJ'O?<.UL;LG-Y.7*VGAU-845P[LQN8MW.4/\`
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M=;BL+<`XCIFB3(._R@DWNB*^'0MG9)8$4>-!R%I3Y?\`WA)'%I"Y#2L^'DNK
MRK^W/*8YW,`3!#(<0HHJ+7'_`*:$*`2#[2**(*_H2U6$7K?U<A2,#+B;@R3<
MG:[+K.))'518#3S:,NA&X=@7&A%LDXW%$2O89ZW:'8MNK[VSJJG-7'2M69I&
MJ+$@6C!.A5*.,E!F*_7'\*_X$:T*G/,);QC/@VXK'Y>2+F<H3#\8GW%8DFIN
MC?@9*J$I%[:JJ(OZT2K!SJYU,=P>9VTYFYZX'<,U9F285Q>7-DDX+JOOC_7<
M5P`-2_M"B^Q6/;EZA]9.PQX9:-W:2H.S;"%#X`"B]L#H(SH`5,R412-CO9<1
ME$5,Z<\[A/Y%N*S^7E3'Y[,XIDF,=(=99(KJ@K9%541%7^E$1/Z$K*=/^NW6
M'I7C'L-TZW%D\/BI#_/<:C.\L#=4!;5PDLMRT``W]H4]JO-V?TJZH;HFUPCM
M70FN;W.J%6'4BLRK"#1,>"5(2[)>&5^`O+B<LC8+LQU3;?\`8G+BO[^3P]QY
MR`!A#E.M@X:F2(OOB*VHE_2MDO\`JJ\V=WANMW3Z/+B;*W/EL9&GS7)<@6'E
M!'I+J"CCYI9;N&@"A%[.E*SQ?7O23FP@&UUZRJ:MCU:D_P"F]>N61J/GT11/
M,3XOT5A2_*\6@^(Y20CS7AX>2\O'Y<\MOI?)>:E!YSGFAN<P@OP4U5%4E_3<
M17^A/:K61ZJ=11VM*V2.8G)M*;D?/WXO,7DNS-0%YR8^R[J;;75[8#[58+GI
M;U35K(3IE6AM=*U6!N&;^'HF0;>:Z.NF69,?-DBPLN>#93,>8ZCSGC_A<SC^
MS/+E-QYQ)A9!)3J32#0IW[2C="TW]JZ(OZ^-;(G>$ZVIO!_J`FYLM_O63`\R
M=F<Y>>Y$N)>;D=N+>H!73[:(M;#W'H;3?82N#ZCNW7-7V9611IFQC0EK'I(P
M(1V/!GC6"D=E2D^1,:@%)#6%>/\`@>5C\O+7'97(XETG\:\;+Q#I516RJ-T6
MR_HNB+^M*U78'4S?_2S+.YWIWEIN'S#\=6''HQ\LS9(P<5LE]D5-L"5/;!%]
MBM;D^DW4TSK"MZ6*Z"UQ/U33ST^T5>AR`:%UT'82F9^2!<?"\YX,S9F2DCRU
M>/R^>5_?R[#<F=;FGD0E.I.<%!([]I12UD5?:2R5MT/O$=<,?O*7U"A;GRS6
M]I\8(\B:+RH^\PWHT-&=N(#RPLGL:4KUFNHG69BFZYUZSI.@MTC4=L5>M9UE
M`9&!-*N"B4HPJP@8V%^$0FHI->?RYXY\7'%9_+RF6?S)2'99275DOMZ'"OQ,
M$1!05_0B(B?JJQ/KMUA<S^6W4YN+)KN+.P4AY"0KJ\V7%1L6D8>*W:;1L!#3
M_9%$KTW.KO7IZ;N`D[J*E+G;_A)';HE*%)R]LF"E$AM,6TJ\O_CVL(ENX\/D
M_P`>>4TS6506`1]S3&6[7'WB\/>_\$JS#K-U3;CX&(&=R*1MKN<S$CS.$`[B
MNJ/P["W$?;\"5DB=&ZA1J/\`T$3KVM)TUFO+J>=<X@)^B_T;6K*UAO0/*\/0
M5+5G.4^/]N>4OI*?Y]])\T_/]6K7?M7M:]_U5B%ZD;[+?7_DTLK,7?\`YTDG
MS_7_`(CGHED=U_V[<+VK6M0Z5=4*#3-A:[IFA-<UNC[7B#(&R*P+!HCB;E##
M*F+%1CD?#F?2VH"B#^6L9SCR<NJ_OY>2-QYV7(:E293IR&%56R5>(*5D*WZT
M1+_JK;\[WANMVY]P8K=>X-SY:7N/"..'`D./*3D4W4!'"9*W94T`$+V]*>U7
M"L=)^IM+HE^UC5-!:X`Z_P!II$(V)4QP-#`:X(`/N2@J3<;#F?2L#)#JEL_+
MCR%*SG'(O[CSLF2U,?E.G)9U:"5>(ZDL5OUIP7]%39GO$=<-P[EQ>\<WN?+2
M=T8575@R7'E5V*KXH+W)*W9Y@HB%[:):LU&];-#![=K:^B]54Z#<M.TMK7.K
M['&%H;*4:C,#YXEFKUZ1A7C"$-#2DEE+>,9QAMY>/RYY;N9G*NL/1G'W%8D.
M*XX*KP,U5%4B]M5417]:)[5:]+ZN]3)^"R^V9N;GNX#/Y!9V18)Q5;F3",'5
MD/C_`%W5<;;-2_M`*^Q7MZKTCJ31\"Q"]1Z_K>OA]MLDVX66)6H*8+!FSD68
M\>:;G(2I7G9\EF*VE2_D\<(QRC.R4[)$!SW3=,!TBI+>PW5;)_2JUC=Z]1M\
M]1Y,2;OK*2\I*@Q`BQRD'K5J."D0,@OL`*D2HGMJM:TUOTMZIZ@OG^J&L=#:
MZI&PL)+HQ;@`1$,UA)Y#K9E.)6'%9Q@BV\O#OR?G85G'+V9N+.3XWF<R4ZY%
MX=DENG!;I_ZHBUN&[>\)UMWWMG_9N\=S9;([6NTOFKSRFU^Q5%:[-O\`XU1%
M'VE1*:NZ6]4M*7)>PM3Z%UU0;LY!)#5V6N`T02JH!C*,E(F9"7%?Y,[+:?.8
M\/E\.)NX\YDF/-9TIUV/=%TDMTNG@6F\^\)UMZAX!-K;WW-ELGMU'&W$COO*
M;>MJ_++3;PA==-<4=*NJ#=#!:O1H37*=?5F\JV6`J.`;>`HF_+CJB*M<.)YS
MP:,*C+RWYSQ_PY\/#PX_W'G%E%-64[YV;>@BOQ4+ZM*K[5^/ZZB7>&ZW'N:3
MO(MSY9=TS,;]'ORN<O.=A(6KS8RMQ:U)JT^WQK9P?26I:_M6U;Q"T"MC=NW<
M)#KEMV#$@);LM@!#VQ#4(62GX5Y3\2,V!A)2GP^3$9O_`+..6;F2GNP0QCCI
ME`;+4+:KV17M+=$_]Y?_`'+[=:=/ZB[XRFRH73C(926]L7'2"?C02.\=AXU=
M4W&P_JD2O.JJ_P#Y"]NM9VOI;U2O.T,[KM^AM=6';&2X$_F^D@:'['DU5VAS
M%>)9G><QG,L0R(C)95X?FI81C\G+QC<><C0OHUB4Z,%!(="+V;$JJ26]I555
M_I6MPPG>$ZV[;V;_`./,#N;+1=D<AYCS)MY48Y4A7"?;T6]ZZKKBFGLJ9>W7
M\LG2WJE<-I_ZW6?0NNCFVOGT%9_I^0"(>LGT@K"!S=?+>G9<QGTT2@1&PROP
M_-PPC^[D6=QYV/"^C6)3HP=)#H1>SI*^I+>TMUO^NF([PG6W`[+_`/'6&W-E
MHVQO-GH_F0/*D?D2%<5]K1;WCJNN:T]G67MUDQ/J]U[,E-M&BFHJ5.*[W%00
MFX9\@4E<C8@D:RU'@#[,OR_^.C166$)0GY/#"<<MPS65;!AL'W$;C*JM)?WB
MK>ZC_P`5K#P^LO5/'P\'CX6=R+4+;3QO8L!<L,%UQ5(SCI;L$2JJJO'PK7!O
MJWUX9E:?FM:@I*)?7^,N'I:0D4G#FMHKGHN5L597E_\`=[:LPFODQX_*WC^[
MD5S6547Q5]S3*6[O'W_A3M?T*M3'UHZJFSGHQY[(JQN@T++#S.$\DU663P[:
M]LO:]\M?/=/57KGV+F@2.\M.T?:$ZKQ9T*O2K:)22>$1";L=^?'A*4M'FFY3
MT1M2\?ERC'(X[-Y;$B88V0XR!JBD@K:]O!>I^GO6OJQTHCR8G3?/Y'#1IA@;
MXQG>6CI-H2`1\%NHH1(GZUK>\*'%'0X@^"PW%A08S$.'&93Y+4>+&:2S'8:3
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MQ2G%*<4IQ2G%*<4IQ2G%*IV,8[E$JYV=;KMAW\`MT>H;`-Y>36I$N+C8(3>]
MU3K&IZ$^E->F!)5;M>CH4%@B]7D24MLKBO*=8-.R'<*J=GAX*Y[@/=GQ>Q;^
MZ"K_`&3.;&D[.V$#JT:FDMA"M-!-&3-:S6-=V.O0H&NK3I&VD8LN0J<7;+F0
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CG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g285899img6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g285899img6.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2@#,`P$1``(1`0,1`?_$`)8```$$`P$!`0$`````
M```````'"`D*!08+!`,"`0$!`0$!`0````````````````$"`P00``$$`@$#
M`P,"`@,/!0$```,!`@0%!@<(`!$2(1,)%!4*,2(6%S(C-4%A<6(S)#1DM=4V
M=I8W&%%24R=7&1$!`0`"`@("`04!`0````````$1`C$#(1)!43)A<8$B$U*1
M_]H`#`,!``(1`Q$`/P"V)R0WGE&17]W@N-OLZK$*DDJFMO8HY$HF3RQJ\$]#
MR6V$)S:@;NX61T:GN.:Y[W.:YK6V-R&KUFOZV7[W;',<G-8@FHD;'J^$HO)"
M+V=[TB0I/-&^B(B>/BO?OWZ<+DHE/JZK2<>%7T!*R0HI992DH:."C!5465-.
MDI!V3BH\`0D[,\5=YKV[=UZ&6$G:SI3^_*%B@YIE.QDB3+H:5@7*]I48Y\ED
MR23W2H']C7-17-:[]/%4Z9,M72A-B-H.TIH<"CM(;Q&A'IL>&VWB=WL<QXYE
M?9Q2*B$&CE[>*>B=T].@E)XY[FF;/HI=5D<<P,NQL45)\HD!:T%[#/[@PVL:
M(XQ_9,UXO"2QKE:TBM<GBTC6MC%F#DNB#H$(Y/[_`,,XK<>-S<C-@R@Q<1TW
MKO)L[M&F,R.ZR+2UQC55!$(16M6SR2X6/7Q&=^Y)4D;$]7=%D]KB&,_#7\CD
MWY.N&M7OO+<>Q'"MKT.=YAKO:N$87*L#4./WU+,%9T)ZT-U/LKL,"[PJYK9+
M72"O\Y#C(QWBSQ::WU]-L3A*[T8(MR&RS=>#Z<S;*N.VHZ/>VXZ>%"D87JC(
MMB0-4U.8RGVT`%C!-GMI4W=;0FC4Q9$@+C@]HQ@M$YXD?[C2S&?/"L%R#_)D
MY#<*=@'U#S-^*+,]3;*)%2\I(,'DGCUKCV1XJ0Y(`K[&\FCZMFTF20%LXAPO
M-!DF8)[/`B#(BMZ.LZIM,ZWP<7QV^8[Y1.9&#LW%QA^&"=D6E[<$V5B&:[!Y
M?X/KD>6QZHR5]B3'&95K^E)D(?NHC"#(B"?$,HGM89SF/1"7336XNWG]FO57
MY*%%HW=T'C[\FG![>/!#,Y4:/+)E![JOW!@P:Z?.)$@Y*XU#2T5S9X8]P2L)
M9T@+T(C`>UR)XO\``O\`EF9TLJRYB>68QGF,8_FN%9!3Y9B&5T]?D&,Y-CUC
M%MZ*_H[:**;66]1:02FASZ^?$,P@BC>YCV.147HX\<M@Z"NUS$_(RXTZ6VZW
MC'Q&U;G_`#^Y-2[MV)P\-TB<28$'+T.6(;&ESV)7Y++R2YK3#598Z*JLXL9&
MN;(E1W,)X'77JMF=O$;=B&ZOR.MA53,H9PZ^-?2L*R0,BNP3;>[-R9%G=9#-
M'$5C;VPUI]XQGZSR>OF)CA$$O['L\FJJDLZONH].4'SK?+M\<]W61>=?QGZ7
M3$[Z;*A8WLW46T\VC:RR*6L<3X=5!S,D'9D"NNF.1[W0K-E?.D#_`,E'1K%(
MXW.O3;\:LC<".5+.;G#S0?*IN(#P`FZ,('E$O"PW[,H%C5@*SLJ:QJAWS*^I
M^Y#CSJLGB]T6.1&JB/&UZ.1#EMKZ[6'>=&28;KVYAN@M/[/W?L.>VLP;4V"9
M3L+*ICB!&\=)B=-+N9PXZG((3YDD411`8KD]PSVM3U5.BR9N(C%^%3Y0I_RG
M<9<RVQF&(XMKS:&N]LY)@.8X3B4FTD5D*D/'A9)KV[:VYES[`1K?%K5@)/<S
MQ/L8,I1>`_$;#79IZ7'PF)Z,#H(+L:I/?D^:0$85K?'M'HVUL\0D1J&>T4JR
M(T[7N(QJ(I&=E1?5?[E\.AS6$X-]YF(+QC`L"M0E.5^-)$C3Y2D$$M*Z=`40
M8)#"]W^L4K6.5%'Y-547HEI?/X;QP,RHF7PJ^JFR*J=5W440II52TB0S5(CD
MKXJ6)ZN+<`5I/><QJ,5CWM>CWA>^)Y8VTU\R504T>E'71XJ19E[D5V,$RS6N
M,K4]J.\L.48G:'#A/$L=HR.(9SU8U55CE)DU_+,>$%SFUT$XVN011L^RQ8<D
MQW#<I3R9)TKY`HQ)#GM1&L)W5B*ODOKU6B@\.8B0MI9(V-'"*.?"CN<Z-4/$
MSLES5>V,UDDQ1N*UR*[Q]I%[.3_#U$V26=&1T%:KY\YN<\NLUX?_``]:4R-M
M#G7+K+;W;FX+IHI<J-A^C-(U=CD-?,R"-%<-KZG(L[KAO&A'HUYZ=K%1?<3H
MZ]?]<[WX02_BK<G+?C]SHW9PHV(5:"-OK'[@,.CL7*$M9OK0<NV;.IF>\YC1
MS+/#278C,\?,I*D#4_HHBR.G=,Z^WTZ%_5>8=!12_,;"%-@<!SH$2'?B'(0+
MSH)B'>$=QJ1XPO,C?=<$;R.<UJKXM<Y51.ZKW5Z.CBK*?P;*J_$AP*[JJ_\`
MT)0IZ^OHVSMT1/\``B)V3^]U(Y=GYU#)^8!@&+3^)W%;:)ZP*YKBW(FPP>JN
MF"`V2/&,VUOE-S?U)C^RLDD21:817':/W$8T@/+LJKU?AOHYL^,'/_BFYQF&
M6?%HM)DUA86%1K;D9MK!\!^M=YAK,/=!P[+UI:USB/(M?`R?++)S&^+6#4JC
M9Z,]$3N_/^#5/RD?E+RK1&%8]P"T9D\G&\XW1AY<RY`9?2S71+O&M.3)LNKI
M,$J;*%(9-IK39,^LF/L2M]HS*6(H6JK)[E9*UTZ9OM>#P/QR?BYQ'AOQ.Q+D
MMG^+PC\GN3F)5696%O8P!K9ZSU)D``7&#ZUHG28S)=,6QJ21[.^\%:Z58&8%
M_D.&'M6>W?VVQ.(L@]'(CG('0FK>4&F=B:#W1C$/+M:[/QFPQ?)J>6,3B)'F
MB5(UK52"#*ZLR"CFM',KYHT0T.:`1AJCV(O19;+F<F,_#IQ6WAPDX08QQ;WM
M]D/<:CV=NFHP.XHKR%>`R34USLK(,JP'(IKH5?7I56UI6WSG281$(6.5%\G^
MJ-::WVFVWM$I/1A7<^?7-LHW;4\3_B?U'?'J-H?(9N6IJ\[LH$4M@?"^..L)
M<?+=BY;90@L1SZS[A!BN<Q2#21%@2Q*OBKNCKUXF=[Q%<7\;/>N2<+?E3VMP
MKV@212Q]V)G6C[RKFR718E=O+1-SD-EC$ET8B*Q\BVK:R]K0]O%Q7S0(BJG9
M%CIVSVT]HZ+O5>8=!#!@T1GMB86$U&QV`<C7TP`,BE8.00*HV4<TNJ>TC$5C
M1^ZKG(GDK>R+T=#VZZ+8X[BUM>6),.R$]'C5A;UCTGL?=P9((Q;:.R0HCN%8
M#=/`)IAJA$(Q'(JN\W(\RU36R!G'<67VDR9!W&F*ZM>3ZF:=TV3*=9?4R5@H
M16E4B_3-=[:JGDCE5KNA2^S(]&VVCUT"'6LJ[5B(</T#(=>:77B2;&)/F'E1
MID88I`GI^Q"(0#WC\55?W$-VVO63$B#),/B\J&4I@CK:(D68R-(",DAC"0'%
M;&.,9^[A>37*TG?R*WR]:L8OBQ%(';%XI8JB5,/LB,5U>P2C&:ZIE9V6,=T:
MN0J-_P`FGN([MV14\>ZPV2']&7R.<,8)I,DPH\>.(ASG,1H@@")BD*8I7JU@
MQ#8U7.<JHB(G=>@K#?#[D$7G-\B'R*_*]D]G&-@@<F%PMXBNLIL`8HVIM=GA
M6N5WE9%*12Q&Y&4-3-0K%5CSVDYGD[U['7?^NLTG[U7#^:/#KGXS_F[K^4NG
MA1HM/EN::^YF8(E<4$N#*O#7A(>Y,9<T+R!:R^RFEM7'C*B(D6[:GCX.;U';
M3^_7B_LZ0>L]AXMMS7.![4P>R#<89LC#L:SK%;2.090V&/973P[RHE,>)SV+
M[T"<Q51%7LJJG]SJO)9BX;OT%%;\QS_CO@+_`,J<A_\`:VH>E>CHXIT_QM_/
MG\?G#KXY.).F]VS-_P!-FFN]10<8LG5_'K8\S%[Z^KCV4T\##LV/6P\1R9KV
M'8UA@3?8[N[O>QJ*J1-NO;;:V8-7Y#W_`",_*:W!A.&<6\9A\>^!O%S*I;LS
MVOMZWQN;L&;G^75`O.ZDZJQ?(;*WD6#,2"^/C]>TS*Y7R)99ED-ZI'`62=,S
MM^57#>''$G47!OCGK;C+I&MDPL%US5$C-L+-X9&095D%E)+99+F6430!CCG9
M'D]U)-*DD:Q@VN>@Q-8(8V-KCMM=KF\N:K\S%C/W/\XW(K&\UE$DU\SD=IO3
MK$$XCUAX7%J-:8F"'%9*(=@W-@33$5J=A*<KW(U$<J=1ZM/'7_#J<UE="IZV
MOJ*R,*'754&)75\0#?`,6%!`.-%C!9Z^(@`$UK4_N(G5>-[N@.@.@.@J^_&]
MD=1S\^8KGU\C%S:5D[4_&"%$X-<4#390TAD2K-(E[-S7'BEDH/PM"#D&:1$7
MW(N2^/IX^*';>772:_-\J]/Y#.J<AX._+KBW+_3Y8<6/MF=K[E!@\ZJDL?'C
M;@U9<4M?GE9*)'[H(MK:T-?9'3NON,N2?XW4=.JYTQ70WX^;GQ?D7HK3^^L+
M,,V+;AUMANQZ3VRM/]/#RZA@W38!2-1$656DENCF3LBM*)R*B*G5>:S%P6'H
MB%'#7E`H6!@'&Z.)/VLH6!DHP7@PK(8)\AA8,8XY"L<YIGKW[(J.[>ANGC:_
MLZ0QH]5]OJEC3()&7TS((]I/GABE:X4OQ<TPJ2-XQC&''&`*F)YL:YSWL<Y2
M7+48>JL\I)->[&11\LQN0^6ZB^@6MI[)OT$I5(&TI[:QC*YR#[H4K#D\W*C^
MZ*].BYA5Z+'YM>Z+<9`*J!?LC&EXU2N`V?2V0CM'&E"G3@3Y4`]BWR>P`&N\
M6'&URO<CV=&2.9];PK%\A`TJQ)PR28TX,2/9)W<YSHSHQZ:\*P<>1&,Y[C#8
MY@E8O@B)X]EJQZ>)_MDVM>/%'=[28=8E%(^TJ`",/=TZ-8(H"?207J@_W"3W
M4[*B(J)ZK"\)&>C*$C\@;F;8<//CAVDW"IA1;DY&2(W&_4<2"OG;NN-D19D3
M*[:K`QS9"S*;`P63HQ!_N%8%BJGJJ(ITZM?;?](0'B;^-U\;.,\9]%T_(;C@
M_.]Z@UCB4C;V4S-J;EH#V.P["ICV.5`;48GL*BH(42GMI9(,=L>*+_-XS%?Y
M/5SW%O;OGQ?"*_\`((^$3B-Q=X20^3?#+3LG6-SJ79&-BVU%BYIL;-(U[K/.
M3)B:6,EF>9?E"5A<8S*;5D:2*T/D"4?W55&M[1OJ[-MML;5)E^+=RX3?WQV,
MT??VHYF=\0\SF:S?&?Y_6+J[)DD99JR>=[W.4H8X#V5.)4[(T=,B=OTZK'=K
MC;/Q5E/HY**WYCG_`!WP%_Y4Y#_[6U#TKT='%3A_'/Q;U%S/^!+BAQTWACD/
M(\&V'QFK:MY#Q@FM,7NFS+M,?S/%Y1FJ2IRK$K'VY<"2-6N&42-7N-SVNGPY
M[6Z]EL^U,7B/OG>WX^ORGYA@>W!V4_"<<R,.K.15#61Y3*S9VD;>4.TQ#<&(
M5LCV5D655630Y%2KZ$5KI=:YR>^;LX>BR=NGCET_\2RS&\\Q7&\WPVZK\DQ'
M,*&IR?%\AJ9#959>8_?0`6E/;U\EG[#PK&OE#*)Z?TF/1>J\;F8?D:Z-R_BW
M\M^>[;JXLJ/4[N9KCDKK6W(\I`RLAH(U+191!'((QPQR:?.<+4K@HKO9C38[
ME1&D:G4>OJN=,.CQQ>WUB7*/CII3D1@TR+,QC<6ML4SR!])(;)9`/>5,>3;4
MABM5>T_'KA9$"4Q?W#DQGL=ZM7JO+M,;64O'1!T",XIR%TOG&Y-I<?<1V#2Y
M!N/2=1A=YM?!:YLXUE@M=L.),L,+?>R_HVU(95_`@%.*,V0^2T*->\;&O8KB
MXLF;Q4?/S@<T'<&_C@WYL^DLW5VS,WIDTOI[Z=Y&V'\PMF`E4H+6N]E6F;+Q
M+'4L;EKFJG9U>B=T5R=&NO7VWD^$?O`7\<OX^HG#CCS)Y6\>";!Y$7VMJ'+=
MLY%-VGN:@,W*\N!_$<BA^TXKGN.TL5,5BV0JQ5'%8\KHBD(Y[W.<L:V[=O:X
MO@R+YX/@PX<<>N`>5\BN&.C9.N,[TIF.*93GKX6>;/S-MWJ6SE$Q?+!EK<XS
M#*8T9,?FW4&V?(CC$0<:";S<HU=VK77V6[8V^3IOQ/N6R[<X1YYQ=R"P]_*^
M*6?F;CP9$IKY)M3;8D6F68Y[$=_8R1J/+@WD+NBN8,2`;^WNB=$[M<;>WQ5J
M7HXH.KW&)V`95?XQ.@%*6FG$@27U^*6,=LY@.[H4T)%GV0O8D1S(1C4\^S7]
MO+NB]5T_4J-#DL@(&UPDG&`BCG/J*ZJC0(K3L7Q*Y21YP#'!W,YB(B#[>:N3
MQ<Y5ZB%QK-C6,23%?'<ZJCPZ"1517,'/DS&,^V&0,4SR32.\)%@K$<J.[`3Q
M<WLX;51\)AJ%UE]C,@181X)#CCF*Z(ZM'*]^%[[8Z2&L0U@P#(\AL1B*WP<G
M=.Z=E]4IX(MD60I-$YPPRI\=[E51$IF29D<CVC;[L<PGRS$(1RN<Y_9BL143
M]WZH4OW##';(V:Y=EA82`A1J$=.26?';.K++GV,Z/+046;)EFBG=$CUW<[$3
MS:A1^B([OU$V.MY!\EM`\4-=GVSR2V[@FE=<1[.%1KEVP;Z'05,B\LF2"5U)
M`?)>AK.YGBAF<&)'8605HGJUBHURH22VXG*@SSQ^9'BASJ^7_A%EF691+;\=
M7$C:..V#+^WI[>,F69#(L8E]DVV+3$4ANR<6)@R6AHX0XQ(RRR4];(D*!JRG
M`;/#TZ]=UTO_`'8OQ\>N37'_`)8Z_7:G&S;N#[JUTV[G8T3,-?W<>]I0Y#5Q
MH$RRI)$J.O\`F]K7QK2.\P'HT@D,WR1%7JO-99XI@'RX<P?CVU3QKWQQIYG;
M^P37UKNOCWG8:?6TV0^TV3DM7?5>046/7F&X=!&:QLY0<NJ5;!.Y!166$5ON
MF&UJN0UIKM;+K]N?]\'/RE47QB<L39UL<EA;Z"V]B`]>[NKL=:"SOJ@4"4ZW
MP[/Z6F;*']UL<2NGF$>*-_N&K;&4@O,S1,='I[-/>8G+HZZT^5#X[]NZ.SOD
MC@?+O2]GI75G\+LVCG,_*18]"UK*S26E?BE?GT'(A5=OB5E?S^X(L>='"4Y4
M5K&KV7JO+=-I<8\J+'Y*_P`EO$WGONKCG1\6-B1MG8MHC$-BQ<HV+#AV51B]
MOD&P;/$)`*;&%OX-7/N04L/%%=)FC%](\LA!B>3P>Y)7HZM+K+[+"WP/_,%\
M>\CA+Q&X?Y5R%Q36/(W!,?IM-.UOL<AL:D9?E4C(SUV//P3(#B?B^2@RN1;1
MV0HXIC;!#/41(['-[N1S[--O:[8\/'^3I\8R\G>.L7F?J'&VR][<7J*P-GD.
MKB^5KL3CZ-QK3(8KA@$0]E=:NF*2YKV>CE@%LA)YD>!B4ZM\7UO%1)?`-^03
MJ#B;J\/#3G!FMC3:DQV>27H/=`XEAE=?@%/;R_J+/66<0J05C?1<1@6$@DVF
ML(\:2.$(QHIT&`<5S8WV==VOMKRL><_^'W$SY\>%-9>\?]U:]RO(L,NL@M^/
M/(7"YD?)\=H\Y@QVP,FP'+206NL/X1R7VX\:[AM:R;",&-+8-Q8S1$KEKM>O
M;]%<[XW_`)`>4?P`;"NN$WR;Z6V9C_&'*,HF6^!Y[65\G**/7%_82VMO,FU?
MD<9&T6R=2Y08GUEE75Y_N]7.5YV1/>+)B.CKMK.V>VGY+E&LOD@X![AQ"!G>
MN^97&V\QJQ'[@9,G;^$X_81E1J/<"VQ_);>GR&CFC:O=P)L6.=B?TF)U7"Z;
M3F5%7\B/Y(W!7B7A5Y0<>MC89RWY'3XLROP_"M87HLBUUC]T:*B5UWL78=,4
ME&M%%DE:YU?3R9EM,4:A:R.CED#F6]>K:\^(9_\`CV[HH]0\0>;WR;\]MMTF
MM97*'E>.;F>V=KR&8;4VK<?HZJNQ]:_[B`'C5S\JS>P@4\2.I1H`#`QV^+$5
MU7LF;--?B(F_E5^9'B5SY^2'A5BTK*["T^.3BYNC$LGV)E*TTU!;2N9&1UTC
M,,YC8I(BLR29@E)0UH*R.$T-)\F&>S**.J2`-=&]-+KI?^ZOA\:>6W&;F)A,
M_8?%S=>O]WX53VS,?M[S7]V&WC4EZZK@7*4=U':T4VFMV5=G',Z+)$([&%3R
M:B]T2O/=;K<;<FS?(SS+^/S0NH]B:3YN\@M;ZP@;ITWG56_`LALEEYSE^$Y%
M76.'6DS%,,K8MED%V]9<QX`OCQGHDEB^J>VY6EUFUO\`7ES>OAK^2FG^,;FC
M2;GOTL<FTMF6.V6J-U4U(6";))&`VME!LJO+:B!(.$$_(,,O:N+8)$\QOEQO
MJHPWL>9KDCU]FGOKB<NAQ_\`W@^(K^6'\VO_`#KTI_#7L^7VC[G:_P`P?K?I
M?J_LO\LOM7\?_?/;]/IOMWN=_7^C^[JO+_GOG&#^-S:!Q/;X!S9+05.608SH
MU=D20DF=P)[KPP;6(V1$=85XY!?-&H496*KO![?)W<S+C]C4EX8;'A/,"KR[
M7CH/NJ\3S4^0Q3%[M:U2FC,DSF!>OCV[(9Z=D_7HU[1[A</MAH-J&R+!GE1/
MWO%]Y"-SO_5@WU!W,3^\KW?X>JGM'RD</=E.\/I,FP$/;R\_J0WDKR_3Q\/:
M@0_#MZ]^_EW_`+W;UA[1Z:?A1D<ZS$?-<NQ/[>-0M*V@H[638R8S7%>6.*18
MSXD:"]5=^TBBD=O)55OHG<>WT?'@V"8QKG'HV,8E7,KJN.]YWIW]R1-FE:-L
MBPG'5$61-D^TWS=V1$1J-:C6M:U"6Y?S-M=Z_P!EU<6CV/@V';`I(5I"O(5/
MFV,TN5U<2[K5(M=<1:^]A3XD>T@*5_LR&,0PO)?%R=UZ)FSA@':7TLU6-?J;
M5[5*Y1C:[!,412/1CR*QB+5?O<@QN=V3NOBU5_1%Z+F_;/X-KO7^L*-<9UK@
MN':\QM9TNS7'L&QBDQ*C6RGN:^=8+4T$&O@+.FN8U2F]OW"*B>2KVZ)FWEA\
MKTUJ#/,CJ,PSC5.MLSRW'X9:ZARG*\&Q?(LCI*\[S$/`J+NWJYEG6PS/D$<\
M02L8Y2.54_<O<N;.'S_DIIK_`/)-9?\`06*_[JZ&;]UB(G'7C[`Q[+\1@Z*T
MW#Q38,R-8Y[C$36.$Q\>S>PA2$EPYV7TH:-E;DLR)+1"B+-$9XR)Y-5%]>AF
MO?%T3I"#%C0H6F]50X4,`8L2)%UYB,>+%BQQM%'C1HX:A@@``)B-8QJ(UK41
M$1$3H9OV\LGCWH.9:T%[+T?J"5=XK9"N<7N).M,,/:XW;@*$X+6@L"TKI=/9
M!-&&]AX[QE:X;51W=J=AF_95Y0XD@+X<UD<T><PL,D64T1`S!F"3WHKP%1S)
M#"QVO\F*BHYB+W3MWZ(2ZOT'HJH@Q*RJTMJ:LK8$<42#75^N</A0844+48&-
M$B1J8<>-'$Q$1K&-:UJ)V1.BYOW6WX=@N$:[IOX<U_AV*X+CR3I]FE#AV/5&
M,4R65K)?,L[#[720X,'ZZQED<4Y?#W#$<KGJKE5>B9SR_68X/A6Q:"9B>P<0
MQ?.L6L4:EAC68X_4Y/03T9W\$F4UW$G5TI&^2]O,;NW?H<<(^<@^&KXILHM9
M5W=_'SQ2E64U1K(,'3V)5XE]H3`L]N'6P(D*.B#&G?VQM[KW<O=RJJF_]-_N
MG*ZGX6\0-$BABTSQ=T!K!T!@619>$:CP3'K,?TZ1/:>ZVKJ,%F8S700N4CS.
M>YXFN55<G?HS=MKS:6S,<!P78>.FQ#8&%8EG.)R"0C2,7S''*?)L=.:M.*57
M%-274.;6E)`E!80+G"51$8US>RHB]$S9YC7DTGIE$1$U'K%$1.R(F!8JB(B?
MHB)]J_3HN;]LU@^MM=ZRKY]1K;`L+U[56MM*OK2LP?%J/$Z^RO9S`CFW4^%0
MP8$:9;3!QQM+)(UQB(QJ.<O9.Q+;>6+R[3>H=@7U)E6>:KUOFV48U'/$QS),
MNP?&,DOJ"+)<Y\F-27%S5S;"JCR'O57L`0;7JJJJ+WZ+FSA\OY*::_\`R367
M_06*_P"ZNAF_=:G_`.*_&'[E]Y_\<=#?>/NWW_[K_*#7WW+[[[7L?>OKOX>^
MJ^[>Q^SZGS][P]/+MT/:_=+ST0=`=`=`=`=`=`P?7):W*N36T-AWF063<-UW
M/+B&(ORZWJBTXLQL!GCW3<?E2Y1G`;&!%F($`O9<(!NR]T54Z-?&#]VN:]K7
M-<CFN1'-<U45KFJG='-5.Z*BHOHO1DA^%XW8DVQG^>`W`N7XU8PH5#&U[!?!
MDUN(6$%X5,LF5&L);F3A%`=&#]J.[_.2^YYJUBM+\8*W;W]%CX0R+ZZJ:0$@
M[(L<]O90ZT)Y)51HXX233!84Y'.1&L:JN55]$Z(RJ*CD1S51S7(BM<BHJ*BI
MW145/145.@167O;#J_;,S4MDJUEA!H8]W(R*RLZ&!0(26L?Z:G8Z5:BL26QA
MR$>@T!V\/7O^G1<?):FN1R(YJHYKD1S7-5%1R*G=%14]%14Z(8A@DFOO.46W
MLZOLCFLP[5@G8W4'RN\@?9*C*K9K@73JN1)FI]O%%CQ)H&@<T31L>Y/5R=T-
M7\<'U1Y`)8`2HIPR8LD(Y$:3'(PP)`#,:0)P&&YPRA*-R.:YJJUS5147MT9?
MHQ@Q@ED2"B!'`-YCG,1H@A")JO(4I7JU@QC8U5<Y51$1.Z]!CZ6\I<CK8MSC
MUM6WM1-:Y\.TJ)T:RKI36$<)[H\R&4T<R,*QS5\7+V<BHOJG08LF;X6(,N27
M+\7''@3V54XY+^I8&%:%4B#K9972T9&GD43D:%ZM(OBO9/1>ABMC<8+`ND/*
M)D=@E,X[B-:%H6M\W%<551B"1B=U<J]NWKT&`+F.(`@1K0^58V&LFR5A0[$M
MY6#@2YB*Y%B1ICY21SR45J_U;'*_T7TZ#WI>TCK5*)MS5+>.B?7MIDL8BVKH
M/=J?6)7(;ZM8G=R?UGAX>J>O097H,-8Y'C]1/J:JUO*BML[^06+15T^RAQ)]
MS)`-"FCU4208<BP,$:HY[1->K45%7]4Z#,]`=`=`=`=`=`=`=`D>]-C#U7J[
M*\O1SON4>`^!CX6,$4DC(+)%B53&!/(BB,T$@GOD:I&=PB?V7OV3HLF:C9L]
M`0\>TKCL#(:H67[NW1D,0>'5!HU,9V*1[=X+.VOATX2QJV1/#51U+9S'^Z@?
M?\$7Q8KG5K/GQPD/VW+@X)I6>6ZO+0%=CE#`A6*UA*Z+:Y2R/#97MH`2I`P"
M@NR&4K!E)':,[1.>@O!RHK8SS2><0\!AZZT]]]EQ(E;;YB<^97\0$"!6)51C
MQO?J*HL>$0[1-@4SAN;[A'O\2]U7U[J+?)`,?DQ\WP/=_*+95;$R=7PLJQG5
MV/Y-6T5G4T%(UQ:^.*L"24^/)^LGRF@<1I@F(UIVJOD542M?,D.DT8VQH^,>
M'DRF?<UTB%@$J;(L'+7`N:^L]F;,KSQ/V2:T!XE2X2QT<A!M1K$5%1.W49O)
MAM1B./67&'=&XLRKFV^3Y[?M@8A,R.EH;C)(0X%O%@U8(-G,?8+-FRC/,PA%
M.BJ('BCD[>E:^<0_W$;*SU7QEH[;)"O^[XEJ^//D#F1XE9(!-#4^_`J3Q)$I
MD,<R(4@HBC0B-(5GBQ$\FMZC/-,GP32M+`XUYOMW;->3(["_JK[+L:QJTJ:2
M)$@W-L%85-E;XD`PFV^0W,AXRQR%D*T<0W@)B*5[GFL^<0\+6]FW0O&'%+3/
M'2W/Q?$(\Z;7#C0H5DT]D9\R#CD:"\D2(RRC?7#B()'HWW&*C55$3HS?--;W
M@V?=XW70LR*'+=Z[DETE?A^"@C5DD&E\/NC/ENCLK%L0P+&T"$ZQI5E*)Y27
M^3Q(@(Y%=6ISXXAZ/\&XMANA5Q*HR$]#B5)A*(?*,<6O!+/5@C)875M`*&/(
M@"E9"+WW^X$;D:Z2KA)W1G:,YS3(>+_&G%=H8YE.<9[0)'PS*K&Q'B6"MKZZ
MNAUOLS5061AF5Q3/ESZZ,I:Z(=7._J7G5RN<3]E:NWQ#GN4<;'\0T2L)OU0,
M?I755'581!?!2#E[UB%K:'%[-L]6S)=/7G0<\T>.899`H*L>JB5_49GFF#Y/
MIB;3XIJ+2*58\BVYFDYV4%`6BHG"U;C=JP1)-(ZI?-;7Q94J:II=M,`Q7.9"
M5O?VT&I#6?GX.$U%JW&;/D@R=2,]VLTA0Q,>N<QE#A.L]C[,=$E1[&Q2>D^=
M*:.$!Y_=C#5@@-&@_#Q5/$EO@Y?:&?7<_/,<TQ@5W_#]]8039=GF6,!6S$P_
M`*\B!F,`V:4C(60WA"M'$.0!114[%>G[Q]R2>,FX:(QW",]Y#7F9XK3PHV#Z
MJJR8SB=A*%53IN8938&GNGYFZZ*:;:V\V;&24?WU416C*)ST3T1*U<R>4C?4
M8'0'0'0'0'0'0'0)/NK4]=NC`I^#65F>F9)F0+&+9`@0+-8LZN-[T9Y(-B)X
M9`5551S6O"147]I&^O<L\,?@FE:7%;2'EF27%ELC84*O6IB9SED:J2RJJI?)
MOVO'H59!AP*."YCE]SVF*8SG.4A'([L@M_\`'\WGIN+N[%ZC%YE_(QZ-6Y/6
MY$8\>IK+ETQE>";'=`=&MF$BB4J3/-A?%ZC(QO=KVJYKA+@HF,XC0XE0AQNG
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M(4"8*66KD-GQ985B35$B/[-1Z=D5%].RB7#29>A(%MFK[V^R_(KG!@`QG[1J
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M3&Z>,$8VU]0:'`C3""<\+'*XY2N_8U._ZJHSXPU71_'/'-+A));;S<LR,CK5
MJ7L^#!JF18]Q+#+L!P:FM:V)'DV!(@5E2'*0\A1-17-&UHVBW+P9;QFH,UVI
M<;$N\DM/M618Y6XWD.&0:^KBQ<@@5I0G2%<7JA+<2*>2>(`A8@G!1[PM\GJQ
M7,49>O1O&W%])-+(BV\[)KA6V,>%83H%751JF!92QR)0:VKJ8X8XI<]D6,R7
M)>XA#_3#1OML1!]7);DXWJ(.@.@.@.@.@.@.@.@.@.@.@.@B;Y7?]XHW_!G^
ME0/^XO\`:O\`3B_]N_\`'_\`9_K75C<X2FX__8-+_I_]E5_]J_VG_H@O[1_U
>W_Y?\?OU&&7Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
